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This thesis comprises 61 papers which describe work undertaken between 1972 and
1985. The research was performed in order to obtain basic information on the
environment and the biochemical processes existing within the female breast. It
was thereby hoped to achieve a better understanding of events which occur during
the development of breast disease, particularly breast cancer.
Hormones are involved not only in the natural development of normal breast but
also in the aetiology of many breast abnormalities and, most importantly, in the
continued growth of a proportion of breast cancers. A major aspect of the research
described in this thesis is concerned with the measurement of steroid hormones,
their metabolism and receptors in the breast, its tumours and secretions.
Additionally studies have been performed to assess the significance of other
markers of tumour behaviour and to determine whether agents such as LHRH analogues
have direct effects within the breast.
The potential of the breast to modify its own hormonal environment has been
investigated by performing in vitro incubations with steroid precursors. Pathways
leading to both active androgens and oestrogens have been identified. Biosynthesis
of 5 reduced androgens occurs in all types of breast tissue but is particularly
associated with apocrine differentiation. The production of oestrogen or
"aromatization" was detected in a proportion of breast cancers but not in non-malignant
tissue. The significance of tumour aromatase is controversial but it may be
important in oestrogen-dependent cancers growing in post-menopausal women who have
low circulating levels of oestrogen.
In order to estimate levels of androgen precursors within the breast, measurements
of DHA sulphate have been made in breast secretions obtained by nipple aspiration
and breast cyst fluids. Remarkably high, but variable, concentrations have been
detected. Further investigations of the composition of such breast fluids have shown
them to have a distinctive composition in terms of ionic content, major types of
immunoglobulins and concentrations of plasma-, platelet-associated and other proteins.
Cyst fluids may be subdivided into two major populations which are lined by different
epithelium and have a differing natural history.
Several series of breast cancers have been analysed for either androgen receptors,
progestogen receptors, cyclic AMP binding proteins, prostaglandins or expression of
lectin binding. These have been suggested to be markers of metastatic potential or
hormone-responsiveness. Inter-relationships have been made with oestrogen receptors
and other tumour/patient characteristics but assessment of clinical value awaits
patient follow-up.
The possibility that polypeptide hormones have direct actions on the breast was
investigated by culturing breast cancer cells with LHRH and its analogues. Marked
inhibitory effects which appear to be mediated by a specific recognition mechanism have
been demonstrated. These findings are reviewed in terms of their significance to the
management of patients with breast disease.
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Abstract
This thesis comprises 61 papers which describe work undertaken
between 1972 and 1 985. The research was performed in order to
obtain basic information on the environment and the biochemical
processes existing within the female breast. It was thereby hoped
to achieve a better understanding of events which occur during the
development of breast disease, particularly breast cancer.
Hormones are involved not only in the natural development of normal
breast but also in the aetiology of many breast abnormalities and,
most importantly, in the continued growth of a proportion of breast
cancers. A major aspect of the research described in this thesis is
concerned with the measurement of steroid hormones, their metabolism
and receptors in the breast, its tumours and secretions.
Additionally studies have been performed to assess the significance
of other markers of tumour behaviour and to determine whether agents
such as LHRH analogues have direct effects within the breast.
The potential of the breast to modify its own hormonal environment
has been investigated by performing in vitro incubations with
steroid precursors. Pathways leading to both active androgens and
oestrogens have been identified. Biosynthesis of 5 «C reduced
androgens occurs in all types of breast tissue but is particularly
associated with apocrine differentiation. The production of
oestrogen or "aromatization" was detected in a proportion of breast
cancers but not in non-malignant tissue. The significance of
tumour aromatase is controversial but it may be important in
oestrogen-dependent cancers growing in post-menopausal women who
have low circulating levels of oestrogen.
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In order to estimate levels of androgen precursors within the
breast, measurements of DHA sulphate have been made in breast
secretions obtained by nipple aspiration and breast cyst fluids.
Remarkably high, but variable, concentrations have been detected.
Further investigations of the composition of such breast fluids have
shown them to have a distinctive composition in terms of ionic
content, major types of immunoglobulins and concentrations of
plasma-, platelet-associated and other proteins. Cyst fluids may
be subdivided into two major populations which are lined by
different epithelium and have a differing natural history.
Several series of breast cancers have been analysed for either
androgen receptors, progestogen receptors, cyclic AMP binding
proteins, prostaglandins or expression of lectin binding. These
have been suggested to be markers of metastatic potential or
hormone-responsiveness. Inter-relationships have been made with
oestrogen receptors and other tumour/patient characteristics but
assessment of clinical value awaits patient follow-up.
The possibility that polypeptide hormones have direct actions on the
breast was investigated by culturing breast cancer cells with LHRH
and its analogues. Marked inhibitory effects which appear to be
mediated by a specific recognition mechanism have been demonstrated.
These findings are reviewed in terms of their significance to the
management of patients with breast disease.
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Cancer of the breast is the most common female malignancy in the
United Kingdom, now affecting one in every fifteen women in
Scotland. It is a disease which appears to metastasize early in
its natural history and, once disseminated, the outlook is bleak.
Survival rates from breast cancer have not significantly improved
over the last 50 years.
Although not having either the immediate life-threatening potential
or emotive implication of breast cancer, the group of conditions
collectively known as "benign breast disease" represent the most
common breast problem which will face the clinician. These
abnormalities create severe anxiety in many women who fear the
presence of cancer or a predisposition to malignancy. This is
particularly so for breast cysts which appear as lumps within the
breast and affect about 8$ of women. Although cysts may be simply
treated by needle aspiration, many refill or recur which results in
repeated treatment and places a heavy burden on clinical time.
There is therefore considerable pressure to understand the factors
which influence the initiation and development of both malignant and
benign diseases of the breast. It is my personal opinion that
major progress to eradicate these conditions will only come from
fundamental research into the biochemical and molecular events
occurring locally within the breast. The results presented within
this thesis reflect this philosophy.
Section 1 describes the investigations performed to assess the
potential of human breast and its tumours to synthesize active
steroid hormones. It has long been known that steroids are
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intimately involved not only in the natural development of normal
breast but also the aetiology of breast abnormalities, notably the
induction and maintenance of growth of a proportion of breast
cancers. Whilst, in premenopausal women, the ovaries are the
primary site of steroid production, after the menopause peripheral
biosynthesis in non-endocrine tissues becomes more important. The
ability of the breast to modify its own environment of active
steroid hormones has therefore been explored by performing in vitro
incubations of breast tissues with radioactively-labelled
precursors. Early studies^ 1 »2) showed that normal, benign and
cancerous female breast were all able to metabolize androgen
precursors. Conversions included the transformation of
dehydroepiandrosterone (DHA) to testosterone and testosterone to A4
androstenedione, 5°C dihydrotestosterone and 5oC androstanediol.
Gynaecomastic male breast tissue also performed some, but not all,
of these steroid conversions^). The report in reference (4) that
a breast cancer could synthesize oestradiol from testosterone was
the first unequivocal evidence for oestrogen biosynthesis or
"aromatization" by human breast tissue. Until this time, it had
been thought that oestrogen biosynthesis was restricted to the
endocrine glands of the gonads and foetal-piacental unit but it is
now recognised that at least one half of breast cancers possess the
activity^jG)^ Aromatization by breast cancers appears to be
inhibited by classical inhibitors of the system such as
aminoglutethimide(7) and tends to be associated with oestrogen
receptor-positive tumours although the correlation is not
absolute(8,9). Local oestrogen production in tumours may have
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clinical significance if levels synthesized are sufficient to
stimulate oestrogen-dependent growth. Such tumours would be
expected to respond to therapies which inhibit tumour aromatase and
there is evidence that this is the case^^^D. Efforts have also
been made to determine factors influencing steroidogenesis in breast
tumours. In vitro addition of oestrogen to incubates of breast
cancer consistently inhibited metabolism of testosterone to its
reduced products and A4 androstenedione^2). Although
hyperprolactinaemia influences 5°< reduction of androgens in rat
mammary tumours (see Section B), no effects were demonstrable on any
aspect of androgen metabolism in human breast tissued3). However,
human breast cancers in which apocrine characteristics were a marked
feature metabolised significantly more testosterone by 5*C. reduction
than those in which apocrine features did not predominate^ All
these aspects of steroid metabolism by human breast tissues have
been reviewed^ ^d 6)#
In order to investigate more extensively the effects of hormone
manipulation on steroidogenesis by breast tissue it was important to
develop an experimental animal model. Studies were therefore
performed with dimethylbenzanthracene (DMBA)-induced rat mammary
carcinomata (section B). These tumours were shown to have a
similar spectrum of steroid transformations as human breast cancer
except that oestrogen biosynthesis was not demonstrated(17). The
growth of many carcinogen-induced mammary tumours are hormone-
dependent and, in particular, may be stimulated by prolactin. It
was thus of interest that hyperprolactinaemia induced in rats either
before or after tumour appearance significantly increased
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reduction of testosterone^®'^) in the cancers. These effects of
hyperprolactinaemia on growth and tumour 5of reduction were markedly
decreased by ovariectomizing the animals(21). Ovariectomy itself
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significatly stimulated 5oc reduction of testosterone by rat mammary
carcinomata, an effect which was reversed by administering oestrogen
to the animals^22). Effects were also observed after in vitro
addition of either oestrogen(23) or prolactin^2^) to incubates of
DMBA-induced tumours. Comparative studies were also performed with
rat mammary tumours which, although originally induced by DMBA, had
been transplanted into successive generations of host animals^2®).
Whilst, at early passages, the tumours were hormone dependent and
regressed after ovariectomy, later tumour generations appeared
ovary-independent^2®). This change in hormone-sensitivity was
associated with a progressive increase in tumour metabolism of
testosterone to 5<X androstanediols(2®). It was therefore of
interest that endocrine ablation treatment of animals bearing
multiple transplanted tumour caused increased 5«C reduction, an
effect which could be reversed by oestrogen replacement^2?).
For comparative purposes, studies were also performed to determine
the pattern of steroid metabolism in other human tissues. These
included normal, benign and malignant thyroid^2®) and metastatic
deposits of a bronchogenic carcinoma^2^).
The impetus to investigate androgen metabolism by breast tissues had
come from the pioneering work of Dr. R.D. Bui brook of the Imperial
Cancer Research Fund who had suggested that urinary and plasma
androgens of women with breast cancer and those who would
subsequently develop the disease were subnormal in comparison with
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control women. These results prompted studies which it was hoped
would produce confirmatory findings in a population of women from
South-East Scotland (Section C). In the event, these
investigations failed to detect any significant differences between
urinary androgens and established prognostic factors measurable at
the time of primary treatment for breast cancer(30) or> indeed, time
to recurrence and survival in these patients(31). Nevertheless, a
by-product of these investigations was that a radioimmunoassay had
been established to measure the androgen conjugate DHA-sulphate in
circulating plasma. Furthermore, my attention had been drawn to
the work of Dr. 0. Sartorius in California who had obtained breast
secretions from non-lactating women by nipple aspiration. Whilst
these fluids had been obtained, as a diagnostic tool, to screen for
the presence of malignant cells, it occurred to me that the
secretions might better reflect the steroid environment within the
breast than measurements of urinary or plasma hormones.
I therefore embarked upon a project to measure DHA-sulphate in
breast fluids which subsequently expanded into a major interest in
the composition of both breast secretions and cyst fluids. The
principle findings are described in Section D. Breast secretions
obtained by nipple aspiration from non-lactating women contained
remarkably high levels of DHA-sulphate(32). The mean concentration
was over 200 fold higher than in circulating plasma. G.l.c.-mass
spectrometric analysis performed in collaboration with Dr. R.W.
Kelly, MRC Unit of Reproductive Biology, confirmed that the material
cross-reacting within the radioimmunoassay was a conjugate of
DHA(32)# Although the levels of DHA-sulphate in breast secretions
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varied greatly between fluids obtained from different women,
concentrations were relatively constant within individual women in
terms of different ducts in the same breast, different breasts of
the same individual and sequential samples from the same women(33).
No significant difference was detected between levels in breast
secretions obtained from normal women and those in patients with
early malignant or benign breast disease(33). However, comparative
data on secretions from tumour- and non-tumour-bearing breast from
the same patients are limited and, interestingly, in contrast to
women with breast disease, there is a tendency for greater variation
between the breasts of individuals with breast cancer(33). The
physiological significance of such large concentrations of hormone
within the breast remains to be determined. Although DHA-sulphate
has little biological activity per se. the metabolic activity of the
breast, as described in Section A, means that it may be transformed
into active hormones which are capable of modifying breast
development. Other studies have been performed in collaboration
with Dr. P.L. Yap, Blood Transfusion Service, on the protein
composition. These showed that breast secretions may contain
measurable levels of immunoglobulins A and G (IgG and IgA),
lactoferrin and ly sozyme^^). The IgA was characterised as the
secretory 11S form which suggests that a secretory immune system may
be functional in the non-lactating breast^).
In addition to breast secretions, fluids aspirated from breast cysts
have been studied. These also may contain remarkably high
concentrations of DHA-sulphate which are higher than those in
circulating plasma but somewhat lower than in breast seeretions(35#
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A feature of DHA-sulphate levels in breast cyst fluids was the wide
variation in concentrations between different cysts. Levels were
not related to age, parity or menopausal status of the patients or
the volume of cyst fluid aspirated^35,36)^ jn patients with
multiple cysts, values for DHA-sulphate in cysts aspirated from the
same breast on the same occasion were relatively comparable but wide
differences sometimes existed between cysts aspirated on different
occasions from the same breast(36). These observations have led to
more extensive studies on the composition of cyst fluids. An
important finding was that the concentrations of Na+ and K+ varied
greatly between different cyst fluids and were related to levels of
DHA-sulphate(37). Furthermore, the distribution of values for Na+
and K+ was suggestive of the existence of more than a single
population of cyst fluids. As a result, cysts are now routinely
classified according to their electrolyte and androgen conjugate
composition(37). The classification appears to relate to the
natural history of cystic disease and, perhaps, subsequent risk of
breast cancer. Thus, work in collaboration with Mr. J.M. Dixon has
shown that cysts may be lined either by classical apocrine or
"flattened" epithelium and that electrolyte content related
absolutely with these histological types(38). Cyst lined by
apocrine epithelium and possessing fluids with high K+ and
relatively low Na+ (Type I) are significantly more likely to be
multiple and recurrent than those with flattened epithelium and the
converse electrolyte composition (Type II)(39,1tO)< Retrospective
analysis of patients with breast cancer who had had a previous cyst
aspiration which could be typed histologically or by electrolyte
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composition showed that these were likely to be Type I, suggesting
that apocrine change occurs more frequently in populations at risk
of breast cancer(39i40). The pH and protein composition of cyst
fluid also vary widely^,43) an(j this variation can largely be
accounted for by different subpopulations of cysts. Thus Type I
fluids have a low pH and the secretory form of IgA whilst Type II
have a higher pH and the non-secretory form of These
results have led me to suggest that Type I cysts are formed by
active apocrine secretion whereas Type II cysts occur by a more
passive process^1*). This theory has had to be modified recently
following the finding that Group II cysts have higher concentrations
of thrombospondin, a platelet-associated protein, than occurs either
in Type I cysts or the circulation^1^). This would indicate that
some form of active process is required to account for the
accumulation of this particular constituent^). These studies on
the composition of breast secretions and cyst fluids have led to the
suggestion that DHA-sulphate may be a useful marker of apocrine
secretion within the breast - the steroid conjugate is also
found in very high concentrations in microcysts which are lined by
apocrine epithelium (^6) and may be detected by immunohistochemistry
in breast cancers which display apocrine features^1*).
I have also been interested in the measurement of biochemical
markers which might predict for the prognosis and behaviour of
breast cancer in terms of aggressiveness, hormone-dependence and
potential for metastatic spread (Section E). Part of the problem
in assessing the value of markers, particularly in the prognosis of
early breast cancer, is the relatively long interval before many
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patients present with recurrent disease and hence the need for an
extended follow-up period. However, a quicker guide to the
potential of tumour markers may be obtained by analysing
relationships with established factors of prognostic value. In
breast cancer, these include tumour involvement of axillary lymph
nodes, tumour size, grade and stage and the most recently validated
factor of tumour oestrogen receptor status. In this respect, I
have been very fortunate to have as a colleague Dr. R.A. Hawkins,
who established a routine assay for the measurement of oestrogen
receptors. This was originally used to assess the effects of
endocrine manipulation and hormone responsiveness in rat mammary
tumours'^7-^9). Whilst the value of oestrogen receptors in
predicting hormone sensitivity of breast cancers, particularly when
accurately corrected for cellularity'50)} iS recognised, the
receptors for androgens in breast tumours have been less extensively
investigated. I, therefore, established an assay for androgen
receptors which could be used routinely for measurements in breast
cancers'51). Results showed that whilst androgen receptor activity
was not related to lymph-node involvement with tumour, there were
significant positive correlations with the presence of both
oestrogen receptors and progestogen receptors'52)< Prostaglandins
have been implicated in the metastatic spread of breast cancer,
particularly in bone. Although breast tumours appear to produce
prostaglandin-like material, most investigators have employed
bioassay or radioimmunoassay techniques which do not definitively
identify prostaglandins. I, therefore, instigated a study
performed by my research associate, Mrs. D.M.A. Watson, in
collaboration with Dr. R.W. Kelly, in which prostaglandins were
measured by gas liquid chromatography - mass spectrometry in
extracts of breast cancers. Definitive evidence was obtained for
the presence of varying amounts of both prostaglandin E2 and F2 oC in
these extracts(53). Whilst concentrations of the prostaglandins
were significantly related to each other, levels were not correlated
with the presence of oestrogen and progestogen receptors(53). An
assay has also been set up and validated by which to measure cyclic
AMP binding proteins in breast cancers(54)# as with the results on
androgen receptors and prostaglandins, the full value of these
measurements is awaiting clinical follow-up of the patients.
Other tumour markers which have been studied are carcinoembryonic
antigen^b)^ various milk proteins(56) and lectin binding sites(57).
Whilst the association of steroid hormones with breast disease has
been extensively studied, the involvement of polypeptide hormones
has been relatively ignored. My interest in polypeptides and the
breast was awakened by a discussion with Dr. H.M. Fraser, MRC Unit
of Reproductive Biology who had long had an interest in luteinizing
hormone-releasing hormone (LHRH) and its analogues. Agonist
analogues of LHRH had been used to treat premenopausal patients with
advanced breast cancer using the rationale that chronic
administration would perturb the pituitary-ovarian axis and produce
a medical castration. The possibility that LHRH and its analogues
could have direct anti-tumour effects had not been explored. We,
therefore, decided to test LHRH analogues against human breast
cancer cell lines maintained in culture (Section F). As a result
we obtained the first unequivocal evidence that an LHRH agonist was
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capable of major direct inhibitory effects on the growth of breast
cancer cells(58). These effects appear to be mediated by a
specific recognition mechanism, being reversed by an LHRH
antagonist(58). Such an action would account for the beneficial
effects reported in postmenopausal women with breast cancer treated
with LHRH agonists and has important implications with regard to
future therapy. Studies are continuing to elucidate more fully the
mechanism of action of LHRH analogues and the susceptibility of
different breast cancer cell types to their action(59).
The results and concepts presented in this thesis have also formed
the basis of reviews on hormones and the breast written as co-author
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_ Evidence for the conversion of dehydro-
"
epiandrosterone through testosterone
to 5a-dihydrotestosterone has been sought in three
breast cancers, two fibroadenomas, one specimen of
fibroadenosis, and six specimens of normal breast
tissue from the same patients. Significant in-vitro
activity was demonstrated in all tissues.
Introduction
Human breast cancer possesses the enzymes
necessary for steroid biosynthesis.1'2 Incubations and
perfusion with various precursor steroids has indicated
that a whole range of conversions may occur.3'1
Jenkins and Ash 5 reported that the conversion of
testosterone to 5 a-dihydrotestosterone was apparently
limited to cancerous tissue and did not occur in the
normal surrounding breast. The study we report was
also performed to determine the specificity of this
activity in breast cancer. Two transformations,
dehydroepiandrosterone (d.h.a.) to testosterone and
testosterone to 5 a-dihydrotestosterone, have been
assessed in samples of cancer, fibroadenoma, and
fibroadenosis of the human breast, and in normal
breast tissue from the same patients.
Methods
Tissue was obtained from three patients with breast
cancer, two with fibroadenomas, and one with fibroadenosis.
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In all the patients, samples were taken both of the lesion
and of the normal breast tissue. Histological examination
of all tissues was carried out initially by frozen section and,
when further studies were required, by embedding in
paraffin. Particular care was taken to exclude neoplastic
infiltration in the normal breast tissue taken from the cancer
patients.
The specimens were finely sliced and incubated for two
hours at 37 °C in Krebs-Ringer phosphate buffer (pH 7-4)
(10 ml. per g. tissue) containing an n.a.d.p.h.-generating
system, 20 uCi tritiated 7a-d.h.a., and 2 uCi (4-14C)
testosterone. The conversions of d.h.a. to testosterone and
testosterone to 5 oc-dihydrotestosterone were determined by
measuring the percentage incorporation of radioactive
labels into the metabolites, which were extracted and
purified by thin-layer chromatography. Details of the
methods are described elsewhere.2-6 The total d.n.a.
content per gramme of wet tissue was estimated in each
specimen by the method of Burton.7
Results
The percentage radioactivity found in the relevant
metabolites is shown in the accompanying table.
Both benign and malignant tumours transformed
d.h.a. to testosterone. There were no consistent
differences in conversion between the groups. The
low value for one fibroadenoma (patient 6) can be
accounted for by further metabolism of testosterone,
since significant 3H-labelling of 5a-dihydrotesto-
sterone and 5a-androstandiol was also found.
All samples of normal and neoplastic tissue reduced
testosterone to 5a-dihydrotestosterone, and, in con¬
trast to the conversion of d.h.a. to testosterone, 5 a-
reductase activity was markedly increased in the fibro¬
adenomas, and to a lesser extent in the normal breast
associated with them, than in the tumours and normal
tissues from the other patients.
Discussion
These results indicate that the conversion of d.h.a. to
testosterone and testosterone to 5a-dihydrotestosterone,
which is known to occur in cancer of the breast, also
occurs in benign tumours and in normal breast tissue.
The demonstration that 5a-reductase was not only
present in normal breast tissue but that its activity
was quantitatively similar to that in the tumour does
not accord with the findings of Jenkins and Ash,6 who
did not find such activity in the specimens of normal









































































The production of large amounts of 5a-dihydro-
testosterone by the two fibroadenomas is especially
interesting. This increased activity is unlikely to be
caused by greater cellularity of the fibroadenomas.
Their d.n.a. content was within the range of that of
the carcinomas and their activity in converting d.h.a. to
testosterone was no different from that of other tissues.
These two patients were taking oral contraceptives,
which may have influenced 5 a-reductase activity in
the breast, since oestrogens affect 5 a-reductase in the
liver 8 and adrenal cortex.9
Although there were quantitative differences in the
different tissues, we conclude that the potential for
producing hormones of high biological activity is
shared by malignant and benign tumours of the breast
and normal breast tissue. Studies are now being
carried out to determine whether similar activity can
be demonstrated in tumours at other sites.
We thank Mr T. Hamilton, who allowed us to study material
from one of his patients, and Miss J. Telford and Mrs A. Boyd
for their skilled technical assistance. This work was performed
with a grant from the Cancer Research Campaign, from
which two of us (W. R. M. and D. McD.) receive full-time
support.
Requests for reprints should be addressed to W. R. M.
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Steroidogenesis in Human Breast Cancer, Benign Breast Disease and
Normal Breast Tissue
WILLIAM R. MILLER, DAVID McDONALD and A. P. M. FORREST
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Human breast cancer can transform certain steroids into physiologically active
hormones and thereby act as a paraendocrine organ (Adams & Wong, 1968; Jones etal.,
1970). Breast carcinoma thus may have the potential to utilize inactive precursors to
produce a local environment of those hormones which, in the experimental animal,
have been shown to influence tumour growth. The aim of the present study was to
determine whether this potential was shared by human benign breast tumours and normal
human breast tissue.
To make the comparison, the following tissues were studied: three breast carcinomas,
two fibroadenomas and one specimen of fibroadenosis of the breast. From each patient
in which the above tissues were removed, a specimen of associated normal breast tissue
which was histologically free from neoplastic change was also examined.
The tissues were finely sliced in Krebs-Ringer phosfhate buffer, pH7.4 (lOml/g of
tissue). An NADPH-generating system (200/j.mol of glucose 6-phosphate, 25mg of
NADP and 50 units of glucose 6-phosphate dehydrogenase) and radioactively labelled
steroid precursors (20/tCi of [7-3H]dehydroepiandrosterone and 2pCi of [4-14C]-
testosterone) were added. Incubation was immediately carried out at 37°C for 2h in
Oi. The steroid interconvcrsions were determined by measuring the percentage incor¬
poration of the appropriate radioactive label into the individual metabolites after extrac¬
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purification and characterization have been described by Fahmy et at. (1968) and
Jones et at. (1970).
The results from these incubations are presented in Tables 1 and 2. As shown in Table
1, a significant amount of dehydroepiandrosterone was metabolized by both malignant
and benign neoplastic tissue and also by the normal tissue associated with each. Never¬
theless, a large proportion of the precursor remained unmetabolized in each incubation,
particularly in the carcinoma and associated-tissue incubations. Testosterone was a
metabolite of dehydroepiandrosterone in all incubations, the conversion being of a
similar magnitude in normal, benign and malignant tissue; the low value obtained in
one fibroadenoma (E.McG.) was probably caused by further metabolism of testosterone,
as 5a-dihydrotestostcrone and 5a-androstanediol were significantly labelled with JH.
The metabolism of testosterone by the breast tissues is shown in Table 2. A significant
amount of testosterone was metabolized by each type of breast tissue, but, with the
exception of the fibroadenoma incubations, a high proportion of the precursor remained
unmetabolized. 5a-Dihydrotestosterone was a metabolite in each incubation; the con¬
version was much greater in the incubations of fibroadenoma and associated normal
tissue than in those of carcinoma and fibroadenosis. Small amounts of 16a-hydroxy-
testosterone were formed from testosterone by the carcinoma and fibroadenoma but
not by the fibroadenosis and associated-normal-breast-tissue incubations. In no incuba¬
tion was oestrogen produced from either dehydroepiandrosterone or testosterone.
These results show that those steroid interconversions which have previously been
demonstrated in human breast carcinoma are also present in benign and normal breast
tissue. All types of breast tissue investigated possessed 5a-reductase, A5-3/3-hydroxy
steroid dehydrogenase, 17/3-hydroxy steroid dehydrogenase and 16a-hydroxylase enzyme
activities. Quantitative differences in steroid metabolism were apparent between different
breast tissues, the two fibroadenomas studied showing greater activity (particularly in
the 5a-reductase enzyme activity converting testosterone into 5a-dihydrotestosterone)
than the carcinomas. The two patients with fibroadenomas were, however, taking oral
steroid contraceptives which are known to influence 5a-reductase activity in the liver
(Schriefers, 1967) and adrenal cortex (Kitay et at., 1970).
The demonstration of 5a-reductase activity in normal tissue is in contrast to the
finding of Jenkins & Ash (1972), who could not show such activity in normal breast
tissue obtained at mastectomy from patients with breast cancer. In the present study the
activity in normal breast quantitatively reflected the corresponding activity of the
associated neoplastic tissue and was low in breasts containing cancers and high in those
with fibroadenoma. The conversion of testosterone into 5a-dihydrotestosterone by
breast tissue and, in particular, the high conversion rate in fibroadenomas is of con¬
siderable interest in view of the high androgenic activity of 5a-dihydrotestosterone in the
prostate (Bruchovski & Wilson, 1968) and its inhibitory action on oestradiol-dependent
rat mammary fibroadenomas (Huggins & Mainzer, 1957).
In summary, it has been shown that human breast carcinoma, human benign breast
tissue and normal human breast tissue all have the potential to convert inactive steroid
precursors into hormones with high biological activity. The further specificity of these
conversions and their effects on the breast and its tumours are still lo be determined.
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Biochem. J. 116, 919-921
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ANDROGEN METABOLISM IN GYNAECOM ASTIC
BREAST TISSUE
W. R. MILLER, D. McDONALD, I. MacFADYEN, M. M. ROBERTS
and A. P. M. FORREST
Department of Clinical Surgery, Royal Infirmary, Edinburgh
(Accepted for publication 26 September 1973)
SUMMARY
The metabolism of [7a-3H]dehydroepiandrosterone and [4-14C]testosterone by
gynaecomastic breast tissue has been investigated and compared with that in
female breast tissue. No conversion of dehydroepiandrosterone to testosterone or
testosterone to 5a-androstandiol was detected in gynaecomastic tissue in contrast to
female breast tissue in which such conversions were demonstrable. This suggests
that 3)9 hydroxysteroid dehydrogenase activity is absent in gynaecomastic tissue. The
relevance of this deficiency is discussed.
INTRODUCTION
Gynaecomastia often represents a symptom of endocrine imbalance. Disorders of the testis
(Hall, 1958; Daly et al., 1963; Treves, 1958), adrenal cortex (Treves, 1958; Staffieri et al.,
1949; Chambers, 1949), liver (Hall, 1958; Rupp et al., 1951; Becker et al., 1967), thyroid
(Ashkar et al., 1970; Becker et al., 1968; Bercovici & Mauvais-Jarvis, 1972), oestrogen meta¬
bolism (Bercovici & Mauvais-Jarvis, 1972; Korenman et al., 1969; Lazarev et al., 1969) and
pituitary gonadotrophin production (Hall, 1958; lull & Dossett, 1964) have been implicated
but in a large number of patients its aetiology remains unexplained. Surprisingly, investiga¬
tion of gynaecomastic tissue itself has been neglected although a tissue factor could be
involved in the condition. The demonstration that human female breast tissue has the
potential to synthesize biologically active androgens (Miller et al., 1973) prompted the present




Breast tissue was obtained at surgery from six patients. Patient 1 was 31 years old with a 13
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year history of bilateral gynaecomastia. Patient 2 was 21 years old with a 4 year history of
right-sided unilateral gynaecomastia. Patient 3 was 24 years old with a 6 month history of
left-sided unilateral gynaecomastia and prior to developing gynaecomastia had been re¬
ceiving phenytoin for 6 months. Patient 4 was 14 years old with a 2 year history of left-sided
gynaecomastia. Patient 5 was 64 years old with a 10 week history of right-sided unilateral
gynaecomastia. Patient 6 was 35 years old with a 6 week history of left-sided unilateral
gynaecomastia. Buccal smear showed the XXY chromosome pattern of the Klinefelter's
syndrome.
Histology
Patient 1. Microscopic examination of the tissue from both breasts showed similar appear- '
ance which consisted of branching and elongation of the mammary ducts with associated
stromal hyperplasia. A few lobular structures with ductules were present but there was no
epitheliosis.
Patient 2. The breast tissue showed considerable increase in dense fibrous connective
tissue. Intraductal hyperplasia and budding of ducts (some of which contained eosinophilic
secretion) was noticeable.
Patient 3. The breast tissue contained dilated ducts embedded in fibrous tissue with evi¬
dence of hyperplasia of the lining epithelium and of periductal fibrosis.
Patient 4. Microscopy of representative sections of tissue showed portions of breast tissue
Fig. 1. Representative microscopic sections of breast tissue from patient 4. H. and E. stained
magnification, x 38. Note in (a) secretion in ducts and evidence of ductal hyperplasia in
addition to stromal hyperplasia.
Androgen metabolism in gynaecomastic breast tissue 125
Fig. 2. Representative microscopic sections of breast tissue from patient 5. H. and E. stained
magnification, x38.
with moderately dilated ducts with which some peripheral fibrosis was associated. There was
slight tendency to epitheliosis in some of the larger ducts (Fig. 1).
Patient 5. The breast tissue contained dilated ducts with some degree of epitheliosis and
was associated with stromal hyperplasia (Fig. 2).
Patient 6. The breast tissue showed marked stromal collogenization with some dilation of
mammary ductal epithelium.
Estimations of plasma and urinary gonadotrophin, testosterone and oestrogens, were
performed for patients 1, 2 and 4 and found to be within normal limits. In patient 6, however,
plasma and urinary gonadotrophins were high, urinary oestrogens low and only urinary and
plasma testosterone levels normal. Values for patients 3 and 5 were not available.
Female patients
Patients A and B were 20 years old with simple fibroadenomas of the breast and had been
receiving oral contraceptives for some months before tissue biopsy. Patient C was 42 years old
with a pericanalicular fibroadenoma and had taken no administered hormones. Patient D was
35 years old with fibroadenosis of the breast with duct ectasia. Patient E was 25 years old
with fibrous dysplasia of the breast. Patients F, G and H were 40, 50 and 50 years of age
respectively suffering from carcinoma of the breast.
The normal tissue from the carcinoma patients was obtained at mastectomy by dissection
from areas of the breast as remote as possible from the primary tumour and the normal
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breast associated with the benign condition by biopsy of tissue adjacent to the lesion. Sections
of the normal tissue so obtained were examined histologically and found to be free from
neoplastic change.
Preparation of tissues and conditions of incubation
All tissues were processed at 0°C until incubation was carried out (within 30 min of tissue
removal). The specimens were finely sliced and incubated for 2 hr at 37°C in Krebs-Ringer
phosphate buffer, pH 7-4 (10 ml/g tissue) containing an NADPH generating system (200
qmol glucose-6-phosphate, 25 mg NADP and 50 units glucose-6-phosphate dehydrogenase)
and the radioactive precursors: 20 pC\ [7a-H3]dehydroepiandrosterone (DHA) and 2 pCi
[4-14C]testosterone.
Purification and characterization of metabolites
Before extraction 500 pg of the appropriate non-radioactive carrier steroids were added in
ethanol. The metabolites were extracted, purified and separated into individual steroids as
described by Fahmy et al. (1968). Each purified metabolite was characterized by comparing
the specific radioactivities of parent steroids and authenticated derivatives. The procedures for
derivative preparation and measurement of cold steroids have been described by Fahmy
el al. (1968) and Jones et al. (1970). Radioactivity was measured by a Nuclear Chicago liquid
scintillation counter. Counting conditions were such that 14C and 3H could be determined
simultaneously with efficiencies in Channels I and II respectively at 16% and 52% and 45%
and 0%.
Table 1. Steroid metabolism by gynaecomastic breast tissue
Metabolism of 3H-DHA
% radioactive label
Patient Patient Patient Patient Patient Patient
1 2 3 4 5 6
DHA 100 99-2 93-8 96-2 95-8 93-7
Testosterone 0 0 0 0 0 0
Metabolism of 14C-testosterone
% radioactive label
Patient Patient Patient Patient Patient Patient
1 2 3 4 5 6
Testosterone 97-10 97-30 96-10 93-40 91-90 95-00
5cv-DHT 2-70 0-68 0-40 0-40 0-47 0-26
5a-A'-diol 0 0 0 0 0 0
4-dione — — 3-60 0-79 1-74 1-20
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RESULTS
The results are presented in Tables 1 and 2. It may be seen that significant amounts of both
the 3H-DHA and 14C-testosterone precursors were metabolized by normal and benign female
breast tissue. Testosterone was a metabolite of DHA and 5a-dihydrotestosterone (DHT) and
5a-androstanediol metabolites of testosterone. In contrast, only very small amounts of the
steroid substrates were metabolized by the gynaecomastic breast tissue. In no incubation was
testosterone produced from DHA and only 5a-DHT and 4-androstenedione but not 5a-
androstanediol were metabolites of testosterone.
o
5-Androstenediol
Fig. 3. 3/J-HSD = 3/i-hydroxysteroid dehydrogenase; 17y?-HSD = 17/f-hydroxysteroid dehy-
drogense; 5a-Rase = 5a-reductase.
DISCUSSION
The inability to detect in gynaecomastic tissue the conversion of DHA to testosterone or
testosterone to 5a-androstanediol is interesting since other steroid interconversions such as the
transformation of testosterone to 5a-DHT and 4-androstenedione were clearly demonstrable.
The pathways of these conversions in other endocrine organs are presented in Fig. 3. It may
be seen that the conversion of DHA to testosterone requires both a 3/i-hydroxysteroid
dehydrogenase (3/>-HSD) and a 17/I-hydroxysteroid dehydrogenase (17/3-HSD) whilst the
conversion of testosterone to 5a-androstanediol requires both a 5a-reductase and a 3/1-HSD.
Since the gynaecomastic tissue was able to transform testosterone to 5a-DHT and 4-andros¬
tenedione, however, such tissue must possess both the 5a-reductase and 17/1-HSD activities.
It would seem, therefore, that gynaecomastic breast tissue lacks 3/I-HSD activity.
This activity was, however, clearly demonstrable in the female breast tissue investigated.
It is unlikely that this difference is sex linked as 3/1-HSD activity has been shown to be present
in both normal male and female tissue such as skin (Baillie el al., 1965; Hodgins, 1971) and
thyroid tissue (W. R. Miller, unpublished results). Indeed 3/1-HSD activity is almost ubi¬
quitous in mammalian tissue (Dorfman & Ungar, 1965).
The absence of 3/i-HSD activity in gynaecomastic tissue could be caused by either a genetic
defect or by complete inhibition/repression of the enzymatic activity which could be demon¬
strated under the appropriate conditions. The first possibility is interesting as certain familial
instances of gynaecomastia do occur (Hall, 1958; Peters et al., 1955) although there was no
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evidence for such in the patients from the present study. It might be expected in such cases
that the defect may also be present in other tissues normally possessing the enzyme activity.
Bercovici & Mauvais-Jarvis (1972) have shown, however, that the 'cutaneous' metabolism of
testosterone to androstanediol is normal in patients with gynaecomastia associated with
hyperthyroidism.
The activity of 3/THSD may be hormonally controlled. In the testes, for example, the ac¬
tivity may be influenced by both steroid and pituitary hormones (Hafiez etal., 1971). Thus
it is possible that the 3/i-HSD activity may be inhibited or repressed in gynaecomastic tissue,
particularly in patients with conditions producing a marked circulating hormone imbalance
such as patients with Klinefelter's syndrome, testicular tumours and those receiving oestrogen
therapy.
A question as yet unanswered is whether this in vitro absence of activity, if reflected in vivo,
would alter the cellular hormonal environment of the breast sufficiently to induce gynae¬
comastic growth. By reducing the production of testosterone, the absence of the activity in
vivo could lead to a local tissue imbalance in the androgen : oestrogen ratio. This would be
in keeping with the observation that many cases of gynaecomastia are associated with states of
hyperoestrogenaemia or hypoandrogenaemia (Bercovici & Mauvais-Jarvis, 1972; Korenman
et at., 1969; Lazarev et at., 1969).
The role of 3/f-HSD in human breast tissue requires further clarification. It is recognized
that female breast tissue is not the ideal control tissue for gynaecomastic breast but com¬
parative studies are handicapped by the difficulty of acquiring suitable non-gynaecomastic
breast tissue. It is hoped to perform further studies should such tissue become available.
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(ESTRADIOL SYNTHESIS BY A HUMAN
BREAST CARCINOMA
W. R. Miller A. P. M. Forrest
University Department of Clinical Surgery, Royal
Infirmary, Edinburgh EH3 9YW
_ Unequivocal evidence is presented for
ummary ^ Synthesjs Qf oestradiol-17/3 from an
androgen precursor by a human breast carcinoma.
Introduction
Evidence that human breast carcinoma can
synthesise oestrogen is unconvincing. The report by
Adams and Wong1 that microsomal preparations of
breast carcinoma could convert testosterone to
oestriol has not been confirmed; contamination with
androgen impurities may explain their findings.2 The
reported transformations of both dehydroepiandro-
sterone and A4-androstenedione to oestrone3 also
have not been confirmed; in any event, they were
extremely small. Using a dual isotope technique, we
have been unable to demonstrate the production of
either cestrone or (Estradiol-17/3 from both dehydro-
epiandrosterone and testosterone in three different
breast carcinomas.4 However, we now report the
synthesis of cestradiol-17/3 in significant amounts by
a tumour incubated with the single precursor,
7a3H-testosterone.
Methods
The patient, a 55-year-old woman, was referred in
July, 1973, with advanced cancer of the breast with'
extensive local disease and pulmonary and skeletal meta¬
stases. She was 5 years post-menopausal and, following
biopsy of the tumour, which was histologically described
by Dr A. H. Wylie as an anaplastic pleomorphic carcin¬
oma of the breast with considerable mitotic activity
(fig. 1), she was treated with tamoxifen (' Novaldex', I.C.I.)
10 mg. twice daily by mouth. She was readmitted to
hospital for assessment 6 weeks after starting the drug
and at that time was adjudged to have shown no response
to the treatment—this on the basis of advancement of
the pulmonary lesions, and the development of neuro¬
logical symptoms and signs suggesting cerebral metastases.
Her disease progressed and she died in October, 1973.
Tumour for incubation was obtained at the time of
biopsy before the patient had started therapy.
2
The tissue was finely sliced and divided into three
portions of 1 g. for incubation in triplicate. The slices
were suspended in 10 ml. Krebs/Ringer phosphate buffer
containing an n.a.d.p.h. generating system and 50 /xCi
7a3H-testosterone. One incubation was used without
further addition as a control system. Either unlabelled
(estradiol-17/3 (1-5 £ig. per ml.) or rat prolactin (50 p,g.
per ml.) was added to the other incubations to determine
the effects of these hormones. All systems were then
Fig. 1—Photomicrographs of representative sections of tumour
studied.
a, x64; b, x 160. Hematoxylin and eosin.
3
incubated by shaking for 2 hours at 37°C in an atmos¬
phere of oxygen. The various conversions were determined
by measuring the percentage incorporation ot tritium
into the metabolites. Details of the methods of steroid
purification, characterisation, and measurement have been
described elsewhere.5
The determination of high affinity-binding activity for
cestradiol-17/3 was also assayed by the method of Feherty
et al.6
Results
The percentage radioactivity found in those meta¬
bolites which were investigated is shown in table I.
The evidence for the production of cestradiol-17/3 is
presented in table II. This is based upon the con¬
sistency of specific radioactivity during the formation
of chemical derivatives. Although there are dif¬
ferences between the three incubations, it can be





Testosterone . . 82-97 81-15 83-97
5a-dihydrotestosterone 1-67 119 1-41
5a-androstanediol 0-85 0-74 0-63
A4-androstenedione 4-71 3-42 4-18
(Estradiol-170 0-37 0-21 0-32
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hydrolysed
OEa methyl 51,600 225 229
ether
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OE2 methyl 29,750 245 121
ether
+prolactin (Estradiol 166,550 875 190]
(50 (xg./ml.) OE2 diacetate 125,250 665 188
OE2 diacetate 73,250 375 195 0-32
hydrolysed




seen that oestradiol-17/3 was a metabolite of testo¬
sterone in each. A4-androstenedione was the major
metabolite identified and, as reported previously,4
5o reduced products, such as 5o-dihvdrotestosterone
and 5«-androstanediol, were formed in significant
amounts.
(Estrogen-receptor activity was not demonstrated.
Discussion
These results are the first demonstration that
human breast cancer can convert a C19 steroid (tes¬
tosterone) into cestradiol-17/?. Taking into account
previous studies, one can now construct the meta¬
bolic pathways for steroid metabolism by human
breast cancer indicated in fig. 2.
The formation of cestradiol-17/3 from a C19
steroid has important implications in understand¬
ing the mechanism of hormone dependence of human
breast cancer. Firstly, it offers, within a unified con¬
cept of cestradiol dependence, an explanation for the
beneficial effect of oophorectomy in the pre¬
menopausal woman and of adrenalectomy and
hypophysectomy in the postmenopausal woman. The
benefit from oophorectomy has long been accepted
as being due to reduction in the levels of circu¬
lating oestrogens, which in the premenopausal
woman vary between 35 and 200 pg. per ml. during
each menstrual cycle.7 However, one cannot explain
the effect of adrenalectomy in the postmenopausal
patient on a similar basis. Not only are circulating
levels of oestrogen low,7 but the human adrenal cortex
secretes small and relatively insignificant amounts of
oestrogen.8
On the other hand, the adrenal cortex secretes large
amounts of C19 steroids, particularly dehydro-
epiandrosterone sulphate, circulating levels of which
in postmenopausal women may exceed 50 fxg. per 100
ml. plasma.9 Conversion of dehydroepiandrosterone
and its sulphate to testosterone by breast-cancer
tissue has been previously demonstrated.3 4 That of
testosterone to cestradiol-17/3 in the tumour under
consideration further indicates that this metabolic
sequence can result in the local formation of active
oestrogen. Reduction of dehydroepiandrosterone-
sulphate secretion following adrenalectomy may
therefore effect a reduction in the concentrations of
oestradiol-17/3 at tumour level.








Fig. 2—Steroid biosynthetic pathways demonstrated in human
breast cancer.
D.H.A. =dehydroepiandrosterone.
of breast cancer which may occur following hypo-
physectomy and pituitary-stalk section, and which can¬
not be explained by deprivation of prolactin. Follow¬
ing pituitary-stalk section, prolactin levels are
elevated, yet remission of tumour growth has been
described.10 On the other hand, both procedures
suppress the secretion of corticotrophin, which is
known to control the production of dehydroepiandro-
sterone sulphate by the adrenal cortex.11
Secondly, the conversion of a C19 steroid to an
active oestrogen at tumour level may also offer an
explanation for the observation that tumours may
be sensitive in vitro to both androgens and
oestrogens, or even to androgens alone.12 The presence
or absence of oestrogen-receptor activity and pos¬
sibly androgen-receptor activity may also contribute
to these differences.
The tumour under study not only converted tes¬
tosterone to oestradiol-17/3 by aromatisation of its A
ring, but also, by 5 a reduction of the same ring,
produced the biologically active androgens—5a-
6
dihydrotestosterone and 5a-androstanediol. In the
rat, 5a-dihydrotestosterone has been shown to inhibit
the growth of mammary tumours,13 whereas oestrogen
stimulates them.14 It is thus possible that the relative
production of 5a-dihydrotestosterone and oestradiol-
17/3 from the same precursor at tumour level may be
of importance in determining the influence of hor¬
mones on tumour growth.
The control of these metabolic pathways is un¬
certain. We have recently shown that 5a-reductase
acdvity in dimethylbenzanthracene-induced rat mam¬
mary tumours is enhanced by the induction of a state
of hyperprolactinasmia.15 Studies are now in progress
to determine whether similar controlling mechanisms
can be identified in human tumours. Although the
three incubations which were performed in this study
included two in which (estradiol or prolactin were
added, any effect of these hormones cannot be dis¬
cussed on the basis of a single tumour. It is notable,
however, that in all three separate incubations the
synthesis of biologically potent oestrogen from testo¬
sterone was demonstrated.
No firm conclusions can be drawn regarding the
hormone dependence of the tumour studied.
Although tamoxifen had no effect on the progressive
growth of the tumour, it was at a very advanced
stage when the patient first was seen and the likeli¬
hood of response was not great. Nor can any firm
conclusions be reached about the significance of
failure to detect oestrogen-receptor activity. The
method used identifies only unoccupied binding sites;
in the presence of significant endogenous oestrogen
production these may well be few. However, it is
tempting to postulate that for this tumour a more
appropriate treatment might have been adrenal¬
ectomy.
We are grateful to the Cancer Research Campaign for
support of this work (grant no. SP 1256); to Prof. W. Duncan,
Dr A. O. Langlands, Dr Maureen Roberts, and Dr Ida
McFayden who were concerned with the clinical care of the
patient at our combined breast clinic; to Dr A. A. Wylie and
Dr A. A. Shivas for reviewing the histology of the tumour and
supplying the photomicrograph shown in fig. 1; and to Prof.
G. Boyd for helpful comments. The rat prolactin used in one
of the incubations was a gift from the National Institutes of
Health (Bethesda, Maryland, U.S.A.).
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The regression of advanced breast
cancer which can follow ovarian ablation is
believed to be due to reduction in the
levels of circulating oestrogen. The bene¬
fit which may follow adrenalectomy in
oophorectomized and in post-menopausal
women cannot be explained on a similar
premise. In post-menopausal women
plasma oestrogens are already low
(England et al., 1974) and the adrenal
cortex secretes only trace amounts of
oestrogen. The main sex hormones secre¬
ted by the adrenal cortex are C19 steroids
(Cameron et al., 1969) which we and
others have shown to be metabolized by
breast tumours (Adams and Wong, 1968;
Jones et al., 1970; Jenkins and Ash
1972; Miller et al., 1973). Recently we
gave unequivocal evidence that the C19
steroid, testosterone could be utilized by
a human breast cancer to synthesize
oestradiol-17/? (Miller and Forrest, 1974).
The aim of this study was to determine
whether this effect was reproducible in
other tumours.
materials and methods
Patients.—Thirteen patients with proved
cancer of the breast were studied. Eight
subjects were at least 5 years postmenopausal,
a further 2 were less than 5 years postmeno¬
pausal and 2 more were experiencing regular
menstrual periods at the time of investigation.
The remaining patient had been oophorecto¬
mized 2 years before the study.
Tumour processing and incubation.—
Following excision, the tumours (11 primary
Accepted 6 October 1975
and 2 secondary recurrences from the chest
wall) were put on ice in the operating theatre.
Sufficient tissue was removed by a pathologist
for histological diagnosis and the remainder
of the tumour was finely sliced and incubated
for 2 h at 37°C in Krebs Ringer phosphate
buffer pH 7-4 (10 ml/g tissue), containing an
NADPH generating system and 45 pCi 7a3If
testosterone. The metabolism of testosterone
was then determined by measuring the per¬
centage of incorporation of 3H into the various
purified metabolites. Details of the metho¬
dology used for steroid purification, charac¬
terization by chemical derivatives and
measurement have been described previously
(Miller, Forrest and Hamilton, 1974). Iden¬
tification of oestradiol-17/j fractions was
based on the following criteria: (a) thefractions
on acetylation and methylation formed com¬
pounds which, on thin layer chromatography,
moved with the same mobility as authentic
oestradiol diacetate and oestradiol-3-methyl
ether respectively; (b) consistent specific
radioactivity was maintained throughout
derivative formation.
results
The percentage radioactivity found in
the various metabolites investigated is
shown in Table I.
All tumours metabolized testosterone
but with considerable variation (17-54%).
The presence of 5a reductase activity was
demonstrated in all tumours and both 5a
dihydrotestosterone and 5a androstanediol
were identified as metabolites. The level
of production of 5a dihydrotestosterone
invariably exceeded that of 5a andros-
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Table I.—Metabolism of 7a3H Testosterone by Human Breast Carcinomata
% Metabolism % Conversion to
5a Dihydrotestosterone 5a Androstanediol A 4 Androstenedione Oestradiol-17/?
EC 17-03 1-67 0-85 4-71 0-37
JC 39-35 1-93 0-69 6-76 0-22
E.Cr 53-79 0-65 0-13 38-49 0-07
A.R. 24-55 2-79 1-18 7-83 0-06
ES 24-48 0-37 0-09 0-39 0-05
CMcD 19-92 0-41 0-09 2-03 0-04
CR 28-94 0-72 0-16 6-90 neg?
GM 26-93 0-58 0-21 3-84 neg?
G.A. 33-36 2-61 1-18 2-91 neg?
MMcN 29-59 0-91 0-38 4-83 neg?
J.M. 27-66 3-04 1-50 0-60 0
MR 27-66 3-04 1-50 0-60 0
JR 27-10 0-44 0-15 0-65 0
neg? = low inconsistent specific radioactivity.
Table II.—Evidence for the Identification of Oestradiol 17/?
Specific activity
Derivative d/min/nmol % Conversion
E.C. Oestradiol free 211
Oestradiol diacetate 225 0-37
Oestradiol methyl ether 229
J.C. Oestradiol free 126
Oestradiol diacetate 118 0-22
Oestradiol methyl ether 121
E.Cr. Oestradiol free 44-7
Oestradiol diacetate 45-5 0-08
Oestradiol methyl ether 41-6
A.R. Oestradiol free 35-3
Oestradiol diacetate 33-8 0-06
Oestradiol methyl ether 34-9
E.S. Oestradiol free 31-7
Oestradiol diacetate 31-8 0-05
Oestradiol methyl ether 29-2
CMcD Oestradiol free 17-8
Oestradiol diacetate 19-1 0-04
Oestradiol methyl ether 18-2
tanediol. All tumours converted testos¬
terone to A4 androstenedione and, in
most, this steroid represented the single
greatest metabolite identified.
Unequivocal evidence (Table II) for
the synthesis of oestradioM 7/7 was found
in 6 tumours, in 2 of which the amounts
were substantial. In 7 tumours oestra¬
diol- 17/? was not identified. Although in
4 of these small amounts of radioactive
label were incorporated in the crude
oestradiol fraction, consistent specific
radioactivity was not obtained in the
derivatives.
comment
These findings confirm that all human
breast cancers can metabolize CI9 steroids.
Furthermore, all tumours studied had
5a reductase activity and were able to
convert testosterone into its 2 active 5a
reduction products, 5a dihydrotestos¬
terone and 5a androstanediol.
In contradistinction, not all tumours
could synthesize oestradiol-17/? and we
conclude that the possession of the aro¬
matizing system is specific to certain types
of tumour. To date, we have not un¬
covered any particular difference between
those tumours which have oestradiol
synthesizing capacity and those which do
not.
Since biologically approximately half
of all human breast cancers do show some
degree of hormone dependence and one-
third markedly so, it is tempting to believe
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that the possession of aromatizing enzymes
may be of importance in this regard. In
this event, the tumours which were capa¬
ble of transforming CI9 steroid into oes¬
trogen could be those which are dependent
on the adrenal cortical source of C19
steroids.
We have already suggested that the
beneficial effects of adrenalectomy and
hypophysectomy could be due to reduc¬
tion of circulating C19 precursor steroids
such as DHA sulphate (Miller and For¬
rest, 1974). The results we now report
are further evidence of such a possibility.
Studies are now in progress to deter¬
mine the relationship of possession of this
synthetic pathway to oestrogen receptor
activity and to the clinical response to
adrenalectomy and hypophysectomy.
The authors wish to thank the Cancer
Research Campaign for Grant No. SP
1256 supporting this work.
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Factors affecting testosterone metabolism by
human breast tissues
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The in vitro metabolism of 7a3H-testosterone by 36 human breast
carcinomas and 4 specimens of 'normal' breast has been studied. All
metabolized testosterone to 5a-dihydrotestosterone, 5a-androstanediol and
A4-androstenedione. Evidence for synthesis of oestradiol-17P was obtained
in 17 of the 36 carcinomas but in no specimen of 'normal' breast. 5a-
reduction of testosterone was significantly higher in tumours from pre¬
menopausal patients and those with a high proportion of parenchyma.
Oestradiol production was also highest in tumours with the least 'stromal
reaction'.
Introduction
There is now abundant evidence that human breast cancer possesses paraendocrine
properties in its potential to synthesize steroid hormones. The C19 steroid, dehydro-
epiandrosterone sulphate, which circulates in large amounts even in postmenopausal
women (Wang et al., 1976), has been shown to be metabolized to testosterone (Jones,
Cameron, Griffiths, Gleave & Forrest, 1970; Miller, McDonald, Forrest & Shivas,
1973). Furthermore, testosterone itself may be transformed into the active androgen
5a-dihydrotestosterone (Jones et al., 1970; Miller et al., 1973; Adams & Li, 1975;
Jenkins & Ash, 1972) and, although initial reports of conversion to oestrogen (Adams
& Wong, 1968) may be explained on the basis of androgen impurities (Dao, 1969), we
have presented unequivocal evidence for the metabolism of testosterone to oestradiol
(Miller & Forrest, 1974) and others have reported the synthesis of small amounts of
oestrone from A4-androstenedione (Jones et al., 1970). Tumour oestradiol production
has since been confirmed by others (de Thibault de Boesinghe, Lacroix, Eechante &
Leusen, 1974; Abul-Hajj, 1975) but it appears that only a proportion of breast cancers
possess the potential (Abul-Hajj, 1975; Miller & Forrest, 1976). We now consider
some factors which might influence the aromatization of testosterone and also its
5a-reduction to active androgens.
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Methods
Patients
Tumour was obtained from 36 women, 24 with primary and 12 with metastatic or
recurrent breast cancer. In 4 patients, 'normal' tissue was also taken from an area of
the breast as remote as possible from the primary tumour. Seven patients were pre¬
menopausal (experiencing regular menstrual periods), 26 were postmenopausal (at
least 5 years since their last regular menstrual period) and 3 menopausal (o to 5 years
from their last regular menstrual period).
Tissues
Following excision tissues were immediately put on ice, finely sliced and incubated for
2 h at 37°C in Krebs Ringer phosphate buffer pH 7-4 (15 ml per g tissue), containing
an NADPH-generating system and 7aH3-testosterone (45 pCi per g tissue). The
reaction was stopped by adding methanol to 80% v/v and the incubations were stored
at — io°C.
Figure i. Examples of grading of tumour differentiation, (a) A well differentiated
adenocarcinoma. Dispersed neoplastic elements consist of well formed tubules or
acini. HE. X 125. (b) A moderately differentiated carcinoma showing some
glandular elements of variable atypism, associated with more anaplastic growth.
HE. X 125. (c) An undifferentiated (or anaplastic) carcinoma in which irregular
clumps and trabeculae of tumour cells are devoid of architecture. HE. X 125.
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Figure 2. Example of grading of tumour 'stromal reaction', (a) Low 'stromal reac¬
tion'—a carcinoma of high cellularity, having only a small component of connective
tissue. HE. X 50. (b) Moderate 'stromal reaction'—a carcinoma of moderate
cellularity, in which a substantial component of connective tissue is associated
with proportionately fewer tumour cells. HE. X 50. (c) Marked 'stromal reaction'
—a carcinoma of low cellularity and correspondingly large element of connective
tissue—a typical 'scirrhous' carcinoma of breast. HE. X 5°.
Before extraction of the metabolites, 500 pg of non-radioactive carriers of those
steroids to be characterized were added to monitor losses. The metabolites were then
extracted, separated into individual steroids and purified by thin-layer chromato¬
graphy by the methods previously described (Miller, Forrest & Hamilton, 1974). The
percentage incorporation of 3H into the various purified metabolites was measured
and the metabolites characterized by chemical derivative formation. The criteria for
identification of oestradiol-iyP have been previously described (Miller & Forrest,
1976). 5a-reduction was estimated by combining the percentage production of
5a-dihydrotestosterone (501-DHT) and 5<x-androstanediol for each tumour
Histology
Sufficient material was available for a valid assessment of the histopathology of the
tumour in 31 cases. The pathologist (A.A.S.), who did not previously know the
steroidogenic potential of the tumours, graded them according to their differentiation
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Table i. Metabolism of 7a3H-testosterone by normal human breast
% conversion to
Patient % metabolism 5Q-DHT 5a-androstanediol A4-androstenedione Oestradiol-i7p
2 3S'3° (39-35) 0-06 (1-93) 0-05 (0-69) 2-30 (6-76) 0 (0-22)
4 24-50 (21 ■50) O-ii (0-57) o*11 (0-25) 0-20 (1-46) 0 (0-17)
14 I7-44 (24-48) o-i2 (0-37) 0-12 (0-09) 0-87 (0-39) 0 (0-05)
IS 25-50 (18 92) 4-70 (0-41) 0-78 (0-09) 2-26 (2-O3) 0 (0-04)
(Figu:res in parenthesis represent % conversions in malignant tissue associated with same patient.)
Table 2. Metabolism of 7a3H-testosterone by human breast carcinomata
% conversion to
Patient % metabolism 5a-DHT 5a-androstanediol A4-androstenedione Oestradiol
1 17-03 1-67 0-85 4-71 °'37
2 39'35 i-93 0-69 6-76 0*22
3 10-70 i-59 1-40 1-63 0*2I
4 20-50 o-57 0-25 1-46 0-i7
S 18-65 0-87 o-io 5-19 0*I2
6 16-20 0-79 0-30 0-30 o-io
7 18-35 3-85 1-31 3-54 0-08
8 18-26 0-49 0-46 2-3° 0-08
9 53-79 0-65 0-13 38-49 0-07
10 24-55 2*79 1-18 7-83 0-06
11 24-92 2-73 0-71 i-43 0-06
12 15-91 0-98 0-51 2-87 0-06
13 18-29 1-70 0-49 °'54 0-06
14 24-48 o-37 0-08 0-39 0-05
15 18-92 0-41 0-09 2-03 0-04
16 23-24 1-70 o-66 I-20 0-04
17 20-79 o-55 o-43 0-49 0-03
18 24-32 3'77 1-67 0-58 0
19 21-80 1-29 0-97 0-58 0
20 26-83 0-58 0-21 3-48 0
21 26-62 1-05 °'94 6-38 0
22 28-94 0-72 0-16 6-90 0
23 33-36 2*61 1-18 2-19 0
24 29-59 0-91 0-38 4-83 0
25 27-66 3-°4 1-50 0-60 0
26 27-10 0-44 0-15 0-65 0
27 11*12 °'94 0-74 5-14 0
28 17-42 1-28 0-37 0-93 0
29 40-41 3-66 0-85 i-73 0
30 10-05 1 -08 °'35 0-37 0
31 I 1-04 2"55 1-03 1-47 0
32 39-02 o-6o 0-18 0-79 0
33 23-34 1-07 0-32 9-42 0
34 20-05 1-42 0-36 0-49 0
35 18-20 1 *13 0-56 0-38 0
36 16-86 1-76 i-35 3-3i 0
(by an assessment of the extent of glandular formation) and 'stromal reaction' (ratio
of tumour connective tissue to parenchyma). Typical examples of grading are shown
in Figures i and 2.
Paraffin sections confirmed that 'normal' tissue was free of malignant or recognizable
premalignant change.


































Figure 3. Comparison of %5a-reduction in tumours from premenopausal and
postmenopausal patients. Significant difference between the groups by Wilcoxon
Rank test (Pc'o-os).
Results
All 4 incubations of normal breast metabolized testosterone to 501-DHT, 501-androst-
anediol and A4-androstenedione. In none was oestradiol-i7|3 identified. In Table 1
the associated results of incubations of the 4 carcinomas from the same breasts are also
given. It is notable that all tumours synthesized oestradiol-i7p.
A.11 36 tumours converted testosterone to 5C1-DHT, 501-androstanediol and
A4-androstenedione (Table 2). In most, the major metabolite identified was
A4-androstenedione and in all the transformation to 5a-DHT exceeded that to
5a-androstanediol. Oestradiol synthesis was identified in 17 tumours and reached or
exceeded o-i% conversion in 6.
Menopausal status
As is shown in Figure 3 the 5a-reduction of testosterone was significantly higher in
premenopausal patients as compared with those from postmenopausal subjects. In
contrast, conversion to A4-androstenedione and oestradiol-17 P was not influenced by
menopausal status. Furthermore, potential for tumour oestrogen synthesis did not
differ between menopausal groups (Table 3).
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Table 3. The effect of menopausal status upon oestradiol synthesis by human breast carcinomas
No. of tumours
No. with oestradiol
synthesis Range of conversion
Premenopausal 7 3 0-0-22%
Menopausal 3 2 0-0 • 06%































Low + moderate High
Figure 4. Comparison of %5a-reduction between tumours of low and moderate
'stromal reaction' and those with high 'stromal reaction'. Significant difference
between the groups by Wilcoxon Rank test (P<o-o2).
Histopathology
The majority of the 31 tumours available for histological examination were poorly
differentiated, only a single tumour being characterized as well-differentiated and 5
carcinomas as moderately differentiated. No relationship was detected between degree
of tumour differentiation and any aspect of the metabolism of testosterone.
Assessment of the ratio of stroma to tumour parenchyma showed 7 tumours with
low, 17 with moderate and 7 with marked 'stromal reaction'. There was no relation¬
ship between the amount of 'stromal reaction' and the level of testosterone metabolized



















Figure 5. Comparison of % conversion to oestradiol-17P between tumours of low
and moderate 'stromal reaction' and those with high 'stromal reaction'. Significant
difference between the groups by Wilcoxon Rank test (P=o-o5).
or its conversion to Azf-androstenedione. However, the 5a-reduction of testosterone
in tumours with low and moderate amounts of stroma i.e. those with the greatest
proportion of parenchyma, was significantly higher than that in tumours with marked
stromal reaction (Figure 4). Similarly, the level of oestradiol synthesis was signifi¬
cantly higher in tumours with lowest stroma and greatest parenchyma (Figure 5).
However, there was no correlation between degree of 'stromal reaction' and the
absolute potential for oestradiol synthesis.
Discussion
These results confirm our previous reports that all human breast cancers and 'normal'
breast can convert testosterone to 501-DHT and 5a-androstanediol (Miller et al., 1973;
Miller & Forrest, 1974). Tumour 501-reduction tends to be higher in premenopausal
women. Whether this is an inherent difference in tumours from premeno¬
pausal women or results from the higher level of circulating hormones in
premenopausal subjects is not known. Although 5a-reductase is influenced by the
endocrine environment in rat mammary carcinomas, oophorectomy increases the
activity and administration of oestrogen decreases 501-reduction (Miller, 1976).
Furthermore, the difference cannot be explained solely on the basis of premenopausal
tumours being the most cellular. Comparison of Figures 3 and 4 show that amongst
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postmenopausal tumours with low 5a-reduction are tumours with relatively high cellu-
larity. Contrary to the findings of Jenkins & Ash, who studied a very small number
of tumours, there was no relationship between the degree of differentiation of each
tumour and its 5(x-reductase. However, in the present study, the number of differen¬
tiated tumours is still small. The production of 5(x-reduced metabolites was, however,
low in tumours with marked 'stromal reaction'. This suggests that, although
fibroblasts possess 5a-reductase activity (Mulay, Finkelberg, Pensky & Solomon,
1972), connective tissue elements of human breast carcinoma show comparatively low
5U-reduction and the activity is primarily associated with other tumour cells.
Conversion of testosterone to oestradiol was identified in only half the tumours
studied. Aromatization was not observed in 'normal' breast, even when tumour within
it had this enzymic activity. This might indicate a change with the development of
neoplasia or it could equally be a measure of the low cellular content of 'normal'
breast tissue. Like others (de Thibault de Boesinghe et al., 1974), we failed to find any
correlation between the menstrual status of the patient or the histopathology of the
tumour and its capacity to synthesize oestrogen. Nevertheless, the amounts of
oestradiol produced were generally less in tumours with marked 'stromal reaction'.
The quantitatively higher synthesis of oestrogen in tumours with a high proportion
of parenchyma and the inability to detect synthesis in normal breast suggest that
aromatizing activity, when present, is primarily associated with tumour parenchyma.
In many tumours, a high percentage of the testosterone metabolized remained
unaccounted for. It was our experience, however, that most of the uncharacterized
radioactivity was associated with highly polar compounds. This would be in agree¬
ment with the results of others who have found polyhydroxylated metabolites in
incubations of breast tumours (Dao, Varda & Morreal, 1972).
The findings in this study suggest that whilst the interconversion of C19 steroids
is commonly associated with the breast and its tumours, the possession of aromatizing
ability is a more selective property. It still remains to determine what factors influence
whether an individual tumour synthesizes oestrogen or not and whether the capacity
for aromatization is associated with the hormone dependency of the tumour.
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Inhibition of Aromatization by Aminoglutethimide
in Breast Cancers —Clinical Relevance
W. R. MILLER
Department of Clinical Surgery, Medical School, University of Edinburgh, Edinburgh, UK
Aminoglutethimide (Orimeten®) therapy in post¬
menopausal patients with advanced breast cancer
gives results comparable with those of surgical
adrenalectomy; remissions occur in about 30% of
women (Wells et al., 1982). This "medical
adrenalectomy", so called because the drug
markedly reduces adrenal production of steroid
hormones (Wells et al., 1978), is achieved in part
by blocking conversion of cholesterol to preg¬
nenolone, the initial step in the biosynthetic
pathway for steroid hormones. In addition,
however, work originally performed with prep¬
arations from placenta (Thompson and Siiteri,
1974) has shown that aminoglutethimide specifi¬
cally inhibits the aromatization reaction which
converts androgens into oestrogens. This is
relevant to the treatment of breast cancer because
tumours responding to aminoglutethimide usually
contain cytoplasmic receptors for oestrogen
(Santen and Wells, 1980).
However, the adrenal cortex produces little
oestrogen (Baird et al., 1969), and in post¬
menopausal women most oestrogen is formed
by extra-adrenal aromatization of androgen
precursors (Grodin et al., 1973) which are
primarily derived from the adrenal. Sites of
peripheral aromatization include adipose tissue,
muscle and skin (Longcope et al., 1978). In the
patient with breast cancer, there is potentially
another important site—the tumour itself (Miller
and Forrest, 1974, 1976).
In vitro studies of steroid metabolism by human
breast cancer have therefore been performed
(Adams and Wong, 1968; Abul-Hajj, 1975; Miller
et al., 1981). Our main findings are summarized
in Fig. 1. All tumours interconvert androgen
precursors "on site". Inactive substrates such as
dehydroepiandrosterone sulphate, present in
breast fluids in large amounts (Miller et al., 1980),
may be metabolized into biologically-active
products. About one-half of breast cancers have
the potential to aromatize androgens into
oestrogen. In most tumours the conversion is
relatively small, but the activity is higher than that
in adipose tissue incubated under the same
o
Figure 1. In vitro steroid metabolism by human
breast cancers. The numbers represent tumours
showing the particular metabolic conversion over
the total tumours studied.
Aminoglutethimide — An alternative endocrine therapy for breast carcinoma, edited by R. W. Elsdon-Dew,
/. M. Jackson and G. F. B. Birdwood, 1982: Royal Society of Medicine International Congress and Symposium
Series No. 53, published jointly by Academic Press Inc. ILondonI Ltd., and the Royal Society of Medicine.
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To investigate the relationship between tumour
aromatization and hormone sensitivity we have
measured cytoplasmic oestrogen receptors and
conversion of (7a3H) testosterone to oestradiol in
110 human breast cancers. Evidence for oestradiol
synthesis (conversion > 0-02% of the precursor)
was obtained in 66 and for oestrogen receptor
activity (> 5 fmol/mg cytosol protein) in 81
tumours. The relationship between presence of
receptor and potential for aromatization is shown
in Table 1. Whereas most receptor-positive
tumours synthesized oestradiol, most receptor-
negative tumours did not. This trend for aroma¬
tization to be associated with receptor-positive
tumours was statistically significant. Additionally,
levels of oestrogen receptor were significantly
higher in tumours with oestrogen biosynthesis
compared with those lacking aromatization.
Table 1
Relationship between potential for tumour






X2 = 7-99 P< 0-005
conditions (Abul-Hajj et al., 1979; Perel et al.,
1980).
It is thus essential to elucidate the biological
significance of tumour aromatization and
determine whether it is related to the response to
endocrine treatments, such as aminoglutethimide,
which might be expected to be active against
aromatase activity. For this purpose, three studies
have been performed:
(1) To confirm that aminoglutethimide will
inhibit aromatase activity in vitro.
(2) To determine the relationship between
tumour potential for aromatization and
oestrogen receptors, which are of
established value in predicting hormone
sensitivity (McGuire et al., 1975).
(3) To correlate these results with the clinical
response of patients with advanced breast
cancer treated with aminoglutethimide.
Investigations and Findings
To determine whether tumour aromatization was
affected by aminoglutethimide, triplicate portions
of 12 human breast cancers were incubated with
(7a3H) testosterone for 2 h at 37°C in the presence
or absence of 0 01 and 0-1 mmolar concentrations
of aminoglutethimide. Seven tumours synthesized
oestradiol, and aminoglutethimide inhibited
production in all of them (Fig. 2). In no incubation
was oestradiol synthesis completely abolished but
inhibitions of between 60 and 85% of control
values were observed at 0-1 mmol concentration.
Figure 2. Inhibition of aromatase in human breast
cancer by aminoglutethimide at two concen¬
trations, as shown by reduction in oestradiol
synthesis.
Because of this finding, it is tempting to
speculate that tumours which not only have
receptors for oestradiol, but also possess the
potential to synthesize oestradiol, might have a
greater need for hormones than tumours without
synthesis and/or receptors. If so, treatments such
as aminoglutethimide which inhibit aromatization
might be more effective in patients whose tumours
possess aromatase activity.
We have therefore measured tumour oestrogen
biosynthesis and receptors in patients with
advanced breast cancer subsequently treated with
aminoglutethimide. The results have been
correlated with the clinical response of the patient
(Table 2). The number of women studied is still
small, but tumours with highest in vitro conversion
to oestradiol and which also possessed oestrogen
receptors were those which responded to amino¬
glutethimide while tumours without aromatizing
potential or oestrogen receptors failed to respond.
It is therefore possible that screening for
aromatase activity in receptor-positive tumours
might permit selection of patients most likely to
respond to aminoglutethimide.
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Table 2
Relationship between tumour oestrogen bio¬
synthesis {percentage conversion of (7<x3H)
testosterone to oestradioi), oestrogen receptor
and clinical response to aminoglutethimide
Oestrogen Oestrogen Clinical
Patient biosynthesis receptor response
A 0-18% + Yes
B 0-09 <% + Yes
C 0-08% + Static
D" 0-03% + Mixed
E\ Not + No
F detect¬ + No
G" able - No
H (<0-02%) - No
"In combination with tamoxifen
Conclusion
It seems likely that the benefits of aminoglute¬
thimide treatment in postmenopausal women with
advanced breast cancer are achieved not only by
blocking adrenal production of hormones at the
level of cholesterol side-chain cleavage but also by
a more selective action against peripheral aroma¬
tization of androgens to oestrogen by adipose and
tumour tissue. Evidence from the interrelationship
with oestrogen receptors and, in a limited number
of patients, response to aminoglutethimide suggest
that tumour biosynthesis may have clinical signifi¬
cance. It seems logical to treat tumours which
have both oestrogen receptors and the potential to
synthesize oestrogen for the receptor, with
regimes which inhibit the aromatase process.
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Discussion
Asked by Dr R. Paridaens (Brussels) whether the
data had been analysed as a function of meno¬
pausal status, Dr Miller said that all the patients
studied for aminoglutethimide effects were
postmenopausal. In the work on oestrogen
receptors and biosynthesis, a few premenopausal
patients had been included but most were post¬
menopausal in this group too.
8
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Steroid Metabolism and Oestrogen
Receptors in Human
Breast Carcinomas
W. R. MILLER, R. A. HAWKINS and A. P. M. FORREST
Department of Clinical Surgery, University of Edinburgh, Edinburgh, United Kingdom
Abstract—Metabolism of la [3H] testosterone and oestrogen receptor activity have been
measured in 54 human breast cancers. All tumors converted testosterone to A4
androstenedione, 5a dihydrotestosterone and 5a androstanediol, but unequivocal evi¬
dence for production of oestradiol was obtained only 29 of the tumours. Thirty-seven
tumours were classified as oestrogen receptor 'positive' containing levels in excess of
5 fmol/mg cytosol protein. Although mean conversions to A4 androstenedione,
5a dihydrotestosterone and 5a androstanediol were all higher in oestrogen receptor
negative tumours as compared with receptor positive group, the differences did not
reach statistical significance. There was, however, a significant trend for oestradiol
synthesis to be associated with oestrogen receptor positive tumours (P < 0.025). All
tumours with very high level of receptors converted testosterone to oestradiol.
INTRODUCTION
Human breast cancer transforms C]8 steroid
precursors into active androgens and oes-
trogens. Thus dehydroepiandrosterone and its
sulphate are metabolised in vitro to
testosterone [1-3], oestrone [1,3] and oestradiol-
17/3 [4] A4 androstenedione is converted to tes¬
tosterone, oestrone and oestradiol-17/3 [5]; and
testosterone metabolised to 5a dihydrotestos¬
terone, 5a androstanediol [2,6] and oestradiol-
17/3 [7-9],
Synthesis of oestradiol from androgen pre¬
cursors of adrenal origin by breast cancers may
be of importance in response of tumours to
endocrine treatments, particularly in post¬
menopausal patients. In these women in whom
circulating oestrogen levels are low, tumour
4 metabolism may provide a supply of oestrogen
required for tumour growth. Currently the
oestrogen receptor activity of a tumour is the
best index of its likely hormone sensitivity (for
recent review [10]), and the present study of 54
tumours was undertaken to determine whether




Fifty-four histologically proven cancers of
the breast from 8 premenopausal, 2 early
menopausal (less than 5 years since the last
Accepted April 1981.
EJC Vol. 17, No. 8—E
menstrual period) and 44 postmenopausal
women were studied. Thirty-nine tumours
were primary carcinomas and 15 local recur¬
rence.
Following excision, tumours were immediately
placed on ice. Sufficient tissue was removed for
histopathological diagnosis and the remainder
used to determine steroid synthesis and oes¬
trogen receptor activity.
Steroid metabolism
A portion of each tumour (0.5 g) was finely
sliced and incubated for 2 hr at 37°C in Kreb's
Ringer phosphate buffer pH 7.4 containing an
NADPH generating system and 22.5 /xCi
[7a3H] testosterone (8.9 Ci/mmole). The reac¬
tion was stopped by addition of methanol
(40 ml) and the incubate stored at — 10°C until
further processing. Before extraction of the
metabolites, 500 tig of non-radioactive carrier
of the steroids to be characterised were added
to monitor losses. The metabolites were then
extracted, separated into individual steroids,
purified by thin layer chromatography and
characterised by the methods previously
described [8, 11]. Characterisation of individual
metabolites was by chemical derivative for¬
mation and based on (a) similar chromato¬
graphic mobilities of parent and derivatized
steroids with authentic standards (b) consistent
specific radioactivity throughout these proce¬
dures. Metabolism was determined by measur¬
ing the percentage of radioactivity in the
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various characterised metabolites after cor¬
rection for procedural losses. Conversions in
excess of 0.02% are detectable by these
methods. Control incubations performed in the
absence of tumour showed negligible metabol¬
ism apart from the production of small
amounts of A4 androstenedione (<0.1%).
Oestrogen receptors
The concentration of oestrogen receptor was
determined by saturation analysis [12]. Tumour
cytosol was incubated overnight at 4°C with
10 pg[2,4,6,73H] oestradiol-17/3 and varying
amounts of non-radioactive oestradiol-17/3
(0,10,30,70,90 and 20,000 pg). Separation of free
and bound steroids was by addition of dex-
trancoated charcoal, the protein bound fraction
being determined by liquid scintillation count¬
ing. After correction for non-specific binding,
the data was analysed according to
Scatchard [13] to derive concentrations of
receptor sites. Activities in excess of 5 fmol/mg
cytosol protein were regarded as receptor posi¬
tive in accordance with recommendations of the
British Breast Group Study Group [14].
RESULTS
All tumours metabolised 7a[3H] testosterone
to A4 androstenedione, 5a dihydrotestosterone
and 5a androstanediol. Evidence for aroma-
tization to oestradiol-17/3 was obtained in 29
tumours (54%); the remaining tumours showed
no evidence for oestradiol synthesis. Con¬
version to oestrone was investigated in several
tumours but its production when detected was
always less than oestradiol and only present in
tumours which synthesized oestradiol.
Metabolism of testosterone to A4 andros¬
tenedione, and 5a dihyrotestosterone (but not
5a androstanediol) in tumours from pre¬
menopausal women was significantly higher
than in those from postmenopausal patients
(Table 1). The proportion of tumours showing
oestrogen synthesis and level of that synthesis
were similar in both menopausal groups.
Thirty-seven (68.5%) tumours were oes¬
trogen receptor positive, the remainder being
negative. The proportion of oestrogen receptor
positive tumours was similar in pre and post¬
menopausal patients but the concentration of
receptor in positive tumours was lower in the 5
premenopausal (Mean 33.4fmol/mg cytosol
protein) than in the 31 postmenopausal
patients (Mean 144.6 fmol/mg cytosol protein).
Although the mean conversions of testos¬
terone to A4 androstenedione, 5a dihydrotes¬
tosterone and 5a androstanediol were higher
in oestrogen receptor negative tumours as
compared with receptor positive group, the
differences did not reach significance (Table 2).
However, there was a significant relationship
between the capacity to synthesise oestradiol
from testosterone and oestrogen receptor
activity (Table 3). Thus the majority of oes-
Table 1. Metabolism, of 7a[3H] testosterone in tumours from pre- and postmenopausal patients
Metabolite
% Conversion (Mean±S.D.)
Premenopausal (8) Postmenopausal (44) Significance*
A4 androstenedione 4.83 ±3.46 4.10 ± 8.84 PC0.01
5a dihydrotestosterone 3.62 ±2.11 1.46 ±1.24 PC0.01
5a androstanediol 1.94 ±2.51 0.82 ±0.81 NS
oestradiol-17/3 0.11 ±0.08(4) 0.09 ±0.07(23) NS
*By Wilcoxon Rank Test.
NS = Not significant.




Oestrogen receptor + ve (37) Oestrogen receptor - ve (17) Significance
A4 andros¬ 2.43 ±3.05 7.78 ±12.85 NS
tenedione
5 a dihydro¬ 1.54 ± 1.40 2.96 ±3.29 NS
testosterone
5a andros¬ 0.74 ±0.75 1.67 ±1.86 NS
tanediol
NS = Not significant by Wilcoxon Rank Test.
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Table 3. Correlation between potential for oestradiol syn¬
thesis and presence of oestrogen receptor
Oestrogen synthesis Without synthesis
OE2R + ve 24
OE2R — ve 5 12
X2 = 5.89 P < 0.025
trogen receptor-positive tumours synthesised
oestradiol from testosterone, whereas most
oestrogen receptor-negative tumours did not.
All tumours with receptors in excess of
120fmol/mg cytosol protein synthesised oes¬
tradiol (Fig. 1).
Mean level of oestrogen receptor in tumours
which synthesised oestradiol was also
significantly higher than that in those without
synthesis.
In those tumours with aromatizing activity
the actual amounts of oestradiol synthesised
did not relate to receptor status and in those
tumours which possessed both activities, levels
of oestradiol synthesis were not related to the
concentration of oestrogen receptors in the
tumour (Fig. 2).
DISCUSSION
The results confirms our other previous
findings[8, 15] that all human breast cancers
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synthesis
Fig. 1. Level of oestrogen receptors in tumours with and without
oestradiol synthesis. The difference between groups is significant by

























oestrogen synthesis (7#conversion )
Fig. 2. Relationship between level of oestrogen receptors and %
conversion to oestradiol in tumours with both activities O pre¬
menopausal; 9 menopausal; # postmenopausal.
terone, 5a androstanediol and A4 androstene-
dione but only a portion of tumours can syn-
thesise oestradiol-17/3. The incidence of oes¬
trogen receptor positive tumours (68.5%) is also
consistent with previous reports (review [10]).
No significant relationship was detected be¬
tween tumour conversion of testosterone to Ci9
steroid metabolites and oestrogen receptor
activity, but there was a significant correlation
between receptors and the capacity to syn-
thesise oestradiol from testosterone. Tumours
with oestrogen receptor activity, particularly
when the level was high, were more likely to
possesss aromatizing enzymes. This finding
differs from two recent reports; but the num¬
ber of tumours reported in them was
small [5,16]. In a single report an inverse cor¬
relation between oestrogen receptors and syn¬
thesis has been described [4], but only 18
tumours were studied and the incidence of
receptor positive tumours and the concen¬
tration of receptor sites were lower than
that generally found [10]. In particular there
was an absence of tumours with high receptor
concentration. This may be relevant as in the
present study these were most likely to syn-
thesise oestradiol.
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The finding of a positive correlation between
oestradiol synthesis by a tumour and its recep¬
tor status suggests that the ability of a tumour
to synthesise oestrogen may be related to its
hormone responsiveness.
The recent observation that the MCF7 cell
line of human breast cancer could synthesise
sufficient oestrogen from extracellular C]9
steroid to maintain oestrogen-dependent
events [17] would support our previous hypo¬
thesis that in postmenopausal women with ad¬
vanced breast cancer the benefit of adrenalec¬
tomy and hypophysectomy may result from a
reduction in the level of Ci9 steroid precursors
reaching the tumour [7].
It must be emphasized that the relationship
between tumour oestradiol synthesis and oes¬
trogen receptors is not absolute; oestrogen
receptor positive tumours may or may not syn¬
thesise oestrogen. Equally, however, not all
oestrogen receptor positive tumours respond to
endocrine ablation[18,19]. It is possible that if a
tumour not only has receptor sites for oes¬
trogen but also possesses the capacity to syn¬
thesize oestradiol, it may be particularly sen¬
sitive to oestrogen or at least have a greater
need for oestrogen than tumours without
biosynthetic potential. (Paradoxically, however,
a tumour with both receptors and aromatase
activities might appear less dependent upon
circulating oestrogens, being in fact more
dependent upon circulating androgens). If this
is so, then screening for aromatase activity in
receptor-positive tumours might permit selec¬
tion of patients who are likely to respond to
endocrine therapy, particularly to regimes such
as adrenalectony, which removes the source of
circulating androgens, or administration of
aminoglutethimide and other compounds,
which inhibit aromatisation [20,21]. Clinical
studies are being conducted to determine these
relationships.
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Tumour steroid hormone synthesis and estrogen receptor status in breast cancer patients
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Summary
The capacity of breast cancer to synthesise active androgens and estrogens has been related to estrogen receptor
(ER) status in 79 postmenopausal patients with breast cancer. Although there was no quantitative relationship
between levels of ER and steroid metabolism in ER positive tumours, there was (a) a positive correlation
between estrogen synthesis and ER positivity and (b) increased androgen synthesis and ER negativity. This
may imply an inherent difference in the handling of hormones in ER positive and negative tumours.
Introduction
The role of ER status in predicting the hormonal
sensitivity of breast cancer is well established (1).
So also is the ability of breast cancer tissue to me¬
tabolise and aromatise CI9 steroids to form es¬
trogens (2, 3). In our study of 54 breast cancers, all
tumours have shown the enzymatic activity to con¬
vert testosterone to its 5a reduced products but only
in 29 has aromatisation been demonstrated by the
synthesis of estradiol 17/? (4).
The interrelationship of these two activities has
also been investigated by ourselves and others but
with conflicting results (4—9). In this study we have
attempted to clarify the relationship by extending
our original number of tumours.
Methods
The breast cancers studied were obtained from 79
postmenopausal women with primary cancer of the
breast. The removed tumour and/or the breast con¬
taining it was placed on ice in the operating theatre
and immediately transferred to the laboratory. Fol¬
lowing removal of sufficient tumour for histological
examination, a portion was dissected free of ex¬
traneous fat and other tissue and divided for assays
of ER activity and steroid metabolism.
ER activity was determined by saturation analysis
(10). A portion of tumour (300 mg) was homo¬
genised in 1 mM Tris monothioglycerol buffer
(1:5 w/v) and centrifuged at 3200 rpm for 20
mins. Aliquots of the resultant cytosol were in¬
cubated overnight at 4°C with 10 pg of 24673H
estradiol and varying amounts of competing non¬
radioactive estradiol (0, 10, 30, 70, 90 and 20,000 pg).
Bound steroid was separated from free by the ad¬
dition of dextran-coated charcoal and the bound frac¬
tion measured after centrifugation by liquid scintil¬
lation counting. The concentration of receptors was
determined from a 6-point Scatchard analysis (11).
Cytosol protein was determined by the method of
Bradford (12) and receptor levels in excess of 5
fmol/mg tumour cytosol protein were regarded as
indicating an estrogen receptor positive tumour.
Steroid metabolism: tumour (500 mg) was finely
sliced and incubated for 2 hours at 37° C in Krebs
Ringer phosphate buffer pH 7.4 containing an
NA-DPH generating system and 22.5 pC\ 7a3H
testosterone (8.9 Ci/mmole). The reaction was
terminated by the addition of methanol and the in¬
cubate stored at — 10°C until further processing.
Before extraction of the metabolites, 500 pg of non¬
radioactive carrier steroid were added for each meta¬
bolite to be purified so that procedural losses could
Addressfor reprints: R.C. Mason, University Department ofClinical Surgery, Royal Infirmary, Edinburgh EH3 9YW, United Kingdom.
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serially transplanted chemically induced rat
mammary tumours. With passage there is loss of
hormone dependence and estrogen receptor activity
along with an increase in 5a reduction (14).
The picture which emerges is that tumours
possessing estrogen receptor protein have an in¬
creased tendency towards synthesising estrogen
from C19 steroids. Conversely, those tumours
without estrogen receptor activity tend to synthesise
larger amounts of active androgens. Whether the
differences in steroid metabolism as observed in vi¬
tro also occur in vivo remains to be shown. It is also
possible that different levels of endogenous precur¬
sor may be present in tumours and this may in¬
fluence steroid metabolism. Equally the clinical rele¬
vance of this relationship between steroid receptors
and metabolism still remains to be defined but it
could be that inhibitors ofperipheral aromatisation,
e.g. aminoglutethimide (15), could be particularly
valuable in those tumours showing both receptor
activity and estrogen synthesis.
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Chart 1. Level of estradiol synthesis in tumors with aromatization.
Table 1
Correlation between potential for aromatization and presence of estrogen
receptor
X2 = 7.99; p = 0.005.
Estrogen syn¬ Without syn¬
thesis thesis
Estrogen receptor positive 55 26

























estradiol synthesis no synthesis
Chart 2. Level of estrogen receptor in tumors with and without estradiol
synthesis. The difference between groups is significant by Wilcoxon rank test
(p< 0.001).
solute. This effect was largely accounted for by the association
of aromatase with estrogen receptors, all tumors with aroma-
tase activity responding to treatment also being estrogen re¬
ceptor positive.
It was also of interest to examine the relationship between
tumor aromatization and response to specific therapies which
might be active against aromatization. The results are pre¬
sented in Table 2, both for adrenalectomy, which removes the
major source of C-19 steroid pecursors in postmenopausal
women, and for the administration of aminoglutethimide, which
also inhibits tumor aromatase (2).
Although numbers are small, tumors with the greatest in vitro
conversion to estradiol were those which responded while
those without aromatization failed to do so.
Discussion
Our report that human breast cancer may synthesize estro¬
gen from C-19 steroid precursors (13) has been confirmed by
several groups (1, 4, 7, 24). When compared with ovarian
production in premenopausal women, the levels of estrogen
synthesized by a tumor may appear insignificant. However, in
postmenopausal women with breast cancer, a tumor may rep¬
resent a major estrogen-synthesizing organ. Using identical
conditions of in vitro incubation, we have found that breast
cancers may have higher aromatase activity than do adrenal
cortex, liver, or fat.2
Fat is generally assumed to be the major site of peripheral
conversion of androgens to estrogens (10, 21). However, direct
! W. R. Miller, Unpublished observations.
comparisons of adipose tissue and breast cancer have always
shown higher biosynthesis of estrogen in tumor (3, 22). Fur¬
thermore, using the methods of the present studies, biosyn¬
thesis of estrogens from dehydroepiandrosterone, A4-andros-
tenedione, and testosterone was consistently below detectable
levels in adipose tissue. The large mass of fat in the body may
compensate for its low synthetic activity and make it the major
source of circulating estrogen in postmenopausal women.
However, "on site" tumor production of estrogen may be more
important for the growth of the breast cancer.
It has been calculated that the MCF-7 cell line of human
breast cancer might synthesize sufficient intracellular estrogen
to stimulate estrogen-mediated events (11). In the present
studies, similar calculations indicate that 0.5 to 12.5 pmol are
formed during incubation. This is sufficient to half-saturate
estrogen receptor sites in the majority of breast cancers.
However, it should be noted that endogenous levels of testos¬
terone in breast tumors are likely to be considerably lower than
are those used in our incubations (20). On the other hand, in
the breast there are high concentrations of other C-19 steroid
precursors (18) which breast tumors may convert to testoster¬
one or metabolize directly to estrogen (1,7,17,19).
In addition to these theoretical considerations, it is important
to relate the results from in vitro incubations to estrogen recep¬
tor status which has already been established to be of clinical
value (12).
The finding of a positive correlation between aromatase and
estrogen receptor activity confirms our previous report (1 7) but
is not in agreement with others (3, 9, 24). However, in these
latter studies, smaller numbers were reported. This may be
important, since the relationship between aromatase and re-
3366s CANCER RESEARCH VOL. 42
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Chart 3. Relationship between level of estrogen receptors and percentage of
conversion to estradiol in tumors with both aromatase and receptor activities.
40 patients with advanced breast cancer
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Chart 4. Relationship between tumor aromatization, estrogen receptors, and
response to endocrine therapy.
Table 2









Aminoglutethimide E. M. 0.18 + Yes
K. S. 0.09 + Yes
J. S. 0.08 + Static
B. E.b 0.03 + Mixed
I. T.b NDC + No
I.H. ND - No
Adrenalectomy J.B. ND _ No
J.R. ND - No
Aromatase activity expressed as percentage of conversion of [7a-3H]testos-
terone to 17/?-estradiol.
In combination with tamoxifen.
c
ND, not detectable, i.e., <0.02%.
ceptors is not absolute and the trend may not be statistically
significant when small numbers of tumors are investigated (1 6).
Our finding is logical in that tumors which synthesize estrogen
would be expected to possess the mechanism (6) by which it
gains access to the nucleus and exerts its effect.
We postulated that tumors possessing both estrogen-syn¬
thetic and receptor activity were more likely to be sensitive to
deprivation of hormones than were those without one or both
of these properties (1 7). The clinical studies that we now report
do not totally support this view. Although there did appear to
be a positive relationship between aromatase activity and clin¬
ical response, this was neither additive to, nor independent of,
estrogen receptor activity. The relationship between tumor
aromatase activity and endocrine responsiveness may be best
shown by studying those forms of treatment which deprive the
tumor of its precursor C-19 steroids or directly inhibit tumor
aromatase. These include adrenalectomy and aminogluteth¬
imide, and it is encouraging to note that tumors with highest
aromatase activity appeared to be more responsive to these
therapeutic methods. However, the numbers of patients studied
are small, and it is now important to establish a prospective
study to determine the relationships between aromatase activ¬
ity, steroid receptor, and tumor sensitivity to endocrine treat¬
ment.
It is difficult to attribute a physiological role for estrogen
synthesis in tumors which lack estrogen receptor activity, al¬
though it has been suggested (1) that these tumors may appear
hormone independent by virtue of their de novo synthesis.
Further studies are required to elucidate this.
One can conclude that estrogen-synthetic activity can be
demonstrated in approximately half of all breast cancers and in
many is likely to be of sufficient magnitude to induce estrogen-
stimulated events. Although aromatase is correlated with estro¬
gen receptor activity, the relationship is not absolute. However,
we have some evidence that estrogen synthesis may be an
important influence on the hormonal sensitivity of a tumor,
especially to regimens such as adrenalectomy and aminoglu¬
tethimide.
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biosynthesis. Measurements of hormones in adrenal arterial and venous
blood indicate that the adrenal also synthesizes only small amounts of
oestrogen. However, the adrenal does produce large amounts of
androgen which can be potentially utilized as precursor for
transformation into oestrogen elsewhere. The observation that in
adrenalectomized, oophoreetomised women, perfusion of androgens causes
plasma oestrogen levels to rise, supports the contention that







A proportion of breast cancers require oestrogen for their continued
growth. The primary sources of this oestrogen in post-menopausal
women are peripheral sites whose aromatase activity transforms
inactive adrenal androgens into active oestrogen. The develoraent of
inhibitors to block this peripheral activity represents a novel and
potentially important form of therapy for breast cancer. In this
respect, aminoglutethimide has already proven to be of value in the
treatment of breast cancer and 4 hydroxy-androstenedione shows promise
for the future. The presence of aromatase in certain patients makes
breast caneer a useful model of peripheral aromatase and screening for
the potential amongst breast cancers may help select patients for
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Inhibition of aromatase by aminoglutethimide in human breast cancers
TABLE
Relationship between tumour aromatase and response to
aminoglutethimide
Response No Response
tumour -ve 0 4
aromatase +ve 8 2
X2 = 6.56, p<0.025
1 0
Figure 1
C 27 steroid ( cholesterol
C 21 steroid ( progestogen
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In Vitro Effects of Oestrogen on Testosterone
Metabolism by Human Breast Cancers
W. R. MILLER and A. P. M. FORREST
Department of Clinical Surgery, Royal Infirmary, Edinburgh, EH3 9TW, United Kingdom
Abstract—The effect of in vitro addition of oestradiol on the metabolism of lv?H
testosterone by 15 human breast cancers has been investigated. Oestradiol significantly
inhibited metabolism and conversion to 5a dihydrotestosterone, 5a androstanediol and A4
androstenedione.
INTRODUCTION
Human breast cancers can metabolise steroid
precursors to active hormones such as 5a
dihydrotestosterone [1, 2] and oestradiol-17/?
[3, 4]. Whilst the metabolism of testosterone
by rat mammary tumours has been shown to
be influenced by oestrogen both in vitro [5]
and in vivo [6], little is known about the effects
of hormones on steroidogenesis in human
tumours. The aim of the present study was
to determine in vitro the effect of oestradiol-
17/1 on testosterone metabolism by human
breast cancer.
MATERIALS AND METHODS
Tumours from 15 patients with proven can¬
cer of the breast were studied: 10 subjects
were at least 5yr postmenopausal, 4 were
premenopausal and had regular menstrual
periods at the time of investigation. One
patient had undergone bilateral oophorectomy
15 months previously.
Following excision the tumours, 10 of which
were primary carcinomas and 5 recurrence on
the chest wall, were processed at 0°C. They
were finely sliced and split into duplicate
portions each weighing 0.5 g to which Krebs
Ringer phosphate buffer pH 7.4 (5 ml), an
NADPH generating system and 20/tCi 7a3H
testosterone (5.7 Ci/mmole from Radio¬
chemical Centre, Amersham) were added.
Incubation was then carried out either in
the presence of oestradiol (1.5/tg/ml) or its
vehicle (propyleneglycohethanol 1:1) by
Accepted 6 January 1978.
shaking at 37°C in an atmosphere of oxygen
for two hours. In two tumours oestradiol-3-
methyl ether (1.5/ig/ml) was added to a
further incubate as an additional control. The
reaction was stopped by the addition of me¬
thanol (40 ml) and the incubate stored at
-10°C.
Before extracting the metabolites, 500 ng
each of non-radioactive testosterone, 5a di¬
hydrotestosterone (5a DHT), 5a androstanediol,
A4 androstenedione and oestradiol-17/1 were
added to each incubate to monitor recovery
losses. Details of the methodology for steroid
purification by thin layer chromatography and
characterisation by chemical derivative for¬
mation have been described previously [7].
Metabolism of testosterone was determined by
measuring the incorporation of radioactive label
into the appropriate metabolites after correction
for recovery losses. Statistical comparisons be¬
tween the results of incubates with and without
added oestradiol were performed by paired t-
tests after logarithmic transformation of the
data.
RESULTS
The results are presented in Table 1. All 15
cancers converted testosterone to 5a DHT, 5a
androstanediol and A4 androstenedione but
synthesis of oestradiol was detected in only 8
tumours. In certain tumours, these products
represented only a small proportion of the
total metabolites; uncharacterized highly-
polar compounds being responsible for most of
the unidentified material.
The addition of oestradiol-17/1 to the in¬
cubates caused significant inhibition of the
metabolism of testosterone (TcO.Ol) and its
865
866 W. R. Miller and A. P. M. Forrest
Table 1. In vitro effects of oestradiol 17/? metabolism of 7a3H testosterone by human breast carcinomas
Testosterone Production of
metabolised 5a DHT 5a Androstanediol A4 Androstenedione Oestradiol
(ng) (ng) (ng) (ng) (ng)
1. Control 203.4 16.3 16.1 103.8 —
+ OE2 102.3 12.9 9.1 7.8 —
2. Control 183.5 38.8 13.3 35.2 0.8
+ OE2 107.5 17.4 7.5 23.1 0.6
3. Control 204.6 4.5 1.1 3.9 0
+ OE2 120.0 3.7 1.0 2.0 0
4. Control 232.4 17.1 6.7 11.9 0.4
+ OE2 209.2 8.9 2.1 7.8 0.4
5. Control 234.3 34.0 7.4 36.7 0.4
+ OE2 258.8 20.6 2.4 3.7 0.2
6. Control 170.3 16.8 8.6 46.8 3.5
+ OE2 188.5 12.0 7.5 33.9 2.0
7. Control 218.0 13.0 9.8 5.8 0
+ OE2 213.4 6.4 3.1 4.2 0
8. Control 537.9 6.6 1.3 382.2 0.7
+ OE2 365.7 7.0 1.3 188.3 0.8
9. Control 107.0 16.0 14.2 16.2 2.0
+ OE2 69.4 13.9 15.3 8.4 1.7
10. Control 196.1 39.5 16.1 4.9 0
+ OE2 214.8 29.6 9.6 2.4 0
11. Control 152.0 11.4 5.7 3.8 0
+ OE2 129.0 9.7 2.7 4.0 0
12. Control 432.8 25.0 14.4 121.7 0.3
+ OE2 381.0 17.8 19.1 95.3 0.3
13. Control 220.4 31.7 24.2 46.6 0
+ OE2 152.4 29.8 14.3 18.0 0
14. Control 182.9 17.1 4.6 5.4 0.6
+ OE2 214.9 8.8 2.1 3.9 0.5
15. Control 168.4 17.7 3.2 4.8 0
+ OE2 68.0 30.6 7.1 2.6 0
Geometric control 211.8 17.4 7.3 19.8
Mean +OE2 164.3 12.9 4.9 8.0
conversion to 5a DHT (TcO.Ol), 5a androsta¬
nediol (T<0.05) and A4 androstenedione (P
<0.01) as compared with control incubates.
No effect was observed on the synthesis of
oestradiol but the small conversions observed
make comparisons difficult.
Oestradiol-3-methyl ether had no effect on
the metabolism of testosterone in the two
tumours (patients 1 and 8) in which its effect
was investigated.
DISCUSSION
These results indicate that oestradiol-17/? in
general, inhibits the metabolism of testos¬
terone by human breast cancer. However,
there is considerable variation not only in its
effect between tumours but also on the con¬
version of testosterone to individual meta¬
bolites in the same tumour. It is possible that
differences in endogenous steroids within tu¬
mours may contribute to this variation. The
concentration of oestradiol-1 lf> added to the
incubates was, in physiological terms, high.
However, this was similar to that which has
been used by others to study oestrogen sensi¬
tivity in human breast cancer [8] and phar-
mocological doses are used when treating pa¬
tients with advanced breast cancer by oes¬
trogen therapy.
That the effect of oestradiol-17/? is not a
non-specific effect of any steroid is shown by
the fact that the same concentration of
oestradiol-3-methyl ether was without effect in
the two tumours to which it was added.
Similar effects of oestrogen have, however,
been described on 5a reduction of C19 ste¬
roids in the human adrenal cortex and pro¬
state [9—10].
Although one of us reported that oestradiol-
17/? inhibited 5a reduction of testosterone
in hormone dependent rat mammary tumours
but not in two hormone independent tumours
[5], there is no evidence for such a relation¬
ship in human tumours. If oestradiol's effect
on steroid metabolism in human tumours
were limited to those which are hormonally
sensitive, one would not expect to observe
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the general inhibitory effects described in this
study. Further, in two patients with recurrent
disease, endocrine treatment failed to induce
remission despite demonstrable in vitro inhibi¬
tion of 5a reduction by oestradiol-17 //
(patients 2 and 14).
Nevertheless, this study does indicate that
metabolism of testosterone by human breast
cancers is not an autonomous process but as
in normal endocrine tissues, can be influenced
by the addition of other hormones.
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Summary
Certain commonly taken pharmaceutical preparations induce increased levels of plasma prolactin. The effects
of these drugs on (a) tumor steroid receptors and metabolism, and (b) plasma hormones and hormone binding
proteins have been studied in postmenopausal women with breast cancer. Two groups have been compared,
18 patients on drug treatment for at least 2 months and 15 subjects with no history of drug ingestion. Patients
taking medication had significantly higher levels of plasma prolactin compared with control women. No
significant difference was observed between the groups with regard to the plasma concentrations of
dehydroepiandrosterone (DHA) and its sulphate (DHS), testosterone, estrone, estradiol-17/?, sex hormone
binding globulin (SHBG), and albumin. Similarly, no difference was observed between these two groups with
regard to estrogen receptor (ER), progestogen receptor (PR), or androgen receptor (AR) levels in the tumors
nor their ability to metabolize (7-3H) testosterone. It is considered that the ingestion of these drugs does not
affect tumor mechanisms involving steroids.
Introduction
The number of prescriptions written annually in the
United Kingdom for tranquilizers and hypnotics
exceeds 50000000 (1). Included in their total are
many for patients with breast cancer (2).
Several of these drugs are known to raise plasma
prolactin (Table 1). Elevation of prolactin is known
to promote the growth of rat dimethylbenzanthra-
cene (DMBA) induced tumors, to influence metab¬
olism of steroids by these neoplasms (13), and to
alter the concentration of estrogen receptors in cell
cultures of human breast cancer (14). Prolactin may
also have a role in the control of secretion of
adrenal androgens, especially DHA and DHS (15),
which have been reported to be associated with the
risk of breast cancer in humans (16). We have
therefore investigated patients with breast cancer
and studied the effects of those drugs which are
known to stimulate prolactin secretion on the levels
of circulating steroid hormones and on steroid
receptors and steroid metabolic activity in the tumor.
Materials and methods
Patients
Thirty-three postmenopausal women (at least 3
years from their last menstrual period) with pri-
Address for reprints: Dr W.R. Miller, University Department of Clinical Surgery, Royal Infirmary, Edinburgh EH3 9YW, UK.
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mary breast cancer were studied. None had received
any previous treatment for their disease. There was
no evidence of neoplasia elsewhere or of endocrine
disease. The women were subdivided into two
groups according to their history of taking drugs. In
group 1 were 18 women who had been taking the
drugs listed in Table 2 for at least 2 months; in
group 2 were 15 women who had no history of drug
ingestion in the previous 6 months. Age and disease
stage were not significantly different between these
two groups of women (Table 3).
Plasma hormones and hormone binding proteins
Peripheral venous blood samples were obtained
from all patients between 5 and 7 days before
mastectomy at 30 min intervals between 9.30 am.
and 11 am. via an indwelling cannula. The samples
were immediately centrifuged, and the plasma sepa¬
rated and stored at — 20° C until analysis. Assays
were carried out between 3 and 12 months after
collection. Prolactin was measured using a double
antibody radioimmunoassay (17) modified for use
with the Kemtek 3000 automated radioimmuno¬
assay system (18). To minimize any effects of stress,
the fourth (11.00 hr) plasma samples were assayed
and results were expressed in mU/1 of IRP75/504.
DHS was assayed using a direct radioimmuno¬
assay (19) employing an antiserum raised against
DHA, which cross-reacts with both DHA and
DHS; since levels of DHS are at least 300 times
greater than DHA, the assay effectively measures
plasma DHS. Samples collected at 10.00 hr and
10.30 hr were assayed and the mean results were
expressed in ng/ml.
DHA was measured using the same radioimmuno¬
assay following ether extraction from the plasma
and back extraction with 0.1 M sodium hydroxide.
The assay was validated by recovery of DHA and
DHS added to standard and unknown plasmas.
Recovery of DHA (80-85%) provided a check on
procedural losses and that of DHS «0.01%) a
check on the efficiency of differential extraction.
Testosterone was estimated using direct radio¬
immunoassay as described by Hillier et al. (20) but
with omission of the chromatography step. Samples
obtained at 10.00 hr and 11.00 hr were assayed and
the mean results were expressed in nmol/1.
Estrone was assayed by ether extraction of the
plasma, backwashing with 8% (w/v) sodium bi¬
carbonate solution, and radioimmunoassay employ¬
ing an antibody raised against estrone 6-carboxy-
methyloxime conjugated to albumin. The sample
obtained at 10.30 hr was used for this assay and the
results were expressed in ng/100 ml.
Estradiol was assayed by ether extraction of
plasma made 30mmol/l with regard to sodium
hydroxide, and radioimmunoassay using an anti¬
body raised against estradiol-17/? carboxymethyl-
oxime conjugated to albumin. Samples obtained at
10.30 hr were also used for this assay and results
were expressed in ng/lOOml.
SHBG was measured by saturation analysis with
precipitation of the bound protein by ammonium
Table 2. Drugs taken by patients in the study.










Phenobarbitone and diazepam 1
Drugs and breast cancer 333
Table 3. Clinical and histological data.
Patient Age TNM Pathology of tumor Histology of nodes
Drug patients
1 60 t3N0 Invasive ductal carcinoma negative
2 79 t2n0 Invasive ductal carcinoma negative
3 67 t2n0 Invasive ductal carcinoma negative
4 71 T3No Undifferentiated carcinoma positive
5 80 T2Nlb Invasive ductal carcinoma negative
6 75 t4n16 Adenocarcinoma positive
7 62 t4nlb Undifferentiated carcinoma positive
8 72 t2nlfc Invasive ductal carcinoma positive
9 69 t2nlfc Anaplastic carcinoma positive
10 64 t4n2 Scirrhous carcinoma positive
11 74 T3N3 Adenocarcinoma positive
12 65 t2n16 Invasive ductal carcinoma positive
13 59 T2N0 Scirrhous carcinoma negative
14 56 t2n0 Invasive ductal carcinoma negative
15 57 t2n0 Adenocarcinoma negative
16 51 T2Nlfc Invasive ductal carcinoma positive
17 75 T2N0 Lobular carcinoma positive
18 66 T2Nlfc Small cell carcinoma positive
Control patients
19 72 T,n0 Undifferentiated carcinoma negative
20 66 t2n0 Invasive ductal carcinoma positive
21 65 t2n„ Undifferentiated carcinoma negative
22 57 t2n0 Undifferentiated carcinoma negative
23 59 t2n0 Invasive ductal carcinoma negative
24 75 t4n3 Anaplastic carcinoma positive
25 67 T2N0 Anaplastic carcinoma negative
26 71 t2n,„ Anaplastic carcinoma positive
27 72 t3n2 Undifferentiated carcinoma positive
28 67 t2n16 Undifferentiated carcinoma negative
29 83 t4n2 Invasive ductal carcinoma positive
30 63 t2nlt Invasive ductal carcinoma positive
31 61 t3n0 Anaplastic carcinoma negative
32 61 t3n2 Invasive carcinoma positive
33 49 T2n0 Infiltrating carcinoma negative
sulphate solution (21). Samples obtained at 9.30 hr
were assayed and results were expressed in pmol/ml
plasma.
Albumin was measured in all samples by a bro-
mocresol green dye binding assay on the Technicon
SMAC analyser using bovine serum albumin as
standard.
Tumor measurements
At operation the specimen containing the tumor
was placed on ice in the operating theatre and
immediately transferred to the laboratory. Follow¬
ing removal of sufficient material for histological
examination, tumor was dissected free of fat and
other tissues and divided into portions for assays of
steroid receptor activity and steroid metabolism.
Steroid receptors
ER levels were determined by saturation analysis
(22). A portion of tumor (300 mg) was homogeniz¬
ed (1:5 w/v) in 1 mmol/1 Tris buffer containing
monothioglycerol and centrifuged at 3200 rpm for
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20 min. Aliquots of the resultant cytosol were
incubated overnight at 4°C with lOpg of (2, 4, 6,
7-3H) estradiol and varying amounts of competing
non-radioactive estradiol (0, 0.03, 0.09, 0.15, 0.21,
0.28, 2.8 and 62nmol/l). Bound steroid was sepa¬
rated from free by the addition of dextran-coated
charcoal, and the bound fraction was measured
after centrifugation by liquid scintillation counting.
The concentration of receptors was determined by
Scatchard analysis (23).
PR was assayed by a similar technique but using
the synthetic progestogen promogestone (R5020) as
ligand.
AR levels were assayed as above using the syn¬
thetic androgen methyltrienolone (R1881) after satu¬
ration ofPR with promogestone (125nmol/l). Using
these conditions, less than 5% of the AR sites were
blocked. Tumor cytosol protein (tcp) concentration
was determined by the method of Bradford (24) and
results for the three steroid receptors studied ex¬
pressed as fmol/mg tcp. Values below 5 fmol/mg tcp
for ER and 20 fmol/mg tcp for PR and AR were
regarded as negative.
Steroid metabolism
Tumor (500 mg) was finely sliced and incubated for
2hr at 37c C in Krebs Ringer phosphate buffer
pH 7.4, containing an NADPH generating system
and 22.5//Ci(7~3H) testosterone (8.9Ci/mmol). The
reaction was terminated by the addition of metha¬
nol, and the incubate was stored at —10 C until
further processing. Before extraction of the metabo¬
lites, 500 pg of non-radioactive carrier steroid was
added for each metabolite to be purified so that
procedural losses could be monitored. Metabolites
were then separated and purified by thin layer
chromatography and characterized by chemical
derivative formation (25, 26). Metabolism was de¬
termined by measuring the percentage of radio¬
activity in the various characterized metabolites.
Using these methods, conversions in excess of
0.02% were measurable. Values below this figure
have been considered as negative.
Incubations performed in the absence of tumor
showed no conversion to any of the metabolites
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Fig. 1. Pathways of tumor testosterone metabolism investigated.
The pathways of steroid metabolism which were
studied are shown in Fig. 1.
Statistical analysis
Because of the non-parametric distribution of these
data, comparisons between groups were made by
the Wilcoxon Rank Sum Test.
Results
Plasma hormones and hormone-binding proteins
Plasma prolactin concentrations in patients who
were taking medication and those who were not are
shown in Fig. 2. The mean level was significantly
higher in those patients on drugs (/? < 0.02), al¬
though one half of them still had values within the
range displayed by the control patients.
The concentrations of the other plasma hor¬
mones and hormone-binding proteins are shown in
Table 4. No significant differences were found
between the two groups of patients.
Patients were regrouped on the basis of plasma
prolactin concentrations to compare those with
elevated prolactin levels (9 patients) with those
within the control range (24 patients). Again no
significant differences were found (Table 5).
Tumor steroid receptors
ER levels were measured in all 33 tumors, PR in 21,
and AR in 19 (Fig. 3). No qualitative or quanti¬
tative differences in any of the three steroid recep-










Fig. 2. Levels of plasma prolactin in controls and long-term
drug patients ( x : patients taking methyldopa; O: patients
taking the other drugs studied). Prolactin levels were signifi¬
cantly greater in the drug patients (p<0.02).
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Fig. 3. Levels of tumor steroid receptors in controls and long-
term drug patients (see Fig. 2 for symbols). No difference
between these groups of patients for any receptor was significant
(p>0.1).
Table 4. Levels of plasma hormones and hormone-binding
proteins in control and long-term drug patients.
Control Long-term drug
Estrone m 3.9 m 3.3
ng/100 ml r 1.5-5.5 r 0.6-6.5 p>0.1
Estradiol m 1.5 m 1.5
ng/100 ml r 1.0-2.1 r 0.7-2.2 /7>0.1
DHA m 2.4 m 2.5
ng/ml r 0.2-5.2 r 1.5-7 p>0.1
DHS m 390 m 420
ng/ml r 70-1330 r 20-1760 /;>0.1
Testosterone m 1.2 m 1.4
nmol/1 r 0.6-2.4 r 0.3-3 /7 >0.1
SHBG m 73 m 70
pmol/ml r 32-178 r 15-195 /7>0.1
Albumin m 44 m 43
g/1 r 34—49 r 34-51 /;>0.1
m = median
r = range
Table 5. Levels of plasma hormones and hormone-binding




Estrone m 3.9 m 3.7
ng/100 ml r 1.4-6.5 r 0.6-4.4 p >0.1
Estradiol m 1.5 m 1.4
ng/100 ml r 0.8-2.2 r 0.7-2.2 /7>0.1
DHA m 2.4 m 2.2
ng/ml r 0.2-6 r 1.0-7.0 />>0.1
DHS m 380 m 400
ng/ml r 70-1330 r 20-1760 /7>0.1
Testosterone m 1.3 m 1.3
nmol/1 r 0.6-3 r 0.3-2.1 /7 > 0.1
SHBG m 72 m 68
pmol/ml r 32-178 r 15-195 p>0.1
Albumin m 43 m 41
g/1 r 34-51 r 34—48 p>0.1
m = median
r = range
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tors were observed between the groups of patients
(p >0.1 in all cases). Regrouping of the data on ER
on the basis of plasma prolactin also failed to show
any significant differences.
Tumor steroid metabolism
The metabolism of testosterone and synthesis of
androgens were measured in all cases. Twenty-one
tumors were investigated for the synthesis of estro¬
gen, of which 13 showed evidence of production
(Figs. 4 and 5). There was a trend for decreased
production of the three androgen metabolites stud¬
ied in tumors from patients on medication, but this
did not reach statistical significance.
After regrouping of the patients on the basis of
plasma prolactin concentration there were still no
significant differences in the amounts of testoste¬
rone metabolized or metabolites formed except for
d4 androstenedione (Fig. 6), which was signifi¬
cantly decreased in the tumors of those patients
with elevated prolactin (/;<0.05).
Methyldopa
Seven patients were taking this drug, which allowed
separate statistical analyses to be performed com¬
paring their results both with other patients re¬
ceiving medication and with non-treated controls.
No differences were found.
Discussion
An obvious problem in the design of this study was
the multiplicity of drugs taken by patients. Only
one drug subgroup (methyldopa) contained suffi¬
cient numbers to study separately. As this group did
not differ from those remaining, it is valid to
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Figs. 4&5. Levels of tumor testosterone metabolism in control or long-term drug patients (see Fig. 2 for symbols). No differences
between these groups of patients for any facet of metabolism attained significance (Test = testosterone, A*A = A4 androstenedione,
E2 = estradiol 17/?, 5 aT = 5a dihydrotestosterone, 5 a A = 5 a androstanediol, 5 RP = 5 reduced products 5 aT + 5 a A.
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Fig. 6. Level of testosterone metabolism and conversion to
d4 androstenedione (A4 A) in tumors from patients with nor¬
mal (N) and elevated (H) plasma prolactin. The differences
between the groups were insignificant for testosterone metabo¬
lism (p>0.l) but significant for conversion to (p<0.05).
effects. A further complication in interpreting the
results is that patients taking drugs were studied
only at one time point, i.e. whilst on medication. As
no data is available on the patients before the start
of drug ingestion, it is not possible to state cate¬
gorically that the drugs were completely without
effect, despite the lack of difference from control
patients. The likelihood that an earlier difference
existed between the groups which was rectified by
administration of the various medications seems
highly improbable, especially as there was no com¬
mon reason for prescribing the drugs.
It is of interest that the ingestion of these drugs
was associated with elevated plasma prolactin con¬
centrations in only half of the patients studied. We
have reported (10) that the effect of phenothiazines
on plasma prolactin is dose-related, but described a
considerable individual variation between patients,
which has also been noted by others (27, 28). In the
present study, ingestion of these drugs did not
influence the levels of steroid hormones irrespective
of the effect on plasma prolactin. This is contrary to
the report of Vermeulen and Ando (15), who ob¬
served raised levels of adrenal androgens in hyper-
prolactinemic patients, but is in agreement with the
findings of others (29, 30).
Our observation that these drugs also did not
influence the levels of steroid receptors within the
tumor or the ability of the tumor to metabolize
steroids, even when hyperprolactinemia was in¬
duced, is in contrast to the results of our studies on
rat DMBA-induced mammary tumors (13). How¬
ever, these latter tumors are known to be particu¬
larly sensitive to prolactin.
It is therefore reasonable to assume that, in
human breast cancer, events involving steroid hor¬
mones are not influenced by the drugs studied. In
this respect we cannot present any evidence which
would contra-indicate the use in breast cancer
patients of drugs which coincidentally raise plasma
prolactin levels.
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Androgen metabolism and apocrine differentiation in human breast cancer
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Summary
Metabolism of (7a-3H) testosterone has been measured in 111 human breast cancers and compared retrospec¬
tively with the degree of apocrine differentiation in the tumors. Cancers in which apocrine characteristics
were a marked feature metabolized significantly more testosterone precursor than those in which apocrine
features did not predominate. Higher metabolism was accounted for by increased conversion to 5a-reduced
products such as 5a-dihydrotestosterone and 5a-androstanediols.
Introduction
Human breast cancers metabolize androgen pre¬
cursors in vitro (1-3). Marked variations in level of
metabolism occur between different tumors (4) but
little is known about factors which influence such
behaviour. A chance observation that a tumor
which metabolized unusually large amounts of tes¬
tosterone also had marked apocrine morphology
on histological examination led to the present
study, in which we have retrospectively related in




Histologically proven cancers of the breast were
obtained at mastectomy from 111 patients. Follow¬
ing excision, tumors were immediately placed on
ice. Sufficient tissue was removed for histo-
pathological investigation including apocrine grad¬
ing, and the remainder was used to determine the
metabolism of testosterone.
Testosterone metabolism
A 500 mg portion of each tumor was finely sliced
and incubated for 2h at 37° C in Krebs Ringer phos¬
phate buffer pH 7.4 containing a NADPH generat¬
ing system and 22.5uCi 7a-3H testosterone. The
reaction was stopped by addition of methanol (40
ml) and the incubations were stored at -10° C until
being processed further. Before extraction of met¬
abolites, 500 ug of non-radioactive carrier of the
steroids to be characterized were added to enable
monitoring of procedural losses. Metabolites were
then extracted as described by Fahmy et al. (5) and
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Fig. 2. Percentage conversion of testosterone to 5a-
dihydrotestosterone by human breast cancers subdivided ac¬
cording to grade of apocrine differentiation (see Methods).
Horizontal lines refer to median value. There is no significant
difference between grades 1 and 2, but grade 3 is significantly
different from both (p<0.01 by Wilcoxon Rank Test).
grated with 5a-androstanediol. This behaviour is


















Fig. 3. Percentage conversion of testosterone to 5a-andros-
tanediols by human breast cancers subdivided according to
grade of apocrine differentiation (see Methods). Horizontal
lines refer to median value. There is no significant difference
between grades 1 and 2, but grade 3 is significantly different
from both (pcO.Ol by Wilcoxon Rank Test).
Discussion
All human breast cancers metabolize testosterone
in vitro, but large quantitative variations in metab¬
olism occur between different tumors and little is
known of factors which influence activity. In the
present study, the association between degree of
tumor apocrine differentiation and metabolic po¬
tential has been investigated.
It has long been recognised that human breast
cancers may show apocrine features (7-17). The
incidence of apocrine differentiation varies in re¬
ported series according to the criteria used by dif¬
ferent authors to define apocrine characteristics.
Carcinomas with marked apocrine features are
most easily recognised by the characteristic copious
pale eosinophilic cytoplasm (13,14), although care
must be taken not to confuse this with staining
artefact. Secretory snouts and vesicular nuclei with
prominent nucleoli, both features of benign apoc¬
rine epithelium, may also be seen (15). Using these
criteria it is generally accepted that between 2 and
15% of all breast carcinomas show marked apoc¬
rine differentiation (10,13,17), although up to 62%
may show apocrine characteristics without this
being a striking feature of the tumor (15). The
finding in this series of 12% with marked and 63%
with some degree of apocrine differentiation, the
remainder having minimal apocrine features,
therefore correlates well with these previous stud¬
ies.
With regard to metabolism of testosterone, large
variations were observed between tumors within
the groups categorized as having either minimal or
moderate apocrine features, and there was no sig-












Fig. 4. Percentage conversion of testosterone to A4-andros-
tenedione by human breast cancers subdivided according to
grade of apocrine differentiation. Horizontal lines refer to me¬
dian value. There are no significant differences between the
groups by the Wilcoxon Rank Test.
nificant difference in any aspect of metabolism be¬
tween these two groups. This would indicate that in
tumors where apocrine development is not a pre¬
dominant feature, the degree of development does
not account for variability in testosterone metabo¬
lism. However, tumors with marked apocrine fea¬
tures metabolized significantly greater amounts of
testosterone than the groups of tumors with lesser
apocrine differentiation. Increased metabolism
was associated with raised production of 5a-di-
hydrotestosterone and 5a-androstanediols. Data
from scans of the distribution of radioactivity in
metabolites also suggested increased transforma¬
tion to other 5a-reduced steroids such as
5a-androstanedione, androsterone, and/or epi-
androsterone. In contrast, conversion to
A4-androstenedione was not enhanced. It there¬
fore seems unlikely that raised metabolism in tu¬
mors with markedly apocrine features is due to a
non-specific effect such as a general increase in
cellularity.
5afAone A4A 5<XT T 5«A'ol
Fig. 5. Typical scans of radioactivity on the t.l.c. plates after
inital chromatography: (a) from a tumor with minimal apocrine
differentiation (Grade 1), and (b) from a tumor with a marked
apocrine differentiation (Grade 3). Spots corresponded to areas
in which radioinert steroid standards migrated. 5aA'one =
5a-androstanedione; AJA = A4-androstenedione; 5aT =
5a-dihydrotestosterone; A = androsterone; EpiA =
epiandrosterone; T = testosterone; 5aA'ol =
5a-androstanediol.)
Several tumors with marked apocrine features
were incubated as explants in short-term organ
culture with 7a-3H testosterone. These all showed
enhanced 5a-reduction compared with carcinomas
without such differentiation. This would suggest
that tumors with marked apocrine features inher¬
ently possess high 5a-reduction and that the ac¬
tivity observed in the present study is not artefac-
tual of the specific incubation conditions or
co-factors employed.
Variations in testosterone metabolism have been
reported to occur between samples of skin taken
from different areas of the body (18) and it is thus
relevant that axillary and perineal skin which con-
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tain cells from apocrine sweat glands display high
metabolism to 5a-reduced steroids (18, 19). This
activity of apocrine tissue probably accounts for the
high concentrations of 5a-reduced androgens
which are found in apocrine fluids (20). It is also of
interest that in human breast cancers the produc¬
tion of GCDFP-15, a protein marker of apocrine
activity (16), may be stimulated by administration
of androgens (21), and that in rabbits androgens
stimulate the growth and activity of normal apoc¬
rine glands (22).
It remains to determine whether raised 5a-re-
ductase in breast cancers with marked apocrine
features is of biological or clinical significance.
5a-dihydrotestosterone retards the growth of rat
mammary tumors (23). It also inhibits estrogen
synthesis in breast cancer cells (24) and competes
with estradiol for estrogen receptors (25). Tumors
with high 5a-reductase activity might therefore be
expected to be associated with good prognosis; as
yet, the present data has not been examined to
determine if this is so. Although some workers
have suggested that apocrine cancers have a better
prognosis (26), others have failed to show that they
have a different prognosis from other histological
types of breast cancer (8, 11).
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Chapter 12
Steroid Metabolism in Breast Cancer
W. R. MILLER
Steroid hormones which may influence the growth and development of both normal
and diseased breast are classically synthesized from cholesterol (Figure 12.1). At one
time, such biosynthesis was thought to be exclusive to the gonads, adrenal cortex and
fetal-placental unit, but it is now recognized that other organs, including breast and
its tumours, perform many of the transformations. Such potential may be important
in influencing the steroid environment within the breast and in the vicinity of breast
tumours.
The evidence for the existence of such steroid metabolism will be reviewed for
breast cancer, benign breast disease, normal breast tissue and breast fat.
STEROIDOGENESIS IN BREAST CANCER
While the evidence that breast cancers can synthesize active hormones from
cholesterol is unconvincing (Abul Hajj 1984; Duncan et al. 1981), there is no doubt
that they can use partially formed precursors which have been produced elsewhere
and released into the circulation. These 'pro hormones' include androgens such as de-
hydroepiandrosterone (DHA) sulphate, which are produced by the adrenal
(Abraham & Chakmakjian 1973) and may accumulate in the breast in high con¬
centrations (Miller& Forrest 1983). Results from studies involving in vitro incubation
(Adams and Wong 1968; Cameron et al. 1971; Couch et al. 1975) or perfusion of the
breast in situ (Jones et al. 1970) indicate that most, if not all, breast cancers
metabolize DHA sulphate to other androgens such as DHA itself, A4 andros-
tenedione and testosterone. These metabolites are, in turn, the more immediate
precursors of active hormones.
Breast cancers, for example, have the capacity to convert testosterone into more
potent androgens such as 5a- dihydrotestosterone and 5a androstanediols (Jenkins &
Ash 1972, Mclndoe & Woods 1981; Miller et al. 1973). Such 5a reductase activity is
classically associated with the prostate in which 5a reduced products promote the
development and function of the gland (Mainwaring 1977). All breast cancers have
capacity for 5a reduction but the level varies greatly between different tumours
(Miller et al. 1978), while rarely reaching that displayed by the prostate (Perel &
Killinger 1983).
Testosterone and A4 androstenedione are the immediate precursors of oestrogen
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Figure 12.1 Major pathways of steroid hormone biosynthesis.
(Figure 12.1) and several groups of workers have provided unequivocal evidence for
the conversion of androgens into oestrogens or 'aromatization' by human breast
cancer (Table 12.1). The proportion of cancers which have this potential varies from
around 50 per cent to 100 per cent in different reported series. Using a method of
rigorous characterization we have obtained evidence of oestrogen production in just
over one-half of breast cancers (Miller et at. 1982a). The levels of oestrogen
synthesized are small in comparison with those in classical endocrine organs, such as
the ovary and placenta, but are comparable to, or higher than, levels in other
peripheral organs with oestrogen biosynthetic activity (Abul-Hajj et al. 1979a; Perel
et al. 1980).
Because other cells, such as adipocytes, may also produce oestrogen (see below),
it is important to demonstrate that oestrogen biosynthesis in specimens of tumour is
truly associated with cancer cells. In this respect, studies of cell lines of breast cancers
are of value and, despite an early negative finding (D'Agata et al. 1978), it is clear that
under optimal culture conditions breast-tumour cells will synthesize oestrogen from
androgen precursors (Maclndoe 1979). Furthermore, different clones of malignant
158 Chapter 12





DHA Oestrone 7/18 (39%) Abul-Hajj el at. (1979b)
2/12 (17%) Miller W.R. (unpublished)
Oestradiol 11/18 (61%) Abul-Hajj et al. (1979b)
64 androstenedione Oestrone 17/17 (100%) Perel et at. (1981)
7/17 (41%) Varela & Dao (1978)
Oestradiol 17/17 (100%) Perel et at. (1981)
10/17 (59%) Varela & Dao el at. (1978)
4/6 (67%) Miller W.R. (unpublished)
Testosterone Oestradiol 9/15 (60%) Abul-Hajj et at. (1979b)
21/23 (91%) Li & Adams (1981)
66/110 (60%) Miller et at. (1982a)
cells from the same tumour may display differing potential for oestrogen production,
thereby demonstrating heterogenity of aromatase activity in cells from a single
tumour (Perel et at. 1983).
Breast cancers also have the capacity to interconvert oestrogens (Figure 12.1).
Oestrone and its sulphate represent the major, although relatively inactive, cir¬
culating oestrogens in postmenopausal women (Baird et at. 1969a; Samojlik et at.
1982) but both may be metabolized into the more potent hormone, oestradiol
(Vignon elal. 1980; Wilking et al. 1980; Willcox & Thomas, 1972). Equally, however
many breast cancers can inactivate oestradiol by performing the reverse conversions
to oestrone (Abul-Hajj et al. 1979b; Geier et al. 1975; Willcox & Thomas 1972 ) or
oestrogen conjugates (Braunsberg et al. 1974. Dao&Libby 1972; Leung et al. 1973).
The balance of these oestrogen interconversions might be critical in determining the
net oestrogenicity within the tumour.
STEROIDOGENESIS IN BENIGN BREAST DISEASE
Benign breast disease encompasses a variety of lesions. While there is no evidence that
any type of benign lesion can transform cholesterol into steroid hormones, inter¬
conversions of androgen and oestrogen, such as those described above, occur also in
several types of benign lesions (Geier et al. 1974; Jenkins & Ash 1972; Lloyd 1979;
Miller el at. 1973; Perel et al. 1981; Willcox & Thomas 1972). In general, the
transformations occur to a lesser extent than in malignant tissue, with the exception
of 5a reduction in cystic disease and certain fibroadenomas, which may display high
levels of activity (Lloyd 1979; Miller et al. 1973).
High levels of steroid hormones may be found in fluids aspirated from breast
cysts (Bradlow et al. 1981; Miller et al. 1982b) and, for example, the median value of
DHA sulphate is on average 50-fold higher than that in plasma (Miller et al. 1983a).
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As high levels of oestrogen conjugates are also present in cyst fluid but are not con¬
centrated from plasma, it has been inferred that these may by synthesized locally
from androgen precursors (Raju et at. 1984).
It has recently been shown that breast carcinomas with marked apocrine
differentiation show enhanced ability to metabolize testosterone to 5a-reduced
products such as 5o-dihydrotestosterone and 5a-androstanediols (Miller el at. 1984).
This observation may explain why cystic lesions of the breast which are frequently
associated with apocrine activity (Haagensen et at. 1981) should also display a high
capacity for 5a reduction.
STEROIDOGENESIS IN NORMAL BREAST TISSUE
Specimens of normal breast tissue taken from areas of mastectomy specimens far
removed from any malignancy show evidence of steroidogenic potential (Couch et at.
1975; Geier et at. 1974, 1975; Lloyd 1979; Miller et at. 1973; Perel et at. 1981).
Metabolism of progestogens, androgens and oestrogens have all been reported,
including the pathways discussed above. The levels of conversions in normal breast
are generally lower than those in benign or malignant breast tissues, and this may be
due in part to the low cellularity of 'normal' resting breast.
Considerable attention has been given to the possibility that normal breast may
synthesize oestrogens but most workers have not detected steroid aromatizing
potential in normal breast tissue (Abul-Hajj et at. 1979a; Deshpande et at. 1976;
Miller et at. 1978). The single group reporting oestrogen biosynthesis described
activities which were much lower than those found in 'parallel' incubations of
malignant tissue (Perel et at. 1980). The general inability to detect oestrogen bio¬
synthesis in normal breast may be due to its low cellularity. Studies of cell lines in
culture should overcome this problem and, recently, biosynthesis has been detected
in epithelial cells derived from human milk (Perel et at. 1984a).
STEROIDOGENESIS IN BREAST FAT
It is clear that fat has significant, albeit limited, capacity for steroid interconversions
(Bleau et at. 1974; Perel & Killinger 1979). Among the transformations validated are
those of DHA to A5 androstenediol (Schindler & Aymer 1973), A4 androstenedione
to testosterone (Perel & Killinger 1979), aromatization of androgens to oestrogens
(Bolt & Gobel 1972; Schindler et at. 1972) and the interconversion of oestrone and
oestradiol (Bleau et at. 1974).
In postmenopausal women, aromatization in peripherally distributed fat
probably represents one of the major sources of circulating oestrogen (Grodin et at.
1973) and there are positive correlations between body weight, degree of obesity and
levels of plasma oestrogens (MacDonald et at. 1978; Vermeulen & Verdonck 1978).
Samples of fat from various parts of the body including breast have been shown to
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synthesize oestrogen in vitro (Beranek el al. 1984; Perel & Killinger 1979). In view of
the relative increase in the proportion of fat to parenchyma in the breast after the
menopause (Anastassiades et at. 1983), local production of oestrogen by breast fat
may be particularly important in postmenopausal women.
CONTROL OF STEROID METABOLISM IN THE BREAST
While pituitary hormones such as growth hormone and prolactin may be trophic for
the breast (Dilley & Kister 1975; Peters et al. 1983; Shiu 1982) there is not any good
evidence that they regulate steroid interconversions in the breast. Although hyper-
prolactinaemia is associated with enhanced testosterone metabolism in carcinogen-
induced rat mammary tumours (Miller 1976), these tumours have a particular
sensitivity to prolactin (Meites 1972; Pearson et al. 1972) which is rarely seen in
human breast cancers (Legha & Swenerton 1979). Drug-induced hyperprolac-
tinaemia in patients with breast cancer is not associated with differences in steroid
metabolism, either by normal or malignant breast (Mason et al. 1983).
Steroid metabolism in the breast may nevertheless, be controlled by polypeptide
hormones. Aromatization of androgens to oestrogen by human breast cancer is
influenced by cyclic AMP (Miller unpublished) and factors which control the
production of cyclic AMP in the breast are therefore likely to affect oestrogen bio¬
synthesis. The situation is analogous to that in adipose tissue where cyclic AMP
stimulates oestrogen formation (Simpson et al. 1983).
Metabolism of steroid hormones is also modulated by steroids themselves
(reviewed by Gower & Cooke 1983). For example, progesterone appears to increase
1713 hydroxysteroid dehydrogenase activity not only in the endometrium (Buirchell &
Hahnel 1975; Tseng & Gurpide 1975) but also in breast fibroadenomas (Fournier et
at. 1982). This would account for the maximum enzyme activity found in normal
breast tissue during the early secretory phase of the menstrual cycle (Pollow et al.
1977). In vitro studies show that oestrogen inhibits 5a reduction (Miller & Forrest
1978) and, conversely, 5a reduced androgens block oestrogen biosynthesis in human
breast cancer (Perel et al. 1984b).
A marked induction of aromatase activity occurs in cultures of cells from either
breast cancer or adipose tissue in the presence of Cortisol and dexamethasone
(Folkerd & James 1983; Perel et al. 1983; Simpson et al. 1983). Prolactin may be
synergistic in this system (Folkerd & James 1984). Whether such hormonal effects
apply only to culture conditions or are reproduced also in vivo is not known.
RELATIONSHIP TO STEROID RECEPTORS
There has been considerable interest in the possible association between tumour
steroid metabolism and the presence of hormone receptors (Table 12.2). Particular
attention has been given to the relationship between oestrogen biosynthesis and
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Table 12.2 Relationship between steroid metabolism and steroid receptors in breast cancer.
ER = oestrogen receptor; E, = oestradiol 1713; PgR = progestogen receptor; AR = androgen receptor.
Steroid conversion Reference Tumours Relationship
Oestrogen biosynthesis Abul-Hajj elal. (1979a)
Li & Adams (1981)
Miller et at. (1979)
Miller el at. (1982a)
Tilson-Mallet et at. (1983)
Varela & Dao (1978)
Oestrogen 1713 dehydrogenase Abul-Hajj et at. (1979b)
Wilking el at. (1980)
Oestrogen sulphotransferase Godfroi et at. (1975)
Leung el at. (1973)
Pewnin el at. (1982)
Pewnin el at. (1980)
Tseng el at. (1983)
Oestrogen sulphatase
5o reduction
Santner el at. (1984)
Tseng el at. (1983)
Wilking el at. (1980)
Abul-Hajj (1979)





















Incidence lower in ER + ve
cf. ER - ve.
Incidence similar in ER +ve
and ER - ve.
No correlation between level of Ej
synthesized and ER status.
Incidence not significantly different
in ER + veand ER - ve.
Incidence higher in ER +vecf. - ve.
Levels of synthesis not correlated
with ER status or level.
Level of ER higher in tumours with
Ej synthesis.
Level of synthesis similar in ER + ve
and ER - vc.
No correlation with PgR status.
Incidence not correlated with ER
status.
Conversion higher in ER poor
cf. ER rich.
Conversion higher in ER poor
cf. ER rich.
Positive correlation with ER status.
Positive correlation with ER status in
primary cancer.
Activity higher in ER +ve
cf. ER - ve.
Activity higher in PgR + ve
cf. PgR - ve.
Activity higher in ER -t-ve/PgR +ve
cf. ER - ve/PgR - ve.
No correlation with ER status.
No correlation with ER status.
No correlation with ER status.
Activity higher in ER + ve
cf. ER-ve.
Activity lower in ER + ve
cf. ER - ve.
No correlation with AR status.
oestrogen receptors. It is clear that oestrogen production may be demonstrated in both
receptor-positive and -negative tumours (Li & Adams 1981; Miller et at. 1982a). There
is, however, no consensus of opinion about whether oestrogen-receptor-positive
tumours are more or less likely to produce oestrogen than their receptor-negative
counterparts.
Several factors may account for disparity between results; these include different
cut-off values for defining oestrogen-receptor-positive tumours, different substrates
162 Chapter 12
and methods for assessing tumour aromatase, and the variation in detection limits
associated with different characterization techniques for oestrogen. Our own studies
showed a significant positive correlation when larger numbers of tumours were
examined (Miller el at. 1982a) and within the group of oestrogen-receptor-positive
tumours, the level of receptor was significantly higher in cancers producing oestrogen
compared to those without biosynthetic activity. However, the level of oestrogen syn¬
thesis does not apparently differ between oestrogen-receptor-positive and -negative
tumours (Li & Adams 1981; Miller el at. 1982a; Tilson-Mallet el at. 1983).
Other aspects of tumour oestrogen metabolism have been reported to be
significantly related to the presence of oestrogen receptors. Thus, there are higher
levels of the oestradiol 1713 dehydrogenase enzyme converting oestradiol into
oestrone in oestrogen-receptor-poor tumours, compared with those which are
receptor-rich (Abul-Hajj el al. 1979b). Several groups have shown that there is also
a positive correlation between the ability of tumours to sulphate oestrogen and the
presence of oestrogen receptors (Table 12.2).
Conflicting data have emerged over the relationship between oestrogen receptors
and the production of 5a reduced androgens. In a small number of tumours, Abul-
Hajj (1979) reported a positive correlation between these parameters, whereas our in¬
vestigations on a larger series of cancers derived from postmenopausal patients
alone, showed higher 5a reductase activity in oestrogcn-receptor-negative tumours
(Mason et al. 1981). No significant relationship has been detected between tumour
androgen-receptor level and the production of its natural binding steroid, 5a
dihydrotestosterone (Mason 1981).
BIOLOGICAL SIGNIFICANCE OF STEROIDOGENESIS
IN BREAST CANCER
If steroid metabolism within the breast is of biological importance, its role must be
local within the breast itself. Effects at sites distant from the breast are improbable
because of the relatively low levels of steroid interconversions within breast tissues
and because, unlike the case of lung tumours (Bower and Gordon 1965), widespread
responses attributable to inappropriate hormone production have not been reported
in patients with breast cancer.
Local hormone biosynthesis may not be important in premenopausal breast
cancer where the ovary releases sufficient steroid hormones into the circulation to
account for the maintenance of hormone-dependent neoplastic growth. It may be
more important in premenopausal cystic disease in which high levels of steroid
conjugates are present within cyst fluid (Bradlow el al. 1981; Miller el al. 1982a).
Evdi a small conversion of these inactive precursors into more active products might
be associated with marked changes in the hormonal milieu within the breast.
However, in the postmenopausal woman, steroid metabolism by the breast may
have relevance to breast cancers which require steroid hormones for their continued
growth. After the menopause, the ovary ceases oestrogen and progestogen
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Figure 12.2 Metabolic conversions producing major changes in biological activity of steroids:
(a) formation of the oestrogenic androgen, A5 androstenediol; (b) synthesis of the potent androgen, 5a
dihydrotestosterone; (c) aromalizaiion of androgens to oestrogens; and (d) interconversion of
oestrogens either by 170 dehydrogenase (dl) or sulphokinase sulphatase (d2).
production, although it still secretes some androgen (Vermeulen 1976). The adrenal
cortex also synthesizes little oestrogen (Baird el at. 1969b) and, while it produces large
amounts of androgens such as androstenedione, dehydroepiandrosterone and its
sulphate (Baird el at. 1969b; Nieschlag el at. 1973), these steroids appear to be largely
inactive within the breast. Nevertheless, such androgens may be metabolised at
peripheral sites into hormones which do have biological effects on breast cells. These
peripheral sites include adipose tissue (Bleau et at. 1974; Perel & Killinger 1979), liver
(Smuk & Schwers 1977), skin (Schweikert el at. 1976), muscle (Longcope et al. 1978)
and, as already discussed, the breast itself. The following discussion reviews the
possible biological significance in breast cancer of specific aspects of steroid
metabolism (Figure 12.2).
Synthesis of A5 androstenediol
The biological importance of A5-androstenediol resides in its oestrogenic activity
(Adams 1983). The steroid binds to oestrogen receptors (Thijssen et at. 1975) and is
capable of eliciting oestrogen-mediated responses, for example induction of pro¬
gestogen receptors (Kreitman & Bayard 1979). Concentrations of A5-androstenediol
required for these effects are about 2nM (Adams et al. 1981), which is about 40-foid
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higher than the level of oestradiol necessary for the same response. Thus, where
oestradiol levels are low in comparison with androgens, as for example in postmeno¬
pausal women, A5 androstenediol may act as an oestrogen, or at least supplement the
stimulus of natural oestrogens.
Measurements of relative levels of A5 androstenediol in tumours (Adams et at.
1980; Maynard el at. 1978; Van Landeghem 1984) support the concept that the
steroid has an oestrogenic potential, particularly in cancers from postmenopausal
women. It remains to be determined whether the tumour concentrations of A5 andro¬
stenediol result from local synthesis. Breast cancers have the capacity to convert
DHA and its sulphate to A5 androstenediol (Adams 1983; Couch el at. 1975) and
there are large amounts of these precursors in the breast (Miller el at. 1980). Further¬
more, as both free and conjugated DHA have very little oestrogenic activity (Adams
et at. 1981) their conversion to A5 androstenediol would necessarily increase the
oestrogenic environment of the tumour.
5a-reduction
5a-reduced androgens are among the most potent androgenic steroids and, indeed,
5a dihydrotestosterone forms the natural ligand for androgen receptors (for review
see Liao 1977). Tissues which are sensitive to androgens invariably show high 5a-
reductase activity (Wilson 1972). It is therefore of interest that breast tissues may also
show a high potential for 5a-reduction (Miller et at. 1978) and that about 30-40 per
cent of breast cancers possess cytoplasmic androgen receptors (Miller et at. 1983b;
Persijn et at. 1975; Teuling et at. 1980). However, it has not been possible to show any
correlation between tumour 5a-reduction and the presence of androgen receptors
(Mason 1981) and despite a recent report (Hackenberg et at. 1984) anti-androgen
therapy has produced little impact on the treatment of breast cancer.
If, therefore, tumour 5a-reductase activity is of biological significance, it is likely
to be independent of androgen receptors. For example, since 5a-reduced steroids are
powerful inhibitors of aromatase activity (Gower & Cooke 1983), tumour 5a-
reductase activity might control oestrogen biosynthesis in situ. In keeping with this,
an inverse correlation has been reported between 5a-reduction and aromatase activity
in breast-cancer cells (Perel et at. 1984b). Some synthetic androgens which have been
used successfully in the treatment of advanced breast cancer have also subsequently
proved to be aromatase inhibitors (Dao 1982).
Aromatase
Amounts of oestrogen synthesised from added substrate during in vitro incubations
of breast cancers are sufficient to elicit oestrogen-mediated events (Miller et at.
1982a). However, calculations on the concentrations of androgen precursors present
as endogenous substrate in the tissue suggest that tumour aromatase is likely to
produce sufficient oestrogen for meaningful responses in only about ten per cent of
all breast cancers (Bradlow 1982; Tilson-Mallett et at. 1983). Although this may
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represent only a small number of tumours, it could be significant if these were
restricted to the one-third of cancers which respond to oestrogen-deprivation therapy.
A critical factor in evaluating the significance of aromatase activity is the amount
of available androgen precursors. As the breast appears to concentrate certain of
these compounds (Bradlow et at. 1983), calculations based on the levels of circulating
androgen may be misleading. To date, little account has been taken of the high
concentrations of androgen conjugates which may be present in the breast (Miller &
Forrest 1983). In view of the existence of sulphatase activity within the breast (Adams
& Wong 1968), the pool of these precursors ought not to be overlooked in terms of
either being directly converted to oestrogen or acting as a reservoir to supplement the
flux of free androgen substrate.
Theoretical calculations indicate that tumour aromatase activity is insufficient to
account for the levels of endogenous oestrogen within the tumour (Bradlow 1982;
Tilson-Mallet et at. 1983), which in postmenopausal women may be greatly in excess
of concentrations in the plasma (Edery et at. 1981; Fishman et at. 1977; Millington et
at. 1974). However, it is equally difficult to account for these high endogenous levels
of oestrogen by other means. Tumour-oestrogen concentrations do not reflect levels
in peripheral plasma (Nagai etal. 1979; Valient et at. 1982). Nor has any reproducible
correlation been found between endogenous oestrogens and levels of oestrogen
receptors (Edery et al. 1981; Nagai et at. 1979; Van Landeghem et at. 1985), the
mechanism by which oestrogen would be most likely trapped within tumour cells.
The presence of aromatase activity in both oestrogen-positive and -negative
tumours and the lack of any relationship between aromatase and progestogen
receptor status (Table 12.2) does not necessarily argue against tumour oestrogen bio¬
synthesis being of physiological significance. Aromatase activity may have a
biological role independent of receptors or may be of significance only in steroid
receptor-positive tumours. Abul-Hajj (1975) has advocated the former possibility
suggesting that oestrogen-receptor-negative tumours appear endocrine independent
only because they can satisfy their hormone needs by means of their own biosynthetic
capacity. This seems unlikely because tumours responding to therapy with aromatase
inhibitors or antioestrogens (which ought to be effective irrespective of the source of
oestrogen) are invariably oestrogen-receptor-positive (Hawkins et at. 1980; Lawrence
et al. 1980). It seems more likely that if oestrogen biosynthesis is to be of significance,
it will be in oestrogen-receptor-positive tumours where a mechanism exists to process
the synthesized steroid. Indeed, if in situ synthesis is a major route by which certain
breast cancers obtain their oestrogen, then it might be expected that these tumours will
respond to therapies which inhibit tumour aromatase.
A study has been set up in which both tumour oestrogen receptors and potential
for aromatization are measured in oestrogen-receptor-positive tumours from post¬
menopausal women with advanced breast cancer who are to be subsequently treated
with aminoglutethimide, an aromatase inhibitor. The numbers of patients studied
are, as yet, small but preliminary data suggest that tumours with both high aromatase
activity and oestrogen receptors are most likely to respond (Table 12.3). Screening for
tumour aromatase may therefore select those most likely to respond to antiaromatase
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Tabic 12.3 Relationship between tumour aronialu.se and response to
aminoglutethimide in patients with advanced bieasl cancer. All turnouts were




1 0.18 Pariial regression
2 0.09 Partial regression
3 0.08 Partial regression
4 0.08 Partial regression
5 0.08 Progression
6 0.06 Partial regression
7 0.06 Progression
8 0.04 Partial regression
9 0.04 Progression
10 0.03 Pariial regression





•Figures refer to percentage production of oestradiol from lJH) testosterone by the
method described by Miller & Forrest (1974).
treatment. These data do not necessarily prove that such antiaromatase agents work
through tumour aromatase, which might simply be a marker of hormone
dependence, or reflect oestrogen synthesis in other peripheral tissues where the
primary action of aminoglutethimide resides. However, it would seem logical to
consider tumours which possess both oestrogen synthetic capacity and oestrogen
receptors as candidates for therapy with aromatase inhibitors.
It has been suggested that local oestrogen biosynthesis in breast cancers may
represent a mechanism whereby they can escape from normal hormonal control
(Abul-Hajj 1975). There is little evidence that with increasing autonomy breast
cancers are more likely to express aromatase activity, but escape from hormonal
control might occur by selection if cells requiring smaller amounts of oestrogen
survive and grow on the oestrogen produced as a result of their own aromatizing
potential. This residual tumour might be expected to respond to treatment with
aromatase inhibitors and, indeed, tumours responding to a previous endocrine treat¬
ment are likely to show a further response to aminoglutethimide therapy.
Oestrogen Metabolism
In comparison with oestradiol, oestrone sulphate has low biological potency, but it
is the major circulating oestrogen in postmenopausal women (Samojlik et at. 1982;
Vignon et at. 1980). Oestrone sulphate also represents a major precursor of tumour
oestradiol in that the enzymes required for the transformation of oestrone sulphate
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into ocstradiol are present in breast cancers (Wilking et at. 1980). This pathway
therefore provides another potential important source of active oestrogen.
A recent study has suggested that, at least in vitro, the activity of the sulphatase
enzyme performing the initial hydrolysis of ocstrone sulphate is quantitatively more
significant in breast cancers than the aromatase activity associated with de novo
synthesis of oestrogen (Santner et at. 1984). There is, however, a problem in assessing
the importance of oestrogen sulphatase in breast cancer in that certain tumours also
possess oestrogen sulphotransferase activity. These tumours, therefore, have the
potential to perform the reverse reactions, synthesizing oestrone sulphate from free
oestradiol. Thus, it is necessary to determine in which direction this metabolic
pathway normally proceeds in breast cancers.
A study in which breast cancers were simultaneously incubated with both
oestradiol and oestradiol sulphate showed that hydrolysis of oestrogen conjugates is
favoured and that the activity of oestrogen sulphotransferase is insufficient to reduce
active oestrogen levels (Tseng et at. 1983). This suggests that tumour-sulphatase
activity represents a major factor controlling concentrations of intracellular
oestrogen, despite the lack of correlation between levels of the enzyme and tumour
oestrogen and progestogen receptors (Table 12.2). However, it is worth emphasizing
that oestrogen sulphotransferase is sensitive to hormones such as progesterone
(Buirchell & Hahnel 1975) and that in vitro incubation in the absence of hormones or
with inappropriate concentrations of cofactors might produce misleading estimates
of the enzyme's activity in vivo. It is also difficult to ignore the association of
oestrogen sulphotransferase with steroid receptors (Table 12.2) and response to
endocrine therapy in patients with advanced breast cancer (Dao & Libby 1972).
CONCLUSION
Steroid metabolism within breast tissue is of especial importance because of the
sensitivity of this tissue to many of the resultant metabolites. Local synthesis is likely
to be most significant when the supply of preformed active hormone reaching the
breast declines after the menopause, although cystic tissue with its associated high
levels of conjugated steroid precursors may represent an exception.
The relatively high metabolic activity of breast cancers and the abundance of fat
within the breast mark these tissues as primary sites of biosynthesis. However,
because pathways of steroid inactivation also exist, the balance between synthesis and
degradation, particularly of oestrogens and oestrogenic hormones, might determine
whether cellular growth is stimulated or inhibited. It is therefore important to
identify the, as yet unknown, factors influencing steroid metabolism within the
breast so that the potential for local control can be exploited.
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Steroid metabolism in breast cancer W R Miller
Steroid hormones which may influence the
growth and development of both normal and
diseased breast are classically synthesized from
cholesterol along the pathways shown in Figure 1.
Initially, such biosynthesis was thought to be
exclusive to the gonads, adrenal cortex and
foetal-placental unit, but it is now realized that other
organs, including the breast and its tumours,
perform many of the transformations. Such
potential may have an important influence on the
steroid environment within the breast.
The evidence for the existence of such steroid
metabolism will be reviewed for breast cancer,
benign breast disease, normal breast tissue and
breast fat.
Steroidogenesis in breast cancer
Whilst the evidence that breast cancers can
synthesize active hormones from cholesterol is
unconvincing,1,2 there is no doubt that they can use
partially-formed precursors which have been
produced elsewhere and released into the
circulatory system. These "pro-hormones" include
androgens, such as dehydroepiandrosterone
(DHA) sulphate, which are produced by the adrenal
cortex3 and may accumulate in the breast in high
concentrations? Results of studies involving the in
vitro incubation of tumour5,6 or perfusion of
the breast in situ7 suggest that most, if not all,
breast cancers metabolise DHA sulphate to other
androgens such as DHA itself, A4-androstenedione
and testosterone. These metabolites are, in turn,
the more immediate precursors of active
hormones. For example, DHA may be converted to
A5-androstenediol? a product with oestrogenic
activity, and testosterone may be transformed into
potent androgens such as 5a-dihydrotestosterone
and 5a-androstenediols510 All breast cancers have
the capacity for 5a-reduction but the degree of
activity varies greatly between individual tumours.11
This appears to be related to the degree of
apocrine differentiation within the cancer, those
with marked apocrine differentiation showing
enhanced production of 5a-reduced metabolites.12
Testosterone and A4-androstenedione are the
immediate precursors of oestrogen (Fig. 1) and the
results of several groups of investigators have
demonstrated the process of aromatization - the
conversion of androgens into oestrogens by human
breast cancer cells?3~17 The proportion of cancers
which has this potential varies from approximately
50% to 100% in different reported series, and by
using a method of rigorous characterization we
have obtained evidence of oestrogen production in
over one half of breast cancers.18 The levels of
oestrogen synthesized are small in comparison
with those in classical endocrine organs such as
the ovary and placenta, but are comparable with, or
higher than, levels in other peripheral organs with
oestrogen biosynthetic activity.15,19
Because other cells, such as adipocytes, may
also produce oestrogen (see below), it is important
to demonstrate that oestrogen biosynthesis in
specimens of tumour tissue is truly associated with
cancer cells. In this respect, studies of cell lines of
breast cancers are of value and it is clear that,
under optimal culture conditions, breast tumour
cells will synthesize oestrogen from androgen
precursors?0 Furthermore, different clones of
malignant cells from the same tumour may display a
differing potential for oestrogen production, thereby
demonstrating heterogeneity of aromatase activity
in cells from a single tumour.21
Breast cancers also have the capacity to
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interconvert oestrogens (Fig. 1). Oestrone and its
sulphate represent the major (although relatively
inactive) circulating oestrogens in postmenopausal
women?2 but both may be metabolised by breast
cancers into the more potent hormone,
oestradiol?325 Equally, however, many breast
cancers can inactivate oestradiol by performing the
reverse conversions to oestrone23'26'27 or to
oestrogen conjugates?8 29 The balance of these
oestrogen interconversions might be critical in
determining the net oestrogenicity potential within
the tumour.
Steroidogenesis in benign breast disease
Benign breast disease encompasses a variety of
lesions. Whilst there is no evidence that any type of
benign breast tissue can transform cholesterol into
steroid hormones, interconversions of androgen
and oestrogen, such as those described for breast
cancer, occur also in several types of benign
lesions?'ia 17 23'26'30 In general, the transformations
occur to a lesser extent than in malignant tissue.
The exception is 5a-reduction in cystic disease30 in
which high levels of metabolites may be a reflection
of associated apocrine activity.
High levels of steroid hormones may be found in
fluids aspirated from breast cysts3132 where, for
example, the median value of DHA sulphate is
about 50-fold higher than that in plasma?3 As high
levels of oestrogen conjugates also are present in
cyst fluid but are not concentrated from plasma, it
has been inferred that these may be synthesized
locally from androgen precursors?4 However, no
direct evidence for aromatization by breast cysts
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has been documented.
Steroidogenesis in normal breast tissue
Specimens of normal breast tissue taken from
mastectomy specimens in an area far removed
from any malignancy, show evidence of
steroidogenic potential?'10,17,26 30 The metabolism of
progestogens, androgens and oestrogens has
been reported. The levels of conversion in normal
breast tissue are generally lower than those in
benign or malignant breast tissues, and this may be
due in part to the low cellularity of "normal" resting
breast tissue.
Although it is possible that the normal breast may
synthesize oestrogens, most workers have not
detected a steroid-aromatizing potential in normal
breast tissue.11'15'36 The only group of investigators
to report oestrogen biosynthesis described
activities in normal tissue which were much lower
than those found in parallel incubations of
malignant tissue.19 The general inability to detect
oestrogen biosynthesis in normal breast tissue may
be due to its low cellularity. Studies of cell lines in
culture should help to overcome this problem and,
whilst an earlier study failed to show aromatization?0
recently, biosynthesis has been detected in
epithelial cells derived from human milk?6
Steroidogenesis in breast fat
In postmenopausal women, aromatization in
peripherally-distributed fat probably provides one
of the major sources of circulating oestrogen?7 and
there are positive correlations between body
weight, degree of obesity and levels of plasma
oestrogens?8 39 Samples of fat from various parts of
the body, including the breast, have been shown to
synthesize oestrogen in vifro.40,42 In view of the
relative increase in the proportion of fat to
parenchyma in the breast after the menopause,43
local production of oestrogen by breast fat may be
particularly important in the case of
postmenopausal women.
Control of steroid metabolism in the breast
As in the case of classical endocrine organs,
steroidogenesis in the breast is probably primarily
controlled by polypeptide hormones, but the
particular hormones involved are yet to be
identified. Thus, whilst prolactin is trophic for the
breast?4-46 drug-induced hyperprolactinaemia in
patients with breast cancer is not associated with
differences in steroid metabolism either by normal
or malignant breast tissue?7
The metabolism of steroid hormones is also
modulated by the steroids themselves?8 For
example, progesterone appears to increase
17/3-hydroxysteroid dehydrogenase activity in
breast fibroadenomas?9 and would account for the
maximum enzyme activity found in normal breast
tissue during the early secretory phase of the
menstrual cycle?0 It has also been suggested that
5a-reduced androgens, which are inhibitors of
oestrogen biosynthesis, might provide an
intracellular control of aromatase activity in
breast cancers?1
A marked induction of aromatase activity occurs
in cultures of cells from either breast cancer or
adipose tissue in the presence of Cortisol and
dexamethasone?2-53 Whether such hormonal
effects apply only to the given culture conditions or
are reproduced also in vivo, is not known.
Relationship to steroid receptors
There has been considerable interest shown in
the possible association between oestrogen
biosynthesis and oestrogen receptors. It is clear
that oestrogen production may be demonstrated in
both receptor-positive and receptor-negative
tumours.14'16,18 There is, however, no consensus of
opinion about whether oestrogen receptor-positive
tumours are more or less likely to produce
oestrogen than their receptor-negative
counterparts.
Several factors may account for the disparity
between results; these include different cut-off
values for defining oestrogen receptor-positive
tumours, different substrates and methods for
assessing tumour aromatase, and the variation in
detection limits associated with different
characterization techniques for oestrogen. Our
own studies18 showed that within the group of
oestrogen receptor-positive tumours, the level of
receptor was significantly higher in cancers
producing oestrogen than in those without
biosynthetic activity. However, the level of oestrogen
synthesis does not generally differ between
oestrogen receptor-positive and receptor-negative
tumours.16,18,54
Other aspects of oestrogen metabolism in
tumours have been shown to be significantly
related to the presence of oestrogen receptors.
Thus, there are higher levels of the oestradiol
17/j-dehydrogenase enzyme (which converts
oestradiol into oestrone) in oestrogen receptor-
poor tumours, compared with those which are
receptor-rich27 Several groups have shown that
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there is also a positive correlation between the
ability of tumour cells to sulphate oestrogen and the
presence in the tumour cells of oestrogen
receptors?9 55,56
Conflicting data have emerged over the
relationship between oestrogen receptors and the
production of 5a-reduced androgens. Abul-Hajj57
observed, in a small number of tumours, a positive
correlation between these parameters, whereas
our investigations on a larger series of cancers
derived from postmenopausal patients alone,
showed higher 5a-reductase activity in oestrogen
receptor-negative tumours?8 No significant
relationship has been reported between levels of
tumour androgen receptors and the production of
the natural binding steroid, 5a-dihydrotestosterone.
Biological significance of steroidogenesis in
breast cancer
If steroid metabolism within the breast is of
biological importance, its role must be local within
the breast itself. Effects at sites distant from the
breast are improbable because of the relatively low
levels of steroid interconversions within breast
tissues and because, unlike the case of lung
tumours?9 widespread responses attributable to
inappropriate hormone production have not been
reported in patients with breast cancer.
Local hormone biosynthesis is unlikely to be
significant in premenopausal patients with breast
cancer, in whom the ovary releases sufficient
steroid hormones into the circulation to account for
the maintenance of hormone-dependent neoplastic
growth. It may be of greater importance in the case
of premenopausal cystic disease, in which high
levels of steroid conjugates are present within the
cyst fluid?132 Even a small conversion of these
inactive precursors into more active products might
be associated with marked changes in the
hormonal milieu within the breast.
In postmenopausal women, steroid metabolism
by the breast may have particular relevance to
patients with hormone-dependent breast cancer.
After the menopause, the ovary ceases to produce
oestrogen and progestogen, although it still
secretes some androgen?0 The adrenal cortex also
synthesizes little oestrogen61 and, whilst it
produces large amounts of androgens such as
androstenedione, dehydroepiandrosterone and its
sulphate?162 these steroids appear to be largely
inactive within the breast. Nevertheless, such
androgens may be metabolised at peripheral sites,
including the breast, into hormones which do have
biological effects on breast cells. It is pertinent,
therefore, to consider further the biological
significance to breast cancer of some specific
aspects of the local metabolism of androgens and
their metabolites (Fig. 2).
Synthesis of A5-androstenediol
The biological importance of A5-androstenediol
resides in its oestrogenic activity. The steroid binds
to oestrogen receptors?3 and is capable of eliciting
oestrogen-mediated responses, eg, the induction of
progestogen receptors64 The concentrations of
A5-androstenediol required for these effects are
about 2nM?3 which is about 40-times higher than
the level of oestradiol necessary for the same
response. Thus, where oestradiol levels are low in
comparison with androgens (as, for example, in
postmenopausal women) A5-androstenediol may
act as an oestrogen, or at least supplement the
stimulus of natural oestrogens.
Results of measurements of the relative levels of
A5-androstenediol in tumours63'65 support the
concept that the steroid has an oestrogenic
potential in breast cancers in postmenopausal
women, but it is not clear whether the tumour
concentrations of A5-androstenediol result from
local synthesis. Breast cancers certainly have the
capacity to convert DHA and its sulphate to
A5-androstenediol6'63 and there are large amounts
of these precursors in the breast4 Whilst both free
and conjugated DHA have very little oestrogenic
activity,63 their conversion to A5-androstenediol
would increase the oestrogenic environment of the
tumour.
5a-reductiort
5a-reduced androgens are amongst the most
potent androgenic steroids, and
5a-dihydrotestosterone forms the natural ligand for
androgen receptors. Tissues which are sensitive to
androgens invariably show high 5a-reductase
activity66 and breast tissues may show a high
potential for 5a-reduction. About 30-40% of breast
cancers possess cytoplasmic androgen
receptors67 68 but no correlation has been shown
between 5a-reduction and the presence of
androgen receptors in tumours, and anti-androgen
therapy has produced few advances in the
treatment of breast cancer.
If, therefore, 5a-reductase activity in the tumour
is of biological significance, it is likely to be
independent of androgen receptors. For example,
since 5a-reduced steroids are powerful inhibitors
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Figure 2
Metabolic transformations producing major changes in biological activity of steroids (a) formation of the
oestrogenic androgen, A5-androstenediol (b) synthesis of the potent androgen, 5a-dihydrotestosterone
(c) aromatization of androgens to oestrogens (d) interconversion of oestrogens either by






















of aromatase activity,48 5a-reductase activity in the
tumour might control oestrogen biosynthesis in
situ. In support of this hypothesis, an inverse
correlation has been reported between
5a-reduction and aromatase activity in breast
cancer cells.61 Some synthetic androgens, which
have been used successfully in the treatment of
advanced breast cancer, have also subsequently
proved to be aromatase inhibitors?9
Aromatase activity
The potential importance of tumour aromatase is
that oestrogen-dependent tumours may satisfy
their hormone requirements by their own capacity
to synthesize oestradiol. However, whilst it is clear
that over 50% of breast cancers has the potential
for aromatization, there are doubts as to the
relevance of the small levels of activity detected in
the majority of tissue samples incubated in
vitro.54'70 Theoretical calculations based on in vitro
conversion rates, estimates of available androgen
precursor and the concentration of oestrogen
required to interact with oestrogen receptors,
suggest that tumour aromatase produces an
effective level of oestrogen in only about 10% of all
breast cancers. This could be of significance if
these tumours were among the one-third of
cancers which respond to oestrogen deprivation
therapy.
There are of course, problems in interpreting
results quantitatively from in vitro studies designed
to detect potential for aromatization rather than to
reflect conditions in situ. For example, little account
has been taken of the high concentrations of
androgen conjugates within the breast which could
supplement the oestrogen precursor pool. Equally,
concentrations of oestrogen substantially less than
those required to saturate oestrogen receptors can
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maintain the growth of hormone-dependent cells'1
Until comparative studies of tumour aromatase
have been performed in cancers with high and low
endogenous concentrations of oestrogen, the
relative contribution of local biosynthesis to the
pool of active hormone cannot accurately be
assessed.
The presence of aromatase activity in both
oestrogen receptor-positive and receptor-negative
tumours,14'16'18 and the lack of any relationship
between aromatase and progestogen-receptor
status54 does not necessarily preclude the
physiological significance of tumour oestrogen
biosynthesis. Aromatase activity may have a
biological role independent of receptors, or it may
be of significance only in steroid receptor-positive
tumours. Abul-Hajj72 has advocated the former
possibility, suggesting that oestrogen receptor-
negative tumours appear endocrine-independent
only because they can satisfy their hormone needs
by means of their own biosynthetic capacity.
This seems unlikely, because tumours responding
to therapy using aromatase inhibitors or
anti-oestrogens (which ought to be effective
irrespective of the source of oestrogen), are
invariably oestrogen receptor-positive73,74 It is
much more likely that if oestrogen biosynthesis is of
significance, it will be in oestrogen receptor-positive
tumours in which a mechanism exists to process
the synthesized steroid.
It has been suggested that local oestrogen
biosynthesis in breast cancers may provide a
mechanism whereby the tumours can escape from
normal hormonal control?2 Whilst there is little
evidence that, with increasing autonomy, breast
cancers are more likely to express aromatase
activity, escape from hormonal control might occur
by a selection process if cells requiring smaller
amounts of oestrogen survive, and are stimulated
by the oestrogen produced as a result of their own
aromatizing potential. This residual tumour might be
expected to respond to treatment with aromatase
inhibitors and indeed, tumours responding to a
previous endocrine treatment are likely to show a
further response to aminoglutethimide therapy.73
Oestrogen metabolism
In comparison with oestradiol, oestrone sulphate
has a low biological potency, but it is the major
oestrogen in the circulatory system of
postmenopausal women?2 24 Oestrone sulphate
also represents a major precursor of tumour
oestradiol, in that the enzymes required for the
transformation of oestrone sulphate into oestradiol
are present in breast cancers?5 This pathway,
therefore, provides another potentially important
source of active oestrogen.
Results of a recent study have suggested that, at
least in vitro, the activity of the sulphatase enzyme
performing the initial hydrolysis of oestrone
sulphate is quantitatively more significant in breast
cancers than the aromatase activity associated
with the de novo synthesis of oestrogen?5 There is,
however, a problem in assessing the importance of
oestrogen sulphatase in breast cancer, in that
certain tumours also possess oestrogen
sulphotransferase activity. These tumours,
therefore, have the potential to perform the reverse
reaction, synthesizing oestrone sulphate from free
oestradiol. Although sulphatase activity appears to
predominate in disrupted cell preparations?6 it is still
not clear in which direction the metabolic pathway
normally proceeds in breast cancers in situ.
Conclusion
Steroid metabolism within the breast is of
especial importance because of the sensitivity of
breast tissue to many of the resultant metabolites.
Local synthesis is likely to be most significant when
the supply of preformed active hormone reaching
the breast declines after the menopause, although
cystic tissue, with its associated high levels of
conjugated steroid precursors, may represent an
exception.
Steroid metabolism in breast cancers and breast
fat merits particular interest. Pathways of steroid
activation and inactivation exist and the metabolic
balance might determine whether cell growth is
stimulated or inhibited. Because of this, it is
important to identify the factors controlling steroid
metabolism within the breast. It may then be
possible to harness the potential to modify the
intracellular environment of hormones and thereby
influence growth.
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The metabolism of dehydroepiandrosterone (DHA) and
testosterone by both human breast carcinomata and dimethyl-
benzanthracene (DMBA)-induced rat mammary carcinomata has been
investigated.
The rat and human carcinomata converted DHA to testosterone
and both DHA and testosterone to 5a(-dihydrotestosterone, 5«-
androstanediol and l6o(-hydroxytestosterone. Tentative evidence
is also presented to indicate that some rat adenocarcinomata
can convert androgen precursors into estradiol-17/3.
Although quantitative differences between incubations
occurred, the spectrum of steroid transformations was similar
in both human and rat tumours. The DMBA-induced rat tumour may
therefore prove to be a valuable experimental model for human
carcinoma tissue with regard to further steroidogenic studies.
INTRODUCTION
The DMBA-induced rat tumour has many characteristics which
are similar to those possessed by human breast carcinoma. Many
of the tumours are hormone responsive ^ ^, and some possess an
estrogen receptor protein similar to that found in human
(2)
carcinomata , a property correlated with their hormone
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responsiveness . It has also been shown that the DMBA-induced
rat carcinoma is capable of performing steroid conversions,
(4 5)
metabolising both DHA and testosterone ' . Recently similar
paraendocrine behaviour has been demonstrated in human carcinomata
(6 7)
. The present paper describes a direct comparison of human
and DMBA-induced rat carcinomata by identical methods to determine
their capacity to transform DHA and testosterone into steroids
which may influence tumour growth.
MATBRIAIS AND METHODS
Steroids
(7°^h)-DHA and (4-"'*^C)-testosterone were obtained from the
radiochemical centre (Amersham) and were found to be
chromatographically homogeneous in the major solvent systems used.
Immediately before use, however, both precursors were purified by
thin layer chromatography (TLC) in solvent system I (Table l).
Unlabelled steroids were obtained from Sigma Ltd., Kingston-
upon-Thames, Surrey; Steraloids Ltd., Croydon, Surrey; and
Ikapharm Ltd. (Israel). The MRC steroid reference collection
generously donated samples of l6o(-hydroxytestosterone.
Human Tumour Tissue
Breast carcinoma tissue was obtained at operation from three
patients. Patient I was aged 50 years, the breast tumour weighed
about 1 g. and was histologically intraduct cancer with a small
focus of invasion. Patient II was aged 40 years. The tumour was
large (approximately 20 g.) and histologically was a non-
differentiated carcinoma of large cell type. Patient III was aged
50 years. The tumour weighed about 4 g. and histologically was a
carcinoma of unknown origin (possibly apocrine).
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Rat Tumour Tissue
Tumours were induced in five 50 day-old female Sprague Dawley
rats with a single dose of dimethylbenzanthracene (30 mg. in 2 ml.
cottonseed oil) given by gastric intubation. Tumours were collected
after killing the rats by cervical dislocation. Histology of the
tumours revealed a squamous carcinoma in Rat II and adenocarcinoma
in all other rats (two adenocarcinomata were present in anatomically
different regions in Rat I - (a) from the inguinal area, and (b)
from the cervical area).
Preparation of tumour tissue and conditions of incubation
The tumours were maintained at 0°C after removal and
incubations were carried out within 30 minutes of removal. Any
adhering fat and normal mammary tissue was removed. The tumours
were then finely sliced. Krebs-Ringer phosphate buffer pH 7.4
(lO ml/g. tumour) was added and sonicated twice for 1 minute with
cooling for 1 minute between sonications. A NADPH generating
system (200 mol. glucose-6-phosphate, 25 mg. NADP and 50 units
glucose-6-phosphate dehydrogenase) was added before the addition
of the purified radioactive precursors (about 20 )ic (7 o(-3h)-DHA
and 2 ^c (4-"^C)-testosterone in 0.1 ml. propylene glycol:ethanol,
l:l). The tumour slices were then incubated by shaking at 37°c
for two hours in an atmosphere of 02• The reaction was stopped
by adding methanol to Q(f/i (v/v) and the incubations stored at
-10°c until processed.
Extraction and Fractionation of steroids
Before extraction, 500 ^g of the non-radioactive carrier
steroids to be investigated were added. The mixture was then
homogenized, centrifuged and the resulting supernatant decanted
off. The residue was rehomogenised with 2 x 20 ml. acetone and
the acetone washings were combined with the aqueous methanol
supernatant and evaporated to dryness. This residue was dissolved
in aqueous methanol and separated into neutral and phenolic fractions
as described by Fahmy, Griffiths, Turnbull and Symington ,
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Characterization of Metabolites
Chromatographic Separation of Steroids
Thin layer chromatography on silica gel HF 254+366 and
alumina PF 254+366 was used to isolate and purify the individual
steroids. The fractionation procedure for the neutral steroids
is shown in figure 1. The solvent systems used are summarised in
Table 1. The phenolic fraction was separated into estrone and
estradiol-17/3 fractions by TLC in system VIII. The individual
estrogens were run as the acetates in TLC system Ilia and then,
after saponification, in system IX.
The steroids were detected on the plates by absorption of
U.V. light at 254 or 350 nm and eluted with ethanol after
deactivation of the gel with a few drops of distilled water.
Microchemical reactions
Acetates were prepared by the method of Zaffaroni and
Burton
Saponification of the steroid acetates and oxidation of free
steroids were performed as described by Griffiths et jfL (10).
Reduction of steroids was performed by adding 10 mg. solid
sodium borohydride to the steroid dissolved in 1 ml. methanol
and leaving the mixture for 15 min. at room temperature.
In all cases steroids were recovered by extraction with
2x5 ml. ethyl acetate after the addition of 3 ml. distilled
water.
Measurement of radioactivity
Radioactivity was measured with a Nuclear-Chicago liquid
scintillation counter Mark I Model 6860. Counting conditions
were such that 14c an^ 3jj could be determined simultaneously
with efficiencies in channel I and II, respectively, of 12$ and
52$ for ^4c, and 45$ and C$ for The absolute quantities of
3h were calculated from readings in channel I after correction
for 14c counts (H' and those for from direct readings on
channel II, no counts being present in this channel under the
conditions specified. No quenching was detected.
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TAB LB I
TLC SOLVENT SYSTBHS AMD CONDITIONS USED TO
PURIFY AND IDENTIFY STEROIDS












Cyclohexane: ethyl acetate (70:30)
Cyclohexane: ethyl acetate (70:50)
Chloroform: ether: acetone:
cyclohexane (lO:50:1:140)
Chloroform: ether: acetone: hexane
(10:50:6:140)
Ethylacetate: ri-hexane: acetic acid:
alcohol (72:13.5:10:4.5)
Ethylacetate: n-hexane: acetic acid
(75:20:5)
Cyclohexane: ethyl acetate (55:45)













XI Cyclohexane: ethyl acetate (50:50)
Unless stated otherwise, silica gel HF 254+366 plates were used in a
Shandon Chromatank. The solvent was run to the top of the plate
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Measurement of unlabelled steroids
Testosterone, l6ot-hydroxytestosterone and derivatives were
determined by U.V. absorption at 240 nm.
All other steroids were measured by GLC analysis on a 5 ft.
column of 3/» 0V1 on Gas Chrom Q (lOO - 120 mesh) (Applied Science
Laboratories Inc.) at 223°C. Testosterone (for free steroids) and




Evidence for the identification of the steroids isolated from
the incubations is summarised in Table 2 (Human Tumours) and Table
3 (Rat Tumours).
Characterization is based on (a) derivative formation;
(b) comparison of the chromatographic mobilities of the free and
derivative steroids with those of authentic steroids; and (c)
consistency between the specific radioactivity (S.A.) of the
purified parent steroid and its prepared derivatives.
Metabolism of DHA
The distribution of radioactivity among the metabolites is
shown in Table 4 and is expressed as percentage of the initial
radioactivity added as DHA. The percentage conversions were
calculated from the average S.A. of each steroid and its
derivatives.
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In each incubation most of the counts remained associated
with DHA. Small but significant H labelling was associated with
testosterone, 50£-dihydrotestosterone and 5o(-androstanediol in
both rat and human tumour incubations. The counts found in these
metabolites were always in excess of 20 x that of background for
testosterone and 5o(-androstanediol fractions, and 10 x that of
background for 5°(-DHT fractions. In each case such JE labelling
gave consistent specific radioactivities in the parent steroid and
derivatives. Similarly the ^h/^C ratios were constant in parent
steroids and derivatives (Tables 2 and 3).
Low counts (more than 4 x background) were also found in
l6fi(-hydroxytestosterone fractions from each human tumour
incubation and two of the rat tumour incubations. Because of the
low radioactivity associated with these fractions, only a single
derivative (the diacetate) was prepared for characterization.
Nevertheless, the specific activity and ^h/^C ratio were
unchanged from parent steroid to derivative.
Similar low levels of % counts were associated with the
estradiol-17j3 fraction from the incubations of the two tumours
from Rat I. The specific % activities and ^e/^C ratios were
constant for the diacetate derivative and parent est radio1-I7j9 in
both fractions. Counts in the corresponding estradiol-17/3
fractions from incubations of human and the other rat carcinomata
CHROMATOGRAPHICSEPARATIONANDPURIFIC TIONOFNEU R LTER IDEXT ACT
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were insufficient to permit characterization. There was no
evidence in any incubation for the formation of estrone.
Metabolism of testosterone
The distribution of radioactivity among the metabolites
isolated is shown in Table 5, the percentage conversions being
calculated in the same manner as those for the metabolites of DHA.
A large proportion of the counts remained associated with
the testosterone precursor in each incubation. There was, however,
greater metabolism of the precursor in the incubations of rat
tissue. In each incubation there was significant labelling
of 5°<-DHT fractions, indicating the presence of 5°C—reductase
activity in the tumours. The level of transformation to 5<X-DHT
was, however, variable, particularly in the rat tissues. Further
evidence for the 5«reduction of testosterone was obtained from
5°C—androstanediol fractions. In all incubations where these
fractions were examined, significant labelling with was
detected.
Small but significant counts (at least 5 x that of
background) were associated with Kft-hydroxytestosterone
fractions from each human tumour incubation and four of the six
rat tumour incubations. The specific activity of these
fractions was alike whether the l6o(.-hydroxytestosterone was
assayed as the free or acetylated steroid.
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Certain of the DHA fractions (Human I, Rat II, IV and V) were
clearly labelled with -"Q - evidence for the conversions of
testosterone to DHA. Similarly -^C counts were detected in DHA
fractions from the other incubations, but at a lower level, which
may represent small incorporation from testosterone.
Low levels of -^C counts were associated with estradiol-17_/3
fractions in the two adenocarcinomata from Rat I. Although the
counts were low (4 x background) the specific activity and
-'h/I'^c ratio were similar in each purified estradiol-17|3 fraction
and its diacetate derivative. Radioactivity in the estradiol-17/3
fractions from all other incubations was too small to allow
characterization. No evidence was found for the formation of
estrone from testosterone in any incubation.
Discussion
(6 7 12)
Several groups of workers ' ' have shown that human
breast cancer may act as a paraendocrine organ by metabolising
steroid hormones. The present study confirms the work of these
authors. It was possible to demonstrate that human breast cancer
tissue can convert DHA to testosterone and both DHA and
testosterone to 5<<-dihydrotestosterone and 5°6-androstanediol in
significant amounts. I6o(-hydroxylase activity was also
demonstrable as evidenced by the production of small amounts of
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labelled. I6o(-hydroxytestosterone in the incubations. The
magnitudes of these transformations were very similar to those
previously reported.
In none of the three human carcinomata examined in the
present study was it possible to detect the production of
either estradiol-17/3 or estrone from the steroid -precursors.
(7)
Jones et al , however, have reported a production of estrone
from 4-androstenedione (0.005fO and DHA (0.0005?S) by human
carcinoma. These levels of conversion would be difficult to
detect using the methods employed in this study.
The rat mammary tumours induced by intragastric
instillation of DMBA were also able to convert DHA to
testosterone and both precursors to 5°(-DHT, 5<*-androstanediol
and 1601-hydroxytestosterone. The magnitude of these
conversions were close to those reported in similar rat
(4)
tumours by King, Gordon and Helfenstein . In the present
study, however, there was also some evidence of aromatization
of steroid precursors in two adenocarcinomata obtained
from a single rat. This activity has not been previously
reported in the DMBA-induced rat adenocarcinoma.
It is interesting to note that the steroid transformations
performed by the two adenocarcinomata obtained from different
sites in the same rat were remarkably similar. It may
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therefore be possible to pool histologically similar tumours
from the same animal in future studies.
The steroid interconversions described are not unique to
mammary carcinomata and have been found in normal human breast
and mammary tissue from pregnant rats The
interconversions, however, assume an additional importance in
mammary carcinomata as the resulting metabolites may influence
the growth of the tumour It is therefore essential to have
an experimental animal model for the human carcinoma in order to
determine which factors are able to affect steroid metabolism in
mammary tumours.
The results from the present study indicate that the
DMBA-induced rat carcinoma and human breast cancer are alike in
their capacity to metabolize steroid hormones. Although there
are quantitative differences between incubations, the spectrum
of activity in both rat and human tumours is identical. This
is further justification for the use of the DMBA-induced rat
tumour as an experimental model for the human breast carcinoma.
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The following trivial names have been used, in the text:
Dehydroepiandrosterone, D.H.A. = 30-hydroxy-5-androsten-17 -one
D.H.A. acetate = 3/J acetoxy-5-androsten-17 -one
5 «cDihydrotestosterone, D.H.T. = 17/3-hydroxy-5o(.-androstan-3-one
5<cD.H.T. acetate = 17/3-acetoxy-5oc-androstan-3-one
Testosterone = 17/3-hydroxy-4-androsten-3-one
Testosterone acetate = 17/E-acetoxy-4-androsten-3-one
l6<t-hydroxytestosterone = 16<V, 17/3-dihydroxy-4-androsten-3-one
l6<.-hydroxytestosterone diacetate = 16<*, 17^-diacetoxy-4-
androsten-3-one
5-androstenediol = 5-androstene-3/S, 17/3-diol
4-androstenedione = 4-androstene-3, 17-dione
5*-androstanediol = 5°d-androstane-3/J, 17/5-diol
5°<—androstanedione = 5<<-androstane-3, 17-dione
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Hyperprolactinemia and Steroid Metabolism by Rat Mammary
Adenocarcinomas1
William R. Miller
Department of Clinical Surgery, University Medical School, Edinburgh EH8 9AG, Scotland
SUMMARY
The metabolism of both testosterone and dehydroepian-
drosterone by 10 adenocarcinomas induced and grown in
the presence of high prolactin (plasma prolactin > 220
ng/ml) was compared with the metabolism of 10 adenocarci¬
nomas induced and grown in the presence of normal levels
(plasma prolactin < 60 ng/ml). The tumors associated with
high prolactin significantly metabolized more testosterone
to both 5a-dihydrotestosterone and 5a-androstanediol. The
metabolism of dehydroepiandrosterone was similar in both
groups of tumors. It is concluded that prolactin may differ¬
entially influence the metabolism of C19 steroids by rat mam¬
mary adenocarcinomas.
INTRODUCTION
The growth and development of rat mammary tumors are
influenced by prolactin (5, 10, 12). There is an increased
occurrence of mammary tumors in rats having high levels of
plasma prolactin (1, 14), and elevation of plasma prolactin
levels accelerates the growth of mammary tumors (4, 13).
Rat mammary tumors also demonstrate paraendocrine activ¬
ity and metabolize steroid hormones such as testosterone
and DHA2 (9, 11). The aim of the present study was to
determine the effect of raising prolactin levels on tumor
steriodogenesis.
MATERIALS AND METHODS
Animals. Two groups of random-bred female Sprague-
Dawley rats were studied. One group received s.c. injec¬
tions of perphenazine (5 mg/kg body weight) from 30 days
of age; the other group received daily doses of injection
vehicle (0.2% citric acid) from the same age. Both groups of
animals received 5 mg 7,12-dimethylbenzanthracene in a
single i.v. injection at 50 days of age. The mammary tumors
so induced were allowed to grow to a size of 2 x 2 cm. The
rats were then sacrificed in diestrous, when the tumors
were taken for incubation and blood was drawn for plasma
prolactin determination. Subsequent analysis of plasma pro¬
lactin allowed the animals to be divided into a group of
1 This work was performed with a grant from the Cancer Research Cam¬
paign, Grant SP 1256.
2 The abbreviations used are: DHA, dehydroepiandrosterone: 5a-DHT, 5a-
di hydrotestosterone.
Received March 24, 1975: accepted October 20, 1975.
animals receiving perphenazine, with values over 220 ng/ml
(high prolactin), and a control group receiving injection
vehicle, with values below 60 ng/ml (normal prolactin). Ten
adenocarcinomas from each group were investigated.
Tumor Incubation. All tumors were processed at 0° until
incubation was carried out (within 30 min of tissue re¬
moval). One g of each tumor was finely sliced in duplicate,
and Krebs-Ringer phosphate buffer, pH 7.4 (10 ml), was
added. The tissue was then sonically extracted twice for 1
min and an NADPH-generating system (200 /umoles glucose
6-phosphate, 25 mg NADP, and 50 units glucoses-phos¬
phate dehydrogenase) and the radioactive precursor (45/v.Ci
of either 7a-['!H]testosterone or Ta-piHjDHA) were added.
The tumor slices were then incubated by shaking at 37° in
an atmosphere of oxygen for 2 hr. The reaction was stopped
by adding methanol to 80% (v/v), and the incubations were
stored at -10° until processed.
Purification and Characterization of Metabolites. Before
extraction, 500 /xg of nonradioactive carrier steroids were
added to monitor recovery losses. The metabolites were
then extracted, separated into individual steroids, and puri¬
fied by thin layer chromatography, as described previously
(11). Each purified metabolite was characterized by compar¬
ing specific radioactivities of parent steroids and authenti¬
cated derivatives. The procedures for derivative formation
and measurement of cold steroids have been described
previously (11). The percentages of steroid metabolism and
interconversions were determined by measuring the per¬
centage of incorporation of radioactive label into the appro¬
priate metabolites after correction for recovery losses.
DNA Measurement. The DNA content of the tumors was
determined by a modification of the method of Burton (3).
RESULTS
Tumor Induction and Growth. There was a significant
difference between the 2 animal groups in their ages at time
of sacrifice (when the tumor size was approximately 2x2
cm), the mean age ± S. E. for the high prolactin group
being 184 ± 14 days and that for the normal prolactin group
being 226 ± 12 days. This difference was due to the in¬
creased growth rate of tumors from the high prolactin
group, there being no difference between the groups in the
time period of tumor induction.
Tumor Steroid Metabolism. A comparison of the percent¬
age of metabolism of testosterone by 10 adenocarcinomas
induced and grown in the presence of prolactin levels in
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excess of 220 ng/ml (high prolactin group) with that by 10
adenocarcinomas generated in the presence of values be¬
low 60 ng/ml (normal prolactin group) is presented in Chart
1. Despite the large spread of activity in both groups of
tumors, the tumors associated with high prolactin tended to
metabolize more testosterone, and the difference between
the groups was significant (p < 0.005). The percentages of
conversion of testosterone to 5a-DHT (Chart 2) and 5a-an-
drostanediol (Chart 3) showed a similar pattern, the transfor¬
mations in the high prolactin group being significantly in¬
creased (p < 0.005 in each case). When the percentages of
production of 5a-DHT and 5a-androstanediol were combined
as a percentage of 5a reduction (Chart 4), there was com¬
plete separation between the 2 groups of tumors, with all
the tumors from the high prolactin group showing greater
5a-reductase activity than did the normal prolactin group.
This increase in 5a reduction largely accounted for the
higher level of testosterone metabolized by the group of
tumors associated with high prolactin.
In contrast, as is shown in Chart 5, there was no differ¬
ence in the levels of DHA metabolized (as estimated by
determining the amounts of DHA remaining unmetabolized)
by the same 2 groups of tumors.
DNA Content. Sufficient material was available for DNA
estimations on 7 of the tumors from the high prolactin
group and 6 from the normal prolactin group. There was no
significant difference between the 2 groups, the mean ±
S. E. for the high prolactin group being 8.62 ± 1.14 mg/g


























Chart 2. Percentage of conversion of testosterone to 5a-DHT by 10 carci¬
nomas induced and grown in the presence of normal prolactin levels com¬
pared with 10 carcinomas induced and grown in the presence of high














Chart 3. Percentage of conversion of testosterone to 5a-androstanediol
by 10 carcinomas induced and grown in the presence of normal prolactin
levels compared with 10 carcinomas induced and grown in the presence of
high prolactin levels. Lines, mean ± S. E. for the group; p < 0.005.
normal high
prolactin prolactin
Chart 1. Percentage of metabolism of 7a-[3H]testosterone by 10 carcino¬
mas induced and grown in the presence of normal prolactin levels compared
with 10 carcinomas induced and grown in the presence of high prolactin
levels. Lines, mean ± S. E. for the group; p < 0.005.
DISCUSSION
These results indicate that elevation of prolactin during
tumor induction and growth gives rise to carcinomas with a




















induction period and that of tumor growth, it is not possible
to indicate whether these changes in tumor metabolism are
a result of the induction of tumors with different potential
for steroidogenesis or whether the differences in tumor
metabolism developed during the growth of the tumors. A
study is being carried out in which prolactin levels are
elevated only after tumor induction, to elucidate this point.
While prolactin has been shown to influence steroid me¬
tabolism in other tissues, such as prostate (2) and testis (6),
it is believed that this is the 1st indication that prolactin may
affect steroid metabolism in mammary tumors. This finding
may assume additional importance, as the 5<*-reduced me¬
tabolites involved are known to influence tumor growth (7,
8).
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Chart 4. Percentage of 5a reduction of testosterone by 10 carcinomas
induced and grown in the presence of normal prolactin levels compared with
10 carcinomas induced and grown in the presence of high prolactin levels.




Chart 5. Percentage of metabolism of 7a-[:,H]DHA by 10 carcinomas
induced and grown in the presence of normal prolactin levels compared with
10 carcinomas induced and grown in the presence of high prolactin levels.
Lines, mean ± S. E. for the group.
metabolism is largely accounted for by raised 5«-reductase
activity, which gives rise to increased production of both
5a-DHT and 5r*-androstanediol as compared with the con¬
trol group. It would seem that these changes in metabolism
are relatively specific, as the percentage of transformation
of another closely related CI9 steroid, DHA, was similar in
both groups of tumors. This would tend to indicate that the
increase in testosterone metabolism of the high prolactin
group is not a result of increased eellularity of tumors, a
conclusion supported by the similar DNA content of tumors
from both groups.
As prolactin levels were raised during both the tumor
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, Effects of Prolactin upon C19 Steroid Metabolism by Rat Mammary
Carcinoma
WILLIAM R. MILLER, ROBERT BUCHAN and A. P. M. FORREST
Department ofClinical Surgery, Medical School, University ofEdinburgh, Edinburgh
EH8 9AG, U.K.
It has been shown that mammary carcinomas induced in female Sprague-Dawley rats
by the administration of the carcinogen dimethylbenzanthracene may metabolize
steroid hormones (King et al., 1964,1965). The aim of the present study was to determine
the effects of increasing the circulating amounts of prolactin upon the metabolism of
dehydroepiandrosterone and testosterone in these tumours.
Two groups of female Sprague-Dawley rats, in whom adenocarcinoma were induced
by dimethylbenzanthracene (5mg intravenously at 50 days of age), were investigated.
One group received perphenazine (fentazin) in daily subcutaneous injections (5mg/kg
body wt.) from the age of 30 days to raise circulating prolactin amounts. The control
group received only vehicle (0.2% citric acid). A comparison of tumours believed
to be induced and grown in the presence of high and normal amounts of circulating
prolactin was therefore possible.
The metabolism of dehydroepiandrosterone and testosterone in vitro was determined
in ten adenocarcinomas from both groups ofanimals. A portion (1 g) of each tumour was
finely sliced in 10ml of Krebs-Ringer phosphate buffer. An NADPH-generating system
(200/j.mol of glucose 6-phosphate, 25 pg of NADP+ and 50 units of glucose 6-phosphate
dehydrogenase) and 45 Ci ofeither [7-3H]dehydroepiandrosterone or [7-3H]testosterone
were added. Incubation was immediately performed at 37°C for 2h in 02.
The steroid interconversions were determined by measuring the percentage incorpora¬
tion of radioactive label into the individual metabolites after extraction and purification
by t.l.c. Details of the methods of steroid purification and characterization have been
described by Fahmy et al. (1968) and Jones et al. (1970).
The metabolism of [7-3H]dehydroepiandrosterone was not influenced by perphen¬
azine treatment, no differences being found either in the amount of metabolism of
dehydroepiandrostcrone or the production of metabolites of dehydroepiandrosterone.
The results from the incubations with testosterone are presented in Table 1. The carci¬
nomas from the perphenazine-treated animals displayed significantly greater metabolism
of testosterone than those from control animals. The amount of metabolism varied con¬
siderably within each group, the variation being not only between individual animals but
between tumours from different sites within the same animal. Of the metabolities of
testosterone the mean production of 5a-dihydrotestosterone was higher (but not signifi¬
cantly so) in tumours from the perphenazine-treated animals. The conversion into 5a-
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By combining the production of 5a-dihydrotestosterone and 5a-androstandiol and ex¬
pressing the result as % 5a-reduction, an estimate of total 5a-reductase activity was
obtained. This was significantly higher in the perphenazine-treated group as compared
with the control group.
The conversion of testosterone into A-4-androstcnedione was also investigated. Al¬
though the mean amount of oxidation into A-4-androstenedione was significantly higher
in the perphenazine group, this was accounted for by two tumours, in which the amount
of oxidation was markedly raised. These two tumours had the lowest 5a-reductase acti¬
vity of the perphenazine group.
It is possible that the increased 5a-reductase activity demonstrated in tumours from
perphenazinc-treated animals is caused by differences in tumour cellularity. The findings
of similar metabolism of another C-19 steroid precursor, dehydroepiandrosterone, and
the similar conversion of testosterone into A-4-androstened ione in both groups of tumours
would, however, indicate that the effects on 5a-reduction of testosterone are relatively
specific. Further evidence for this has come from preliminary studies in which ovine pro¬
lactin (50^g/ml) has been added to incubation mixtures of dimethylbenzanthracene
adenocarcinomas in vitro with similar effects on testosterone metabolism.
Prolactin has been shown to influence the metabolism of testosterone in other steroid-
metabolizing organs. For example, Boyns et at. (1972) have demonstrated that prolactin
not only increased uptake of testosterone in rat prostatic cultures but changed the ratio
of 5a-dihydrotestosterone to testosterone in favour of the non-reduced form. This effect
upon 5a-reduction in the prostate is opposite to that demonstrated in the present study
of rat mammary tissue.
Boyns, A. R.,Cole, E. N., Golder, M. P., Danutra, V., Harper, M. E., Brownsey, B., Cowley, T.,
Jones, G. E. & Griffiths, K. (1972) in Prolactin and Caranogenesis (Boyns, A. R. & Griffiths,
K., eds.), pp. 207-216, Alpha, Omega, Alpha Publishing Co., Cardiff
Fahmy, D., Griffiths, K., Turnbull, A. C. & Symington, T. (1968) J. Endocrinol. 41, 61-68
Jones, D., Cameron, E. H. D., Griffiths, K.,Gleave, E. N. & Forrest, A. P. M. (1970) Biochem. J.
116, 919-921
King, R. J. B., Gordon, J. & Heffenstein, J. E. (1964) J. Endocrinol. 29, 103-110
King, R.J. B., Panattoni, M., Gordon, J. & Baker, R. (1965) J. Endocrinol. 33, 127-132
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The Effect of Perphenazine Treatment on Testosterone Metabolism by
Established Rat Mamillary Carcinomas
PETER BUCHAN, ALISON T. FRASER and WILLIAM R. MILLER
Department ofClinical Surgery, Medical School, University ofEdinburgh,
Edinburgh EHS 9AG, Scotland, U.K.
Mammary carcinomas may be induced in female Sprague-Dawley rats by the adminis¬
tration of the carcinogen 7,12-dimethylbenzanthracene. These tumours metabolize
testosterone (King et al., 1964), particularly by 5a-reduction to 5a-dihydrotestosterone
and 5a-androstanediol (Miller, 1976). In a previous study, tumours obtained from ani¬
mals rendered hyperprolactinaemic by giving perphenazine during the period of tumour
induction and growth showed enhanced conversion of testosterone into 5a-reduced
metabolites (Miller et al., 1974a). The aim of the present study was to determine if similar
effects could be elicited by administering perphenazine to animals with established
tumours and raising plasma prolactin concentrations during the growth period alone.
Tumours induced in female Sprague-Dawley rats by intragastric administration of
dimethylbenzanthracene (30mg in cotton-seed oil) at 50 days of age were measured
three times weekly by calipers. Animals bearing tumours showing continuous growth
were allocated to control or treatment groups when the tumour size was about 1.5 cm x
1.5cm. The treatment group received daily subcutaneous injections of perphenazine
(5mg/kg body weight) until being killed 12 days later. Control animals did not receive
the drug over the same time-period. Measurement of tumour size continued during
treatment until excision at death. The metabolism of testosterone in vitro was then de¬
termined in ten tumours from each group. A portion of each tumour (0.5 g) was finely
sliced and sonicated in 5ml of Krebs-Ringer phosphate buffer, pH7.4. An NADPH-
generating system (100/(mol of glucose 6-phosphate, 15/nriol of NADP+ and 25 units
of glucose 6-phosphate dehydrogenase) and 20/rCi of [7a-3H]testosterone were added
to give a final volume of 7.5ml. The incubations were then shaken in an atmosphere of
02 at 37°C for 1 h.
1976
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ascombinedconversioninto5a-dihydrote t stero end-andr stane i l.Signifi anciscal ul tbtWil oxoR nktes .N. , significant. Control Perphenazine-treated SignificanceMetabolism oftestosterone(%) 49.07±4.59 67.65±3.82 PcO.OlConversionint 5a-dihydrotestosterone(%) 5.98±0.98 17.28±3.54 P<0.05Conversioninto 5a-androstanediol(%) 26.68±4.47 44.66±2.90 PcO.Ol
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The steroid interconversions were determined by measuring the percentage incorpora¬
tion of radioactive label into the individual metabolites after extraction and purification
by t.l.c. Details of the methods of steroid purification and characterization have been
described by Miller et al. (19746).
When sufficient tumour material was available, the DNA content was measured by
the method of Burton (1956).
All but one of the tumours from the perphenazine-treated group showed an accelera¬
tion of growth during the treatment period, whereas those from control animals showed
no significant change.
The results from the incubations with [7a-3Htestosterone are summarized in Table 1.
Tumours from perphenazine-treated animals showed significantly higher metabolism of
testosterone than those from control animals. The major metabolites of testosterone in
tumours from both control and perphenazine-treated animals were 5a-dihydrotesto-
sterone and 5a-androstanediol. The conversion into both 5a-dihydrotestosterone and
5a-androstanediol was, however, significantly higher in tumours from the perphenazine-
treated group. The increase in 5a-reduction alone accounts for the higher concentrations
of testosterone metabolized by tumours from this group. These effects of perphenazine
are unlikely to be mediated by an increase in tumour cellularity, as the tumour DNA
content was similar in both groups of animals.
It is concluded that short-term administration of perphenazine stimulates growth
and testosterone metabolism in dimethylbenzanthracene-induced rat mammary carci¬
nomas. Preliminary results show that these changes were accompanied by an increase in
plasma prolactin.
Burton, K. (1956) Biochem. J. 62, 315-323
King, R. J. B., Gordon, J. & Helfenstein, J. E. (1964) J. Endocrinol. 29, 103-110
Miller, W. R. (1976) Br. J. Cancer 33, 474-477
Miller, W. R., Buchan, R. & Forrest, A. P. M. (1974a) Biochem. Soc. Trans. 2, 312-314
Miller, W. R., Forrest, A. P. M. & Hamilton, T. (19746) Steroids 23, 379-395
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perphenazine and Testosterone Metabolism by Mammary Tumours in
Oophorectomized Rats
PETER BUCHAN and WILLIAM R. MILLER
Department of Clinical Surgery, Medical School, University of Edinburgh,
Edinburgh EH8 9AG, Scotland, U.K.
Rat mammary tumours induced by the carcinogen 7,12-dimethylbenzanthracene in
female rats metabolized testosterone, particularly by 5a-reduction to 5a-dihydrotesto-
sterone and 5a-androstanediol (Miller, 1976). It has also been shown that these conver¬
sions were significantly elevated in tumours from animals treated with perphenazine
(2-{4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-l-yl}ethanol) (Buchan et a/.,
1976). Additionally, perphenazine stimulated tumour growth, raised plasma prolactin
concentrations and interrupted the normal oestrous cycle. To determine the relative
influence of prolactin and ovarian hormones on tumour growth and steriod metabolism,
the effects of perphenazine have been studied in oophorectomized animals.
Female Sprague-Dawley 50-day-old rats were given 7,12-dimethylbenzanthracene
(30mg in cottonseed oil) intragastrically. Tumours subsequently induced were measured
three times weekly by calipers throughout the study. Animals bearing tumours that
showed continuous growth were allocated to the treatment or the control group
when the tumour size exceeded 2cm x 2cm. The allocation was performed on the day of
dioestrus when all animals were bled from the tail vein and bilaterally oophorectomized.
The treatment group of rats additionally received daily subcutaneous injection of
perphenazine (5mg/kg body wt.) from the day of oophorectomy until death 14 days
later. Control animals received daily doses of the injection vehicle (corn oil) over the
same period. Immediately before death, blood was taken for plasma prolactin
determination by radioimmunoassay, and tumours taken for steroid metabolism
studies in vitro. Ten tumours from both animal groups were investigated: 0.5g of each
tumour was finely sliced and incubated at 37 C for 1 h in 5ml of Krebs-Ringer phos¬
phate buffer, pH 7.4, containing 20,uCi of [7a-3H]testosterone and NADPH-generating
system (Buchan et a/., 1976). Methods for purification and characterization of testo¬
sterone and its metabolites have been described in detail previously (Miller etal., 1974).
The effects of the treatment regimes on plasma prolactin concentrations are shown in
Table 1. Both groups of animals had similar prolactin values at the time of allocation.
However, whereas oophorectomy alone resulted in a fall in plasma prolactin concen¬
tration in each animal, oophorectomy in combination with perphenazine treatment
produced an increase in prolactin in all animals. The difference between pre- and post-
treatment values was significantly for both animal groups.
Oophorectomy alone produced an immediate regression of all tumours. In the
oophorectomy-plus-perphenazine group, however, there was a variable response in
tumour growth, certain tumours increasing in size throughout the time of study whereas
others regressed, usually after a short period of continued growth.
The metabolism of [7a-3H]testosterone by tumours from both groups of animals is
shown in Table 2. Tumours from animals given perphenazine in addition to oophorect-
Table 1. Effect of oophorectomy and subsequent perphenazine administration on plasma
prolactin concentrations
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Table 2. Metabolism of [7a-3H]testosterone by tumours from the animal groups studied
Significance, by Wilcoxon-Rank test, of perphenazine-treated animals paired with























57.65±4.83* 8.97±2.32J 33.22±4.43f 42.17±6.13f
omy showed significantly higher metabolism of testosterone than tumours from rats
subjected to oophorectomy alone. In all tumours, irrespective of the animal group from
which they were derived, the major metabolites of testosterone were 5a-dihydrotesto-
sterone and 5a-androstanediol. Although the mean conversions into both metabolites
were greater in tumours from animals given perphenazine, the differences from the
oophorectomy alone-group were not significant.
The present results contrast with effects in intact animals where perphenazine,
although producing a similar elevation in plasma prolactin values, stimulates tumour
growth and causes a highly significant increase in tumour 5a-reduction of testosterone
(Buchan et al., 1976).
In summary, perphenazine failed to reproduce, in animals deprived of ovarian
hormones, the marked stimulatory effects on mammary-tumour growth and steroid
metabolism that it produces in endocrine-intact animals.
Buchan, P., Fraser, A. T. & Miller, W. R. (1976) Biochem. Soc. Trans. 4, 1100-1102
Miller, W. R. (1976) Br. J. Cancer 33, 474-477
Miller, W. R., Forrest, A. P. M. & Hamilton, T. (1974) Steroids 23, 379-395
Br. J. Cancer (1976) 34, 296
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HORMONAL STATUS AND TESTOSTERONE METABOLISM OF
DMBA-INDUCED RAT MAMMARY CARCINOMAS
W. R. MILLER
From the Department of Clinical Surgery, University Medical School, Edinburgh EHH 9AC
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A major pathway of steroid
metabolism in rat mammary carcinomas
is the reduction of testosterone to 5a
dihydrotestosterone and 5tx androstanediol
(King, Gordon and Helfenstein, 1964;
Miller, Forrest and Hamilton, 1974). In
vitro addition of oestradiol 17/? to incu¬
bations of hormone-dependent rat
mammary carcinomas is associated with
an inhibition of 5a reduction of testo¬
sterone (Miller, 1976a). The aim of the
present study was to determine if in vivo
hormone manipulation was associated
with similar changes.
A single i.v. injection of 5 mg 7-12-
dimethylbenzanthracene (DMBA) was
given to 24 randomly bred female Sprague
Dawley rats at 50 days of age. The size
of the tumours which were induced was
monitored twice weekly by measuring
with calipers 2 diameters at right angles.
When the tumours were 2x2 cm in
size, animals were allocated to one of
3 groups. Those in Group I were killed
without further treatment, those in Group
II were oophorectomized and killed 14
days later and those in Group III were
oophorectomized but 14 days later re¬
ceived daily s.c. injections of 1 fig oestra¬
diol in corn oil for a further 14 days,
when they were killed. In all animals,
oophorectomy led to regression of tumours;
all those subsequently given oestradiol
showed regrowth.
Tumours were harvested at death and
treated at 0°C. Each was finely sliced
in Krebs Ringer phosphate buffer pH 7-4
(lOml/g tumour) and an NADPH-
generating system (200 /tmol glucose-6-
Accepted 25 May 1976
phosphate, 30 ymol NADP and 50 u
glucose-6-phospliate dehydrogenase/g
tumour) and 7a 3H-testosterone (45 /iCi/g
tumour) added. The incubation systems
were then shaken for 1 h at 37°C in an
atmosphere of 02. The reaction was
stopped by adding methanol to 80% v/v
and the incubations stored at — 10°C
until processed.
Before extraction, 500 fig of non¬
radioactive carrier testosterone (17/?-
hydroxy-4-androstene-3-one), 5a di¬
hydrotestosterone (17/?-hydroxy-5a-an-
clrostane-3-one) from Sigma Chemical Co.
(St Louis, Mo.) and 5a androstanediol
(5a-androstane 3/? 17/9 diol) from Stera-
loids Inc. (N.Y.) were added to monitor
recovery losses. The metabolites were
extracted, separated into individual
steroids and purified by thin layer
chromatography as described previously
(Miller et al., 1974). The metabolism of
testosterone by conversion to 5a dihydro¬
testosterone and 5a androstanediol were
determined by measuring the percentage
incorporation of radioactive label into the
appropriate metabolites after correction
for recovery losses.
The 1 )NA content of the tumours was
determined by a modification of the
method of Burton (1956).
The pattern of testosterone metabolism
by tumours from the 3 groups of animals
is shown in Table I. There was an
increased metabolism of testosterone in
tumours harvested 14 days after oophor¬
ectomy, an effect reversed by administra¬
tion of oestradiol 17/?. Tumours from
oestrogen-treated animals showed signifi-
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Table I.—Endocrine Status and Tumour Metabolism of 7a3H-testosterone
% Testosterone
Endocrine status metabolized







cantly less metabolism of testosterone
than those from either intact or oophor-
ectomized groups.
Although 5a dihydrotestosterone was
a metabolite of testosterone in all tumours,
there was no significant difference in its
production between the animal groups,
despite a lowered mean production in the
group receiving oestrogen. In contrast,
the conversion of testosterone to its other
major 5a reduced product, 5a andro-
stanediol, was clearly influenced by
hormone manipulation, and was
significantly increased in tumours from
oophorectomized rats. The subsequent
administration of oestradiol was associated
with a significant decrease in production
of 5a androstanediol, to levels comparable
with tumours from the intact group.
Sufficient material was available for
determination of 1 )NA content in 6
tumours from each group. No significant
differences were observed (Table II).
Table II.—DNA Content of Tumours
Studied
DNA content
Endocrine status of animal (mg/g tumour + s.e.)
Intact (6) 7-00 + 0-74
Oophorectomized (6) 7-69 + 0-79
Oophorectomized +
oestradiol (6) 7-66 + 2-03
Figures in parenthesis are number of tumours
studied. No significant differences between the
groups by Wilcoxon-rank test.
% Conversion to
5a Dihydrotestosterone 5a Androstanediol
Mean + s.e. (range) Mean + s.e. (range)
These results indicate that, in female
Sprague Dawley rats bearing DMBA-
induced mammary carcinomas, oopho¬
rectomy is associated with an increase in
tumour metabolism of testosterone, a
phenomenon which may be reversed by
in vivo administration of oestradiol. A
similar pattern was observed in the
conversion of testosterone to 5a
androstanediol. Increased production of
5a androstanediol in tumours from
oophorectomized animals alone would
account for the higher levels of testo¬
sterone metabolized by these tumours.
In contrast, reduced formation of 5a
androstanediol does not fully account for
the decreased levels of testosterone
metabolized in tumours from oestrogen-
treated animals: reduced conversion to
5a dihydrotestosterone in these tumours
also contributes to the decreased meta¬
bolism of testosterone.
As the DNA content of tumours from
each animal group was similar, these
changes are unlikely to be caused by
differences in tumour cellularity.
Furthermore, the decreased metabolism
and conversion of testosterone to 5a
androstanediol following in vivo admini¬
stration of oestrogen may be reproduced
in vitro by addition of oestradiol to
incubations of hormone-dependent rat
mammary carcinomas (Miller, 1976a).
Because the methods used in these








53-10 + 5-05 (34-5-74-5)
66-50 + 5-25 (53-5-88-0)




15-50 + 3-90 (4-4-30-7)





13-95 + 1-50 (8-4-20-3)
27-00± 3- 70 (16-4-49-1)




♦Tumours from hormonally unmanipulated animals.
♦♦Tumours from animals 14 days after oophorectomy.
♦♦♦Tumours from animals oophorectomized but 14 days later given oestradiol (1 /ig in corn oil) for a
further 14 days.
(-.Significance between groups by Wilcoxon rank tests.
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all 4 isomers of 5a androstanediol (Miller,
1976a), it is not possible to determine if
the production of a particular isomer is
preferentially affected by hormone
manipulation. However, only 17/?
isomers of androstanediol were identified
as metabolites of testosterone in human
breast cancer (Cameron et al., 1971).
It is possible that oophorectomy and
oestrogen administration affect tumour
metabolism indirectly, by respectively
lowering and raising circulating levels of
prolactin, to which the growth of DMBA-
induced tumours are particularly sensitive
(Meites, 1972; Pearson et al., 1972).
Nevertheless the in vitro addition of
oestradiol (Miller, 1976a), as well as
prolactin (Miller, 19766), has been shown
to influence testosterone metabolism by
DMBA rat tumours and both hormones
may therefore be implicated in the
changes effected by the endocrine manipu¬
lations described in this study.
Whether the effects of oestrogen ad¬
ministration are caused directly by
oestradiol 17/?, or indirectly by prolactin
secretion, or both, the lower synthesis of
5a dihydrotestosterone and 5a andro¬
stanediol in growing tumours from
animals given oestrogen, as compared
with regressing tumours after oophor¬
ectomy, is in keeping with the growth-
inhibiting properties of 5a reduced steroids
(Huggins and Mainzer, 1957). However,
without further work to determine the
sequence of events following hormone
manipulation, it is not possible to indicate
whether changes in steroid metabolism
occur before or concurrently with those
in tumour growth, or whether the change
in tumour growth itself leads to differences
in metabolism of testosterone.
The author thanks Professor A. P. M.
Forrest for his interest and encouragement
and the Cancer Research Campaign for
supporting this work.
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Female Sprague Dawley rats given
7-12-dimethylbenzanthracene (I)MBA) de¬
velop mammary carcinomata, most of
which are hormone-dependent, regressing
following oophorectomy but regrowing
after oestrogen administration (Huggins,
1963). In these tumours, regression may
also be produced by administration of oa¬
red need steroids (Huggins, Briziarelli and
Sutton, 1959; Huggins and Mainzer, 1957).
It is therefore of interest that DMBA-
induced rat mammary tumours have the
potential to synthesize 5a-redneed steroids
(King, Gordon and Helfenstein, 1964;
Miller, Forrest and Hamilton, 1974). The
aim of the present study was to determine
the effects of oestrogen on tumour 5a-
reduction of testosterone.
Tumours were induced in randomly
bred female Sprague Dawley rats by
intravenous administration of 5 mg DMBA
at 50 days of age. When the tumours
were approximately 2x2 cm in size the
rats were oophorectomized. Fourteen
days after oophorectomy the animals were
given daily subcutaneous injections of
oestradiol-1 Ifi in corn oil (1 fig or 5 fig).
This regime was continued for a further
14 days when the animals were sacrificed
by exsanguination. No injection was
given on the day of sacrifice. Tumour
size was monitored throughout the study
by measuring with calipers the two major
diameters at right angles, and expressing
the size of the resulting multiple in cm2.
Measurement was performed twice weekly
until oophorectomy and three times
weekly thereafter. Only tumours which
showed consistent regression after oopho¬
rectomy and regrowth with oestrogen
treatment were classified as hormone-
dependent and taken for incubation.
All tumours were processed at 0°C until
incubation (within 30 min of tissue re¬
moval). The tumours were finely sliced
and split into duplicate portions each
weighing 1 g. Krebs-Ringer phosphate
buffer pH 7-4 (10 ml), an NADPH-
generating system (200 //mol glucose-6-
phosphate, 30 /fmol NADP and 50 units
glucose-6-phosphate dehydrogenase) and
45 /iCi 7a-3H testosterone (sp. act. 12-4 Ci/
mmol from Radiochemical Centre, Amer-
sham) were added to each. One incubation
mixture was used without further addition
as a control; to the other was added
oestradiol-17/? (1-5 fig/ml) to determine
the effects of oestrogen. Both systems
were then incubated by shaking at 37°C
in an" atmosphere of oxygen for 1 h.
The reaction was stopped by adding
methanol (60 ml) and the incubations
were stored at — 10°C until the steroids
were isolated and characterized.
Before extraction, 500 fig non-radio¬
active carrier steroids (testosterone (17/7-
hydroxy-4-androsten-3-one), 5a dihydro-
testosterone (17^-hydroxy-5a-androsten -
3-one) and 5a androstanediol (5a-andro-
stane 3/? 17/7 diol)) were added to monitor
recovery losses. The metabolites were
extracted as described by Fahmy et al.
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(1968) and separated into individual
steroids by continuous elution thin layer
chromatography for 2 h on Silica gel
HF254-)- 366 in chloroform: acetone (98: 2).
Purification of testosterone and 5a di-
hydrotestosterone involved sequential
acetylation and hydrolysis; that for 5a
anclrostanediol sequential oxidation and
reduction (derivative formation and
chromatography systems as in Miller
et al., 1974). Although 5a androstanediol
was added as the 3/? 17/? isomer, the
methods described estimate total produc¬
tion of all 4 isomers of 5a androstanediol
since the isomers migrate together in the
initial chromatography system and the
subsequent oxidation step yields a com¬
mon product, 5a androstanedione. The
percentage metabolism of testosterone
and conversion to 5a dihydrotestosterone
(DHT) and 5a androstanediol were deter¬
mined by measuring the percentage incor¬
poration of radioactive label into the
appropriate metabolites after correction
for recovery losses. Total 5a-reduction
was calculated by combining the per¬
centage production of both 5a DHT and
5a androstanediol.
The results from these incubations are
presented in Table I. There was a wide
variation in metabolism of testosterone
between individual tumours. In vitro
addition of oestracliol produced variable
results on the level of testosterone metab¬
olized, although the most common effect
was one of inhibition. Of the two 5a-
reduced metabolites of testosterone, the
production of 5a androstanediol usually
exceeded that of 5a DHT, in incubations
without added oestradiol. The in vitro
addition of oestradiol produced variable
effects on the production of 5a DHT,
although in tumours with the highest
control production of 5a DHT, oestradiol
was consistently inhibitory. Oestradiol
inhibited the production of 5a andro¬
stanediol in all carcinomata, with a
single exception, a tumour in which
oestradiol exclusively affected the produc¬
tion of 5a DHT. This meant that total
Table I.—In vitro Effects of Oestradiol on Steroid Metabolism by 10 Hormone-
dependent Rat Mam?nary Carcinomata
% Testosterone % 5a DHT % 5a Androstanediol
Tumour metabolized produced produced % 5a-reduction
1.* Control 16-85 5-85 9-60 15-45
Treated 25-25 4-50 0-80 5-30 (-66)
2.* Control 51-50 9-20 28-05 37-25
Treated 37-05 12-15 1-75 13-90 (-63)
3.* Control 87-30 7-00 38 • 20 45-20
Treated 71-30 9-10 24-00 33-10 (-25)
4 * Control 38-30 12-55 23 • 05 35-41
Treated 36 • 20 8-75 15-45 24-20 (-32)
5* Control 34-70 6 • 25 14-25 20-50
Treated 26-90 4-55 11-05 15-60 (-24)
6-t Control 89-10 22-75 37-20 59-95
Treated 77-15 7-85 39-95 47-80 (-20)
7-t Control 63 • 90 36- 10 27-05 63 ■ 45
Treated 40-05 14-15 22-20 36-35 (-43)
8-t Control 38-35 9-80 28-45 38-25
Treated 37-35 8-95 20 • 30 29-25 (-24)
9-t Control 73-35 9-95 33-10 43-05
Treated 69-25 8-00 25-09 33-05 (-23)
10-t Control 74-45 37-70 35-80 73-50
Treated 69-10 26-65 25 ■ 50 52-15 (-29)
Control: Tumour incubated without oestradiol.
Treated: Tumour incubated in the presence of 1-5 //g/ml oestradiol.
Figures in parentheses represent percentage change produced by addition of oestradiol.
* Tumour regrowth following administration of oestradiol (1 fig/day).
| Tumour regrowth following administration of oestradiol (5 /ig/day).
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Table II.—In vitro Effects of Oestradiol on Steroid Metabolism by








1.* Control 72-10 14-49 7-26 21-75
Treated 58-97 12-44 7-50 19-94 (-8)
2.f Control 89-27 42-72 22-17 04-89
Treated 92-35 41-61 45-64 87-25 ( + 34)
Control: Tumour incubated without oestradiol.
Treated: Tumour incubated in the presence of 1-5 ^g/ml oestradiol.
Figures in parentheses represent percentage change produced by addition of oestradiol.
* Tumour growth continuous after both oophorectomy and administration of oestradiol (1 /zg/day).
f Tumour growth continuous after oophorectomy but stimulated by administration of oestradiol
(1 /<g/day).
5a-reduction was inhibited by oestradiol
in all tumours, the level of inhibition
varying between 20 and 65%.
Whilst in some tumours inhibition of
5a-reduction alone would account for the
effects of oestradiol on percentage metab¬
olism of testosterone, in certain tumours,
oestradiol must have also affected other
steroid conversions. The production of
A4 androstenedione and 5a androstane-
dione was also investigated in several
tumours, but never exceeded 1 % and did
not appear to be influenced by in vitro
addition of oestradiol.
These results indicate that oestradiol
1 7/? may influence steroid metabolism by
rat mammary carcinomata. In vitro
addition of oestradiol reduces tumour
synthesis of 5a-reduced metabolites from
testosterone, particularly 5a androstane¬
diol.
Although this is the first report that
oestrogen may affect the production of
5a-reduced steroids by mammary cancers,
it is well documented that 5a-reduction
may be hormonally controlled in other
tissues such as liver (Schriefers, 1967),
adrenal cortex (Kitay, Coyne and Swygert,
1970) and prostate (Farnsworth, 1972).
In common with the results presented in
this study for mammary tissue, oestradiol
inhibits 5a-reduction in both adrenal
cortex and prostate.
The synthesis of 5a-reduced steroids
assumes added importance in mammary
tumours because both 5a DHT and 5a
androstanediol inhibit the growth of the
hormone-dependent rat mammary tumour
(Huggins et al., 1959; Huggins and
Mainzer, 1957). These effects of oestradiol
in decreasing tumour synthesis of 5a-
reduced steroids would therefore be in
keeping with oestradiol's growth-
promoting effects in hormone-dependent
tumours. In this context it is interesting
that the same concentration of oestradiol
failed to inhibit 5a-rednction in two
hormone-independent rat mammary car¬
cinomata (Table II). Further numbers are
required before it will be possible to
determine if this represents a distinction
between hormone-dependent and hormone-
independent tumours.
Although the level of oestradiol added
in vitro (1-5 //g/ml) is high compared with
normal plasma levels in female rats
(0-1-4-4 ng/100 ml, Hawkins et al., 1975),
the dose used in this study is comparable
with that which in vitro inhibits 5a-
reduction of testosterone in prostatic
tissue (Griffiths et al., 1970; Jenkins and
McCafferty, 1974) and that used in
predicting oestrogen sensitivity in human
breast tumours (Salih, Flax and Hobbs,
1972).
It remains to be seen, however, if
oestradiol in vivo has similar effects on
tumour steroidogenesis. Although
oophorectomy increases the level of 5a-
reduction in rat mammary carcinomata,
an effect which can be reversed by
administration of oestrogen (Miller et al.,
1974), this could be caused by changes in
circulating oestrogen or prolactin.
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In Vitro Effects of Prolactin upon
Testosterone Metabolism by Rat
Mammary Adenocarcinomata*
WILLIAM R. MILLER
Department of Clinical Surgery, University Medical School, Edinburgh EH8 9AG, Great Britain
Abstract—The effects of in vitro addition of prolactin (50 Hgjml) uPon the con¬
version of testosterone to 5a dihydrotestosterone (5a DHT) and 5a androstanediol by
incubates of rat mammary carcinomas have been investigated. The studies have been per¬
formed on (a) primary adenocarcinomata induced by the carcinogen 1,12-dimethyl-
benzanthracene (DMBA) in female Sprague-Dawley rats, and (b) transplantable
tumours obtained by serial transplantation of a further DMBA-induced tumour into
neonatally thymectomized rats. In incubations of primary DMBA-induced tumours,
addition ofprolactin inhibited the production of both 5a DHT and 5a androstanediol,
the overall 5a reduction being between 27 and 40% lower than that in control incuba¬
tions. In contrast, prolactin failed to inhibit, and in some cases stimulated, the 5a
reduction of testosterone in the transplantable tumour.
INTRODUCTION
Both prolactin and steroid hormones are
known to influence the growth and develop¬
ment of rat mammary tumours [1-3]. In the
DMBA treated rat, there appears to be a direct
correlation between plasma prolactin levels
and the genetically determined susceptibility
to mammary cancer [4], Elevation of plasma
prolactin levels accelerates the growth of
mammary tumours [5-7] and conversely
lowered levels may cause tumour regression
[8]. Similarly, administration of steroids of the
androstane series such as 5a dihydrotestosterone
may inhibit the growth of mammary tumours
in the rat [9, 10].
The aim of the present study was to deter¬
mine the in vitro effects of prolactin, upon the
production of 5a androstane steroids by rat
mammary tumours.
Accepted April 1, 1976.
*This work was performed with a grant from the
Cancer Research Campaign, grant number SP 1256.
MATERIAL AND METHODS
Tumour tissue
(a) DMBA-induced tumours. Random bred
female Sprague-Dawley rats were given 5 mg
dimethylbenzanthracene (DMBA) intra¬
venously at 50 days of age. Subsequently
induced mammary tumours were allowed to
grow to 2 x 2 cm in size. At this stage, three
rats were sacrificed by exsanguination and the
tumours incubated; three others were sequen¬
tially oophorectomised and given oestradiol-1 7/1
(1 /tg) to determine tumour hormone depend¬
ence. All tumours regressed after oopho¬
rectomy but renewed growth following oestro¬
gen administration and were therefore hormone
dependent.
(b) Transplanted tumours (TG 3). The tumour
studied was originally induced by DMBA as
above, in an inbred Sprague-Dawley rat
(ADRA) [4]. It was serially transplanted into
further ADRA rats (neonatally thymectomized)
by dorsal skin implantation and studied at its
2nd and 6th passages. Although all the tumours
investigated were derived from intact rats, the
679
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same tumour at its 6th passage in other rats,
failed to regress following oophorectomy but
was stimulated by oestradiol (1 fig daily).
Tumour growth was therefore independent of
oophorectomy but sensitive to oestradiol.
Tumour processing and incubation
All tumours were processed at 0°C until
incubation was carried out (within 30 min of
tissue removal). One gram of each tumour was
finely sliced and Krebs Ringer phosphate
buffer pH 7-4 (10 ml), an NADPH generating
system (200 fi mol glucose-6-phosphate, 25 mg
NADP, and 50 units glucose-6-phosphate
dehydrogenase) and the radioactive precursor
(45 fid 7a- 3H testosterone) added. Duplicate
incubations were set up with the addition of
either ovine prolactin, rat prolactin or rat
growth hormone (50 gg/ml). The tumour
slices were then incubated by shaking at 37°C
in an atmosphere of oxygen for 1 hr. The
reaction was stopped by adding methanol to
80 % (v/v) and the incubations stored at — 10°C
until processed.
Purification and characterization of metabolites
Before extraction, 500 fig of non-radioactive
carrier steroids were added to monitor recovery
losses. The metabolites were extracted, sepa¬
rated into individual steroids and purified by
thin layer chromatography, as described
previously [11]. The percentage of metabolism
of testosterone and conversion to 5a DHT and
5a androstanediol were determined by measur¬
ing the percentage of incorporation of radio¬
active label into the appropriate metabolites
after correction for recovery losses.
RESULTS
The effects on testosterone metabolism of
in vitro addition of prolactin to incubations of
DMBA-induced tumours are presented in
Table 1. No consistent effects were produced
by prolactin on the absolute level of testosterone
metabolised. Prolactin, however, inhibited the
conversion of testosterone to both 5a DHT and
5a androstanediol. Estimates of total 5a reduc¬
tion obtained by combining the production
of 5a DHT with that of 5a androstanediol
showed that prolactin produced a consistent
inhibition of 5a reduction (27-4-403% of
control incubations), irrespective of the type
of prolactin used, or whether the tumour was
obtained from intact, or endocrine manipulated
rats. Similar in vitro addition of rat growth
hormone at the same concentration had
negligible effects in 4 tumours and inhibited
5 a reduction in only one tumour (to a lesser
extent than prolactin).
The results of similar studies using the
transplanted tumour are presented in Table 2.
In these incubations, the overall level of
testosterone metabolism was extremely high
and relatively unaffected by the addition of
prolactin. In contrast to the primary DMBA
tumours, in this transplanted tumour, prolactin
tended to increase the percentage of production
of 5a DHT and total 5a reduction of testoster¬
one.
DISCUSSION
The results presented in this study indicate
that the 5a reduction of testosterone by rat
mammary carcinomas may be influenced by
the in vitro addition of either rat or ovine
prolactin. These effects may be partially
specific to prolactin as the in vitro addition of
growth hormone at the same concentration
had less or no effect on testosterone meta¬
bolism.
In primary DMBA-induced tumours, pro¬
lactin consistently inhibited the production of
5a reduced metabolites of testosterone. This is
interesting in view of the inhibitory properties
of the 5 a androstane steroids on the growth of
hormone dependent rat mammary tumours
[9, 10]. Although evidence for hormone de¬
pendence was obtained for only three of the
DMBA tumours studied in this series, it was
our experience that the majority of DMBA
tumours induced in this group of animals were
hormone dependent. It would therefore be in
keeping with the growth promoting effects of
prolactin on hormone dependent tumours that
prolactin should inhibit the production of 5a
reduced steroids at tumour level.
The results from in vitro incubations of the
transplanted tumour differ from the primary
DMBA tumours in two major respects. Firstly,
although the DNA content and cellularity of
the two groups of tumours were similar, the
overall metabolism and 5a reduction of tes¬
tosterone in control incubations was, in general,
higher in the transplanted tumour. Secondly,
prolactin tended to stimulate 5a reduction in
the transplanted tumour in diret contrast to its
inhibitory effects in the primary tumours.
Several factors may be implicated in these
differences between transplanted and DMBA
tumours. Firstly, whereas the DMBA tumours
are likely to be hormone dependent, the trans¬
planted tumour failed to regress following
In Vitro Effects of Prolactin
Table 1. Metabolism ofJa-^H testosterone by DMBA induced tumours
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Per cent Per cent Per cent
testosterone conversion to conversion to Per cent
Rat metabolised 5a DHT 5a androstanediol 5a reduction
A* Control 94-80 28-50 25-40 53-90
+ prolactin (rat) 85-00 (-10-3) 13-20 (-53-6) 21-30 (-16-1) 34-50 (-36-0)
+ growth hormone 90-20 (- 4-9) 24-20 (-15-1) 22-10 (-13-0) 46-30 (-14-1)
Bf Control 46-50 5-50 27-05 32-55
+ prolactin (rat) 35-10 (-24-5) 3-90 (-29-1) 17-00 (-37-2) 20-90 (-35-8)
+ growth hormone 46-10 (- 0-9) 6-20 (+12-7) 26-70 (- 1-3) 32-90 ( + M)
C* Control 47-45 16-15 14-15 30-30
+ prolactin (rat) 43-10 (- 9-2) 8-40 (-49-0) 13-55 (- 4-2) 21-95 (-27-6)
+ growth hormone 48-20 (+ 1-6) 13-60 (-15-8) 17-20 ( + 21-55) 30-80 ( + b7)
Df Control 42-50 5-05 20-10 25-15
+ prolactin (rat) 37-10 (-12-6) 2-50 (-50-5) 13-30 (-33-8) 15-80 (-37-2)
E* Control 33-85 5-65 12-45 18-10
+ prolactin (ovine) 34-75 (+ 2-6) 5-50 (- 2-7) 7-60 (-39-0) 13-10 (-27-6)
+ growth hormone 31-60 (- 6-7) 5-00 (-11.5) 11-55 (- 7-2) 16-55 (- 8-6)
Ft Control 47-80 19-20 11-20 30-40
+ prolactin (ovine) 59-40 ( + 24-3) 9-40 (-51-1) 8-75 (-21-9) 18-15 (-40-3)
+ growth hormone 44-45 (- 7-0) 19-40 (+ 1-0) 3-95 (-64-7) 23-35 (-23-2)
Figures in parentheses represent the percentage of change caused by addition of prolactin or growth hormone
(50 ^g/ml).
* Intact rat.
fRat sequentially oophorectomized and given oestradiol (I /zg daily).
Table 2. Metabolism ofhx-zH testosterone by transplanted tumours
Per cent Per cent Per cent
testosterone conversion to conversion to Per cent
Rat metabolised 5a DHT 5a androstanediol 5a reduction
1* Control 88-70 19-90 31-30 51-20
+ prolactin (ovine) 95-50 ( + 7.7) 26-50 (+ 33-2) 59-00 ( + 88-5) 85-50 ( + 67-0)
2* Control 96-80 9-65 33-60 43-25
+ prolactin (ovine) 97-15 ( + 0-3) 21-90 (+127-0) 30-30 (- 9-8) 52-20 ( + 20-7)
3* Control 98-70 13-30 66-15 79-45
+ prolactin (ovine) 95-50 (- 3-3) 16-50 (+ 24-0) 66-10 (0) 82-60 (+ 4-0)
4f Control 94-00 9-50 39-20 48-70
+ prolactin (rat) 97-00 (+ 3-1) 24-50 (+158-0) 31-70 (-19-1) 56-20 (+15-4)
5t Control 96-70 3-40 50-70 54-10
+ prolactin (rat) 88-05 (- 9-0) 5-25 (+ 54-4) 55-10 (+ 8-6) 60-35 (+11-6)
*Tumour at 2nd passage,
fTumour at 6th passage.
Figures in parentheses represent % change caused by addition of prolactin.
oophorectomy; the effects of prolactin may
therefore reflect differences between hormone
dependent and hormone sensitive tumours.
Secondly, there are different circulating pro¬
lactin levels in the two strains of rats used—
the ADRA strain, in which the transplanted
tumour was induced and subsequently trans¬
planted, has a lower basal level of circulating
prolactin, in comparison with the random-
bred variety in which the primary DMBA
tumours were induced [4].
At present, it is not possible to remove the
strain difference as tumour induction rate by
DMBA in the ADRA rat is exceptionally low
and the transplanted tumour is not accepted
by randomly bred animals.
In conclusion, it is worth emphasizing that
whilst prolactin has already been shown to
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affect steroid metabolism in other tissues, such
as the prostate [12] and testis [13], its effects in
mammary tumour tissue may assume added
importance in view of the properties of the
5a reduced metabolites involved to influence
tumour growth.
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THE EFFECT OF (ESTROGEN ON STEROID METABOLISM
BY RAT MAMMARY CARCINOMAS
W.R. MILLER and J. TELFORD (Edinburgh).
Human breast cancer can act as a paraendo-
crine organ by transforming steroid precursors
into hormones with powerful biological acti¬
vity (Adams and Wong Miller and Forrest 3).
Thus breast cancer has the potential to trans¬
form dehydroepiandrosterone sulphate which
circulates in large amounts in the plasma of
both pre- and postmenopausal women into
the active androgens, 5 a dihydrotestosterone
(5 a DHT) and 5 a androstanediol. The active
(Estrogen, oestradiol 17p, may also be synthe-
sised by a similar pathway. A summary of
our findings on steroid metabolism by human
breast cancers is presented in table I. All tu¬
mours converted dehydroepiandrosterone to
testosterone and testosterone to 5 a DHT and
5 a androstanediol but only a proportion of
carcinomas could synthesise oestradiol 17(1
The aims of these studies are twofold :
firstly to determine if steroid metabolism dif¬
fers in hormone dependent and hormone inde¬
pendent tumours. Secondly to determine in
these two types of tumour the effects of oes-
tradiol on tumour steroidogenesis, especially
5 u reduction. Work is in progress, studying





dence of these human tumours is not yet
known. Parallel studies have therefore been
performed in experimental animal tumours
whose hormone dependence is already defined.
It is this work using rat mammary tumours
which is the subject of this paper.
Mammary tumours induced in female Spra-
gue Dawley rats may be classified as hormone
dependent or hormone independent according
to their response to oophorectomy. Hormone
dependent tumours regress following oopho¬
rectomy but regrow on administration of daily
injections of oestradiol 17(1 In contrast hor¬
mone independent tumours continue to grow
even after oophorectomy.
Using this differential response after oopho¬
rectomy as the criterion of hormone depen¬
dence, steroid metabolism in five hormone
dependent rat mammary carcinomas has been
compared with that in two hormone indepen¬
dent tumours.
Each tumour was finely sliced and split into
duplicate portions both weighing one gram.
The slices were then suspended in Krebs Rin¬
ger phosphate buffer and 50 fiCi of H3 testos¬







TABLE I. — Steroid conversions by human breast cancer.
Precursor Metabolite Total tumours
investigated
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further addition as a control incubation; to the
other, (estradiol was added at a concentration
of 1.5 pg/nal to determine the effects ol (es¬
trogen. Both systems were then incubated for
1 hour at 37"C in an atmosphere of oxygen.
The pattern of steroid metabolism was de¬
termined by measuring the percentage incor¬
poration of :'H into the metabolites after puri¬
fication and characterization. There are two
major 5 a reduced products of testosterone
(5 o dihydrotestosterone and 5 u androstane-
diol). Total 5 ri reduction was therelore deter¬
mined by combining the % production of both
metabolites.
The results obtained from these incubations
are presented in table II. Regarding the over¬
all testosterone metabolism in the control incu¬
bations. there was a wide variation in metabo¬
lism between individual tumours ranging from
20 to 90 % transformation. Nevertheless the
two hormone independent tumours were
TABLE 11. — Metabolism of 7a H testosterone by
rat mammary cart inomas.
15.45
5.30 ( — 66 <;, )
37.25
13.95 (— 63 fA)
35.60
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amongst those with the highest metabolism.
In r/fro addition ol (estradiol 17|> to the incu¬
bations produced variable results on the level
of testosterone metabolised, although the most
common ellect was that of inhibition.
There was no difference between hormone
dependent and hormone independent tumours
m total 5 <t reduction ol control incubations.
However, the effects of (estradiol on 5 u re¬
duction were different in the two types of tu¬
mour. Thus, in each ol the hormone depen¬
dent tumours, the incubation containing (es¬
tradiol showed consistently less 5 u reduction
than the corresponding control incubation.
The level of inhibition of 5 a reduction by
(estradiol was between 25 and 65 <•/,, of the
control value. In contrast cestradiol did not
inhibit 5 it reduction in either of the hormone
independent tumours, having no effect in one
tumour and stimulating 5 u reduction in the
other.
The inhibitory effects of (estradiol on 5 u
reduction in hormone dependent tumours is
interesting, as 5 u reduced products power¬
fully inhibit the growth of the hormone depen¬
dent rat mammary tumour (Huggins and
Main/or '). The eflccts of (estradiol in de¬
creasing tumour synthesis ol 5 a reduced ste¬
roids are therefore in keeping with the growth
promoting effects of (estradiol in hormone
dependent tumours.
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fer in hormone dependent and hormone inde¬
pendent tumours; b) oestradiol may promote
the growth of hormone dependent tumours by
reducing tumour levels of 5 a reduced steroids.
It remains to be seen if (estradiol has similar
effects in human breast tumours.
« « O
a) Les effets de l'oestradiol sur la 5 u reduc¬
tion sont differents pour les tumeurs hormono-
dependantes et non.
b) L'oestradiol peut stimuler la croissance
de tumeurs hormonodependantes en reduisant,
dans la tumeur, la teneur en steroides 5u re-
duits.
c) L'application de ces donnees au cancer
du sein dans l'espece humaine n'est pas encore
demontree.
J
Br. J. Cancer (1980) 42, 326
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Summary.—A rat mammary carcinoma induced by 7-12 dimethylbenzanthracene
was serially transplanted into successive generations of thymectomized host animals.
After its 2nd passage, the growth of the tumour appeared hormone-dependent,
regressing after oophorectomy and regrowing with administration of oestradiol 17/3
to the host. Third-generation transplanted tumours, however, showed only a tran¬
sient regression after oophorectomy, and the growth of tumours after further
passages appeared ovary-independent. Loss in hormone dependency was not
accompanied by histological changes. There was however a progressive increase
with successive transplantation in the ability of tumours to metabolize 7a[3H] testo¬
sterone in vitro. This was accounted for by raised tonversion to 5a androstanediol.
Rat mammary tumours induced by the
carcinogen 7-12 dimethylbenzanthracene
(DMBA) have been shown to metabolize
testosterone, primarily by 5a reduction,
an activity which may be influenced by
hormones both in vitro (Miller, 1976a) and
in vivo (Miller, 19766,c; Buchan et al.,
1976). The growth of most DMBA-
induced tumours is hormone-dependent.
In the study reported in this paper a rat
mammary tumour, originally induced by
DMBA, has been transplanted into suc¬
cessive generations of host animals. Effects
of transplantation on hormone depen¬
dence and tumour metabolism of testo¬
sterone have been investigated.
materials and methods
Atiimals.—All animals used were of an
inbred strain of Sprague-Dawley rat, ob¬
tained from the Animal Diseases Research
Association (ADRA), Moredun Institute,
Edinburgh.
Tumour line.—The line (TG5) was derived
from a mammary tumour induced in a female
ADRA rat by i.v. administration of 5 mg
DMBA at 50 days of age. A portion of this
primary tumour was cut into 1mm cubes in
Hartmann-Ringer lactate solution. These
were aspirated into a narrow-bore cannula
using a syringe and then implanted through
a small skin incision on to the back of neo-
natally thymectomized host animals. Once
established, these tumour transplants were
classified TG 5/1. Successive generations of
tumour were transplanted in the same way
and classified TG 5/n, where n represents the
number of passages.
Experimental protocol.—Except for TG 5/1,
which was established in only a single animal,
each tumour generation was studied in 4
animals. Two animals were killed without
having received endocrine manipulation, and
the tumours removed.
The remaining 2 rats were bilaterally
oophorectomized and 10 days later given
daily injections of oestradiol 17/3 (I yg in
0-2 ml corn oil) for a further 10 days, when
the animals were killed and the tumours
removed. Tumours were measured with
calipers on alternate days from when palpable
until death. Size was expressed as the product
of 2 diameters at right angles in cm2.
Tumour steroid metabolism.—A portion of
each tumour (0-5 g) was finely sliced in Krebs-
Ringer phosphate buffer, pH 7-4 (5 ml). An
NADPH-generating system and 20 yd
|7a3H] testosterone was added and the
systems incubated for i h at 37°C in an
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atmosphere of O2. Reaction was halted by
addition of methanol (30 ml) and the incuba¬
tions stored at — 10°C until the metabolites
were characterized by the methods previously
described (Miller et al., 1974). Metabolism and
conversion of testosterone were determined
by measuring radioactive label in the appro¬
priate metabolites. Estimation of 5a reduc¬
tion was obtained by combining the produc¬
tion of 5a-dihydrotesterone with that of 5a-
androstanediol.
DNA estimation.—Tumour DNA content
was determined by a modification of the
method of Burton (1956).
RESULTS
Tumour growth
The effect of endocrine manipulation
was not studied in the primary DMBA-
induced tumour or at its initial trans¬
plantation. Pattern of growth following
oophorectomy and subsequent oestrogen
administration is, however, shown in the
Figure for tumours at their 2nd, 3rd, 4th
and 7th passages. Tumours at their 2nd
passage (TG 5/2) regressed after oophor¬
ectomy, but regrew on administration of
oestradiol. Oophorectomy of animals bear¬
ing TG 5/3 tumours produced only trans¬
ient tumour regression, and the size 10
days after oophorectomy exceeded that
before ablation. In contrast the growth of
TG 5/4 tumours appeared not to be
affected by oophorectomy though there
was evidence for accelerated growth once
oestrogen was administered. All subse¬
quent generations of transplanted tumours
responded in this way to endocrine
manipulation.
Tumour histology
No obvious change in tumour histology
was seen during successive transplantation,
and fibrosarcomatous development which
can appear during transplantation (Horn







Fig.—Growth patterns of TG 5 transplantable tumours following oophorectomy (Ox) and administra
tion of oestrogen (OE2). Day O represents day of oophorectomy, TG 5/n tumour generation when
n is number of passages and (a) and (b) represent individual tumours listed in Table II.
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Table I.—Metabolism of [7a3//] testosterone by TG 5 transplanted tumours from endocrine
unmanipulated animals
%5<*
Transplant DNA content % Testosterone % 5aDHT Androstanediol °//o
generation (mg/g tumour) metabolized produced produced 5cx reduction
TG 5/1 5-89 38-30 10-54 23-07 33-61
TG 5/2 6-08 41-62 7-34 23-47 31-81
6-40 31-68 7-24 20-83 28-07
TG 5/3 7-00 59-05 9-14 40-07 49-21
5-23 51-96 7-65 36-67 44-32
TG 5/4 7-26 68-62 10-97 52-09 63-06
5-52 74-18 9-87 59-94 68-81
TG 5/7 5-17 71-89 17-70 51-41 69-11
4-46 74-25 14-46 55-20 69-66
Table II.—Metabolism of [7a3//] testosterone by TG 5 transplanted tumours from
endocrine-ablated, oestrogen-treated animals
% Ba-
Transplant DNA content % Testosterone % 5aDHT Androstanediol °//o
generation (mg/g tumour) metabolized- produced produced 5ct reduction
TG 5/2 (a) 5-03 49-89 12-74 30-27 42-81
(b) 4-65 43-25 9-04 30-00 39-64
TG 5/3 (a) 4-26 53-40 12-43 34-58 47-01
(b) 4-28 57-62 12-79 38-15 50-94
TG 5/4 (a) 4-30 69-71 9-54 50-50 60-04
(b) 4-30 69-80 15-21 41-72 56-93
TG 5/7 (a) 5-19 66-90 7-12 48-64 55-76
(b) 4-35 70-57 12-90 50-55 60-45
Tumour steroid metabolism
The results from incubations of tumours
with 7a3H testosterone are presented in
Tables I and II. In all tumours, Sareduc-
tion of testosterone to 5adihydrotesterone
and 5aandrostanediol accounted for most
of the metabolism. In tumours from endo-
crine-unmanipulated animals (Table I)
transformation of testosterone was roughly
similar in TG 5/1 and TG 5/2 tumours.
However, metabolism was higher in
tumours from the TG 5/3 generation, and
a further raised level of metabolism was
noted in TG 5/4 and TG 5/7 tumours. This
change in metabolism with successive
transplantation was accounted for by a
parallel increase in 5a reduction of testo¬
sterone, this being particularly evident in
the conversion to 5aandrostanediol. Re¬
sults in tumours from animals after endo¬
crine procedures are shown in Table II. A
similar but less marked trend of increasing
metabolism and 5a reduction of testo¬
sterone with successive generations of
tumours was evident. No progressive
changes in tumour DNA content were ob¬
served with serial passage in either endo¬
crine-manipulated or unmanipulated ani¬
mals.
discussion
The TG5 rat mammary tumour line was
derived from a tumour induced by DMBA
in a female Sprague-Dawley rat. No infor¬
mation is available on the hormone de¬
pendence of this primary tumour or its
ist-generation transplant, but at 2nd
passage the growth of the tumour ap¬
peared hormone-dependent, regressing
after oophorectomy. With successive
transplantation, however, the tumour
first showed only transient regression
(TG5/3) and then no regression after
oophorectomy (TG 5/4 onwards). Similar
changes after transplantation in tumour
growth pattern from ovary-dependent to
ovary-independent have been reported in
other transplantable rat mammary turn-
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ours (De Sombre et al., 1976; Horn et al.,
1976). Whilst later generations of trans¬
plantable tumours do not regress after
oophorectomy, they may retain some
degree of sensitivity to hormones (Hilf,
1972). In the present study the growth of
TG 5/4 and TG 5/7 tumours, though not
influenced by ovarian ablation, appears
to be stimulated by administration of
oestrogen to oophorectomized animals.
Although oestrogen-receptor activity was
detectable in cytosols from TG 5/7
tumours (mean receptor level 3-4 fmol/mg
protein, K(/ 0-45 x I0~10m) the levels were
much lower than in DMBA-induced hor¬
mone-dependent rat mammary tumours
(Hawkins et al., 1978).
In addition to determining the effects of
tranplantation on tumour endocrine re¬
sponse, successive generations of tumours
have been examined for their ability to
metabolize testosterone in vitro. In all
generations of tumours studied, Set-re¬
duced products were the major metabo¬
lites of testosterone. However, with suc¬
cessive transplantation there was an
increase in tumour metabolism and 5a
reduction of testosterone, such that there
was a doubling of 5a reduction between
TG 5/1 and TG 5/7 tumours taken from
endocrine-unmanipulated animals.
5aandrostanediol (3a 17/3) appeared to
be the metabolite most consistently
affected and it may be that the effects of
5a reduction are secondary to those on
3ahydroxysteroid dehydrogenase. How¬
ever, under the incubation conditions
used, 5aandrostanediol was the single
greatest 5a reduced product identified,
and effects on 5a reduction are most
likely to be evident in this metabolite. A
similar but smaller rise in 5a reduction
with increasing number of passages was
evident in endocrine-treated animals.
Endocrine manipulation itself has been
shown to influence 5a reduction in these
tumours: oophorectomy increases the
activity and oestrogen administration to
oophorectomized animals decreases the
5a reduction (Miller et al., 1979). The
effects of oestrogen administration can,
however, be variable, and this may have
masked the full effects of transplantation.
It is tempting to speculate that the
changes in testosterone metabolism are
linked with the transition of tumour
hormone dependency. Metabolism in TG
5/2 tumours, which regress after oophor¬
ectomy, and TG 5/1 tumours is similar and
much lower than in TG 5/4 and TG 5/7
tumours, which do not regress after
oophorectomy. Tumours of the TG 5/3
generation, which only show transient
regression after oophorectomy, have inter¬
mediate metabolism. It is interesting
therefore that in the mouse 5a reduction
of testosterone is lower in androgen-
dependent mammary tumours than in
these which are independent (Yamaguchi
et al., 1974). Although no significant
difference in steroid metabolism was de¬
tected between hormone-dependent and
independent DMBA-induced rat mam¬
mary tumours (King et al., 1965) endo¬
crine-treated animals were used and in the
present study effects in such animals were
more difficult to detect than in un-
manipulated animals. Furthermore the
levels of tumour 5a reduction were at least
10-fold less (King et al., 1964) than those
reported in the system used in the present
study. It is possible that the apparent
relationship detected in this study be¬
tween hormone dependence and steroid
metabolism is only causal and that some
other feature of transplantation has caused
the observed increase in testosterone
metabolism.
Difference in tumour growth rate is
unlikely, as all tumours were actively
growing at the time of study. A simple
increase in tumour cellularity is also un¬
likely, because there was no evidence for
an increase in tumour DNA content or
histology with transplantation. However,
a general increase in cellular metabolism
cannot be excluded, and no information is
available on the metabolism of other
steroid precursors.
Until the specificity of the changes in
steroid metabolism is further defined, the
physiological relevance of these effects
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must remain in doubt. However, to the
author's knowledge this is the first docu¬
mented observation that successive trans¬
plantation may affect tumour steroid
metabolism. That a change in tumour
hormone dependence occurs concurrently
and the steroid conversion involved is one
which may be hormonally influenced
(Miller, 1976a,b,c; Buchan et al., 1976)
gives added interest to the findings.
The author is grateful to Professor A. P. M. Forrest
for his interest and encouragement and the Cancer
Research Campaign for supporting this work with
Grant No. SP 1256. The help of Mrs D. Gray, who
transplanted and measured the tumours, and Dr
A. A. Shivas, who reviewed the tumour histology, is
also acknowledged.
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Human and rat mammary tumours meta¬
bolize steroid hormones and thus have the
capacity to modify their local hormonal
environment (Adams & Wong, 1968;
Jones et al., 1970; King et al., 1964; Miller
et al., 1974). In previous studies, we have
investigated the metabolism of testos¬
terone by a predominantly ovary-depen¬
dent DMBA-induced mammary tumour,
and have shown it to be sensitive to levels
of other hormones present in vitro (Miller,
1976a), or in vivo (Miller, 19766, c; Buchan
et al., 1976). We now report a study of the
metabolism of androgens by ovary-inde¬
pendent tumours derived by transplanta¬
tion. By using multiple tumours trans¬
planted to a single rat, it has been possible
to examine tumours derived from the
same host animal before and after 2
endocrine manipulations.
All animals were of an inbred strain of
Sprague-Dawley rat, obtained from the
Animal Diseases Research Association
(ADRA), Moredun Institute, Edinburgh.
Two lines of transplantable tumours were
used: TG3 and TG5. These were histologic¬
ally carcinomas, originally induced in
female "ADRA" rats at 50 days of age by
i.v. administration of 5 mg of DMBA.
Both tumours were then serially trans¬
planted by dorsal skin implantation of
tumour fragments into neonatally-thymec-
tomized hosts. At the time of study TG3
was at its 6th passage and TG5 was at its
7th passage.
Three separate portions of a single donor
tumour were implanted at different dorsal
Accepted 16 October 1978
sites in each neonatally thymectomized
host animal at 50 days of age. Tumours
were measured twice weekly throughout
the period of study. When the largest tu¬
mour reached 1-5x1-5 cm in size it was
removed through a dorsal skin incision
and the animal was immediately bilater¬
ally oophorectomized. Ten days later, a
further tumour was excised. The animals
were then given daily injections of oestra-
diol-17/3 (1 p.g in 0-2 ml corn oil) for a
further 10 days.
The remaining tumour was excised and
the animals were killed, no injection of
oestradiol being given on the day of death.
Eight rats were so treated (4 with TG3
tumours and 4 with TG5 tumours). Con¬
trol animals (2 with TG3 tumours and 2
with TG5 tumours) were treated similarly
except that a sham oophorectomy was
performed in place of an oophorectomy
and the injection vehicle replaced oestra¬
diol
After excision, portions of each tumour
(0-5 g) were used for steroid-metabolism
studies. Each was finally sliced at 0°C in
Krebs-Ringer phosphate buffer pH 7-4
(5 ml). An NADPH-generating system and
radioactive precursor (20/xCi ofeither 7a(3H)
dehydroepiandrosterone (DHA) or 7a(3H)
testosterone) was added. The incubation
systems were shaken at 37°C in an atmo¬
sphere of O2 for 2 h (TG3 series) or 1 h
(TG5 series—on account of the high acti¬
vity found in the tumour lines). The reac¬
tion was stopped by adding methanol to
80% v/v and the incubations stored at
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Figure.—Growth patterns of TG3 and TG5 transplantable tumours. Solid dots are values for experi¬
mental animals with oophorectomy followed by oestrogen (OE2). Each point represents mean size
of the 4 tumours (each from a separate animal) which were subject to both hormone manipulations,
with the exception of the final point for TG5 (mean of 3 tumours: one animal killed on Day 18).
Open dots are values for control animals with sham oophorectomy followed by corn oil. Each point
represents the mean of 2 tumours (each from different animals) which were subject to both mani¬
pulations, with exception of the final point for TG5 (value for a single tumour: one animal killed on
Day 18). Bars represent s.e. mean. Day 0 represents day of oophorectomy or sham operation.
— 10°C until the metabolics were charac¬
terized. To measure losses, 500 fj.g of each
non-radioactive carrier steroid to be in¬
vestigated was added. The metabolites
were then extracted and separated into
individual metabolites as described pre¬
viously (Miller et al., 1974). Purification of
all steroid fractions except 5a androstane-
diol was achieved by sequential acetvla-
t.ion and hydrolysis; 5a androstanediol
by sequential oxidation and reduction.
Methods for derivative formation and
characterization of metabolites have
been described previously (Miller et al.,
1974). Metabolism and conversion of
precursors were measured by determining
the incorporation of radioactive label into
the appropriate metabolites after correc¬
tion for losses. 5a reduction of testosterone
was estimated by combining the produc¬
tion of 5a dihydrotestosterone with that of
5a androstanediol.
The pattern of tumour growth through¬
out the endocrine procedures investigated
is shown in the Figure. Tumour growth was
continuous after oophorectomy, but after
the administration of oestradiol there was
some evidence for accelerated tumour
growth, especially in the TG5 line. Sham
oophorectomy and administration of corn-
oil vehicle had little effect on tumour
growth.
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The general histological appearance of
both tumour lines was not changed by
either oophorectomy or oestrogen ad¬
ministration, in terms of cell number, cell
type, necrosis or polyploidy.
The % metabolism of testosterone and
its conversion to unreduced products by
TG3 tumours are shown in Table I. All
TG3 tumours, irrespective of the animal
from which they were derived or its en¬
docrine status, metabolized large amounts
(86-99%) of the testosterone precursor.
Despite this high metabolic activity,
oophorectomy caused an increase in tu¬
mour testosterone metabolism in each
animal. This effect was consistently re¬
versed by the administration of oestrogen
to the oophorectomized animals. In each
animal, oophorectomy was also associated
with an increase in tumour 5areduction of
testosterone. Subsequent oestrogen ad¬
ministration to oophorectomized animals
then led to decreased tumour production
of 5areduced metabolites, although tu¬
mour Sareduction still remained higher
than that in corresponding tumours from
the intact individuals. Of the individual
5ared need metabolites investigated, the
effects were most marked on oaandrostane-
diol, perhaps because its production was at
least twice that of 5adihydrotestosterone
in all TG3 tumours. The rise in 5areduced
metabolites produced by oophorectomy
was significantly different from the small
change caused by sham ablation in the con¬
trol group (P<0-05 as based on t test of
the logarithms of the ratio between the
groups.) Similarly, the fall in tumour 5a-
reduction apparent after administration
of oestradiol was significantly different
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75-3, 74 -6, 64-9, 81-3
74-5, 70-8, 57-7, 84-8
71-3, 69-2, 76-5, 66-7
15-0, 17-9, 18-4, 13-6
15-5, 21-0, 22-3, 18-0
13-9, 22-3, 17-3, 23-3
from the effect of injection vehicle in
control animals (P<0-01).
The results obtained from incubations
of TG5 tumours are presented in Table II.
As with the TG3 series, oophorectomy
was associated in each animal with an in¬
crease in tumour metabolism and 5areduc-
tion of testosterone; these effects were
reversed after administration of oestradiol
to the animals. Both 5a dihydrotestos-
terone and 5a androstenediol were equally
affected by treatment. Transformation to
both these 5areduced metabolites was alone
sufficient to account for the changes in
testosterone metabolism produced by hor¬
monal manipulation.
The metabolism of 7a[3H]DHA was
investigated in duplicate portions of the
same TG3 tumours used to study the
metabolism of testosterone. The distribu¬
tion of radioactivity from 7a[3H]DHA
after incubation is shown in Table III. The
metabolism of this steroid (16-43%) was
less extensive than that of testosterone.
Oophorectomy and oestrogen treatment
failed to influence the overall metabolism
of DHA or the production of its major
metabolite, A5 androstenediol. Metabo¬
lism of 7a[3H]DHA was also similar in
tumours from control animals subjected
to sham oophorectomy followed by injec¬
tion of vehicle.
As both TG3 and TG5 tumours main¬
tain their histological appearance during
serial and multiple transplantations, they
provide useful models for studying the
effects of sequential operations within in¬
dividual animals, without the need to take
14
biopsy samples from individual tumours,
a procedure which alone may change tu¬
mour behaviour. In the present communi¬
cation we have utilized these tumour lines
to study the effects of endocrine manipu¬
lation on steroid metabolism.
Compared with ovary-clependent
DMBA-induced tumours (Miller, 19765),
both the ovary-independent transplant¬
able tumour lines had a high capacity to
metabolize 3H-testosterone, especially by
5areduction. In both TG3 and TG5 tu¬
mours, oophorectomy was associated with
increased metabolism of testosterone,
whereas administration of oestrogen re¬
versed the effect. These changes could be
accounted for largely by parallel changes
in the production of 5areduced metabolites.
However, it is unlikely that the changes
were nonspecific since the overall meta¬
bolism of dehydroepiandrosterone and
conversion to its major metabolite A5
androstenediol were, by contrast, un¬
influenced by endocrine manipulation.
Furthermore, there were no obvious histo¬
logical changes in tumour appearance,
such as increase in cell number after
oophorectomy or cell death after oestrogen
treatment, which might directly account
for the changes in testosterone metabolism
resulting from endocrine manipulation.
The pattern of changes in testosterone
metabolism after endocrine manipulation
does not differ from that observed pre¬
viously with DMBA-induced ovary-de¬
pendent tumours (Miller, 19766). Thus the
sensitivity of steroid metabolism to en¬
docrine manipulation does not differenti-
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ate between tumours dependent on the
ovary for their growth and those which are
not. However, the transplantable tumours
were derived originally from DMBA-
induced tumours, and at least one of the
lines (TG5) was ovary-dependent in its
first and second transplant generations.
Since (1) oestrogen receptors are present
in the tumours (Hawkins et al., 1978) and
(2) tumour growth, whilst not ovary-
dependent, may be enhanced by oestradiol-
17yS administration (Figure), it seems likely
that these tumours have retained some hor¬
monal sensitivity during transplantation.
Similar progressive changes in hormone
dependency with succeeding transplant
generations have been shown for other
transplantable tumours (Sluyser & Van
Nie, 1974; DeSombre et al., 1976; Horn
et al., 1976). The transplantable TG3 and
TG5 tumours may thus resemble the trans¬
plantable R3230AC tumour, which has
been described by Hilf (1972) as ovary-
independent but hormone-sensitive.
It is thus possible that the changes in
steroid metabolism observed in these trans¬
plantable ovary-independent TG3 and
TG5 tumours following endocrine manipu¬
lation are related, at least in part, to some
residual hormonal sensitivity.
The authors thank Professor A. P. M. Forrest for
his interest and encouragement and the Cancer Re¬
search Campaign for supporting this work with
Grant No. SP 1256.
We are also indebted to Mr D. Drewitt and Mr
I. W. J. Wallace who originally induced and trans¬
planted the tumour lines used in this study, Mrs D.
Gray who subsequently transplanted and measured
later generations of the tumours, and Dr A. A.
Shivas who reviewed the histology of the tumours.
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Previous studies (Adams and Wong,
1968; Jones et al., 1970; Miller et al.,
1973) have shown that both normal and
neoplastic breast tissues perform steroid
conversions similar to those in the classic
steroid secreting organs of the ovary,
testis and adrenal. The present paper
describes a study of human thyroid
tissue used to determine the potential of
normal and neoplastic endocrine tissue
of another type to metabolize C19 steroids
in vitro.
In particular, attention was focused
upon the transformation of DHA to
testosterone and the 5a reduction of
testosterone, activities which produce
metabolites of greater biological activity
than the parent substrate.
materials and methods
Three specimens of thyroid cancer of
adenocarcinomatous (or follicular) type (Fig.
1) and 3 of simple nodular goitre (Fig. 2)
were examined. Normal thyroid tissue also
was obtained from 3 patients; one of these
had no thyroid disease, one had a gland
containing a carcinoma, the other a nodular
goitre. In the latter two instances the tissue
was histologically normal. All material was
freshly obtained from the operating theatre
and taken in the frozen section laboratory for
immediate incubation.
All tissues were processed at 0°C until
incubation was carried out (within 30 min
of tissue removal). The specimens were
finely sliced and incubated for 2 h at 37°C in
Krebs-Ringer phosphate buffer, pH 7-4
(10 ml/g tissue) containing an NADPH
generating system (200 p,mol glucose-6-phos-
phate, 25 mg NADP and 50 units glucose-6-
phosphate dehydrogenase) and the radio¬
active precursors: 20 /xCi(7a-3H)dchydro-
epiandrosterone (DHA) and 2 ^tCi(4-14C)
testosterone.
The steroid interconversions were then
determined by measuring the percentage
incorporation of the appropriate radioactive
labels into the various purified metabolites.
The methods for steroid purification and
characterization have already been described
in detail (Miller, Hamilton and Forrest,
1974).
results
The results of these experiments are
presented in the accompanying Table.
Normal, goitrous and malignant thyroid
tissue were all capable of extensively
metabolizing the DHA precursor. Testo¬
sterone was isolated as a metabolite of
DHA in each type of thyroid tissue, but
it accounted for only a small amount of
the precursor used.
By contrast, the metabolism of testo¬
sterone by the same tissues was slight and
in 2 of the 3 normal thyroid tissues,
metabolism was entirely absent. In com¬
parison with normal thyroid, the metabo¬
lism of testosterone was greater in nodular
and malignant tissue. Both 5a dihydro-
testosterone and 5a androstanediol were
characterized as metabolites of testosterone
in nodular and malignant tissue, but there
was no evidence for 5a reduced products
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Age , *-—— , % as
and Histology of % as dihydro¬ % as
Patient sex tissue % metabolized testosterone % metabolized testosterone androstane
1 8M Adenocarcinoma 38-40 0-17 18 • 80 0-24 0-18
Normal tissue 52-50 0 0 0 0
2 27M Adenocarcinoma 92-01 3-16 10-10 0- 14
3 67F Adenocarcinoma 95-17 0 10-10 0-39 0-49
4 58F Nodular goitre 79-10 0-63 4-99 0-61 0-15
Normal tissue 51-13 0-53 0 0 0
5 25F Nodular goitre 59-37 1-38 16-80
6 54F Nodular goitre 65-67 0-26 2-61 0-48 0-13
7 18F Normal tissue 65-70 0-21 2-80 0 0
in normal tissue even when it was associ¬
ated with neoplastic tissue possessing 5a
reductase activity.
Evidence for the conversion of either
DHA or testosterone to 16a hydroxylated
derivatives or oestrogen was not detected
in any incubation material.
discussion
These results confirm the observations
of Schneider et al. (1972) that thyroid
tissue can metabolize DHA extensively.
This ability is not confined to normal
tissue, but is also present in both goitrous
and malignant states.
High metabolism was restricted to
DHA and the same thyroid tissues metabo¬
lized much less of the testosterone pre¬
cursor. Small but significant amounts of
both 5a dihydrotestosterone and 5a andro-
stanediol were formed from testosterone
in incubations of both goitrous and
malignant thyroid. No such evidence for
the 5a reduction of testosterone was found
in the 3 incubations of normal thyroid,
despite the fact that thyroxine stimulates
5a reduction in other tissues (Tomkins,
Gordon and McGuire, 1960).
In two instances, 5a reduction in patho¬
logical thyroid tissues was obtained even
when the adjacent normal thyroid did
not display the activity. Although the
number of incubations is too small to
draw firm conclusions, the possibility
exists that pathological change in the
thyroid is accompanied by the acquisition
of potential to perform steroid conversions
not shown in normal tissue.
In a previous report (Miller et al.,
1973) we have described the metabolism
of DHA and testosterone by human
normal and neoplastic breast tissues,
using identical methods to those used for
the thyroid tissue studied in this com¬
munication. It is worth noting that the
amounts of the individual steroid precur¬
sors metabolized were different in the two
types of tissue, thyroid showing greater
metabolism of DHA but less of testo¬
sterone, compared with breast tissue.
Nevertheless, with the exception of
normal thyroid tissue, the production of 5a
dihyclrotestosterone and 5a androstane-
diol from testosterone was quantitatively
similar in thyroid and breast tissues, as
was the conversion of DHA to testosterone
in all tissues examined. This suggests
that these conversions are relatively non¬
specific. Further evidence for this is the
demonstration of similar transformations
in human skin (Hodgins, 1971; Wilson,
1972) and metastatic deposits of a bron-
chiogenic cancer (Miller, unpublished
results).
We are grateful to Professor A. R.
Currie for allowing us to use fresh material
from the frozen section laboratory.
We also thank Mr Donald Mcintosh,
who operated on some of the patients
included in this study, for his co-operation,
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and Mr D. McDonald, Miss J. Telford and
Mrs A. Boyd for their skilled technical
assistance.
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Steroid interconversions by metastatic
deposits of a human bronchogenic carcinoma
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Minces of a cervical node involved by metastases of a bronchogenic
carcinoma metabolized extensively both C21 and C19 steroid precursors.
Pregnenolone and dehydroepiandrosterone (DHA) were transformed
largely to A-5-androstenediol. Both 5-a-dihydrotestosterone and 5-a-
androstanediol were metabolites of testosterone.
Introduction
Bronchogenic carcinomas are known to be associated with a variety of paraendocrine
syndromes (Bower & Gordon, 1965), these being due to elaboration of protein and
polypeptides with hormone-like activity (Mason, Ratcliffe, Buckle & Mason, 1972).
No information is available of the steriodogenic capacity of bronchogenic cancer and
reports of steroid effects by them are rare (Daughtrey, Chesney, Spear, Gentsh &
Larsen, 1967). In this report we describe a study of steroid biosynthetic activity in a
secondary deposit of bronchogenic cancer in a lymph node.
Methods
The subject was a 74-year old man who first presented with enlarged glands in the
neck. On biopsy these were shown to be involved by metastatic deposits from an
anaplastic bronchogenic tumour. One of the nodes was taken for incubation and a
typical microscopic field of the tissue is shown in Figure i(a) and (b).
Incubation conditions
The tissue was finely sliced and split into 3 equal portions. Krebs Ringer phosphate
buffer pH 7-4 (ioml/g tissue), an NADPH generating system and 50 pCi of either
[7-a-3H]pregnenolone, [7-a-3H]DHA, or [7-a-3H]testosterone were added. Each was
incubated for 2 h at 37°C in an atmosphere of oxygen. The steroid metabolites were
extracted, purified and characterized as described elsewhere (Miller, Hamilton &
Forrest, 1974). Conversions were determined by measuring the percentage incorpora¬
tion of 3H into the metabolites after correction for manipulative losses.
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Figure i. (a) Low power view of the tumour—anaplastic carcinoma showing some
local necrosis (right upper field). H + Ex too; (b) Detail of (a)—moderate cellular
pleomorphism is present and a large cell type predominates. The morphology is
typical of many bronchogenic carcinomas. H + E x 450.
Results
The results are presented in Table 1 and summarized in Figure 2. All 3 substrates
were extensively metabolized. The presence of desmolase activity was demonstrated
by the conversion of pregnenolone to A-5-androstenediol and DFIA. Only a very
small transformation of pregnenolone to progesterone was obtained. The major
metabolite of DHA was also A-5-androstenediol, but small amounts of A4-andro-
stenedione and testosterone were also produced. Testosterone itself was metabolized
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to both 5-a-dihydrotestosterone and 5-a-androstanediol, but a large proportion of the
substrate remained unaccounted for. There was no evidence for the production of
oestrogen from any of the precursors.
Table i . % Metabolism of 7-a-3H steroid precursors by bronchogenic carcinoma
Pregnenolone DHA Testosterone
Pregnenolone 60-82 — —
Progesterone 0-08 — —
DHA 0-31 SS-76 —
A-5 -Androstenediol 14-18 37-25 —
Testosterone — 0-06 36-40
A-4-Androstenedione — 0-05
5 -a-Dihydrotestosterone — — °*43
5 -a-Androstanediol — -—• 12* io
oh
PREGNENOLONE DHA TESTOStERONE DIHYDROTESTOSTERONE 5« ANDROSTANEDIOL
CH3
I
PROGESTERONE A i ANDROSTENEDIONE
Figure 2. Pattern of steroid metabolism present in tumour studied.
Discussion
These results indicate that bronchogenic carcinoma may have the potential to
synthesize steroid hormones.
Precursors such as pregnenolone and DHA, which are normally present in the
plasma in high concentrations, were extensively metabolized. The production from
pregnenolone of high amounts of A-5-androstenediol and only small amounts of
progesterone would seem to indicate relatively high desmolase and reductive activities
in comparison with oxidative pathways. Preference for reductive metabolism was also
confirmed by the production from DHA of high amounts of A-5-androstenediol, but
only low amounts of A-4-androstenedione. The production of 5-a-dihydrotestosterone
and high amounts of 5-a-androstanediol from testosterone is interesting in view of the
high androgenic activity of these compounds in prostate (Bruchovsky & Wilson,
1968) and skin (Wilson & Walker, 1969).
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These steroid conversions are qualitatively identical to those which we, and others,
have demonstrated in the breast and its tumours (Miller et al., 1973), and in cancer
of the thyroid (Miller, Shivas & Forrest, 1974). Quantitatively the metabolism of each
precursor was greater for the bronchogenic tumour than that for breast cancer
(Miller et al., 1973), or for lymph nodes involved by breast cancer (unpublished
results). However, the demonstration that bronchogenic carcinoma can synthesize
active androgenic steroids may be of importance in view of the reported incident of
masculinization association with the presence of a bronchial tumour (Daughtreyer al.,
1967)—symptoms such as acne, male hair distribution, breast atrophy and clitoral
enlargement which disappeared on tumour excision, could be explained on the basis
of excessive production of androgenic steroids by the tumour.
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Summary.—Urinary aetiocholanolone levels have been measured in 417 women
aged between 20 and 70 years. The women were drawn from South East Scotland
and South Wales and consisted of patients with either benign or malignant disease
of the breast and control patients suffering from no detectable breast disorder.
The pattern of aetiocholanolone excretion with respect to age and menopausal
status has been defined in each group of patients.
No significant differences in urinary levels have been detected between patients
with breast disease, whether benign or malignant, and control patients. More
detailed examination of the 201 women with early cancer of the breast has also
shown that there is no consistent correlation between pre-operative aetiocholanolone
levels and factors of prognostic significance detectable at the time of primary treat¬
ment—tumour size, grade, round cell infiltration, histological involvement of nodes
by tumour and the clinical palpability of lymph nodes.
It would seem, therefore, that the prognostic value of pre-operative aetiocho¬
lanolone measurements is somewhat limited in patients with early breast cancer.
It is noted, however, that low levels of aetiocholanolone are associated with post¬
menopausal patients, a group in which the prognosis is generally poorer than that
in pre-menopausal women.
Considerable interest in the relation¬
ship of urinary androgen metabolites with
breast cancer has been provoked by the
studies of Bulbrook and his colleagues
(Bulbrook et al., 1962). These workers
have indicated that (a) some women with
advanced cancer have subnormal levels
of urinary aetiocholanolone and are un¬
likely to respond to major endocrine
ablation (Atkins et al., 1968a, b); (b) a
proportion of women with early breast
cancer also have abnormally low aetio¬
cholanolone levels (Bulbrook et al., 1962)
and that this is associated with poor
prognosis (Hayward and Bulbrook, 1968);
(c) " normal " women who subsequently
develop breast cancer have lower mean
excretion of aetiocholanolone than
matched controls (Bulbrook, Hayward
and Spicer, 1971).
Whilst it is now accepted that low
aetiocholanolone levels are associated with
a proportion of patients with advanced
breast cancer who have a poor prognosis
(Kumaoka et al., 1968; Cameron et al.,
1970), the situation in patients with
early disease remains equivocal, several
studies indicating that aetiocholanolone
levels are normal in these women (Alquist,
Jackson and Stewart, 1968; Wade et
al., 1969; Cameron et al., 1970). With
the recent finding that C19 androgenic
steroids may act as precursors for tumour
growth promoting hormones (Miller and
Forrest, 1974), it is even more important
to resolve this conflict.
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In an effort to do so, we have retro¬
spectively examined the results of urinary
aetiocholanolone measurements performed
in two major centres in normal women
and in patients with either early cancer
or benign disease of the breast. These
have been analysed with regard to age
and menopausal status, in order to define
the normal pattern of excretion in patients
and controls, and then related to other
factors of known prognostic significance.
PATIENTS AND METHODS
Urine was obtained from 417 hospital
in-patients in Cardiff and Edinburgh. Pa¬
tients were excluded from the study if they
had known endocrine disease, had been
receiving steroid preparations of any type
or had a history of cancer at any site other
than in the breast.
Control patients.—These were 23 women
from Cardiff and 22 from Edinburgh who
were admitted to hospital for elective surgery
for conditions not involving the breast.
None was suspected of having malignant
disease of any kind. The majority were
to undergo cholecystectomy, but others
included patients awaiting surgery for her¬
nias, duodenal ulcers and varicose veins.
These patients were therefore subjected to
similar pre-operative stress as subjects with
breast disorders.
Benign breast disease.—The 163 women in
this group had benign disease of the breast
proved by excision biopsy. No further
histological classification of the 76 women
from Cardiff was made but the pathological
records were checked to ensure that the
diagnosis of benign disease was correct.
Sufficient numbers of pre-menopausal
women from Edinburgh with benign breast
disease were studied to subdivide this group
further.
Group 1—fibrocystic disease of the breast
(17 patients) (those patients in whom the
predominant histological abnormalities
were the presence of fibrosis and cyst
formation);
Group 2—epitheliosis (17 patients) (lesions
in which epitheliosis of a marked degree
was present);
Group 3—fibroadenomata (25 patients).
Cancer patients.—There were 60 patients
from Cardiff and 141 patients from Edinburgh
with invasive carcinoma of the breast. All
of these cases were deemed to have operable
or early cancer of the breast and the majority
were of international clinical Stages I and II.
A few cases were in international clinical
Stage III, solely on account of a primary
tumour of a size greater than 5 cm diameter.
Menstrual status.—Each of the groups
has been further divided according to their
menstrual status, by the following criteria:
Pre-menopausal—patients with regular-
menstrual periods;
Menopausal—patients whose periods were
diminishing in frequency or whose last
period was within 2 years of primary
treatment;
Post-menopausal — patients whose last
period had occurred more than 2 years
before treatment.
Tumour grade.—Histological grade of the
primary tumour was assessed in 191 of the
201 patients, using the criteria of Patey and
Scarff (1928, 1929). In this classification,
increasing grade reflects an increase in
tumour malignancy (Champion and Wallace,
1971).
Round cell infiltration.—At the time of
grading, a semi-quantitative assessment of
round cell infiltration was also carried out,
as described by Champion, Wallace and
Prescott (1972).
Tumour size.—The clinical size of the
tumour was measured by 2 independent
observers at the time of presentation. The
tumour was measured in 2 planes at right-
angles and the larger diameter was recorded
in cm.
Lymph node involvement.—The clinical
status of the axillary nodes was assessed
by 2 observers before operation. Micro¬
scopical examination for the presence of
tumour was carried out in all cases from
which lymph nodes had been removed.
In Cardiff, where the standard operations
were either a simple mastectomy with
pectoral node biopsy or a modified radical
mastectomy, axillary node histology was
available. In Edinburgh, where simple and
radical mastectomies were performed, it
was possible to make a histological assess¬
ment of the radical mastectomy group only
(68 patients), no axillary nodes being avail-
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able from those patients undergoing simple
mastectomy.
Urine collection and analysis.—Urine was
collected from all patients pre-operatively;
in Cardiff for 48 h and in Edinburgh for
24 h before operation.
The techniques used for estimation of
aetiocholanolone were based on that de¬
scribed by Thomas and Bulbrook (1964),
and Thomas (1965). Different modifications
of these basic methods were introduced
separately in Cardiff (Cameron et al., 1970)
and Edinburgh (Sneddon, 1969). These
variations have led to minor differences
between centres with respect to extraction,
purification and measurement of aetio¬
cholanolone, all of which are unlikely to
affect quantitation. One major difference
between the methods employed in the
2 centres, however, was the use of con¬
jugated internal standards in Cardiff and
free steroid standards in Edinburgh in order
to monitor manipulative losses. This is
likely to result in different absolute values
for aetiocholanolone in any given specimen
of urine. The results from the 2 centres
are therefore presented separately. Never¬
theless, any differences in aetiocholanolone
values between the centres ought to be
consistent, and the same relationship between
aetiocholanolone and other parameters there¬
fore would be expected in results from both
Cardiff and Edinburgh.
results
The mean and standard deviation for
the ages of the patient groups under
study in Cardiff and Edinburgh is shown
in Table I. The pre-menopausal, benign
and control groups from Cardiff are
considerably younger than the correspond¬
ing cancer group. To achieve com¬
parability, only individuals aged 30 or
more have been compared in the subse¬
quent tests of significance (see below).
As statistical analysis of urinary ster¬
oids with age revealed a log normal
distribution (Cameron et al., 1970), aetio¬
cholanolone levels have been expressed
in logarithms to the base 10 of the con¬
centration (pg/24 h).
Age and menopausal status
Scattergrams relating aetiocholanolone
levels to age and menopausal status in
the patients with early breast cancer,
from Cardiff are shown in Fig. 1 and
from Edinburgh in Fig. 2. These figures
also show the regression lines of aetio¬
cholanolone with age for the pre- and
post-menopausal patient groups. The re¬
gression coefficients for these lines do
not differ significantly from zero. Age per
se, therefore, has little effect on aetio¬
cholanolone excretion in patients from
either city. There is, however, a signi¬
ficant difference between the mean levels
of aetiocholanolone in the pre- and post¬
menopausal patients, there being a sub¬
stantial reduction in aetiocholanolone
excretion after the menopause.
Analysis of the control and benign
disease groups (restricted to 30 years
and older) also revealed a similar pattern.
Once subdivided into pre- and post¬
menopausal patients, age had no
significant effect on the level of urinary
aetiocholanolone. The pre-menopausal
patients, however, showed significantly
increased levels compared with post¬
menopausal patients (Fig. 3, 4).
Information was available from a
number of patients under the age of
30 years—15 patients with benign disease
and 5 control patients from Cardiff.
These data are included in Fig. 5 and 6,
which show the relationship between
the aetiocholanolone excretion for all of
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Fig. 1.—Scattergram relating aetiocholanolone levels to age and menopausal status in 60 patients with
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Fig. 2.—Scattergram relating aetiocholanolone levels to age and menopausal status in 141 patients
with early breast cancer from Edinburgh.
the pre-menopausal control patients and
for those with benign breast disease.
In the benign group, there is a gradual
increase in aetiocholanolone levels up
to the age of 30 years, beyond which
the mean level of excretion becomes
relatively constant. This relationship is
not apparent in the small number of
women in the control group.
Variation with breast disease
This information is presented in Fig.
3 and 4. Analysis of variance showed
no significant difference in mean aetio-





















Fig. 3.—Urinary aetiocholanolone levels by menopausal status in control subjects and patients with

















Fig. 4.—Urinary aetiocholanolone levels by menopausal status in control subjects and patients with
early breast cancer and benign breast disease from Edinburgh (lines refer mean + standard error
for the groups).
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Fig. 5.—Scattergram of aetiocholanolone levels against age in 58 premenopausal patients with















Fig. 6.—Scattergram of aetiocholanolone
levels against age in 12 premenopausal













Fig. 7.—Urinary aetiocholanolone level in
premenopausal patients with either fibro¬
adenomata, fibrocystic disease or epithel-
iosis of the breast (lines refer to mean +
standard error for the groups).
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cholanolone levels between benign, cancer
and control patients, whether pre- or
post-menopausal, in women from either
Cardiff or Edinburgh. The further sub¬
division of the Edinburgh patients with
benign breast disease into those with
fibroadenomata, fibroadenosis or epithe-
liosis, revealed no differences between
these groups (Fig. 7).
Correlation with other clinical and tumour
parameters
Size, malignancy grade and round cell
infiltration of the primary tumour, to¬
gether with clinical palpability of lymph
nodes, were assessed in 191 patients from
the 2 centres. Histological examination
of lymph nodes was performed on 120
patients. The partial correlation coeffi¬
cients of aetiocholanolone with each of
the other variables are shown in Table II.
Table II.—Partial Correlation Coefficients







Age -0-29 0-00 -0-02
Grade 0-30* 0-01 -0-19*
Round cell -0-30* 0-15 0-18*
involvement
Clinical involve¬ 0-11 0-02 0-01
ment
Histological 0-12 0-02 —
involvement
Size 0-22* 0-07 0-01
*P < 0-05.
These coefficients reflect the association
between aetiocholanolone levels and each
of these variables, after mutual association
with menopausal status and with each
of the other variables, has been taken
into account (Steel and Torrie, I960).
In the Edinburgh series, the full set
of partial correlation coefficients could
only be obtained for the 68 patients
undergoing radical mastectomy, from
whom histological examination of nodes
was possible.
No consistent correlation was found
between aetiocholanolone levels and any
of these factors of prognostic significance.
Significant but diverging relationships
were, however, observed in Cardiff and
in the full Edinburgh series with regard
to both tumour grade and round cell
infiltration. No obvious reasons are ap¬
parent for these paradoxical observations.
discussion
Using data obtained separately from
the 2 centres, it has been possible to
define the excretion of aetiocholanolone
in control women and patients with
benign and malignant breast disease,
with respect to their age and menstrual
status. By examining the data from
patients with early breast cancer, it has
also been possible to relate these aetio¬
cholanolone levels to other factors known
to be of prognostic significance.
The relationship between urinary aetio¬
cholanolone and age has previously been
expressed in the form of a quadratic
equation (Cameron et al., 1970), increasing
age being associated with decreasing
aetiocholanolone excretion. Whilst the
present results are in accord with these
findings, they also indicate that age per
se is not associated with lowered aetio¬
cholanolone levels. If the results are
re-plotted after dividing the patients into
pre- and post-menopausal groups, then
age alone fails to influence urinary aetio¬
cholanolone excretion significantly. It
seems, therefore, that the reduction in
aetiocholanolone observed with increasing
age is a result of the increasing proportion
of post-menopausal women. This rela¬
tionship is also observed in control
patients and in those with benign breast
disease.
The present study, using a large
number of patients, confirms the findings
of Wacle et al. (1969) and Cameron et
al. (1970) that the mean urinary aetio¬
cholanolone levels of patients with early
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breast cancer are no different from those
with either benign disease or in-patient
controls. The observation that patients
with epitheliosis (believed to be a pre-
malignant condition) have normal aetio-
cholanolone levels does not support the
suggestion that low aetiocholanolone levels
may occur in women susceptible to
breast cancer.
It has not been possible to demonstrate
any consistent relationship between pre¬
operative urinary aetiocholanolone and
any single one of a series of clinical and
morphological factors of known prog¬
nostic significance in women with early
breast cancer. These observations, there¬
fore, are at variance with the suggestion
that aetiocholanolone is of major prog¬
nostic significance in early breast cancer
(Hayward and Bulbrook, 1968). In this
respect, the time of the urine collection
may be of importance. The data in
the present study is based upon pre¬
operative specimens whereas those in
Bulbrook's study related to urine collected
10 days after mastectomy. It is now
known that mastectomy, possibly via
the stress of surgical procedures, in¬
fluences both urinary and plasma levels
of androgenic steroids (Hayward and
Bulbrook, 1968; Wang et al., 1974).
Conversely, patients awaiting surgery are
likely to suffer pre-operative stress and
this may also contribute to differences
in pre- and post-operative steroid excre¬
tion.
It should be noted, however, that
this study shows one group of patients,
i.e. the post-menopausal women, who
are likely to have low urinary aetio¬
cholanolone levels. It is therefore inter¬
esting that pre-menopausal women over
35 years with breast cancer have a better
prognosis than those women who are
post-menopausal (Hamilton et al., 1974).
We therefore emphasize the importance
of menopausal status in early breast
cancer and suggest that it should be taken
into account when assessing the possible
predictive value of urinary aetiocho¬
lanolone.
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Urinary EtiochoSanolone and Prognosis in Early
Carcinoma of the Breast
R.J. PRESCOTT, MSc, PhD, W. R. MILLER, BSc, PhD, and
T. HAMILTON, MB, ChB, PhD, FRCSE
Etiocholanolone levels have been measured in both premastectomy and postoperative urines from 86
women with early breast cancer. Levels did not differ between patients subsequently surviving five
years following mastectomy and those dying from recurrent disease within this period.
Key words: etiocholanolone, carcinoma of the breast
INTRODUCTION
Evidence has been presented that, in patients with early breast cancer, etiocholano¬
lone, especially in combination with corticosteroids, may predict disease recurrence and
survival following mastectomy [Hayward and Bulbrook, 1968] . Others have claimed that
levels of urinary androgens are without prognostic value for the patient with early disease
[Alquist et al, 1968]. This conflict may arise in part by the fact that some investigators
assayed preoperative urines while others have used postoperative samples [Hayward and
Bulbrook, 1968]. In this paper we present results from both premastectomy and post¬
operative urines collected from patients with early breast cancer. The survival status of
these patients five years after mastectomy is available and has been related to both pre-
and postoperative levels of urinary etiocholanolone alone, and in combination with
urinary corticosteroids as the discriminant function of Bulbrook et al [1960].
METHODS
The 86 patients studied formed part of the Edinburgh Breast Cancer Trial
[Hamilton et al, 1974]. All had invasive, "operable" carcinoma of the breast and were
of international clinical stages I and II, or were patients with stage III disease suitable for
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either of two treatment options: radical mastectomy or simple mastectomy plus radical
radiotherapy. There were 23 premenopausal patients (experiencing regular menstrual
periods), 54 postmenopausal patients (whose last period had occurred more than 2 years
before treatment), and 8 menopausal patients (experiencing irregular periods or within
2 years of their last menstruation). The menopausal status of one woman was not recorded.
Twenty-four-hour urine collections were made on the day prior to mastectomy and
postoperatively 7—10 days after operation. Urinary etiocholanolone levels were measured
by the procedure described by Sneddon [1969] and 17-hydroxy corticosteroids by the
method of Metcalfe [1963]. The discriminant function was calculated as described by
Bulbrook et al [1960].
DF = 80 — 80 X [17-hydroxy corticosteroids (in mg)] + etiocholanolone (in qg)
All statistical tests of significance were based on the logarithms of the etiocholano¬
lone levels, and parametric tests were applied (analysis of variance, t tests).
RESULTS
Of the 86 patients 29 died within five years of mastectomy.
The preoperative and postoperative etiocholanolone levels for all patients are plotted
in Fig. 1. There was a similar distribution for both surviving and nonsurviving patients.
Most of the points in Figure 1 lie above the line along which the preoperative and post¬
operative values are equal, indicating that in the majority the urinary levels of etiocholano¬
lone were lower after mastectomy.
Only 11 of the 47 women with stage I disease (23%) died within five years. This
compared with 12 deaths among 23 women with stage II disease (52%) and 6 of 16
women with stage III disease (38%). Although mortality is dependent upon the stage of
disease, the etiocholanolone levels showed no statistically significant differences between
stages. This was true of preoperative levels, postoperative levels, and the percentage drop
in level. Nor were there significant differences in etiocholanolone level between survivors
and nonsurvivors within any stage.
Of the 23 premenopausal 5 women (22%) died within five years, compared to 5 of
the 8 menopausal women (63%), and 19 of the 54 women who were postmenopausal
(35%). There was no statistically significant difference at the 5% level between survivors
and nonsurvivors in any menopausal group with regard to a) preoperative eticholanolone
level, b) postoperative etiocholanolone level, or c) change in etiocholanolone levels be¬
tween pre- and postoperative urines (Fig. 2). In Figure 2c there is the suggestion of a
consistently greater fall in etiocholanolone levels among nonsurvivors, but examination
of an appropriately weighted mean difference by standard parametric methods failed to
show statistical significance at the 5% level.
There were significant differences in the preoperative levels of etiocholanolone
between the menopausal groups (p < 0.01), but neither the postoperative levels nor the
drop in level demonstrated statistically significant differences between the menopausal
groups (p > 0.05).
The mean levels of Bulbrook's discriminant function in various subgroups are given
in Table I. The discriminant function is largely a reflection of the etiocholanolone level
and the conclusions on the discriminant function are equivalent to results from the
etiocholanolone data alone.
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Fig. 1. Preoperative and postoperative levels of urinary etiocholanolone in women who were a) alive
b) dead five years after mastectomy.
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Fig. 2. Distribution of etiocholanolone levels in subgroups defined by menopausal status and five-year
survival, with means ± one standard error marked (log scale).
DISCUSSION
These results indicate no difference between survivors and nonsurvivors five years
after mastectomy in the levels of urinary etiocholanolone. This conclusion was valid
whether the measurements were performed on urine collected preoperatively or immediate¬
ly postoperatively. Even combination with urinary corticosteroids (discriminant function)
failed to distinguish between survivors and nonsurvivors. Accordingly, in our hands,
etiocholanolone or discriminant values alone were of no assistance in forecasting survival
after mastectomy.
It has been suggested, however, that etiocholanolone when combined with stage of
disease, tumor grade, and menopausal status of the patients, may reveal a group of patients
Etiocholanolone and Breast Cancer Prognosis 351
TABLE 1. Mean Values of Bulbrook's Discriminant Function (DF) (± Standard Error of Mean) in
Subgroups of Patients Alive Five Years After Mastectomy and Patients in Corresponding Subgroups
of Patients Dying Within Five Years of Mastectomy
Preoperative Postoperative
Number of patients DF level DF level Drop in DF
Subgroup Alive Dead Alive Dead Alive Dead Alive Dead
Stage
I 36 11 1,000 708 636 360 363 347
(±174) (±280) (±142) (±188) (±117) (±171)
II 11 12 1,267 1,334 555 623 713 711
(±309) (±417) (±152) (±145) (±240) (± 370)
III 10 6 608 1,061 274 420 334 641
(±211) (±491) (±77) (±198) (± 184) (±399)
Menopausal status
Premenopausal 18 5 1,411 2,708 739 838 672 1,871
(±258) (± 857) (±190) (±389) (±156) (±697)
Menopausal 3 4 1,392 644 1,727 564 - 335 80
(±421) (±51 1) (±718) (±62) (±297) (±497)
Postmenopausal 35 20 654 702 344 376 310 326
(±127) (±129) (±85) (±106) (+104) (±97)
with poor prognosis [Hayward and Bulbroock, 1968]. While it is our experience that as a
group postmenopausal patients have both lower urinary etiocholanolone and a poorer prog¬
nosis then premenopausal subjects [Hamilton et al, 1974], the addition of etiocholanolone
to menopausal status and stage failed to improve prognostic accuracy. Furthermore, we have
already shown that etiocholanolone does not appear to correlate with tumor parameters of
possible prognostic significance [Miller et al, 1975].
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SUMMARY
Breast secretions obtained from non-lactating women by nipple aspiration contain high levels of mater¬
ial which cross-reacts with an antibody specific for dehydroepiandrosterone (DHA) and its sulphate. On
thin layer chromatography, the cross reacting material migrates with DHA sulphate and after solvolysis
with free DHA. The mass spectrum of the major component of solvolysed extracts after gas liquid
chromatography (g.l.c.) also closely resembles that of authentic DHA. Quantitative estimates by
g.l.c.-mass spectrometry of DHA in solvolysed extracts are similar to those obtained by radioimmuno¬
assay of DHA and, after correction for recovery losses, compare well with radioimmunoassay values for
DHA sulphate in the original secretions. It is concluded that breast secretions contain remarkably high
concentrations of DHA sulphate.
INTRODUCTION
Breast secretions may be obtained from non-
lactating women (both parous and nulliparous) by
nipple aspiration [1], Preliminary results have shown
that these secretions may contain high levels of mater¬
ial which cross-reacts strongly with an antibody
raised against DHA-3/f-monohemisuccinate conju¬
gated to ovalbumin [2], We now present evidence
that this is DHA sulphate.
EXPERIMENTAL
Breast secretions
Breast secretions were collected by nipple aspira¬
tion using a suction cup as described by Sartorius [3],
Details of subjects and secretions are presented in
Table 1. At the time of study all women had no his¬
tory of breast abnormality except for subjects 3, 11
and 14 who presented with fibrocystic disease, and
patient 12 who had carcinoma of the right breast.
Table 1. Details of secretions studied
Subject
Menopausal
Status Parity Volume of Secretion fid)
1. Postmenopausal Parous L(a) 100 L(b) 85 R 10*
2. Premenopausal Parous L 40 R 170
3. Menopausal Parous L(a) 40 L(b) 85
4. Premenopausal Parous A+L 150 R 200
B L 135 R 300
C L 65 R 340
D L 40
5. Postmenopausal Parous L 105
6. Premenopausal Parous R 40
7. Menopausal Parous L 45
8. Premenopausal Parous R 15
9. Premenopausal Nulliparous A L 35 R 310
B L 40
10. Premenopausal Parous R 40
11. Premenopausal Parous L 80
12. Premenopausal Parous L 215 R 240
13. Premenopausal Parous L 20
14. Premenopausal Nulliparous R 30
15. Premenopausal — L 20
* L = Left Breast; R = Right Breast; a,b = different ducts in the same breast,
t A.B.C.D = Secretions collected on different occasions.
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All values are the mean of three determinations.
Cross-reaction calculated from ratio of molar mass of DHA sul¬
phate to cross-reacting steroid, required to displace 50% of the radio¬
ligand, multiplied by 100.
Postmenopausal subjects were at least 2 years past
their last menstrual period. Volume of secretion was
measured by collection in calibrated capillary tubing.
Secretions were stored diluted in phosphate buffer
pH7 at — 20°C. until assay.
Plasma
Peripheral blood was taken by venipuncture im¬
mediately before aspiration of breast secretions and
collected in heparinized tubes. Plasma was separated
within 30min and stored at — 20°C. until assay.
Radioimmunoassay
Radioimmunoassay of DHA sulphate was per¬
formed directly on diluted breast secretions and peri¬
pheral blood plasma using the method of Buster and
Abrahams[4]. The antibody used was supplied by Mr
B. A. Morris, Department of Biochemistry, University
of Surrey and showed the specificity presented in
Table 2. The same antibody was used to determine
free DHA levels in solvolysed secretions using DHA
to construct the standard curve.
Isotope tracer studies
[7aH3]-DHA sulphate (170,000 c.p.m., about
34 pmol) was added to aliquots of diluted breast se¬
cretions. The secretions were evaporated to dryness
and the residue reconstituted in alcohol in prep¬
aration for thin layer chromatography (t.l.c.) on silica
gel H.F. 254 + 366. Chromatography was performed
in system I, isopropanol-chloroform methanol-water
(10:10:5:2 by vol.) for 2h after which the area run¬
ning with the mobility of authentic DHA sulphate
was eluted with alcohol. The eluate was evaporated to
dryness and solvolysed by dissolving in 0.05M sul¬
phuric acid saturated with sodium chloride (5 ml). An
equal volume of ethyl acetate was added and incu¬
bated overnight at 40°C. The ethyl acetate layer was
taken off and the aqueous fraction re-extracted with
ethyl acetate. The bulked ethyl acetate fraction was
evaporated to dryness and dissolved in alcohol, in
preparation for thin layer chromatography. Chroma¬
tography was then performed in system II,
chloroform-acetone (97:3 v/v) and the fraction migra¬
ting with authentic DHA eluted. Aliquots of secretion
were taken for radioimmunoassay and estimation of
radioactivity at the outset and after each chroma¬
tography step of the procedure.
G.l.c.-mass spectrometry
For identification purposes trimethyl silyl (TMS)
derivatives of steroids and extracts were prepared [5].
Quantitative analysis was performed on tertiary butyl
dimethyl silyl (TBDMS) derivatives using deuterated
isoandrosterone as internal standard. This was pre¬
pared by hydrogenating DHA 3.5 (mmol) with plati-
nium oxide catalyst in the presence of deuterium to
give 5,6 dideutero isoandrosterone. This material
(350/imol) was equilibrated for 12 h with potassium
hydroxide in D,0 and the steroids extracted with
ether. After evaporation the residue was recrystallized
from acetone/hexane to give 5,6,16,16 tetradeutero
isoandrosterone. This standard was added to an ali¬
quot of the solvolysed extract of breast secretion and
dried down under nitrogen. The residue was deriva-
tised as the TBDMS ether as described previously [6].
The steroids and internal standard were measured in
a Dupont 490B mass spectrometer coupled through a
glass jet separator to a Varian 1400 gas chromato-
graph. The gas chromatographic column used was a
10 m SE 30 support coated open tubular column
(SGE Ltd) maintained at 210°C. The transfer lines
were maintained at 250°C and the source temperature
was 240°C. The steroids were quantitated by measur¬
ing the peak heights of the M-57 peaks (m/e 345 for
DHA, m/e 347 for androsterone and isoandrosterone
and m/e 349 for the tetradeutero isoandrosterone
internal standard). Standard mixtures derivatised
Dehydroepiandrosterone sulphate in breast secretions 147
alongside samples were used to construct a ratio-
mass plot from which the mass of the various steroids
present in the secretion was read. The intra-assay
variation was 7.3% for androsterone, 20.5% for isoan-
drosterone and 9.5% for DHA. The limit of detection
was 3.5 pmol.
RESULTS
Radioimmunoassay of breast secretions
All breast secretions studied contained high con¬
centrations of material cross-reacting with the anti¬
body to DHA-3B-monohemisuccinate. Levels in se¬
cretions were between 50 and 350 fold higher than in
plasma from the same patients (Table 3). Concen¬
trations in secretions obtained from the same
patient [4] on several occasions were remarkably con¬
sistent. Assay of secretions at different dilutions pro¬
duced a dose response curve parallel to that of plasma
and a standard curve of DHA sulphate (Fig. 1). After
ether extraction, the antigen was still present in the
aqueous fraction, less than 1% of the cross-reacting
material being found in the organic phase.
After t.l.c. of the secretions in system I, material
cross-reacting with the antibody was found in the
area whose mobility corresponded to that of authen¬
tic DHA sulphate. No cross-reacting material was
located in other areas including that corresponding to
DHA glucuronide. After solvolysis of the antigen and
t.l.c. in system II, the cross-reacting material migrated
with authentic free DHA.
[7a3H]-DHA sulphate was added as tracer to three
secretions and isotope tracer studies performed as de¬
scribed in the methods. The results are presented in
Table 4 and it can be seen that the specific radioac-
Table 3. Concentration of DHA sulphate-like material
(/rmol/1) as estimated by radioimmunoassay in breast
secretions and plasma
Subject Breast secretions Plasma
1. La 160 3.10
Lb 260
R 322
2. L 416 2.44
R 395
3. L(a) 867 5.03
L(b) 846
4. A L 839 5.37
R 607
B L 1,000 5.72
R 725
C L 995 4.33
R 541
D L 964 4.46
5. L 468 2.48
6. R 863 5.08
7. L 676 3.10
8. R 1,110 2.91
9. A L 2,010 9.00
R 1,770
B L 1,720 8.01
10. R 742 6.07
11. L 160 1.65
12. L 215 1.70
R 208
13. R 1,120 4.16
14. R 537 —
15. L 1,330 —
Legend as Table 1.
tivity as expressed as a ratio of 3H to cross-reacting
material (in DHA or DHA sulphate equivalents)
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Fig. 1. Dose response curves using standard DHA sulphate (DHAS), breast secretion (3La) and plasma
from the same patient (diluted as indicated and 0.5 ml assayed in duplicate).
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Table 4. Isotope tracer studies of breast secretions
Specific
radio-
Secretion Preparation Total c.p.m. Total nmol* activity
Diluted secretion 170,000 16.6 10,200
I3L After t.l.c. system I 121,500 12.1 10,000
After solvolysis
and t.l.c. system II 52,500 5.2 10,100
Diluted secretion 170,000 12.1 14,000
I4R After t.l.c. system I 147,000 10.1 14,600
After solvolysis
and t.l.c. system II 66,000 4.6 14,300
Diluted secretion 170,000 19.0 8,900
15L After t.l.c. system I 117,500 10.3 11,400
After solvolysis
and t.l.c. system II 53,500 4.8 11,100
* As estimated from radioimmunoassay as DHA sulphate before solvolysis and
DHA after solvolysis.
G.l.c.-mass spectrometry
Material isolated from the secretions after solvo¬
lysis and derivatisation to TMS ethers was subjected
to g.l.c.-mass spectrometry. The largest component
had a retention time identical to authentic DHA.
When analysed by mass spectrometry, the spectrum
of this constituent closely resembled that of authentic
DHA-TMS ether (Fig. 2). The spectra showed a mol¬
ecular ion at m/e 360, a peak at m/e 129 characteristic
of TMS ethers of 3/?-hydroxy-A5 compounds [6]
together with peaks at m/e 231 (M-129); there were
other peaks corresponding to loss of trimethyl silanol
(M-90) at m/e 270 and M-(90 -1- 15) at m/e 255. The
peak at m/e 304 is probably due to the loss of C 15-17
from the steroid D ring. Several other g.l.c. peaks
were present in solvolysed extracts and epiandroster-
one and androsterone were identified by their reten¬
tion times and mass spectra.
Quantitation of DHA, androsterone and epiandros-
terone by g.l.c.-mass spectrometry of TBDMS ethers
was performed in solvolysed extracts of 20 secretions
and results are presented in Table 5. In each case
DHA represented the major steroid identified
although variable amounts of androsterone and
epiandrosterone were also present. Analysis of ether
extracts of pre-solvolysis secretions failed to demon¬
strate significant amounts of either free DHA, andros¬
terone or epiandrosterone.

















Fig. 2. Comparison of mass spectrometry of authentic DHA and solvolysed sample of breast secretion
both derivatized as TMS ethers.
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1 L(a) 6.24 3.29 2.41 2.51
L(b) 10.05 7.28 3.96 0.90
R 1.39 1.35 0.86 0.76
2 R 22.35 17.15 2.69 5.03
L 6.93 7.84 3.27 7.30
3 L(a) 19.95 24.35 4.89 3.37
L(b) 57.20 54.90 7.58 2.07
4AL 88.40 56.30 11.00 5.99
R 88.40 81.60 11.90 6.68
BL 84.60 72.45 12.35 12.80
R 95.70 98.80 14.90 15.30
CL 32.25 28.10 5.51 5.51
5 L 25.40 21.85 3.65 2.75
6 R 59.70 49.95 4.34 2.75
7 L 15.95 18.05 1.83 0.48
8 R 9.02 9.36 2.75 1.17
9AL 36.75 36.95 8.95 10.35
10 R 17.50 16.65 2.96 5.27
11 L 5.13 4.15 1 38 2.75
12 L 27.75 24.25 6.40 5.51
Legend as Table 1.
Comparison of levels as measured by radioimmunoassay
and g.l.c.-mass spectrometry
In solvolysed extracts of 20 secretions, DHA levels
were measured by both radioimmunoassay and
g.l.c.-mass spectrometry. In each case, levels detected
by both methods were of a similar order of magnitude
(Table 5) and the correlation about a line of linear
regression was highly significant at P < 0.001 (Fig. 3).
Losses during solvolysis were determined in 10 se¬
cretions by measuring the recovery of added tracer
[7a3H]-DHA sulphate (20,000 c.p.m., about 4pmol).
It was thus possible to calculate DHA sulphate levels
in the original secretions from g.l.c.-mass spectro¬
metric estimates of DHA in the solvolysed extract.
< These have been compared with values for DHA sul¬
phate obtained by radioimmunoassay performed di¬
rectly on diluted secretions (Fig. 4). Correlation of
estimates of DHA sulphate by the two methods is
highly significant (P < 0.001).
DISCUSSION
We have previously reported that breast secretions
from nonlactating women contain large amounts of
material cross reacting with an antibody largely
specific for DHA and its sulphate [2], Details of
further characterization of the material is now
presented. The cross-reacting material is not ether ex-
tractable and moves with the mobility of authentic
DHA sulphate during thin layer chromatography.
However, once solvolysed the mobility changes to
that of free DHA. If [7a3H]-DHA sulphate is added
to secretions as tracer, the ratio of radioactivity to
cross reacting material remains constant throughout
these procedures, g.l.c.-mass spectrometry analysis of
the solvolysed material confirms the identity of DHA;
variable amounts of epiandrosterone and androster-
one are also present. The levels of DHA in solvolysed
extracts are similar whether estimated by radio¬
immunoassay or g.l.c.-mass spectrometry. Although
the mass-spectrometric data relates to DHA in solvo¬
lysed extracts, significant amounts of free steroid are
unlikely to have been present before solvolysis as all
secretions were extracted with ether at the outset of
characterization. After chromatography in t.l.c. sys¬
tem I which separated DHA sulphate from DHA glu-
DHA ( nmol ) by g I.e.- mass spectrometry
Fig. 3. Correlation between DHA content in solvolysed
extracts of breast secretions as estimated by radioimmu- .
noassay and g.l.c.-mass spectrometry. Regression line
y = 1.09 x + 0.922 correlation coefficient r = 0.972.








Fig. 4. Correlation between DHA sulphate concentrations in breast secretions as assayed by direct
radioimmunoassay and calculated from g.l.c.-mass spectrometric estimates of DHA in solvolysed
extracts. Regression line y = 0.933 x + 54.8. Correlation coefficient r = 0.973. Breast secretions exam¬
ined were 4CL, 4CR, 4DL, 9AL, 9AR, 9BL, 10R, 11L, 12L and 12R.
(^jmol / t}g.t.c. - mass spectrometry
curonide, no cross reacting material was found with a
mobility of DHA glucuronide. Furthermore, calcula¬
tion of DHA sulphate levels in secretions from
g.l.c.-mass spectrometric determination of DHA in
their solvolysed extracts (after correction for proce¬
dural losses and molecular weight changes) agrees
well with values for DHA-sulphate obtained directly
by radioimmunoassay—even in those secretions sub¬
ject to chromatography before solvolysis.
This data provides conclusive evidence that breast
secretions may contain remarkably high levels of
DHA sulphate. Values may be as much as 300 fold
higher than in plasma from the same woman.
Although it has been reported that breast cyst fluids
may contain high levels of androsterone and DHA
sulphate [7] and oestrogen conjugates [8], we believe
this is the first report of high levels of C19 steroid
conjugates in breast secretions. Raised levels of other
hormones have been reported in breast secretions [9]
but in absolute amounts, these are small compared
with the levels of DHA sulphate detected in this
study. Similarly although levels of progesterone
may be high in perinatal mammary secretions from
women [10] and cow's milk during early preg¬
nancy [11] the values are 10-100 fold less than those
of DHA sulphate in breast secretions from non¬
pregnant women.
At the present time it is not possible to state
whether the high levels of DHA sulphate in breast
secretions are due to active synthesis by the breast or
the result of concentration from plasma sources.
However, it has been reported that the amounts of
steroid conjugates transferred from plasma to milk
are minimal [12] although this may not be relevant as
levels of DHA sulphate in human milk are low
(Miller, W. R„ unpublished results). The physiological
implications of elevated levels of DHA sulphate in
breast fluid remain to be elucidated but breast tissues
are capable of utilizing DHA sulphate as a precursor
for more powerful hormones such as testosterone [ 13]
and plasma levels of DHA sulphate may differ in
women with varying risk to breast cancer [14],
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Summary
Human breast secretions as collected by nipple aspiration have been analysed for dehydroepiandrosterone
sulphate by radioimmunoassay. All secretions collected from non-lactating normal women contained
remarkably high levels of dehydroepiandrosterone sulphate as compared with plasma taken at the same time.
Although there was a large range of concentrations, levels were of a similar magnitude in different ducts from
the same breast and in different breasts from the same individual. No significant difference was detected
between secretions from pre and postmenopausal women. Sequential sampling of breast secretions through
the menstrual cycle in two normal premenopausal women showed no cyclic variation in dehydro¬
epiandrosterone sulphate concentration. There was also no significant difference between levels in breast
secretions obtained from normal women and patients with either malignant or benign breast disease. Analysis
of secretions from tumour and non-tumour bearing breasts in cancer patients failed to show consistent
differences although, in contrast to normal women, the variation between breasts in individual patients was
often marked.
Introduction
Information on the steroid hormone content of
human non-lactating breast secretions is limited. A
report that free oestrogens are present in higher
concentrations than in plasma (1) was not con¬
firmed in our laboratory (2). On the other hand
we found that breast secretions contained large
amounts of material cross reacting with an anti¬
body specific for dehydroepiandrosterone and its
sulphate (2) and subsequently characterised this as
dehydroepiandrosterone sulphate by GLC-mass
spectrometry (3). We now describe our findings on
a large series of secretions obtained from both
normal women and patients with breast disease.
Materials and methods
Subjects
Breast secretions were obtained from 53 of 90
women studied at random. There were 22 normal
women, 7 with fibrocystic disease, 2 with breast
pain and 22 with breast cancer. Twenty-eight
women were premenopausal, 14 postmenopausal
(>two years past their last menstrual period), 9
menopausal and 2 of unknown menstrual status.
The date of the last menstrual period was noted for
all premenopausal women.
Breast secretions were collected by aspiration
using a nipple cup as described by Sartorius (4).
These were stored, diluted between 100 and 500 fold
in 0.2M phosphate buffer pH 7.0, at -20° C. In
each woman, attempts were made to collect secre¬
tions from both breasts but this was only possible in
34; in 9, secretions were obtained from the left
breast alone and in 10 from the right breast alone.
Four women were studied on more than one oc¬
casion. A total of 122 secretions were collected with
volumes varying between 10 and 250 p\.
Peripheral blood was taken immediately before
aspiration of breast secretions, collected in hepa-
rinised tubes, centrifuged and the plasma stored at
— 20°C.
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Radioimmunoassay
Radioimmunoassay of dehydroepiandrosterone
(DHA) sulphate was performed directly on diluted
breast secretions and peripheral blood plasma using
the method of Buster and Abraham (5). The speci¬




Sixty-seven secretions were collected from 22
normal women. The mean DHA sulphate concen¬
tration in breast secretions and plasma for these
subjects is shown in Table 1.
In 15 women, secretion was obtained from both
right and left breasts. The results are presented in
Fig. 1. Concentrations of DHA sulphate were
comparable in secretions from different breasts in
the same individual.
In two women, secretion was obtained from
different ducts in the same breast. These results are
shown in Table 2 and indicate that DHA sulphate
levels were again of similar magnitude.
Because of the similarity of values in secretions
from the same women, in the following compari¬
sons, results of multiple secretions from the same
left breast DHA-sulphate (/jg/ml)
Fig. 1. DHA sulphate levels in secretions from both breasts of
normal women. The line is that on which points should fall if
concentrations were identical in both breasts. Where the same
woman was studied on more than one occasion, values for each
breast have been averaged.
Table 1. Levels of DHA sulphate (/rg/ml) as measured by






° Sixty-seven secretions and 35 plasma samples were obtained
from twenty-two normal women - certain subjects were studied
on more than one occasion.
Table 2. Comparison of DHA sulphate concentration (/rg/ml) in
secretions from separate ducts in the same breast.
Subject EMcA RMcQ
Left breast duct 1 195 287
duct 2 112 218
Right breast duct 1 128 156
duct 2 172 —
duct 3 122 —
individual have been averaged.
No relationship was apparent between DHA
sulphate levels in secretions and age of the women
(Fig. 2) nor was there a significant difference
between secretions from pre and postmenopausal
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Fig. 2. The relationship between DHA sulphate levels in breast
secretions and age in normal women. Where more than one
secretion was obtained from an individual, the values have been
averaged.











Fig. 3. Levels of DHA sulphate in breast secretions from pre and
postmenopausal normal women. Lines are mean and standard
error of the mean. Where more than one secretion was obtained
from an individual, the values have been averaged.
secretions with values in excess of 200 /rg/ml came
from premenopausal women and the number of
postmenopausal women studied was small.
The effect of sequential sampling through the
menstrual cycle on DHA sulphate concentrations in
breast secretions has been studied in two women.
Both had regular menstrual periods and no history
of taking oral steroids, no family history or past
history of breast disease and no clinical or radio¬
graphic breast abnormality. One subject (R) was
aged 45 years and multiparous, the other (E) was
aged 30 years and nulliparous. Secretions were taken
from both breasts on seven occasions through
consecutive menstrual cycles (at about seven day
intervals for subject R and five day intervals for
subject E). Between 10 and 250 p\ of secretion was
collected on each occasion but there was no obvious
cyclic change in volume or total protein content of
secretion. Levels of DHA sulphate in secretions and
peripheral plasma are shown in Fig. 4. Throughout
the cycle there was remarkable high concentrations
of DHA sulphate in secretions compared with
plasma (secretion 100-250 fold higher than plasma)
and in each patient, concentrations in secretions
from the left breast were always higher than those










Fig. 4. Levels of DHA sulphate in breast secretions and plasma
taken from 2 normal premenopausal women through the men¬
strual cycle. • Secretion from left breast, O secretion from right
breast, A plasma.
cyclic pattern in DHA sulphate levels in secretions
or plasma during the menstrual cycle and no
evidence for a decrease in concentration in secre¬
tions with continued sampling.
Women with breast disease
Levels of DHA sulphate in secretions from women
with benign and malignant breast disease are com¬
pared with those from normal women in Table 3
and in Fig. 5. No significant differences were
detected and, like normal subjects, most women
with benign and malignant disease had levels in
secretions many times higher than in their plasma
(Fig. 6).
In thirteen women with breast cancer, secretions
were obtained from both breasts so that com¬
parison between tumour bearing and non-tumour
270 WR Mitler et al.
Table 3. Levels of DHA sulphate (ag/ml) in secretions from Table 4. Levels of DHA sulphate (/rg/ml) in secretions from
normal women and patients with benign or malignant breast tumour bearing and non-tumour bearing breasts of women with
disease. breast cancer.
Normal Benign Breast cancer Subject Tumour Non-tumour
(22) (9) (22) bearing bearing
Mean + SEM 149±30 119±33 109±33 1. 155.0 140.0
Range 9-575 6-247 1-678 2. 60.0 62.0
3. 1.6 0.5
Figures in parentheses represent the number of patients studied. 4. 3.2 3.5
Where more than one secretion was obtained from an individual, 5. 19.2 30.5
values for each were averaged before calculation of the means for 6. 18.4 118.0
the group. This accounts for the difference in mean for the 7. 57.0 44.0
normal group as presented in Table 1 which was calculated by 8." (a) 456.0 320.0
directly meaning the values for the total number of secretions (b) 216.0
collected from normal women. 9. 76.0 64.0
10. 34.5 34.0
11. 200.0 111.0
bearing breasts could be made (Table 4). Although 12. 1.9 17.6
in about one half of patients there were large
13. 21.5 4.3
variations in DHA sulphate levels between breasts
of the same individual, in some cases the tumour
° Secretions were obtained from two separate ducts (a and b).
bearing breast gave secretions with higher concen¬















































































benign disease breast cancer
Fig. 5. DHA sulphate levels in breast secretions from normal
women, patients with benign breast disease and those with breast
cancer. Where more than one secretion was obtained from an
individual, the values have been averaged. • premenopausal, 3
menopausal, O postmenopausal.
Fig. 6. Ratios of DHA sulphate between breast secretions and
plasma in individual normal women and patients with either
benign breast disease or cancer. Within the benign disease group
• fibroadenosis or fibrocystic disease, O mastalgia.
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Concentrations of 1 IS IgA and IgG in breast secretions
1 IS IgA and IgG were detectable in all the breast secretions obtained from normal sub¬
jects; values ranges from 4.5 to 237.6 g/1 and 1.4 to 67.1 g/1, respectively. The mean
(±S.E., n = 18) 11S IgA concentration of 117.2 ± 15.3 g/1 was significantly higher than
the mean IgG concentration of 7.3 ±3.7 g/1 (P< 0.001; unpaired f-test), but no signifi¬
cant correlation existed between 11S IgA and IgG values for each individual secretion (r =
0.2204, P <0.40; Table 1).
In an attempt to assess the validity of the immunoglobulin concentrations observed in
breast secretions, the value for the right breast was compared with the value obtained for
the left breast, where secretions were obtained from both breasts on the same occasion.
Where more than one secretion was obtained from a breast on a particular occasion (e.g.
subject 5, secretions 37Li, 37L2), the mean value for tire breast was used for the compari¬
son. IgA values for the right breast ranged from 63 to 206% of the values seen for the left
breast (mean ± S.E. = 119 ± 24; n = 5) while corresponding IgG values showed a greater
degree of variation (due to the IgG value for secretion 32L, subject 5) ranging from 4 to
114% (mean ± S.E. = 67 ± 18%). In three subjects (Nos. 2, 3 and 5) the secretion ob¬
tained from each of two different ducts within the same breast was assayed separately.
11S IgA and IgG concentrations were very similar in two subjects (Nos. 2 and 3) but
showed a two-fold variation in the third (subject No. 5), suggesting that a variation in the
immunoglobulin concentration of secretions might occur between ducts in the same
breast (Table 1).
In view of the small number of subjects studied, and the incomplete clinical data, it
was not possible to assess the relationship of age, menstrual status or parity to immuno-
gobulin concentrations of breast, secretions. However, high concentrations of 11S IgA
were found in breast secretions in all the subjects studied, particularly in the secretions
obtained from postmenopausal or nulliparous subjects (Nos. 2 and 4; No. 6). Concentra¬
tions of 1 IS IgA were in general very similar to the range of concentrations seen in post¬
partum colostrum and milk (McClelland et al., 1978). As in colostrum and milk, the ratio
of IgA present in the breast secretions from healthy subjects to IgA present in serum was
very much greater than the corresponding ratio for IgG (Table 1). The reason for the high
concentrations of IgG detected in the secretions of subjects 4 and 5 is not clear.
Among the small number of secretions studied from subjects with breast disease, all
but two of the secretions (31L, 33L) were within the range of 11S IgA concentrations
found for secretions for normal subjects. Similarly, all but two secretions (15R, 30R)
were within the range of IgG concentrations seen in the secretions of normal subjects.
This suggests that no major differences are likely to be present between breast secretions
obtained from normal subjects and those obtained from patients with breast disease
(Table 2).
Fig. 2. Gel filtration on a Sepharose 4B column (2.2X90 cm) of (a) mammary secretion obtained
from a healthy non-lactating woman (b) colostrum (•) and milk (o) and (c) normal adult serum (X).
3-ml fractions were collected and assayed by radioimmunoassay using an 11S IgA standard (colostrum,
milk and mammary secretion) or a 7S IgA standard (normal adult serum); antisera used were either
rabbit anti-a chain (indicated in a by •) which detects all forms of IgA, or anti-llS IgA/FSC (used
only in a and indicated by o) which detects only llS-IgA and free secretory component. The arrow
indicates the elution volume of a Blue Dextran marker (B.D.: void volume).
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Concentrations of lactoferrin in breast secretions
Concentrations of lactoferrin similar to the concentrations found in colostrum and
milk were detected in 5 out of 10 breast secretions obtained from three normal subjects
(Nos. 5, 6 and 7). The failure to detect lactoferrin in the remaining secretions was proba¬
bly due to the dilution (1/200 to 1/500) of the secretion before assay.
DISCUSSION
In the breast secretions obtained from healthy non-lactating women the IgA was 11S
as indicated by 12SI-labelled 11S IgA binding inhibition curves and gel filtration analysis.
This was confirmed using anti-1 IS IgA/FSC which indicated that it was the complete 1 IS
IgA molecule that was detected, and not the 10S form. Interestingly, high molecular
weight forms of IgA (>400 000 daltons) were also detected by gel filtration, as was
demonstrated in early colostrum (Wadsworth, 1978). This IgA could possibly represent
aggregation of 11S IgA or the synthesis of high molecular weight forms (>11S). Very
little IgA immunoreactive material eluted at the same volume as 7S IgA.
Absolute concentrations of IgA and IgG in normal breast secretions are very similar to
the values found in colostrum and milk (McClelland et al., 1978). The ratio of IgG in
normal breast secretions to IgA in serum was much higher than the corresponding ratios
of IgG, indicating that the 1 IS IgA found in normal breast secretions was due to selective
transport or local synthesis. As there is little 11S IgA in adult semm (Waldman et al.,
1970), the 11S IgA detected must be a product of local synthesis. This confirms the ear¬
lier report of Drife et al. (1976), who detected IgA synthesis in 81% of cultures of normal
human breast tissue.
In the present study, IgA and IgG were detected in all samples from both normal and
diseased breasts, with a wide range of concentrations observed. In contrast, Petrakis et al.
(1977), reported the absence of IgA and IgG in a number of normal breast secretions and
secretions from cancerous breasts, with mean concentrations seventeen and three times
lower, respectively, than in our study. This difference may be attributed to the use of a
less sensitive method of detection of immunoglobulins (rocket Immunoelectrophoresis),
to the possible use of a standard different from our 11S IgA standard (Schuurman, 1977;
Green'berg et al., 1978), or because their assays were performed on undiluted samples. Our
results would suggest that if a deficiency exists it is a relative rather than an absolute one.
Although high concentrations of 11S IgA were detected in the normal breast secre¬
tions the volume of the secretions was very small and hence the total 1 IS IgA synthesis
by the non-lactating breast is very much less than that of the lactating breast. Only a
fraction of the total secretion lying within the mammary ducts of the non-lactating breast
is obtained by aspiration with the suction cup, and the values for IgA, IgG and lactoferrin
observed should therefore be considered as being representative of the ductal secretion
nearest the nipple, rather than of the entire breast. For the secretions obtained from nor¬
mal subjects on a particular occasion (whether from left or right breast), IgA concentra¬
tions with respect to each individual patient vary up to two-fold. IgG concentrations vary
similarly with the exception of secretion 32L. This suggests that measurements of immu¬
noglobulin concentrations in breast secretions may be a valid procedure despite the
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and that the amount of these steroids in cyst fluid is not
correlated with the volume of the cyst. The results of the
present study would confirm these findings. Most cyst fluids
contained large quantities of DHAS, but there was an
extensive range of concentrations present in different cysts.
In addition, GLC-MS confirmed the presence of large
amounts of androsterone conjugate. Epiandrosterone con¬
jugates were also present, and their high concentration
probably accounts for the inconsistencies sometimes ob¬
served between the methods of radioimmunoassay and
GLC-MS in the estimation of DHAS in cyst fluids. The
antibody used in the radioimmunoassay cross-reacts signif¬
icantly with epiandrosterone sulfate (2). It thus seems likely
that in some cyst fluids, results from radioimmunoassay
represent not only DHAS but also a contribution from other
closely related steroid conjugates.
Because of the broad range of DHAS found in cyst fluids,
it was of interest to examine factors that might influence
these levels. Although most cyst fluids were obtained from
premenopausal patients, no account was taken of the stage
of the menstrual cycle in which they were collected. No
cyclic pattern has been observed for DHAS levels in either
plasma (d) or breast secretions (7). We could detect no
significant correlation between cyst fluid concentration of
DHAS and age, menopausal status, or parity of the patients.
A similar lack of correlation has been reported by Bradlow
et al. (5).
In a small number of cases we were able to analyze several
cysts from the same women. There was a good correlation
between DHAS levels in cysts aspirated from the same
breast at the time, but larger variations were apparent
between cysts from different breasts of the same women
even when these were sampled at the same time. Cysts
aspirated from the same women on sequential visits showed
broad differences in DHAS concentrations, even though
they may have been derived from the same breast. Similar
observations have been made by others (7). The widely
different values that may be observed in cysts aspirated
from the same breast on separate occasions and, indeed,
from both breasts of the same women when studied at the
same time, makes comparative studies between different
groups of women very difficult. It will be necessary to
discover why such variations exist and the mechanism by
which steroid conjugates accumulate in breast cysts. They
may be derived from the breast secretory units or represent
a transudate from the circulation. It is thus significant that
breast secretions obtained by nipple aspiration also contain
high levels of DHAS. Our limited comparison of breast
secretions and cyst fluids obtained from the same women
suggests that breast secretions invariably contain the higher
concentration. It therefore seems likely that certain cyst
fluids represent accumulation and dilution of breast secre¬
tions by blockage of the ducts in which they reside. Our
observation (8) that cyst fluids with high DHAS concentra¬
tions contain only low levels of albumin, whereas those with
low DHAS have high concentrations of albumin would
support this contention and suggest that the diluent is
plasma derived. It may be necessary to subdivide cyst fluids
according to whether the derivation of their major constit¬
uents is breast or plasma before meaningful studies on their
composition can be performed.
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Androgen Conjugates in Human Breast
Secretions and Cyst Fluids
W. R. Miller and A. P. M. Forrest
University Department of Clinical Surgery, Medical School,
Edinburgh EH8 9AG, Scotland
Despite many years of research, it has not been possible to demonstrate conclu¬
sively that risk or presence of breast disease is associated with specific hormonal
abnormalities. However, most studies have measured hormones excreted in urine
or circulating in blood. Such measurements may not reflect the endocrine environ¬
ment within the breast itself. In order to obtain a better estimate of the milieu within
the breast, we have measured hormones in breast fluids. This chapter is concerned
with levels of dehydroepiandrosterone (DHA) sulfate and other related androgen
conjugates in human breast secretions and cyst fluids.
METHODS
Breast secretions were obtained by nipple aspiration, applying a slight negative
pressure by means of a syringe attached to a nipple cup (5). In this way, 132 breast
secretions were obtained from 51 nonlactating women. (Where possible, secretion
was obtained from both breasts of the same woman, and some subjects were studied
on more than one occasion.) The women comprised 21 normal subjects who had
no evidence of breast abnormality, 9 patients with benign breast disease, and 21
with breast cancer.
Cyst fluids were obtained by needle puncture of 100 tension cysts of the breast
in 82 different women. Eight patients had multiple cysts, and 5 were studied on
more than one occasion.
Radioimmunoassay was performed directly on all breast fluids after dilution with
phosphate buffer, using the method of Buster and Abraham (1) and the antibody
described previously (3). DHA-sulfate was also measured by gas-liquid chroma¬
tography (g.l.c.)-mass spectrometry in 20 breast secretions and 6 cyst fluids (3).
Results from the two methods were comparable.
In measuring androsterone and epiandrosterone conjugates, all estimations were
performed by g.I.e.-mass spectrometry (3).
RESULTS AND DISCUSSION
Breast Secretions
The mean value for DHA-sulfate in the 132 breast secretions investigated was
345 p.mol/1 (Table 1). This was more than 100-fold higher than that in plasmas
77











FIG. 1. Breast secretion:plasma ratios of DHA-sulfate in 21 normal women. Where more than

















FIG. 2. DHA-sulfate concentrations in breast secretions obtained from the same individuals
on different occasions. Day 0 represents the first occasion on which secretion was obtained.
• A ■ x represent secretions from left breast of different women; o A □, right breast.
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TABLE 1. Levels of DHA-sulfate (pmoi/i) as measured by radioimmunoassay in




3 132 breast secretions and 63 plasmas were obtained from 51 women. Cer¬
tain subjects were studied on more than one occasion, and secretions were of¬














FIG. 3. Levels of DHA-sulfate in breast secretions from pre- and postmenopausal normal
women. Lines are mean and standard error of the mean. Where more than one secretion was
obtained from an individual, the values have been averaged.
from the same women. However, there was wide range in concentrations of DHA-
sulfate in breast secretions (5-2,000 p.mol/1). In addition, there was great variation
in the secretiomplasma ratio of DHA-sulfate between different women. The data
for the 21 normal women investigated are presented in Fig. 1 and show that DHA-
sulfate concentrations in breast secretions always exceeded those in plasma, but the
relative excess varied greatly, between seven- and 400-fold in different subjects.
It was of interest to investigate parameters that might account for the differences
in DHA-sulfate levels in breast secretions between different women; but before










normal women benign disease breast cancer
FIG. 4. DHA-sulfate concentrations in breast secretions from normal women, patients with
benign breast disease, and those with breast cancer. Where more than one secretion was
obtained from an individual, the values have been averaged.
doing so, it was necessary to determine the variation that might exist between
secretions from the same individual.
We have already shown that concentrations of DHA-sulfate are of a similar
magnitude in breast secretions from different ducts of the same breast and from
different breasts of the same individual (4). To determine the consistency of DHA-
sulfate levels in breast secretions with repeated sampling of individuals, secretions
have been obtained, on more than one occasion, from the breasts of 4 premenopausal
women. Results are presented in Fig. 2. Some variations in DHA-sulfate concen¬
trations were apparent in secretions collected from the same breast on separate
occasions, but the differences were small in comparison with those observed between
different women. There was also no evidence for a decrease in DHA-sulfate con¬
centration with continued sampling despite total volumes in excess of 1.5 ml being
obtained from individual breasts. Thus, there is a relative uniformity of DHA-
sulfate in secretions obtained from the breasts of individual normal women as studied
over the short-term period.
Among other factors investigated to account for variation in DHA-sulfate con¬
centration between breast secretions from different women were the effects of
menopausal status and the presence of breast disease. No significant difference was
apparent between DHA-sulfate levels in breast secretions from pre- and postmen¬
opausal normal women (Fig. 3) although the mean value in the premenopausal








FIG. 5. Concentrations of DHA-sul-
fate in breast cyst fluids. Bars repre¬
sent medians. Lines are range of
values in breast secretions and plas¬




group was double that in the postmenopausal. However, the number of secretions
studied in the postmenopausal group was small because of the relative difficulties
in obtaining secretions from these women; it is possible that with larger numbers
the difference observed may reach statistical significance.
Levels of DHA-sulfate in secretions from women with either benign or malignant
breast disease are compared with those from normal women in Fig. 4. No significant
differences were detected between the groups, but it is probably premature to exclude
the possibility that disease affects the accumulation of DHA-sulfate in breast se¬
cretions. The groups of women investigated were not well matched; most normal
subjects were premenopausal, whereas the majority of those with breast cancer
were postmenopausal. Furthermore, in women with breast disease, no account has
been taken of the breast in which the lesion was situated, and secretion may have
been obtained from the unaffected breast. Studies of individuals comparing secretion
from diseased and nondiseased breasts may provide more meaningful information.
Breast Cyst Fluids
All 100 cyst fluids analyzed contained DHA-sulfate as estimated by radioim¬
munoassay, but there was a wide range of concentrations (1.5-1,155 p.mol/1). Like
breast secretions, most cyst fluids contained high levels of DHA-sulfate, but ap-
LR LR LR L R LR
FIG. 6. DHA-sulfate concentrations in multiple cysts aspirated on the same occasion from the
same breast (upper) and different breasts (lower) of the same individuals. L = left breast.
R = right breast.
FIG. 7. DHA-sulfate concentrations in multiple cysts aspirated from the same breasts on
separate occasions. The numbers within arrows represent the number of weeks elapsing be¬
tween consecutive aspirations of the same breast.
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FIG. 8. Ratios of epiandrosterone:DHA and androsterone:DHA conjugates in breast cyst fluids
and secretions.
proximately 15% contained values that were similar to those in plasma (Fig. 5).
We have, therefore, examined factors that might account for the large variation in
DHA-sulfate concentrations between different cysts. However, there was no cor¬
relation between DHA-sulfate levels and the age, menopausal status, parity, and,
in premenopausal subjects, stage of the menstrual cycle of the women from whom
the cysts were derived. Nor were DHA-sulfate levels related to the volume of cyst
fluid aspirated.
Certain patients had multiple cysts and others had cysts aspirated on more than
one occasion, and these have allowed us to assess variations within individuals.
When multiple cysts were aspirated from the same breast on the same occasion,
DHA-sulfate levels within the cysts often were comparable (Fig. 6). However,
when cysts were aspirated from different breasts of the same individuals, larger
variations in hormone concentration were observed (Fig. 6). Five women had cysts
aspirated from the same breast on more than one occasion at intervals varying
between 3 weeks and 2 years (Fig. 7). Large variations in DHA-sulfate levels were
observed frequently in these cyst fluids although they were derived from the same
, breast. Such variations in DHA-sulfate between cysts fluids from individual women
must complicate comparative studies between groups of different women.
Androsterone and Epiandrosterone Conjugates
Twenty breast secretions and 6 cyst fluids were analyzed by g.I.e.-mass spec¬
trometry for DHA, androsterone, and epiandrosterone conjugates. Large amounts
84 ANDROGEN CONJUGATES IN BREAST FLUIDS
of each were detected in all fluids. In breast secretions, DHA-sulfate always rep- ,
resented the major androgen conjugate (the ratios of androsterone and epiandros-
terone:DHA were always <1; Fig. 8). By contrast, in cyst fluids, levels of 1
epiandrosterone and, to a lesser extent, androsterone conjugates sometimes exceeded
those of DHA (Fig. 8). The significance of the difference between breast secretions
and cyst fluids and whether or not it represents metabolism within cysts remain to
be elucidated.
SUMMARY
Both breast secretions from nonlactating women and breast cyst fluids contain
large but variable amounts of DHA-sulfate and other closely related androgen
conjugates. Little is known about how these hormones accumulate within breast
fluids or what factors influence their concentration.
With regard to breast secretions, there appears to be a relative uniformity in
DHA-sulfate levels within the breasts of normal women. Preliminary data have
failed to detect significant differences in concentrations in secretions from patients
with benign or malignant breast disease as compared with those from normal women.
Comparisons of DHA-sulfate levels in breast cyst fluids between different groups
of women are hampered by the observation that multiple cysts in the same women,
particularly if situated in different breasts or aspirated on separate occasions, can
show widely differing concentrations.
Finally, the physiological significance of high concentrations of DHA-sulfate
within the breast is unknown. The hormone has only weak biological activity, but
it may be metabolized by the breast to form more active compounds (2).
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One hundred human breast cyst fluids have been analysed for sodium (Na+),
potassium (K+) and dehydroepiandrosterone (DHA) sulphate. Concen¬
trations varied greatly between individual cyst fluids, Na+ from 20 to
185 mmol/1, K+ from 5 to 160mmol/l and DHA-sulphate from 15 to
87 pmol/1. Analysis of the inter-relationships between Na+, K+ and DHA
sulphate revealed two major sub-populations of cyst fluids—one group in
which Na+ levels were markedly in excess of K+ and DHA sulphate concen¬
trations were low and the other in which K+ was the predominant cation and
DHA sulphate concentrations were high.
Introduction
In Western countries, 7% of women present with a palpable cyst in the breast
(Haagensen et al., 1981). Women with cystic disease are believed to have an increased
risk of developing breast cancer (for reviews see Azzopardi, 1979; Haagensen et al.,
1981), yet comparatively little is known about the aetiology of cysts or the composition
and derivation of cyst fluid.
Recent work on the composition of cyst fluid has shown that concentrations of elec¬
trolytes (Gatzy et al., 1979; Bradlow et al., 1981/>) and conjugates of androgens (Bradlow
et al., 1981a; Miller et al., 1982) and oestrogens (Raju et al., 1977) vary widely between
individual cyst fluids.
The present study describes the interrelationships between concentrations of electro¬
lytes and androgen conjugates and suggests a classification of cyst fluids on the basis
of these constituents.
Materials and methods
One hundred breast cyst fluids were obtained by needle aspiration from 85 patients.
In 75 subjects a single cyst was aspirated but, in 10, multiple cysts were drained (Table
1). Volumes varied from 0-7 to 50 ml.
*J. M. Dixon is a Wellcome Surgical Research Fellow.
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Table 1. Electrolyte classification of multiple cysts
Breast 1 Breast 2
Patient Cyst 1 Cyst 2 Cyst 3 Cyst 1
1 Na+ Na+




6 K+ K+ K+ K+
7 K+ K+
8 K+ K+
9 K+ K+ Mix































Figure 1. Concentrations of sodium and potassium in human breast cyst fluids. Horizontal lines
represent mean level. Vertical lines represents reference range for human plasma.
Estimates of concentrations of Na+ and K+ were performed by flame photometry
(EEL model 150 flame photometer) on cyst fluids diluted 1:200 in distilled water.
Androgen conjugates were measured by radioimmunoassay using an antibody
described previously (Miller et al., 1980). While this antibody is largely specific for
dehydroepiandrosterone and its sulphate, it does cross-react with epiandrosterone con¬
jugates. The results from the radioimmunoassay therefore reflect levels of both DHA
sulphate and closely related androgen conjugates (levels of free DHA are very low in
comparison with conjugated steroid). For simplicity, however, values from the radio¬
immunoassay have been expressed as units of 'DHA sulphate'. All statistical analyses
were performed using non-parametric tests (Kendall Rank and Wilcoxon Rank tests
as indicated).
Results
The levels of Na+ and K+ in the cyst fluids are shown in Figure 1. Values for both
ions varied enormously and, in the case of potassium, were usually greatly in excess












Figure 2. DHA-sulphate levels in human breast cyst fluids. Dotted vertical lines represent range
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Figure 3. Relationships in human breast cyst fluid between (a) Na+ and K+; (b) DHA sulphate
and Na+; (c) DHA sulphate and K+. Significance values from Kendall rank test.
of the reference range in plasma. Distribution about the mean of values for both ions
was suggestive of there being more than one population of cyst fluids.
The concentrations of DHA-sulphate in each of the 100 human breast cyst fluids
is shown in Figure 2. Levels varied from 1-5 to 870 (lmol/1 with a median value of
80 p.mol/1.
Interrelationships between K+, Na+ and DHA-sulphate are shown in Figures 3(a),
(b) and (c). These were all statistically significant by the Kendall Rank test (p< 0-001
in each case). The correlations between Na+ and both K+ and DHA sulphate were











Figure 4. Ratio of Na+/K+ in human breast cyst fluids. Lines represent arbitrary divisions to












Figure 5. DHA sulphate levels in human breast cyst fluids subdivided according to electrolyte
classification Na+ represents fluids with Na+: K+>4, mix fluids with Na+: K+ 1—4 and K+
fluids with Na+: K+ <1-0.
inverse relationships whereas that between K+ and DHA sulphate was in a positive
direction.
As the distribution of values for both Na+ and K+ suggested that there was more
than one population of cyst fluids, the 100 samples examined were arbitrarily subdivided
into three groups according to Na+ and K+ by means of their concentration ratio
(Figure 4). One group was of 47 fluids in which the K+ concentration exceeded that
of Na+ (K+ fluids), another of 43 fluids in which the Na+ concentration was above
four-fold higher than that of K+ (Na+ cyst fluids), and a further group of 10 fluids
with intermediate electrolyte values (mix cyst fluids). Values for DHA-sulphate in these
subgroups of fluids are shown in Figure 5. Concentrations of DHA-sulphate in K+ cyst
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category were similar to the K+ group but significantly higher than the Na+ group
0<oooi).
Ten patients had multiple cysts aspirated on the same day. The electrolyte classifica¬
tion is shown on Table 1. In eight women, multiple cysts were of the same electrolyte
group; two patients had cysts of different grouping although in one case the cysts
co-existed within the same breast.
Discussion
Although the present study confirms that levels of Na+, K+ and DHA-sulphate vary
widely between different cyst fluids (Bradlow et al., 1981a, b; Miller et al., 1982), it
has shown that there are significant associations between the concentration of these
constituents. Thus, levels of Na+ are inversely correlated with concentrations of both
K+ and DHA-sulphate. The values for Na+ and K+ are also not distributed symmetri¬
cally about their mean values and distribution is suggestive of more than one population
of cyst fluids. It is possible to use the relative concentrations of Na+ and K+ to identify
presumptive sub-groups of cyst fluids. This arbitrary classification based on electrolyte
composition also subdivides the cyst fluids into those with high or low levels of DHA
sulphate.
It therefore can be shown that 90% of cyst fluids fall into one of two major sub¬
groups—one type (K+ fluids) contains high concentrations of K+ and DHA-sulphate
and low concentrations of Na+ whereas the other type (Na+ fluids) has the reverse
composition. Bradlow and his colleagues (198H) have independently classified cysts
on electrolyte composition but found a higher proportion of K+ cysts as compared with
the present study.
The derivation of Na+ and K+ subgroups of cyst fluids still remains to be defined.
They may reflect different sources of constituents or differences in secretory activity
of the epithelium lining the cysts. The composition of Na+ cysts is akin to that of plasma
in respect of Na+, K+ and DHA-sulphate. However, although DHA-sulphate levels
in K+ cyst fluids are similar to those in breast secretions obtained by nipple aspiration
(Miller et al., 1981), Na+ is the predominant ion in such breast secretions. Simple
accumulation of these breast secretions is therefore unlikely to account for the formation
of K+ cyst fluids.
It seems more likely that the constituents of K+ cyst fluids result from apocrine
activity by the epithelium lining the cyst. Apocrine secretions characteristically contain
high concentrations of K+ and DHA-sulphate (Labows et al., 1979). Our preliminary
results examining cells lining the walls of excised cysts would support this concept.
The relevance of this classification of breast cyst fluids still remains to be elucidated
and it should be noted that different types of cyst fluids may co-exist within the same
breast although it is more usual for multiple cysts to be of the same type. It may be,
however, that a sub-population of cysts occurs in women at high risk of epithelial
proliferative changes including cancer.
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The morphological basis of human
breast cyst populations
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Forty human cysts have been examined to determine the relationship
between the epithelial lining and the content of sodium (Na +) and
potassium (K+ ) in the cyst fluid. The ratios of Na+ to K+ for cysts
lined by flattened epithelium were higher in all cases than the values
obtained for cysts lined by apocrine epithelium. These findings
suggest a morphological basis for the two populations of human
breast cyst fluids which can be defined on cationic content.
Human breast cyst fluids can be separated into two major
populations on the basis of the relative concentrations of
sodium (Na+) and potassium (K + ) (1, 2). The two major
groups are: (i) fluids in which concentrations of K+ exceed
those of Na + ; and (ii) fluids in which levels of Na+ greatly
exceed those of K. + . Cyst fluids in which K+ is the predominant
cation contain high concentrations of the androgen conjugate
dehydroepiandrosterone sulphate (DHA sulphate) (2) and
contain the secretory (lis) form of immunoglobulin A (IgA)
(3, 4), indicating that the epithelium lining such cysts is active
and secretory. In contrast cyst fluids in which Na+ greatly
predominates, contain low levels of DHA sulphate (2) and the
non secretory (7s) form of IgA and would be indicative of a less
active epithelium. To date, however, no evidence has been
reported to show that differences in breast cyst composition are
associated with the nature of the lining epithelium. The aim of
the present study was to investigate the relationship between
the morphology of epithelium of human breast cysts and the
cationic content of cyst fluid.
Materials and methods
Morphological assessment of the epithelium lining 40 human breast
cysts was performed either by: (i) centrifuging an aliquot of cyst fluid
and examining the stained deposit cytologically (26 cysts from 22
patients); or (ii) dissecting cysts from tissue obtained at mastectomy or
biopsy and submitting the cyst wall for histological processing and
serial sectioning (7 cysts from 6 mastectomy specimens and 7 cysts from
6 biopsy specimens).
The aspirates of cyst fluid were stained by Papanicolaou's technique
(Pap) and by periodic acid Schiff after diastase digestion (PAS diastase).
Dissected cyst specimens were stained by haematoxylin and eosin
(H & E) and PAS diastase. PAS diastase positive granules in the
cytoplasm of cells were used as a positive method of identification of
apocrine epithelium (5). All cyst fluid aspirates and dissection speci¬
mens were assessed by a consultant pathologist with a specific training
in breast histology and cytology.
The concentration of Na T and K + in the 40 cyst fluids was measured
by flame photometry (EEL model 150 flame photometer) on a 1 in 200
and a 1 in 400 dilution of cysts fluid in distilled water.
Results
It was possible to identify two major types of epithelial cells in
both cytological and dissection preparations: (i) acidophilic
cells (on H & E) with copious granular cytoplasm containing
PAS diastase positive granules, luminal apical snouts and
nuclei showing prominent nucleoli—apocrine epithelium; (ii)
basophilic cells (on H & E) having less cytoplasm and contain¬
ing no PAS diatase positive granules—-flattened epithelium.
Figs. 1 and 2 show examples of apocrine and flattened
epithelial cells in breast cyst aspirates. Fig. 3 shows the specific
glycolipid granules in the cytoplasm of apocrine cells. Figs. 4
and 5 demonstrate apocrine and flattened epithelium in dis¬
section specimens with Fig. 6 showing the apical position of the
glycolipid granules in apocrine epithelium.
In this series no cyst showed a mixture of apocrine and
flattened epithelium in either aspiration or dissection speci¬
mens. In 22 cysts the lining was assessed as apocrine (14
aspiration and 8 by dissection) and in 18 the lining was
flattened simple epithelium (12 by aspiration and 6 by dis¬
section).
The correlation between the morphology of the lining epi¬
thelium as assessed in cytological preparations and dissection
specimens and the Na + /K+ ratio is shown in Fig. 7. Cysts with
flattened epithelium had significantly higher Na + /K+ ratios
than cysts lined by apocrine epithelium (P< 0-001 Wilcoxon's
Rank Sum test). On the basis of Na + /KA ratios it was possible
Fig. 1. Cytological preparation of a cyst aspirate showing apocrine
cells. The cells have copious pale granular cytoplasm with vesicular
nuclei showing prominent nucleoli (Pap x 480).
Fig. 2. Cytological preparation of a cyst aspirate showing simple
flattened epithelium. The cells have small amounts of cytoplasm,
deeply staining nuclei and no special features (Pap x 480).
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Fig. 3. Cytological preparation of a cyst aspirate stained to show the
specific glycolipid granules found in apocrine cells. The vesicular nuclei
with prominent nucleoli, also a feature ofapocrine epithelium, are easily














Fig. 7. The ratios of sodium (Na+) and potassium (K* ) in the
cysts where the epithelium was assessed as apocrine or flattened by
examination of aspiration and dissection preparations.
Fig. 4. Dissection specimen of an apocrine cyst. The cells are
columnar and have basally situated nuclei, abundant cytoplasm and
apical snouts containing deeply staining intracytoplasmic glycolipid
granules (H & Ex 128).
to distinguish completely between apocrine and flattened epith¬
elial cysts, those cysts lined by apocrine epithelium having a
ratio of 2 or less and those lined by simple flattened epithelium
a ratio of greater than 3.
»
Fig. 5. Dissection specimen of a flattened epithelial cyst. The
epithelium is attenuated and flattened andfew cells are visible in any
one section (H & Ex 256).
Fig. 6. Dissection specimen showing the apical position of the
glycolipid granules in apocrine epithelium (PAS diastase x 256).
Discussion
Approximately 7 per cent of all women in the Western world
develop a breast cyst (6). Certain studies have shown that these
women are at increased risk of developing breast cancer (5, 6)
although others have been unable to confirm this finding (7). In
view of their frequency and their possible relationship to breast
cancer, it is surprising that little is known of the composition or
derivation of human breast cysts. Recently breast cyst fluids
have been divided into two major groups on the basis of the
relative concentrations of Na+ and K+ (1, 2, 8). These two
groups of fluids have also been shown to contain significantly
different levels of the androgen conjugate DHA sulphate and
to contain different molecular forms of IgA (2-4). The present
study has demonstrated that the epithelia lining these two
groups of cysts are morphologically different. All cysts where
the Na+/K+ ratio was 2 or less were lined by apocrine
epithelium and those with a ratio of greater than 3 were lined
by flattened epithelium.
This subdivision on the basis of the Na+ /K+ ratio is similar
to that used by us to discriminate between cysts with high and
low DHA sulphate (1,2). Cysts with a low Na+/K+ ratio had
high levels of DHA sulphate. Such cysts have been shown in the
present study to be lined by apocrine epithelium. It is of note
that apocrine secretion from axillary skin has also been shown
to contain high concentrations of DHA sulphate (9).
Electron microscopic studies of breast cyst epithelium have
shown that apocrine cells contain many mitochrondria and
apical secretory granules, in contrast to flattened epithelial cells
which contain few organelles (10). Apocrine secretion is per¬
formed by expelling the contents of the intracellular secretory
granules and is more accurately termed merocrine (5). The
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finding of high potassium, the major intracellular cation, in
cysts lined by apocrine epithelium, correlates well with what is
known of the ultrastructure and method of secretion of
epithelium of apocrine type.
Studies of patients with multiple cysts in one or both breasts
have shown that, in the majority, the cysts had a similar
electrolyte composition (2) and were therefore likely to be lined
by the same type of epithelium. This observation suggests there
may be a factor which determines whether patients develop
cysts lined by apocrine or flattened epithelium. Apocrine
change has been reported to occur more frequently in popula¬
tions at high risk of breast cancer (11-13) and the results from
this study show that the presence of apocrine epithelium in
cystic disease may be detected by electrolyte analysis of breast
cyst fluid. It is therefore possible that such analysis will be
helpful in identifying patients at increased risk of breast cancer.
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The success of Danol in benign breast disease
has been demonstrated in numerous open
studies. Now confirmation has come from a
recent placebo-controlled trial.
"This randomised double-blind crossover
study of danazol treatment confirms that
the drug reduces symptoms and
nodularity in patients with mastalgia..:'
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By Michael Baum, Hon Director, CRC Clinical Trials Centre, and
Hilary Cooper, Remploy Research Nurse, Kings College Hospital
Medical School, London.
This paper attempts to estimate the cost of benign breast disease, both from
the point of view of the patient and that of the health service, and makes
recommendations as to how these costs may be reduced.
During the first two years of itsexistenc the breast clinic at
King's College Hospital (established in
January 1980) diagnosed 1272 patients.
Of these, 1028 had some form of
benign breast disease or no apparent
abnormality and 244 had cancer, the
single most common diagnosis. Table 1
shows the numbers of each diagnostic
sub-group.
Just under half the patients who
attended the clinic were discharged
following clinical examination sup¬
plemented by mammography in
selected cases. Patients presenting with
simple cysts (13%) were dealt with by
single or multiple needle aspiration
(see below); 19% had discrete solid
lumps or areas of mammographic
suspicion which were subjected to
open biopsy when no malignancy was
found. This number is identical with
the number of patients whose biopsy
ultimately confirmed the presence of
cancer. The proportion of one benign
biopsy to one malignant biopsy com¬
pares favourably with others reported
from diagnostic clinics such as this
one1'2. A higher benign to malignant
biopsy proportion might be expected
from screening clinics .
The patient
Any symptom related to the breast
causes the patient intense anxiety,
mainly due to fear of cancer. Just
before attending the clinic, this anxiety
reaches a peak. It can be detected by
asking the women about insomnia and
the ingestion of alcohol or anxiolytics
in the week preceeding her first
appointment at the clinic. If a biopsy is
indicated, a further intense period of
anxiety builds up beforehand and while
waiting for the result. Any attempts to
reduce the biopsy rate, therefore, must
be applauded.
In addition, serious cosmetic prob¬
lems may result from repeated small
biopsies, or removal of breast quan-
drants in the search for small mammog¬
raphic abnormalities.
There are also small numbers of
women who are developing a neurosis
because of the publicity given to breast
self-examination and early diagnosis of
cancer. They repeatedly attend the
clinic for reassurance.
While it has taken many years to
educate general practitioners to view
all discrete lumps in the breast with
suspicion, rapidly referring patients to
the surgeon, we think that general
practitioners now act cautiously and
need to be re-educated. This was
discussed in detail in a recent
publication4. Table 2 lists our opinion
on which patients general practitioners
should refer to the clinic.
Once the general practitioner is
convinced that a specialist opinion is
required, the waiting period must be
reduced to a minimum. If it is impossi¬
ble for an open-house policy to be
offered in a hospital, then the breast
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woman has to wait more than a week
following the receipt of a referral
letter. Once the patient has been seen
at the clinic, if, following clinical
examination and mammography, rapid
reassurance cannot be provided, then
histological diagnosis of the suspicious
area must be expedited. Cyst aspira¬
tion or aspiration cytology should
become more widely available and
out-patient needle biopsy, ideally with
frozen section, may also reduce this
period of uncertainty. Finally, we think
it is time to evaluate critically the whole
subject of breast self-examination and
to consider whether or not it saves
lives5.
The Health Service
It costs the NHS a great deal of
money to set up a breast clinic. The
clinic takes up the time of medical,
nursing and clerical staff and its mam¬
mography service involves capital out¬
lay for equipment and sessional pay¬
ments for radiographers and radio¬
logists. Inevitably, too, the establish¬
ment of such a clinic increases the
demand for beds and theatre time for
in-patient biopsy.
Hospital costs would be reduced if
general practitioners shouldered more
responsibility for women presenting
with breast symptoms. Also, out-pa¬
tient biopsy or cytology would reduce
the need for theatre time and bed
occupancy, and a policy of repeatedly
aspirating cysts might reduce the biop¬
sy rate.
Surprisingly, many clinicians believe
that cyst aspiration is hazardous be¬
cause an intracystic cancer might be
missed or a solid tumour, if punctured,
might disseminate the cancer. Howev¬
er, a number of recent publications
have demonstrated the safety of the
procedure6-7, and, with this in mind,
we intend to critically review our own
policy.
All women presenting at our clinic
with solitary cysts are treated by needle
aspiration. On each reattendance, a
new cyst appearing in a different part
of the same breast, or in the other
breast, is aspirated. Biopsy is indicated
only if any of the lumps turn out to be
solid, if a residual lump is found at the
site of aspiration at one month follow-
up, if frank blood is found in the
aspirate or if recurrent cysts occur at
the same site as the original aspirated
cysts. Finally, biopsy is, of course,
indicated if mammography is reported
as suspicious.
In the two-year period under review,
130 cases were managed in this way.
Seventy-one per cent of patients were
dealt with at a single aspiration, 20 per
cent at two aspirations and the remain¬
der required five or more aspirations,
many of these patients continuing to
return with new cysts at each visit. Of
the total group, 29 per cent were
submitted to open biopsy. The out¬
come is shown in Table 3. Of these 38
patients, only three were subsequently
shown to have cancer. One of these
was a solid lump that had appeared
during the follow-up of a woman with
multiple cysts. The other two were
intracystic cancers demonstrated by
bloody fluid in the cyst aspirate. All the
suspicious mammograms were false
positive and not one of the cases with a
residual lump or recurrent cyst at the
site of the first aspiration was positive.
A policy of cyst aspiration seems safe.
Mammograms performed following
cyst aspiration were not only unhelpful
but positively misleading and solid
lumps and bloody taps must be sub¬
jected to excision biopsy.
There appear to be two distinct cyst
syndromes. One group of women pre¬
sented with a solitary cyst which could
be dealt with in one or two visits. The
other group (about 10 per cent) con¬
tinued to form cysts. To date, an
analysis of all demographic factors and
drug history has failed to distinguish
the type of women likely to develop
one of these syndromes. Further re¬
search into the endocrine background
of these two groups of patients is
obviously indicated.
Our policy for mammography has
now changed. All patients over the age
of 30 referred to the clinic with breast
symptoms now have their mamogram
performed before the clinical examina¬
tion, as we suspect that a recently
aspirated cyst may cause the radiolog¬
ist difficulty in interpretation.
Conclusions
Benign breast disease is a common
problem which creates severe anxiety
in many women and a heavy burden on
an overstretched National Health Ser¬
vice. A policy of re-educating general
practitioners when it is safe not to
refer, may reduce this problem. Cyst
aspiration or needle aspiration cytolo¬
gy may also reduce the burden to both
patient and Health Service. A critical
evaluation of the cost effectiveness of
mammograhy and breast self-examina¬
tion is also urgently required. In so far
as patients are presenting when the
tumours are smaller and there is less
node involvement than previously ex¬
perienced, self-examination may save
lives but it may also simply prolong the
period of observation.
Finally, we think it is important for
all specialists to recognise their ignor¬
ance in the area of benign breast
disease. We do not know its aetiology
or natural history, therefore it must be
very difficult to evaluate its treatment!
A great deal more research is needed,
yet research costs money and most of
the money available is directed into
studies concerning breast cancer.
A complete version of this paper will
shortly be published as part of the
symposium proceedings of the Journal
of the Royal Society of Medicine.
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When I was first
approached by Winth-
I I rop Laboratories and
the Medical News
Group to edit a new journal
relating to breast disease my ini¬
tial response was one of dismay
and rejection of the offer on three
counts. My first retort was 'Not
another journal! My desk is
already cluttered with unread
back numbers of serious scientific
journals as well as many of the
giveaway medical journals.
Secondly, I suggested in a some¬
what sanctimonious way that 1
would rather not have my name
associated with anything that was
unequivocally promotional in na¬
ture, and, finally, (always remem¬
ber the real reason is given last) I
was far too busy to take on yet
more responsibility with the in¬
evitable persecution of meeting
deadline after deadline. Neverthe¬
less, 1 saw no harm in prolonging
the discussions for a little while in
the amiable company of my puta¬
tive co-editors over an excellent
dinner. Somewhat mellowed by
the fine food and wines, we began
to see how my initial reactions
could be neatly turned upon them¬
selves and used to their own
advantage. Firstly, we all agreed
there are far too many journals
and it is impossible these days to
keep up-to-date with the litera¬
ture. Say, if someone were to do
this for us and produce a service
booklet with abstracts of the liter¬
ature within our field of interest
and regular up-to-date reviews by
experts in fields co-terminus to
these interests?
by Michael Baum
Secondly, there surely can be
nothing sinister in a journal which
is unashamedly promotional, as
the aims of industry and the aims
of academic progress can often be
served by the same mechanism if
these exchanges are conducted in
an openhanded manner. After all
there is excellent precedent for the
type of journal that we are laun¬
ching and I think it is fair to
acknowledge at this point the
welcome contributions made by
such journals as Cancer Topics
(sponsored by Lederle) and Re¬
views on Endocrine Related Can¬
cers (sponsored by ICI).
Finally, as far as my last objec¬
tion was concerned, the pub¬
lishers reassured me that they
would have everyone else to do the
work and 1 would merely have to
sit back and take the credit. So at
last, after the gestation period of
about a year, 'Breast News'
emerges from the womb as an
infant prodigy. Because of the
commercial interests of the spon¬
sors the emphasis of this journal
will be directed at 'benign breast
disease' and in fact that was the
first title we thought of for this
journal. However, we soon real¬
ised that this was far too narrow
an objective to take, as the de¬
marcation between benign and
malignant disease is often unclear
and to some extent artificial and
one of the important aspects of a
study of benign disease is the
mechanism by which this may or
may not express itself subsequent¬
ly as invasive carcinoma. Never¬
theless, it is still intended to
concentrate on benign breast dis¬
ease as it is under-researched and
the impact it makes on the lives of
women throughout this contry
under-estimated. For example,
the first article in the first issue of
this journal, which relates to the
experience of one busy breast
clinic, emphasises the predomi¬
nance of benign breast disease
amongst women presenting with
symptomatic breasts and the cost
to the patient in terms of misery
and anxiety, together with the cost
to the Health Service in terms of
clinical resources.
We hope this journal will be of
value and interest to busy clini¬
cians throughout the United King¬
dom. We hope that occasionally
we will produce controversy and
we would, therefore, encourage a
lively correspondence column.
We hope that the abstract service
and diary will be of practical help
and that the review articles will
also keep you up to date in areas
outside your own immediate spe¬
cialty. Vou may, of course, choose
to throw the wretched thing away,
but we intend that the journal will
have shelf-life and for this reason
rigid binders will be provided
within which to store your copies.
We would like to think that this
infant prodigy will thrive and as
my brother (the paediatrician) is
wont to say, 'Breast fed is best fed'
and I sincerely hope
that you will find that
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Miller, Lecturer, University Department of Clinical Surgery, Royal
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INTRODUCTION
Breast cysts were first distinguishedfrom arcinomas n 1829 by Astley
Cooper1. They are the commonest
cause of a benign breast mass affecting
approximately 7 per cent of all women
in the Western World2. It has been
reported that these women may be at
increased risk of subsequent breast
cancer2'3. In view of the length of time
which has passed since their identifica¬
tion, their frequency and association
with hyperplasia and breast cancer, it is
surprising that comparatively little is
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hormones6-7 in cyst fluids have been
measured and shown to vary widely
between individual cysts. We have
measured sodium (Na+), potassium
(K+) and the androgen conjugate
dehydroepiandrosterone sulphate
(DHA sulphate) in 100 cyst fluids and
confirmed this wide variation. (Figures
1 and 2). However, we found signifi¬
cant interrelationships between these
three substances, with inverse correla¬
tions between Na+ and both K+ and
DHA sulphate and a direct correlation
between K+ and DHA sulphate (Fi¬
gures 3a, b and c). It was also evident













plasma cyst breastfluids secretions
Figure 1. Concentrations of sodium and
potassium in human breast cyst fluids.
Horizontal lines represent mean values.
Vertical lines represent reference range
for plasma.
6
Figure 2. DHA sulphate levels in human
breast cyst fluids. Dotted vertical lines
represent range in human plasma and
breast secretions obtained by nipple
aspiration. Horizontal lines represent
median values.
normally distributed around the mean,
indicating that there may be more than
one population of cyst fluids. This was
particularly evident in a plot of the
ratio of Na+ to K+ (Figure 4). Cyst
fluids could be divided into two groups,
one having a high and the other a low
Na+/K+ ratio. DHA sulphate concen¬
trations in these two populations were
significantly different, levels being
higher in fluids with low Na+/K+ ratios
(Figure 5).
Further studies have shown that pH,
concentration of albumin and IgG and
type of IgA also vary in the two
populations of cyst fluids as defined by
electrolyte content.
Relationship of epithelial lining of
cysts and cyst fluid composition
Morphological studies of the epithe¬
lium lining breast cysts have been
undertaken to determine whether dif¬
ferences in the composition of the two
populations of breast cysts are related
to the nature of the lining epithelium.
The epithelium lining 40 breast cysts
was characterised by either histology
or cytology. This was then compared
with the composition of the cyst fluid.
Two types of epithelium were identi¬
fied in both histological and cytological
preparations:-
(1) acidophilic cells on haematoxylin
and eosin stained sections (H &
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Figure 3. Relationships in human breast
cyst fluid between (a) Na+ and K+ (b)
DHA sulphate and Na+ (c) DHA sul¬
phate and K+. Significance values from
Kendal rank test.
E), with copious cytoplasm con¬
taining granules which stain by the
periodic acid Schiff (PAS) techni¬
que after diastase digestion, have
luminal snouts and nuclei with
prominent nucleoli — apocrine
epithelium.
(2) basophilic cells (on H and E)
having less cytoplasm with no
specific features — flattened
epithelium.
Figures 6,7,9 and 10 show examples of
apocrine and flattened cells in histolo¬
gical and cytological preparations with
the PAS positive glycolipid granules
characteristic of apocrine epithelium
being demonstrated in Figures 8 and
11.
Comparison of the epithelial lining













Figure 4. Ratio of Na*/K* in human
breast cyst fluids. Two populations are
evident, one with a high and the other















Figure 5. DHA sulphate in human breast
cyst fluids subdivided according to elec¬
trolyte classification intofluids with high
Na IK+ and low Na+IK ratio.
and aspiration specimens and the Na+/
K+ ratio in cyst fluid (Figure 6) showed
all cysts lined by apocrine epithelium
had a lower Na+/K+ ratio than those
lined by flattened epithelium. Similarly
subdivision of cysts according to histol¬
ogy of the epithelial lining split DHA-
sulphate values into two separate
groups, those with apocrine epithelium
having high concentrations and those
with flattened epithelium having low
concentrations of DHA sulphate (Fi¬
gure 13).
Apocrine cyst fluids thus have a low
Na+/K+ ratio and high concentrations
of DHA sulphate. Apocrine secretion
occurs by expulsion of cellular contents
via intracytoplasmic vacuoles2 and the
finding of high potassium concentra¬
tions in fluids derived from apocrine
«r y.«» -ff" •■ ; .1 ' »•".
Figure 6. Histological specimen of an
apocrine cyst. The cells are columnar,
have basally situated nuclei, apical
snouts and abundant cytoplasm contain¬
ing intracytoplasmic glycolipid granules
(H &EX 240).
Figure 7. Histological specimen of a
flattened epithelial cyst. The epithelium
is flat and attenuated and has no specific
features (H & E X 480).
Figure 8. Histological specimen showing
the apical position of the PAS positive
glycolipid granules in apocrine epithe¬
lium. (PAS Diastase X 320).
cells is consistent with this activity. It is
of interest that apocrine secretion from
axillary skin has been shown to contain
high concentrations of DHA
sulphate8. It is also of note that the
colour range of apocrine axillary sweat
(yellow to green to bluish black) is
identical to that seen in breast cysts9.
Relationship of cyst fluid
populations to natural history and
breast cancer risk
Whilst two populations of breast
cysts may be defined on the basis of
composition and the nature of epithe¬
lial lining, it remains to determine
whether these two subgroups have any
clinical relevance. Preliminary studies
suggest that these two groups differ in
terms of their natural history and their
association with the subsequent de¬
velopment of breast cancer.
We know that about half of all
women, who present with cystic dis¬
ease will have a single cyst, a third of
patients will develop between 2 and 5
cysts and the remainder have in excess
of 52. Our own data from a prospective
analysis of 100 consecutive patients
followed over 2 years show 45 per cent
of patients had 1 cyst, 46 per cent had
2-5 cysts and 9 per cent had in excess of
5. All cysts aspirated from these 100
patients were classified on the basis of
electrolyte composition as apocrine
(Na+/K+<3) or flattened (Na+/
■fe •, '
-




Figure 11. Cytological preparation of a
cyst aspirate stained to show the specific
glycolipid granules found in apocrine
cells. The vesicular nuclei with promin¬
ent nucleoli, also a feature of apocrine
epithelium are easily seen. (PAS diastase
X 480).
K+5=3). The relationship of cyst type to
the natural history of cystic disease was
then examined.
Of the 100 patients, 43 developed
single or multiple cysts of flattened
type, 44 patients developed single or
multiple cysts of apocrine type and 13
patients had mixtures of the two types
of cysts. Patients with a single cyst were
more likely to have a flattened cyst and
as the number of cysts aspirated in each
patient increased, so the proportion of
apocrine cysts also increased. (Table
!)•
There were 56 episodes where pa¬
tients had multiple simultaneous cysts
and in 48 (88 per cent) all cysts were of
the same type, ie all apocrine or all
flattened. A total of 43 patients de¬
veloped sequential cysts and in 32 (74
7
Figure 9. Cytological preparation of a
cyst aspirate showing apocrine cells. The
cells have copious pale granular cyto¬
plasm with vesicular nuclei showing
prominent nucleoli (Papanicolaou X
480).
Figure 10. Cytological preparation of a
cyst aspirate showing simple flattened
epithelium. The cells have a small
amount of cytoplasm, deeply staining
nuclei and no special features. (Papani¬
colaou X 480).
RELATIONSHIP OF EPITHELIUM LINING HUMAN BREAST CYSTS















Figure 12. Ratio ofA'a+IK+ in cystfluids
where the lining epithelium of the cyst
was assessed as apocrine or flattened by
examination ofhistological or aspiration
specimens.
per cent) of these, all cysts aspirated
over the two year period were of the
same type. Thus, patients who have
multiple cysts, whether they are simul¬
taneous or sequential usually develop
cysts of one or other type.
A comparison of the frequency of
further cysts in the groups of patients
who presented with either apocrine or
flattened cysts showed that patients
who had single or multiple apocrine
cysts were more than 5 times more
likely to develop further cysts.
A review of 400 patients with breast
cancer identified 10 patients who had a
previous history of cyst aspiration
where the aspirated cysts could be
classified on the basis of cytology or
electrolyte composition. Nine of these
patients had single or multiple apoc¬
rine cysts and one had a single flattened
DHA SULPHATE IN HUMAN BREAST CYST FLUIDS











Figure 13. DHA sulphate levels in cyst
fluids where the lining epithelium of the
cyst was apocrine or flattened.
cyst. This ratio is markedly different to
that in the general population with
cystic disease (see above) and is in
keeping with other observations that
apocrine change occurs more frequent¬
ly in populations at risk of breast
cancer .
Conclusion
Two populations of human breast cysts
can be identified. They differ in the
nature of the lining epithelium and the
composition of cyst fluid. Preliminary
studies show that the groups are associ¬
ated with clinical differences in natural
history. It is also possible that these
two groups also differ in their associa¬
tion with subsequent breast cancer.
Larger numbers of patients and further
follow up is necessary to confirm this.
Acknowledgements
J. M. Dixon is a Wellcome Surgical
Research Fellow and acknowledges the
support of the Wellcome Trust. Thanks are
accorded to Professor A. P. M. Forrest for
allowing us to investigate patients under his
care.
Figures 1,2,3a, b and c are produced by
kind permission of Clinical Oncology.
Figures 6 and 8-11 are produced by kind
permission of the British Journal ofSurgery.
References
1. Cooper AP. Disease of the Breast Part
1. London. Longmans, 1929.
2. HaagensenCD,BodianCand
Flaagensen DE. Breast carcinoma risk
and detection. London. Saunders,
1981.55-80.
3. AzzopardiJG. Problems in breast
pathology. London. Saunders, 1979.
57-91.
4. Bradlow HL, Skidmore FD, Schwartz
MK, and Fleisher M. Cation levels in
human breast cyst fluid. Clin Oncol
1981; 7:388-390.
5. Gatzy JT, Zayloun MP, Gaskins Kand
Pearlman WH. Electrolytes of breast
cyst fluid. Clin Chem 1979; 25:745-748.
6. Bradlow ML, Schwartz MK, Fleisher
M ,etal. Accumulation of hormones in
breast cyst fluid. J Clin Endocrinol
Metab 1979; 49:778-782.
7. Miller WR, Roberts MM, Creel RJ,
Yap PL, Kelly RW and Forrest APM.
Androgen conjugates in human breast
cyst fluids. J Natl Cancer Inst 1982; 69:
1055-1068.
8. LabowsJN,PretiG,HoelzleE,
Leyden J and Kligman A. Steroid
analysis of human apocrine secretion.
Steroids 1979; 34:249-298.
9. Hurley HJ and Shelley WB. The
human apocrine sweat gland in health
and disease. Springfield USA.
Thomas. 1961: 78-96.
10. Scheurch C, Rosen PP, Hirut AT, etal.
A pathologic study of benign breast
diseases in Tokyo and New York.
Cancer 1982;50:1899-1903.
11. WellingsSR, Jensen HM and Marcum
RG. An atlas of subgross pathology of
the human breast with reference to
possible precancerous lesions. J Natl
Cancer Inst 1975; 55:231-275.
12. Page DL, Vander-ZwagR, Rogers
LW, Williams LT, Walker WF and
Hartmann WH. Relation between
component parts of fibrocystic disease
complex and breast cancer. J Natl
Cancer Inst 1978; 61:1055-1063.
Table 1: Comparison of the % ofcysts which were classified asflattened or apocrine by
electrolyte composition in group ofpatients who had totals of1,2-5 or >5 cysts
aspirated over a 2 yearperiod.
Number of Number of % of cysts which were Ratio
cysts aspirated patients Flattened Apocrine Apocrine
Flattened
1 45 76 24 0.3
2-5 46 25 75 3.0
>5 9 6 94 15.7
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All breast cysts aspirated from a series of J00 patients followed for a
minimum period of 2 years were classified on the basis of electrolyte
composition as apocrine or flattened, this being the nature of the
epithelium lining the two populations of breast cysts. Patients v,i'h a
singlecysl weremorethan3 timesas likely to have a flattened rather than
an apocrine cyst. Multiple cysts, whether simultaneous or sequential in
any individual patient, were usually all of the same type, and were more
commonly apocrine than flattened. A comparison of the frequency oj
subsequent cysts in patients whose initial cysts were of either apocrine or
fattened type showed further cysts were over 5 times more common in
patients who presented with apocrine cysts. These observations suggest
that the natural history of cystic disease is closely related to cyst type.
keywords: Human breast cystic disease, recurrent cystic disease, apoenne epithelium
Some 7 per cent of women ir> the Western world develop a
palpable breast cyst1. Approximately half of these women will
have a single cyst,a third develop between tyvoand five cysts and
the remainder have more thirn five1. No factor has been defined
which allows one to determine whether a patient will develop
single or multiple cysts. Laboratory studies have shown that
human breast cysts can be separated into two populations on the
basis of the relative concentrations of sodium Na*) and
potassium (K +) in cyst fluid2 ~4. This variation has been shown
to be due to differences in the epithelium lining the two groups of
cysts4. The aim of the present jtudy was to determine whether
cyst type is related to the natural history of cystic disease.
Patients and methods ,■
A prospective analysis has been carried out on 100 consecutive patients
presenting for the first time with a breast cyst and followed for a
minimum period of 2 years. Concentrations of Na* and K < were
estimated in all cyst fluids aspirated from these 100 patients over the
period of follow-up, by flame photometry (EEL model 150 flame
photometer) after dilution to ] in 200 or 1 in 400 with distilled water.
Cyst fluids were classified as apocrine if NaVK'<3 or flattened if
Na"7K*534.
Statistical comparison of groups was by the y2 test.
Results
Over the period of study, 43 patients had only a single cyst
aspirated, 46 developed between 2 and 5 cysts and 9 women had
in excess of 5. A total of 247 cysts were aspirated from the 100
patients: 177 cysts were classified as apocrine and 70 as flattened
on the basis of electrolyte composition. Forty-three patients
developed single or multiple cysts of flattened type, 44 patients
developed single or multiple cysts of apocrine type and 13
patients had mixtures of the two types of cysts.
Natural history: single or multiple cysts
Table J shows the percentage of cysts which were apocrine
and flattened in patients subdivided according to the total
number of cysts they had aspirated during the study period.
Patients with a single cyst were more likely to have a flattened
cyst and, as the number of cysts aspirated per patient increased,
so also did the proportion which were apocrine This is more
clearly illustrated in Figure / where the ratio of
apocrine:flaiiened cysts is plotted according to the total number
of cysts aspirated from each patient.
Multiple cysts
There were 56 episodes where patients had multiple simul¬
taneous cysts and in 48 (88 per cent), all cysts aspirated from
individual patients were of the same type, i.e. all were apocrine oi
all were flattened. Forty-three patients developed sequential
cysts, and in 32 (74 per cent) of these, all cysts aspirated from any
one patient over the 2 year period were of the same type.
Natural history: cysts on one or more than one occasion
Of the total group of patients, 43 had cysts aspirated on more
than one occasion. Overall 14 per ceni of those presenting
initially with flattened cysts, 72 per cent of those presenting with
apocrine cysts and 50 percent of those with mixtures of cysts,
went on to develop further cysts (Table 2). Thus patients
presenting with apocrine cysts developed a further cyst over 5
times more frequently than those who presented with flattened
cysts. In order to determine that this was not just the case for
patients with multiple cysts, patients were split into two groups,
those with a single and those with multiple cysts at presentation
(Table 3). The same trend existed for a greater frequency of
further cysts in the apocrine group, regardless of whether
patients originally had single or multiple cysts aspirated.
Discussion
Two populations of human breast cysts can be defined on the
basisoftheNa4/K4 ratio in cyst fluid2 4. By typing cysts on the
basis of the electrolyte composition this study has shown that
patients who develop more than one breast cyst tend to develop
cysts of the same type. In any individual patient therefoie
multiple cysts whether simultaneous or sequential are likely to
contain fluids which all have a similar composition. This
Table 1 Comparison of the percentage of cysts which were classified a.
flattened or apocrine on the basis of electrolyte composition in the groups
of patients with I, 2-5 and >5 cysts
Percentage of cysts
which were classified as
No. of No. of
aspirated patients Apocrine Flattened
I 45 24 76
2-5 46 75 25
>5 9 94 6
190












1 2 3 4+5
number of cysts
>5
Figure 1 The ralio of apocrine:flattened cysts us classified by elec¬
trolyte composition in the groups of patients with 1,2, J, 4 and 5 and > 5
cysts
suggests there may be a factor which determines which type of
cysts an individual patient develops.
From previous studies it is known that the composition of
cyst fluid relates to the nature of the epithelium lining4. Cysts
with a low Na+/K+ fluid ratio (< 3) are lined by apocrine
epithelium and those with a high ratio (>3) are lined by
flattened epithelium4. Apocrine epithelium is known to be an
active secretory epithelium and apocrine cyst fluid contains high
concentrations of secretory products3"6. In contrast flattened
epithelium appears less active and fluids from cysts lined by this
epithelium, more closely resemble plasma3"5. Data from this
study show that patients who present with apocrine cysts are
more than 5 times as likely to develop further cysts as those
with cysts lined by flattened epitheliunj. Furthermore patients
who develop more than five cysts appear to have almost
exclusively apocrine cystic disease. This study then indicates a
clear relationship between the natural history ofcystic disease in
individual patients and cyst type.
A number of treatments have been tried to reduce the
numbers of cysts patients develop. From this study, it is
apparent that any agent which reduces apocrine secretory
activity may reduce the frequency* of cyst formation. The
combined oral contraceptive pill has been reported to reduce
both apocrine secretion7 and the frequency of breast cysts8.
Other drugs capable of reducing apocrine secretory activity may
therefore also prove useful in the treatment of breast cystic
liseasc.
It has been shown that, of patients with cystic disease, treated
)y aspiration, it is those who have multiple cysts aspirated who
nay be at increased risk of breast cancer1. Multiple cysts have
>ecn shown in this study to be predominantly apocrine. This
vould suggest therefore that patients who have apocrine cysts
fiay be more likely to develop breast cancer than those with
aliened cysts. The studies which have shown that apocrine
hange is found more commonly in populations at risk of breast
sneer* 13 would support such a view.
This study has shown that the majority of those patients with
Table 2 Comparison of the frequency of further cysts with groups of
patients who initially presented with either flattened, apocrine or mixtures




















* Significantly greater frequency of further cysts in die apocrine than in
the flattened group P< 0-0005
Table 3 Frequency of further cysts in patients subdivided into 2 groups
(i) according to whether they had a single or multiple cysts at presentation




























* Significantly greater frequency of further cysts in apocrine compared
with flattened graaip P<00005
apocrine cysts will develop further breast cysts. Estimation of
either electrolyte composition or pH of breast cyst fluid allows
differentiation ofcysts lined by apocrine epithelium3 s,>4. It may
also be that patients with these cysts are at greater risk of breast
cancer. Electrolyte analysis or assessment of the pH of aspirated
breast cyst fluid may therefore provide useful information
regarding the likely natural history ofcystic disease in individual
patients.
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The Relationship of Cyst Type to Risk Factors for
Breast Cancer and the Subsequent Development of
Breast Cancer in Patients with Breast Cystic
Disease
J. M. DIXON,*t A. B. LUMSDEN'J and W. R. MILLER*
University Departments of *Clinical Surgery and IPathology, Royal Infirmary, Edinburgh EH?> 9YW, U.K.
Abstract— The frequency of epithelial hyperplasia and papillary apocrine change
in patients with palpable breast cysts lined by either apocrine or flattened
epithelium has been compared. Hyperplasia of any degree, severe hyperplasia with
or without atypia and papillary apocrine change were all seen significantly more
frequently in patients with clinically palpable apocrine cysts. Twelve patients were
identified with breast cancer with a history of cyst aspiration, in whom all cysts
aspirated could be classified as apocrine or flattened on the basis of cytology or
electrolyte composition of cyst fluid. Eleven patients had single or multiple
apocrine cysts and one had a single flattened cyst. This represents a significantly
increased preponderance of apocrine cysts as compared with that normally seen in
patients with cystic disease. The mastectomy specimens of those 11 patients with a
history of apocrine cyst aspiration more frequently contained hyperplastic changes
and non-invasive carcinoma than age- and rnenopausal-matched controls who did
not have a history of cystic disease. This study suggests that patients who develop
cysts lined by apocrine epithelium may be at a greater risk of subsequent breast
cancer than those with flattened epithelial cysts.
INTRODUCTION
Some 7% of all women in the Western World
develop a palpable breast cyst [1], and it has been
reported that these women are at increased risk of
breast cancer [1-3]. Pathological studies per¬
formed in patients with cystic disease have shown
that the subsequent incidence of breast cancer is
greatest in those women with epithelial hyper¬
plasia associated with cysts [2-8]. The majority of
women with cystic disease are not biopsied but
treated by simple aspiration, and it remains
uncertain which of these women are at greatest
risk.
From studies of the composition of aspirated
cyst fluids it has been possible to identify two
populations of breast cysts on the basis of
electrolyte content [9, 10]. The composition
Accepted 15 March 1985.
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appears to be directly related to whether the cyst is
lined by apocrine or flattened epithelium [11].
The aim of the present study was first to compare
the frequency and degree of hyperplasia in groups
of patients with the two types of cysts and second
to classify those cysts aspirated from patients who
subsequently developed breast cancer.
MATERIALS AND METHODS
During the 1960s it was the practice in
Edinburgh to biopsy all palpable breast lumps,
even if they were considered cystic. From the years
1966 and 1967 all patients who were clinically
thought to have a palpable breast cyst were
identified and the histology from each patient was
reviewed. The nature of the lining epithelium of
two groups of cysts was noted: (i) cysts bigger than
3 mm, which have been defined previously as
macrocysts [1]; and (ii) cysts bigger than 1 cm,
which would make them clinically palpable. Any
pathological change in each of these groups of
10-17
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biopsy specimen was recorded. Particular atten¬
tion was paid to the presence of foci of apocrine
change, papillary apocrine change and any
hyperplasia. Hyperplasia, when present was
assessed on a five-point scale using similar criteria
to those of Wellingset al. [12]: grade I, normal; II,
minimal or moderate hyperplasia; III, severe
hyperplasia; IV, hyperplasia with atypia; and V,
carcinoma in situ.
From a review of patients with breast cancer, 12
were identified who had a history of cyst
aspiration and where all cysts aspirated could be
classified either on the basis of cytology (five
patients) or electrolyte composition (seven
patients) as apocrine (apocrine cells on cytology
or Na+/K+ ratio in cyst fluid <3) or flattened
epithelium (simple epithelial cells on cytology or
Na+/K+ ratio in cyst fluid ^3). It has been
previously shown that lining epithelium and
electrolyte composition of cysts are directly
related [11].
The mastectomy specimens of these 12 patients
were reviewed, as were 12 age- and menopausal
status-matched controls who did not have a
history of cyst aspiration. The presence of cysts,
apocrine change, hyperplasia and carcinoma in
situ was recorded.
The x2 test was used to compare the frequency
of pathological changes in the biopsiesof patients
who had cysts lined by eitherapocrineor flattened
epithelium, and also to compare the ratio of
women who had apocrine or flattened cysts in the
group with breast cancer with that from a
consecutive series of 100 patients treated in this
department [13]. McNemar's test was used to
compare the frequency of pathological changes in
the pairs of matched mastectomy specimens.
RESULTS
One hundred and thirty-six patients underwent
biopsy for single or multiple breast cysts during
1966 and 1967 in the Royal Infimary, Edinburgh.
In six of the biopsies no macrocyst (>3 mm) was
identified and in 14 biopsies the epithelium
lining the macrocyst had become detached and
was not present on the sections examined. Thus
biopsies from 116 patients contained macrocysts
suitable for analysis, of which 80 contained
macrocysts lined only by apocrine epithelium, 30
contained macrocysts lined only by flattened
epithelium and six had cysts lined by both typesof
epithelium. The 80 patients with apocrine cysts
had a total of 183 macrocysts and the 30 with
flattened cysts a total of 38. Thus on average there
were 2.3 macrocysts per patient in the group with
apocrine cysts, significantly more than the 1.3
macrocysts per patient in the group with flattened
cysts (F < 0.01). Eighty-six of these 116 biopsies
contained cysts which were bigger than 1 cm and
which would therefore have been clinically
palpable and suitably treated by aspiration; 50
biopsies contained only apocrine cysts, 30 only
flattened cysts and six mixtures of the two types.
There was a mean of 2.2 cysts >1 cm in the
apocrine group and 1.2 cysts >1 cm in the
flattened group, the difference being significant
(F < 0.01).
A summary of the pathological changes in the
biopsy specimens from the 110 patients who had
either all apocrine or all flattened macrocysts and
of the 80 with palpable apocrine or flattened cysts
>1 cm are present in Tables 1 and 2. Separate foci
of apocrine change, papillary apocrine change
and epithelial hyperplasia were all significantly
more common in patients with apocrine cysts.
Hyperplasia of a severe degree (grade III) or with
atypia (grade IV) were only seen in patients with
palpable apocrine cysts.
The 12 patients who subsequently developed
breast cancer had a total of 33 cysts aspirated.
Three of these had only a single cyst, five had two
cysts aspirated, one had three, two developed four
cysts and one had nine cysts. Eleven patients had
single or multiple apocrine cysts and one patient
had a single flattened cyst. No patient had
mixtures of the two types of cyst. This ratio of 11
apocrine: 1 flattened is significantly different from
that of approximately 1:1 in a consecutive series of
100 patients treated by aspiration previously
reported by us (F < 0.01) [13]. It is also different
from the 50:30 ratio of patients with palpable cysts
in the histological study (F < 0.05).
Table 1. Comparison of the frequency of pathological changes in the
surrounding breast tissue in the groups of patients who, on biopsy, were shown to
have macrocysts all lined by either apocrine or flattened epithelium
Cyst epithelium
No. and % of patients in each group with:
foci of papillary hyperplasia hyperplasia
No. of apocrine apocrine grade grade













Significantly greater frequency in apocrine group: *P < 0.005; tf < 0.05.
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Table 2. Comparison of the frequency of pathological changes in the
surrounding breast tissue in the groups of patients who, on biopsy, were shown to
have cysts >1 cm (palpable), all lined by either apocrine or flattened epithelium
No. and % of patients in each group with:
foci of papillary hyperplasia hyperplasia
No. of apocrine apocrine grade grade
Cyst epithelium patients change change II-IV III-IV
Apocrine 50 44* (88%) 32* (64%) 39* (78%) 9f (18%)
Flattened 30 1 2 ( 40%) 8 (27%) 8 (27%) 0 (0%)
Significantly greater frequency in apocrine group: *P < 0.01; 1P < 0.02.
The frequency of pathological changes in the
mastectomy specimens of the 12 patients with a
past history of cyst aspiration and 12 matched
controls is presented in Table 3. It can be seen that
cysts greater than 1 cm in size were seen only in the
mastectomy specimens of those patients with a
past history of aspiration of apocrine cysts.
Apocrine change, papillary apocrine change,
hyperplasia and carcinoma in situ were also seen
more frequently in this group.
DISCUSSION
Controversy exists as to whether patients with
cystic disease are at increased risk of breast cancer,
although it is generally accepted that individuals
with severe hyperplasia, epithelial atypia and
papillary apocrine change are at a significantly
higher risk [1-8]. Two populations of breast cysts
lined by either apocrine or flattened epithelium
have been described [11] and this study has clearly
shown that histological risk factors for breast
cancer are significantly more common in patients
with clinically palpable apocrine cysts.
A number of other observations support this
finding. First, in populations with a high risk of
breast cancer, apocrine change is a more common
finding in the breast than in populations with a
low risk [14]. This may indicate that the
proportion of patients with cystic disease who
have apocrine cysts may vary in different parts of
the world and may relate to the breast cancer risk
of that area. Second, it has been reported that
women with palpable breast cysts who have
histological evidence of apocrine change within
the breast are more than 11 times more likely to
develop breast cancer than those women with
cysts without evidence of apocrine change [15],
Third, it has previously been noted that there is an
association between apocrine change and epith¬
elial hyperplasia [12, 14-17].
Having established that histological risk
factors for breast cancer were more frequent in the
biopsies of patients with apocrine cysts, it is of
interest that this study has shown that cysts
aspirated from patients who later developed
breast cancer were more likely to be apocrine.
Furthermore, those patients with apocrine cysts
were more likely than matched controls to have
within their breasts epithelial hyperplastic
changes and non invasive carcinoma. It has been
suggested that women who have cysts aspirated at
different times develop breast cancer more often
than those who have cysts on only one occasion
[1]. We have previously shown that women with
apocrine cysts are more likely to develop
subsequent cysts [13, 18]. This, and the finding of
a greater frequency of hyperplasia in the apocrine
cyst group, add support to the concept that
patients with apocrine cysts are more at risk of
breast cancer.
The observation that individual patients with
multiple cysts tend to develop cysts lined by only
apocrine or only flattened epithelium has been
previously reported [13, 18] and is confirmed in
Table 3. Comparison of the frequency of pathological changes in the mastectomy specimens of 12 patients with
a prior history of cyst aspiration and 12 matched controls
Papillarv
No. of Cysts Cysts Apocrine apocrine Hyperplasia Caicinoma
Breasts patients >3 mm >1 cm change change 111 + IV in situ
PH* of apocrine cysts 11 lit 9+ lit lit lit 8t
PH of flattened cysts 110 0 0 0 0
Matched controls 12 3 0 2 1 2 2
• PH = past history.
tSignificanily greater frequency of these pathological changes in mastectomy specimens of patients with apocrine cysts;
P < 0.01 by McNemar's test.
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this study. This suggests that there may be a
factor, possibly genetic [19] or hormonal, which
determines whether patients develop cysts lined
by apocrine or flattened epithelium. This same
factor, therefore, may also influence the sub¬
sequent risk of breast cancer [14].
The findings in this study relating cyst type in
patients treated by simple aspiration and breast
cancer cannot be directly compared with those of
any other studies. This is because all previous
reports relate to histopathological studies of
biopsy material. As the majority of patients with
cystic disease are not biopsied but treated by
simple aspiration, the results of these studies are
of limited relevance to clinical management. We
have previously shown that the electrolyte
composition of cyst fluid is closely related to the
nature of the epithelium lining the cyst [11]. As
the behaviour of the two cyst types differ in
relation to both natural history [13, 18] and
subsequent breast cancer risk, analysis of the
composition of cyst fluid may be of value in the
management of patients with cystic breast disease.
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pH of human breast cyst fluids
J. M. Dixon, W. R. Miller and W. N. Scott
University Department ofClinical Surgery, Royal Infirmary, Edinburgh
EM3 9YW
(Accepted for publication 4 June 1984)
The pH of 106 human breast cyst fluids has been measured immediately
following aspiration. Values ranged from pH 6 • 3 to 7 • 8. They correlated with
the ratio of Na+ to K+ in cyst fluid and differed significantly in the two popu¬
lations of fluids which can be defined on electrolyte composition. Storage of
cyst fluid for one month at — 20°C resulted in an increase in pH by a mean
of 0 ■ 9 of a unit. pH provides a simple method for typing cyst fluids and
this may be of clinical importance as there is evidence that there are differ¬
ences in the natural history and association with breast cancer in the two
populations of breast cysts.
Introduction
Two separate populations of human breast cysts can be defined on the basis of the
ratios of sodium (Na+) to potassium (K+) in cyst fluid (Bradlow et al., 1981; Dixon
et al., 1982; Miller et al., 1983). It has been shown that this variation in fluid com¬
position reflects different types of epithelium lining the two groups of cysts (Dixon
et al., 1983a).
The aims of the present study were to measure the pH of fresh cyst fluid and to
determine if differences in pH exist between the two populations of cyst fluids defined
on electrolyte composition and to investigate the effect of storage on pH.
Patients, materials and methods
One hundred and six breast cyst fluids were aspirated from 74 patients into air tight
syringes, placed on ice and pH measured within one hour, using a Corning 178
pH/blood gas analyser. Na+ and K+ concentrations were measured in the same fluids
by flame photometry (EEL model 150 flame photometer) after dilution 1 in 200 and
1 in 400 with distilled water. Fluids were then stored at — 20°C and pEI was remeasured
in 10 samples after 1 week and 1 month of storage.
Statistical correlation of pH and Na+/K+ ratio was by the Kendall rank test. Com¬
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Figure 2. Correlation of pH and the Na+/K+ ratio of 106 breast cyst fluid.
Results
The pH values of the 106 cyst fluids ranged from 6 3 to 7-8 (Figure 1). There was
significant positive correlation between pH and Na+/K+ ratio,p <0-001 by the Kendal
rank test (Figure 2). Composition of pH in fluids subdivided into different types accord¬
ing to Na+/K+ ratio showed no overlap in values between the two populations (Figure
3), the difference between the groups being significant by the Wilcoxon rank sum test
(/><0 001).
The effect of storage on pH in 10 cyst fluids is shown in Figure 4. After 1 week
pFI had increased in all fluids by a mean of 0 • 4 and by 1 month it had increased further
by a mean of 0 • 9 of a pH unit over initial values.
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Figure 3. pH of cyst fluids separated into two populations on the basis of Na+/K+ ratio. The
















Figure 4. Effect of storage on pH in 10 cyst fluids.
Discussion
Human breast cyst fluids have been previously reported to be alkaline, with a pH range
of 7-6—9 0 (Gatsy et al., 1979). These measurements were however performed on
stored samples and this study has shown that fresh cyst fluids are acidic or neutral
and only become alkaline on storage. pH has been shown to correlate with the ratio
of Na+ to K+ in cyst fluid and to differ in the two populations of cyst fluids defined
on the basis of Na+/K+ ratio. Cysts with a low Na+/K+ ratio are thought to be lined
by apocrine epithelium and cysts with a high ratio to be lined by flattened epithelium
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pH than flattened cysts. This is of interest as apocrine secretion occurs by expelling
the contents of intracellular secretory granules (Azzopardi, 1979) and intracellular fluid
has a lower pH than extracellular fluid (Waddell & Bates, 1969). Apocrine secretion
from the axilla has also been noted to be acidic (Hurley & Shelley, 1960). In contrast
the fluid in flattened cysts is considered to arise by transudation (Dixon et al., 1983/>).
The findings of different pH values in the two groups of cysts thus correlate well with
the different modes of formation which have been proposed.
It appears that patients with apocrine cysts are more likely to develop further cysts
and may be at a greater risk of breast cancer (Haagensen et al., 1981; Dixon & Miller
unpublished). As apocrine cyst fluids are acidic, measurement of pH may be useful
in the determination of cyst fluid type. Recently we have used Multistix (Ames Division
Miles Laboratories Limited, England) to assess pH immediately after aspiration. This
has proved a useful, simple method of identifying cyst fluid type and studies on its
value are continuing.
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Wide variations in the concentrations of IgA, IgG, lactoferrin, lysozyme and
albumin were found in 96 cyst fluids obtained from 75 patients with gross
cystic disease of the breast. Sedimentation coefficient determination were per¬
formed on 19 of the cyst fluids with the highest IgA concentrations in an
attempt to discover the basis for the wide variation and two types of cyst fluids
were found: cyst fluids that resembled external secretions such as colostrum
of milk with the IgA wholly or predominantly in the 11S (secretory) form,
and low concentrations of IgG and albumin, and cyst fluids that resembled
serum with the IgA wholly or predominantly in the 7S (serum) form, and
high concentrations of IgG and albumin. Some cyst fluids contained low
concentrations of all proteins measured, and no relationship was observed
between the concentrations of the proteins studied, and age, parity or
menstrual status.
Introduction
Although gross cystic disease (GCD) and carcinoma of the breast share a common
predisposing factor (Haagensen, 1971), the mode of formation of the fluid within the
cysts in GCD is still not known. Histologically, GCD appears to be characterized by
hyperplasia of acinar epithelium associated with dilatation of the terminal ducts
(Schnug & Cavanagh, 1966) and it has been proposed that breast cyst fluid is a
unique secretion from breast epithelial cells, possibly in response to abnormal hormone
secretion (Haagensen et al., 1979).
In an attempt to discover the origin of cyst fluid, we have measured the concen¬
trations of various proteins in the cyst fluids. Concentrations of secretory IgA (1 IS IgA)
were measured as this protein may reflect both local IgA plasma cell activity and
mammary epithelial function (Lamm, 1976). Lactoferrin and lysozyme were measured
*Part of this work was performed while P. L. Yap was at the MRC Reproductive Biology Unit,
Edinburgh.
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as they are synthesised by glandular acini (Masson et al., 1966) and epithelium (Kraus
& Mestecky, 1971) respectively. In addition serum IgA (7S IgA), IgG and albumin
were measured to assess the presence of serum proteins in cyst fluid.
Materials and methods
Cyst fluid
A total of 96 cyst fluids were obtained by needle aspiration from 75 women presenting
with GCD. Multiple cysts were aspirated in 17 women and four women had the same
cyst aspirated on more than one occasion. The age of the patients ranged from 31 to
55. Information on parity and menstrual status were available on only 69 and 71 patients
respectively (Table 1). In addition, fluid was obtained from three galactocoeles in a
patient following a recent pregnancy. All fluids were stored at — 20°C till assay.
Qiiantitation of IgA
IgA was measured by double antibody RIA (Yap et al., 1979), using a purified 11S
IgA standard (Newcomb et al., 1968). The antiserum (rabbit anti-a chain) used in all
IgA measurements, unless otherwise specified, was raised in rabbits immunised with
7S IgA (Platts-Mills & Ishizaka, 1979). In addition, sucrose fractions from density
gradient ultracentrifugation for sedimentation coefficient determinations were further
analysed by RIA using an antiserum, prepared in rabbits immunised with 11S IgA
(Dakopatts) and further adsorbed with 7S IgA. This antiserum (rabbit anti-llS IgA/
FSC) only reacted with the conformational determinant of 11S IgA and the accessible
determinant of free secretory component, and did not react with 7S IgA (Yap et al.,
1980).
Quantitation of IgG, lactoferrin, lysozyme and albumin
Single radial immunodiffusion was used to quantify IgG, lactoferrin, lysozyme and
albumin using reagents and standards described previously (McClelland et ai., 1978).
The lower limit of detection of these proteins was 100mg/l, 50 mg/1, 90 mg/1 and
50 mg/1 respectively.
Sedimentation coefficient determination
Sedimentation coefficient determinations were carried out using a 25% to 45% sucrose
density gradient (236 000 X g for 3 hours) in a vertical rotor (OTD-50, Sorvall). Frac¬
tions of 0 ■ 1 ml volume were collected from the bottom of the tube, diluted and stored
at — 20°C till RIA with either rabbit anti-a chain, or rabbit anti-llS IgA/FSC. Two
different standards were used: a serum IgA standard (Rowe et al., 1972) for the
measurement of IgA in ultracentrifugation fractions when the IgA detected was pre¬
dominantly 7S, and the 11S IgA standard described above when the IgA detected was
predominantly 11S. In a few cyst fluids, fractions from ultracentrifugal analysis were
also assayed using anti-1 IS IgA/FSC and the 1 IS IgA standard. Three marker proteins
were used; a non-radioactive 7S human IgG marker and radioactive 125I-IgG and
125I- 11S IgA markers.
Table1.Compositionfcystfluidanrelati shipt ge,ritydme strualst s
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Table 2. Effect on cyst fluid of reaspiration of cyst after 21 days
IgA IgG Albumin
Cyst Volume concentration concentration concentration
Patient no. (ml) (mg/1) (mg/1) (mg/1)
1 5 8-0 266 390 1100
10 8-0 44 120 360
2 12 NK 42 130 550
13 NK 32 100 300
3 18 NK 64 100 200
19 NK 88 480 2500
4 22 5-0 275 1400 6400
25 3-0 7 100 240
The second cyst fluid for each subject was aspirated 21 days after the initial aspiration of
the cyst.
NK = not known.
Fraction no.
Figure 1. Sucrose density gradient ultracentrifugation to determine the sedimentation coefficient
of IgA in five samples of cyst fluid 8(1), A A; 13(2), O O; 26, ■ ■; 31, A A;
57, • • (see Table 3) and a sample of fluid from a galactocoele □ □. A 25—4-5% w/v
gradient was used, and 0 • 1 ml fractions collected from the bottom of the tube and immuno-
assayed using an 11S IgA standard (cyst fluid 8(1), 13(2) and galactocoele fluid) or a 7S IgA
standard (cyst fluid 26, 31 and 57) and anti-a chain. The two arrows indicate the position of
radioactive 11S and 7S markers, and the hatched area a non-radioactive 7S marker.
Results
IgA, IgG, lactoferrin, lysozyme and albumin concentrations in cyst fluids
Of the 96 cyst fluids investigated, all had measurable amounts of IgA, but IgG, lacto-
ferrin and albumin could only be detected in 44 (46%), 68 (71%) and 69 (72%) fluids
respectively. Lysozyme was only detected in four cyst fluids examined with concen¬
trations ranging from 0 13 and 0-54 g/1. Concentrations of all the other proteins were
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Fraction no.
Figure 2. Sucrose density gradient ultracentrifugation to determine the sedimentation coefficient
of IgA in three samples of cyst fluid 5(2), • •; 48, • ■ •; 26*, • •. Anti-a chain
was used, with a 11S IgA standard (cyst fluid 5(2) or a 7S IgA standard (cyst fluid 48, 26*).
The two arrows indicate a position of radioactive 11S and 7S markers. Experimental conditions
were identical to those described for Figure 1.
Fraction no.
Figure 3. Sedimentation profile of three cyst fluids (13(2), O O; 26, ■ ■; 31, A A)
and fluid from galactocoele (□ □) when the fractions described in Fig. 1 were immuno-
assayed using anti-US IgA/FSC (which only detects 11S IgA and free secretory component)
and an 1 IS IgA standard.
variable and there was no obvious relationship between menopausal status, parity, age
of the patients, volume of cyst fluid aspirated and the concentrations of IgA, IgG,
lactoferrin and albumin (Table 1).
Multiple cysts were obtained from 17 patients, but the values again were not
consistent, varying by up to 15-fold for some of the proteins measured.
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Table 3. Classification of cyst fluids by the sedimentation coefficient of the major
IgA peak
IgA IgG Albumin Lactoferrin
Cyst fluid concentration concentration concentration concentration
no. (mg/l) (mg/l) (mg/l) (mg/l)
IgA Peak in 7S Position
4 796 740 6400 440
26 669 2900 6400 25000
31 639 1600 12200 640
37 664 1500 13950 400
42 867 720 1820 230
48 286 1350 8900 690
57 676 3100 17050 1010
61 939 2750 13050 ■ 300
26 334 2150 6400 1320
Arithmetic
mean 652 1868 9574 3330
SE 73 300 1602 271
IgA Peak in 11S Position
5(2) 390 ND 200 1080
8(1) 780 ND 200 1240
8(2) 475 ND 200 1240
10(1) 499 ND 70 1840
10(2) 407 100 270 1730
13(2) 776 100 120 720
18 432 ND 50 350
38(1) 308 760 1170 580
44 422 110 470 1400
23 493 ND 240 1200
Arithmetic
mean 498 268 299 1138
SE 50 164 103 151
P NS <0 001 <0 001 NS
NS = Not significant.
ND = Not detectable.
In the three fluids obtained from the patient with galactocoeles following a recent
pregnancy, mean (SE) concentrations of IgA, IgG, lactoferrin, lysozyme and albumin
were 2-99 (1-73), 0-010 (0-003), 2-02 (0-57), 0-22 (0-17) and 0-60 (0 01) g/1
respectively. As expected, high concentrations of IgA and lactoferrin were present in
the galactocoele fluid.
Effect of reaspiration of cyst on concentrations of milk proteins
Four patients were studied on more than one occasion. In each case there was a 21-day
interval between the initial and subsequent aspiration. In three of the four patients,
values of IgA, IgG and albumin were lower in the second aspiration, suggesting that
the aspiration procedure itself was not resulting in an increased albumin or IgG
concentration (Table 2).
Sedimentation coefficient determination of IgA in cyst fluids
Sedimentation coefficient determinations were performed on the IgA present in
the 19 cyst fluids with the highest IgA levels where there was sufficient material for
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analysis. This was to confirm the observation of 7S IgA in a single cyst fluid (by gel
filtration, data not shown) and to ensure that the correct standard was being used for
the measurement of IgA by RIA in the cyst fluids.
The major peak of IgA immunoreactivity in nine of the cyst fluids studied had ident¬
ical sedimentation characteristics to the 7S marker, while in the remaining ten, it was
identical with the 11S marker. The IgA in fluid from the galactocoele was in the 11S
position (Figure 1). Mixtures of 7S and 11S IgA immunoreactivity were seen in two
cyst fluids (Figure 2).
To confirm that the immunoreactive IgA in the same position as the 11S marker
was truly 11S IgA, some fractions were reanalysed, but using anti-US IgA/FSC. The
cyst fluid that had previously been found to have a 11S peak of IgA immunoreactivity
again showed a 1 IS peak of immunoreactivity using anti-1 IS IgA/FSC. The fluid from
the galactocoele also showed a 11S peak of IgA immunoreactivity using anti-1 IS
IgA/FSC, confirming that in these two fluids it was the complete 11S IgA molecule
that was being detected (Figure 3).
The 19 cyst fluids that were analysed by sucrose density gradient ultracentrifugation
were therefore divided into cyst fluids where the IgA was wholly or predominantly either
7S or 11S. When the two categories of cyst fluids were compared, it was found that
mean IgG and albumin concentrations were significantly greater in the cyst fluids where
IgA was one of the 7S form than in the cyst fluids where IgA was of the 11S form.
(/>< 0-001 in all cases, Student's /-test; Table 3).
Discussion
Particular interest has been shown in the study of GCD because of the higher than
expected incidence of breast carcinoma in patients who had previously had gross cystic
disease (reviewed by Veronesi & Pizzocara, 1968). Biochemical analysis of the cyst
fluids is at present incomplete: CEA (Fleisher et al., 1974), various enzymes (Schwartz
et al., 1976), protein hormones (Srivastava et al., 1977; Bradlow et al., 1979) and other
proteins (Haagensen et al., 1979) as well as various steroid hormones (Bradlow et al.,
1976) including dehydroisoandrosterone sulphate (Bradlow et al., 1981a), oestriol con¬
jugates (Raju et al., 1977) and a progesterone binding component (Pearlman et al.,
1973) have all been found in cyst fluids, but the origin of the fluid within the cyst
remains unresolved.
Cyst fluids from patients with GCD were therefore analysed to investigate the possi¬
bility that the cyst fluid might either reflect the synthetic activity of the surrounding
breast tissue, or the transit of serum proteins into the cyst. It was thought that this
might lead to an understanding of the mechanism of cyst formation.
The results of this study show that a wide range of concentrations of IgA, IgG, lacto-
ferrin and albumin can be detected in cyst fluids. Although the rate of detection was
a reflection of the sensitivity of the assay method used, the high detection rate for lacto-
ferrin, which is not normally detectable in serum suggests that the cyst fluid probably
does indicate the synthetic activity of the surrounding breast epithelium. Interestingly,
lactoferrin concentrations in cyst fluid were about one fifth the concentration in milk
(McClelland et al., 1978).
Density gradient ultracentrifugation was used to characterise the IgA detected. Of
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19 cyst fluids analysed by ultracentrifugation, half contained IgA that was wholly or
predominantly of the 11S type, and the remaining half contained IgA of the 7S type.
The latter cyst fluids also contained high concentrations of two other serum proteins,
IgG and albumin, suggesting that components of serum were entering the cyst by some
unknown route. In these cyst fluids, the mean concentrations of IgA, IgG and albumin
were approximately four-fold lower than the corresponding concentrations in adult
serum. The high concentrations of 11S IgA present in some cyst fluids suggested that
local mammary synthesis of 1 IS IgA was occurring, as little 1 IS IgA is present in serum
(Waldman et al., 1970).
Insufficient data was present to draw any firm conclusions about the relationship
between protein concentrations, and the various clinical parameters recorded but the
results of this study indicate that breast cysts may be more heterogenous than previously
thought, and that two or more types of cysts may occur in gross cystic disease of the
breast. One type of cyst contains fluid reflecting the synthetic activity of the surround¬
ing mammary epithelium and sub-epithelial plasma cells, while another type of cyst
appears to contain serum components. The suggestion that two types of cysts may exist
has been reported by Barlow et al. (1981^). An alternative explanation is that the fluid
contents of the cyst may be changing over a period of time, and that the differences
in protein concentration we may have observed do not reflect different types of cysts,
but possibly similar cysts at different stages in their formation. Further studies involving
reaspiration studies of the same cyst are therefore required, as are studies of whether
the determination of protein concentrations is of any clinical importance to the patient.
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Hormonal Correlates of Apocrine
Secretion in the Breasta
W. R. MILLER, J. M. DIXON, AND A. P. M. FORREST
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Royal Infirmary
Edinburgh EII3 9YfV, Scotland
INTRODUCTION
High, but variable levels of the androgen conjugate dehydroepiandrosterone (DMA)
sulfate are present in breast fluids and tumors.' 6 Evidence will be presented that these
relate to apocrine activity within the breast. This conclusion is based on (1) mea¬
surements of DMA sulfate in secretions obtained by nipple aspiration and breast fluids
derived from micro- and macrocysts and (2) the distribution of androgen conjugates
within normal lobules, cysts, and cancerous lesions of the breast.
METHODS
Radioimmunoassay was performed on all breast fluids after dilution with phosphate
buffer using the method of Buster and Abraham7 and employing an antibody whose
specificity has been previously described." The antibody crossroads primarily with
DMA and its sulfate, but also shows significant crossreactivity with DHA glucuronide
and epiandrosterone conjugates.
Gas-liquid chromatography-mass spectrometry was performed on extracts of sol-
volysed breast secretions, as described previously,2 and involves analysis as the tertiary
butyl dimethyl silyl (TBDMS) derivatives.
Immunohistochemical studies were performed on frozen sections "(3-5/x) of fresh
tissue. These were incubated successively in 10% normal rabbit serum, the antisera
to DHA sulfate (raised in sheep) diluted in 10% normal rabbit serum and 5% human
serum (containing undetectable levels of DHA sulfate), and pcroxidase-conjugated
rabbit anti-sheep antibody. Visualization was achieved with the use of diaminoben-
zidine, which turns brown when peroxidase is present.
"This work was supported in part by a grant from the Cancer Research Campaign.
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RESULTS
Normal Breast Secretions
Breast secretions were obtained by nipple aspiration, from women volunteers who
had no clinical evidence of breast abnormality; aspiration was done by applying a
slight negative pressure to the nipple by means of a syring j^ttached to a cup.'
The levels of DHA sulfate in 100 secretions obtained from 61 women were mea¬
sured by radioimmunoassay. The results are presented in Figure 1 and show an
enormous range of values from 20 to 2250 p.mol/L (median value, 270 p.mol/1).
Data obtained from gas-liquid chromatography-mass spectrometry confirmed that the
material erossreacting with the antibody in the radioimmunoassay was a conjugate of
DHA. The major component of solvolyzed extracts of breast secretions on gas-liquid













FIGURE 1. Levels of DHA sulfate in breast
secretions from normal women. Horizontal Inn




DHA. Levels of DHA were also similar, whether measured by radioimmunoassay or
by gas-liquid chromatography-mass spectrometry.
Peripheral blood was taken by venipuncture immediately before aspiration of breast
secretions in 20 normal women. In each case, the level of DHA sulfate was higher
in breast secretion than in plasma. Although the average value was more than 100-
fold higher in secretions than in plasma, the breast seeretiomplasma ratio for DHA
sulfate varied from 7 to 380 between individual women (Table 1).
In an attempt to localize DHA sulfate within normal breast, immunohistochemic.il
studies were performed on frozen sections of material from bilateral reduction mum-
moplasties performed in two patients. The secretion in normal breast lobules which
stained pink with hematoxylin and eosin contained material crossreacting with the
antibody for DHA sulfate (Fig. 2). There was little or no apparent staining within
the cytoplasm of normal breast lobular epithelium. Secretions in breast ducts also
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table l. Levels of DHA-Sulfate (/xmol/L) in Breast Secretions and Plasma from
Normal Women
Subject Breast Secretion" Plasma Ratio
1 1,028 3.26 315
2 168 1.75 96
3 318 1.92 165
4 194 2.43 80
5 567 4.21 135
6 306 1.94 158
7 396 2.43 163
8 23 3.29 7
9 867 2.28 380
10 1,482 7.05 210
11 122 1.74 70
12 249 2.00 125
13 828 5.71 145
14 165 2.04 81
15 173 3.08 83
16 277 1.26 220
17 118 2.36 50
18 284 2.02 140
19 192 3.97 48
20 299 3.05 98
"Where more than one secretion was obtained per subject, the values have been averaged.
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FIGURE 2. Normal human breast lobule stained by the immunoperoxidase technique to show
the presence of DHA sulfate. (Frozen section; magnification X40).
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stained heavily in the peroxidase studies; some staining was localized in ductal-
epithelium.
Microcysts
Mierocysts were arbitrarily distinguished from maerocysts by being impalpable
within the breast and smaller than 3 mm in diameter. Forty microcysts were identified
in eight biopsy specimens for benign breast disease and 14 mastectomy specimens for
breast cancer. The fluid from microcysts was collected by aspiration into fine glass
tubing. All samples contained high levels of DHA sulfate as measured by radioim¬
munoassay, the concentrations being similar to those in breast secretions and much
in excess of those in plasma (Fig. 3).
f
FIGURE 3. Levels of DHA sulfate in human
breast microcysts. Horizontal lines represent
median values; vertical lines show range of val- -





After collection of the fluid, the microcysts were examined histologically and
subjected to immunoperoxidase staining for DHA sulfate. Examples of the results are
shown in Figure 4. The microcysts were lined by epithelium which showed apocrine
features and which also stained deeply positively with the anti-DHA sulfate antibody.
Macrocysts
Levels of DHA sulfate in fluids obtained from palpable breast cysts varied enor¬
mously from 2 to 700 p.mol/l. (Fig. 5). This large concentration range means that
MILLER el at.: APOCRINE SECRETION 279
1
FIGURE 4. Human breast microcyst epithelium stained by the immunoperoxidase technique
to show the presence of DHA sulfate. (Frozen section; magnification X400; reduced by 20%.)
certain cyst fluids have values of DHA sulfate similar to thosf in plasma while others
have levels similar to those in breast secretions. Factors that'might account for this
large variation were examined. No significant relationships were detected between
DHA sulfate and cyst fluid volume or age, parity, or menopausal status of the patients.
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FIGURE 5. Levels of DHA sulfate in human
breast macrocysts. Horizontal lines represent
median values; vertical lines range of values for
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FIGURE 7. Distribution of the ratios of [Na+]
to [K+] in fluids from macrocysts. Two sub-
populations are apparent with either a low
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FIGURE 8. Comparison of DHA sulfate lev¬
els in human breast cyst fluids with either a
low (<4) or high (>4) Na+:K+ ratio. Differ¬
ence between the grcmps is significant by the
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Breast Carcinomas
Frozen sections from 20 cases of human breast cancer were processed for he¬
matoxylin and eosin histologic examination and for immunohistochemical study using
antibody against DHA sulfate. The hematoxylin and eosin-stained sections were graded
for apocrine differentiation and the immunohistochemical sections for the degree of
staining for DHA sulfate. There was a highly significant correlation between the
presence of apocrine features within the breast tumors and the degree of staining for
DHA sulfate (Table 2). Furthermore, within the tumors displaying apocrine differ¬
entiation, the staining for DHA sulfate was particularly localized in cells having
apocrine features, as shown in Figure 12.
tooo-
DHA-S
{ umol / I )
FIGURE 9. Comparison of DHA sulfate
levels in human breast cyst fluids subdivided
according to their predominant type of IgA
Difference between the groups is significant




Evidence has been presented that levels of DHA sulfate in normal, benign, and
malignant breast are related to the apocrine activity of the tissue. In fluids from benign
breast cysts, there are strong positive correlations between levels of DHA sulfate and
K"" (normally an intracellular cation), 1 IS IgA (a marker of secretory activity), and
the presence of an apocrine epithelium cyst lining. Since no significant relationships
were evident between DHA sulfate and other variables such as cyst fluid volume, and
menopausal status, age and parity of the women, these data are compatible with the
notion that in the fluids that contain high levels of DHA sulfate these high levels are
produced as a result of apocrine activity of the cyst lining In contrast, those fluids
MILLER et al.\ APOCRINE SECRETION 283
a
FIGURE 10. Histologic specimens of the epithelium lining human breast cysts, (a) Apocrine
epithelium (hematoxylin and eosin stain; magnification X 120). (b) Flattened epithelium (he¬
matoxylin and eosin stain; magnification X240).
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FIGURE 11. Comparison of DHA sulfate levels in





with low levels of DHA sulfate probably result from a more passive non-apocrine
process. It is therefore consistent that microcysts which, in our limited series, were
wholely lined by apocrine epithelium should show the highest concentrations of DHA
sulfate.
This relationship between DHA sulfate and apocrine activity was not restricted
to benign apocrine epithelium and, in a small group of cancerous breast tumors, there
was a significant positive correlation between degree of apocrine activity and staining
for DHA sulfate. These immunohistochemical studies indicated that in cases of breast
cancer showing apocrine differentiation, the DHA sulfate is primarily associated with
apocrine cells.
table 2. Relationship Between Degree of Apocrine Differentiation and Degree of
Staining with DHA Sulfate Antibody Peroxidase Technique
Degree of Apocrine
Differentiation
Degree of Staining for DHA Sulfate"
0 + + +
Absent 6 0 0
Minimal 1 7 1
Moderate 0 1 4
Note: The correlation between apocrine differentiation and staining was statistically significant
using the Kendall rank correlation test T = 0.85 (j> < 0.001).
"Degree of staining for DHA sulfate was classified as 0 if there was no apparent staining, +
if only occasional cells stained, and + + if there was a substantial proportion of cells showing
the stain.
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Further support for the concept that DHA sulfate may be a marker of apocrine
activity is the report of high concentrations of the steroid in other apocrine secretions
such as apocrine sweat from axillary glands.10
High concentrations of DHA sulfate were demonstrated in breast secretions ob¬
tained by nipple aspiration from breasts without clinical abnormality. Histochemical
staining for DHA sulfate also indicated that the eosinophilic secretion within the
lumen of normal lobules contains large amounts of androgen conjugate. By inference,
these observations may be taken as evidence of apocrine activity within normal breast
cells. It ought to be emphasized, however, that if these lobules represent the deep-
FIGURE 12. Tumor with marked apocrine differentiation stained by the immunoperoxidase
technique 10 show the presence of DHA sulfate. (Frozen section; magnification X 100.)
seated source of the secretions obtained by nipple aspiration, modification of the
composition of the fluids is likely to occur by selective reabsorption or further secretion
during the passage through the ductal system. The constituents of nipple aspirates
would therefore not necessarily reflect the activity of normal breast lobules.
The origin, biological significance, and clinical relevance of DHA sulfate within
apocrine cells of the breast still remain to be elucidated. It is possible that DHA
sulfate could be synthesized locally from other steroid precursors, cholesterol orcholesterol sulfate, but such biosynthetic capacity has never been convincingly dem¬
onstrated wiihin the breast. It seems more likely that DHA sulfate is selectively
concentrated from plasma where it circulates in large amounts for a blood-bornehormone and is almost exclusively derived from the adrenal cortex. Bradlow et al.'"und that among a series of radioactively labeled hormones administered to women
gross cystic disease of the breast, DHA sulfate alone accumulated in breast cystu'ds; this finding is consistent with a mechanism of selective concentration.
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DHA sulfate and other closely related androgen conjugates have little biological
activity per se'2,13 but they may be pre-hormones of steroids with more potent prop¬
erties.'4'5 There is evidence that breast tissues may utilize DHA sulfate as a precursor,"
and pathways have been traced that lead to both active androgens and estrogens."""
Cancerous breast tumors with marked apocrine differentiation display a high potential
to produce 5 a-reduced androgens." These steroids have potent androgenic activity
and it is interesting that apocrine activity itself is stimulated by androgenic steroids.20
It may also be relevant that, in addition to androgen conjugates, estrogen conjugates
are present in high concentrations in breast cyst fluids, but these are not concentrated
from the circulation.21 The suggestion is that estrogen conjugates may be derked
locally within the cyst by aromatization from androgen precursors such as DHA
sulfate. Unpublished data from this department indicate a strong correlation between
concentrations of DHA sulfate and estrone sulfate in breast cyst fluids.
Several recent studies22 24 have suggested that the presence of apocrine activity
within the breast is a predisposing factor for breast cancer. If this is so, then the
measurement of DHA sulfate within breast fluids and tissues may form a useful
marker to determine those at increased risk.
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Summary
Thrombospondin, /J-thromboglobulin and platelet factor 4 were measured by
radioimmunoassay in fluids from 50 human breast cysts. yS-Thromboglobulin con¬
centrations were < 4-330 ng/ml (median 13.5 ng/ml), while normal plasma con¬
tained 14-80 ng/ml. Cyst fluids contained 8-225 ng/ml platelet factor 4 with a
median of 25 ng/ml (range in plasma 6.5-29 ng/ml). Thrombospondin levels in cyst
fluids were 65-55 000 ng/ml (median 2 500 ng/ml) and 92% contained concentra¬
tions above the plasma range (58-215 ng/ml). When cyst fluids were classified by
their electrolyte composition, group II cysts had similar levels of platelet factor 4 but
significantly higher levels of /I-thromboglobulin and thrombospondin than group I.
From the remarkably high concentrations of thrombospondin within cyst fluids and
the differences between cyst types, it seems that either the protein is synthesised
locally or selectively accumulated. Increased platelet activation is unlikely to be the
source of the high thrombospondin levels in group II cysts.
Introduction
Cysts are the most common benign lesion of the breast [1] and women with cystic
disease appear to have an increased risk of developing breast cancer [1,2]. Despite
this, comparatively little is known about the composition of cyst fluid. Recently,
however, it has been shown that cyst fluids may contain unusually high concentra¬
tions of steroid conjugates [3,4] and specific proteins [5,6], It is also possible to
Correspondence to: Dr. W.R. Miller, University Department of Clinical Surgery, Royal Infirmary,
Edinburgh EH3 9YW, Scotland, UK.
0009-8981/85/S03.30 © 1985 Elsevier Science Publishers B.V. (Biomedical Division)
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classify cyst fluids into two major sub-groups according to electrolyte composition
[7] and the histological nature of the lining epithelium [8].
Our unpublished observations that milk contains high concentrations of thrombo-
spondin prompted the present investigation into platelet associated proteins in cyst
fluids. Thrombospondin is a glycoprotein which was first isolated from the extracell¬
ular medium after thrombin treatment of platelets [9], but has since been shown to
be synthesised and secreted by endothelial cells [10,11], smooth muscle cells [12] and
fibroblasts [13]. On the other hand, /1-thromboglobulin (/8-TG) is a platelet-specific
protein [14], and platelet factor (PF4) has been identified only in platelets [15] and
mast cells [16]. In this paper, we report the presence of thrombospondin, y3-TG, and
PF4 in breast cyst fluids, and their distribution in the major subpopulations of cysts.
Materials and methods
Fifty breast cyst fluids were obtained by needle aspiration from 45 patients.
These represented aspiration of a single cyst in 42 women and multiple cysts in 3
subjects. The fluids were centrifuged at 600 X g for 10 min and the supernatant
stored at — 20°C until assayed.
Concentrations of Na+ and K+ were measured by flame photometry (EEL model
150 flame photometer) after dilution 1 in 200 and 1 in 400 with distilled water.
Fluids were then classified as group I if the concentration ratio of Na+ to K+ was
less than 4 (25 fluids) or group II if the ratio was > 4 (25 fluids).
Thrombospondin was measured by radioimmunoassay essentially as described by
Dawes et al [17]. Polyclonal antibody was raised in New Zealand white rabbits using
thrombospondin purified from human platelets as immunogen. Thrombospondin
was radiolabeled with 125I using the chloramine T technique of Greenwood et al
[18]. Assays were carried out in 0.05 mol/1 phosphate buffer pH 7.4 containing 2%
horse serum and 1% Tween 20. Each tube contained antiserum (50 gl of a
concentration sufficient to bind 50% of the tracer), [125I]thrombospondin (50 jal of
10 ng/ml) and standard or sample, in a final volume of 250 jal. After incubation
overnight at 20°C, free thrombospondin was separated from that bound to antibody
using donkey anti-rabbit IgG antiserum (Scottish Antibody Production Unit) cou¬
pled to Sepharose 4B.
/8TG and PF4 were purified from human platelets by affinity chromatography on
heparin-Sepharose. Radioimmunoassays for these proteins are similar to that for
thrombospondin and are described by Bolton et al [19] and Dawes et al [20].
Antisera for all three radioimmunoassays were as described in previous publications.
In all cases cyst fluids gave parallel dilution curves to standards and serum samples,
indicating that the proteins in the different fluids were antigenically indistinguisha¬
ble using these polyclonal antisera.
Results
The levels of /3TG, PF4 and thrombospondin in cyst fluids are shown in Figs. 1













group I group II group I group H
Fig. 1. Levels of fiTG and PF4 in cyst fluids subdivided according to electrolyte composition (group I
Na+ : K+ < 4, group II Na+ : K+ > 4). Solid lines represent median values for the sub-groups, broken
line the level of sensitivity and vertical lines the range for each protein in blood plasma. There was a
significant difference in fiTG between the two sub-groups by Wilcoxon Rank test (p <0.001) but no
significant difference in PF4 levels.
which had undetectable levels of /STG. There was a wide range of values for /?TG
(< 4 to 330 ng/ml). Twenty-four of the 50 fluids (48%) contained concentrations
within the reference range for normal blood plasma of 14-80 ng/ml (11); all but 2
of the remainder possessed lower levels. Values for PF4 in cyst fluids ranged
between 8 and 225 ng/ml (median value 25 ng/ml). In 34 fluids, concentrations fell
within the reference range of 6.5-25 ng/ml for normal plasma (11), the remaining
16 fluids possessed levels in excess of those in plasma. Whilst there was a very large
range of values for thrombospondin in cyst fluids, the concentrations were usually
greatly in excess of those in normal plasma (Fig. 2). The median value of 2 500
ng/ml for thrombospondin for all cyst fluids was about 25-fold higher than that in
plasma (range 57-216 ng/ml (9)).
The effects of sub-dividing the cyst fluids according to their electrolyte class is
shown in Fig. 1 for ySTG and PF4 and in Fig. 2 for thrombospondin. Concentrations
of ySTG were significantly higher (p < 0.001) in group II cysts compared with group
I. However, whilst the median value for /3TG in group II cysts was over 3-fold
higher than in group I, there was a large overlap in values between the two groups.
No significant difference was apparent in PF4 between the sub-classes of cysts and
the median value was similar in both groups. In contrast, there was a highly







Fig. 2. Levels of thrombospondin in cyst fluids subdivided according to electrolyte composition.
Horizontal lines represent median values for the sub-groups and the vertical line the range for blood
plasma. There was a significant difference between the groups by Wilcoxon Rank test (p <10-6).
of cysts. The median value in group II cysts was 7-fold higher than in group I and all
fluids containing in excess of 6000 ng/ml were from group II.
Discussion
These results are the first report of the presence of several platelet-associated
proteins in breast cyst fluid. Whilst levels of /8TG were in general similar to or lower
than those in normal plasma, concentrations of thrombospondin were markedly
higher in most cyst fluids, and raised levels of PF4 were also detected in a
proportion of fluids.
The presence of PF4 concentrations above those found in normal plasma is
interesting. It is unlikely to be derived directly from platelets, as equivalently
elevated levels of ySTG, which is released from the platelet at the same time as PF4,
were not observed. Diffusion from the plasma is equally unlikely, for PF4 circulates
as a large complex which is present in plasma at lower concentrations than jSTG in
both normal and clinical situations [20]. However, it is thought that PF4, unlike
/3TG, may be cleared from the circulation by binding to heparan sulphate on the
vascular endothelium [21], and it could be transferred to cyst fluids by this route.
Alternatively it may derived from tissue mast cells, which do contain PF4 but not
ySTG [16]. This raises the question of whether mast cells are activated in cystic
disease.
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The thrombospondin levels in cyst fluids also cannot be explained on the basis of
platelet release. Indeed, in some cases they are higher than the concentrations
(11.5-30.75 /xg/ml) achieved in serum. We have not excluded the possibility that the
material in cyst fluid is not identical to platelet thrombospondin but, this seems
unlikely. The two are antigenically indistinguishable using our polyclonal antisera,
and are currently being tested with a range of monoclonal antibodies raised against
platelet thrombospondin.
It is of great interest that thrombospondin is not only present at higher concentra¬
tions in cyst fluid than plasma but additionally shows highly significant differences
in levels between the two major sub-groups of cyst fluid. Thus group II fluids, which
are characterised on the basis of containing high concentrations of Na+ but low
levels of K+, possessed higher concentrations of thrombospondin and ySTG than
group I fluids which have comparatively higher K+ and lower Na+. Group II fluids
also have the 7S non-secretory form of immunoglobulin A [22] and are invariably
lined by thin attenuated epithelial cells [8J. Because of this, it has been inferred that
the contents of such fluids accumulate in a passive manner [22,23], possibly as a
transudate from blood, as suggested above for /ITG. However, the extraordinarily
high levels of thrombospondin in group II cyst fluids would suggest that either there
is an active but selective accumulation process against a concentration gradient or
that the protein is synthesised locally within the breast, possibly by the cells of the
cyst wall. The active cell type has yet to be identified, but is unlikely to be the
apocrine cells as there are lower levels of thrombospondin in group I cysts which are
usually lined by active apocrine cells [8] and whose fluids also possess the 11S
secretory form of immunoglobulin A [22]. Concentrations of thrombospondin in
saliva are within the normal plasma range (unpublished results), supporting the
conclusion that thrombospondin is not a simple marker of apocrine activity. The
accumulation of platelet-associated proteins in the breast is not restricted to cystic
fluids and our preliminary results indicate that other breast fluids such as galactor-
heic secretions and those obtained by nipple aspiration from non-lactating women
also contain very high concentrations of thrombospondin.
The significance of high concentrations of this particular protein within the breast
is unknown. It is thought to form part of the matrix involved in platelet aggregation,
and may therefore be associated with thrombus formation. However, as it becomes
increasingly clear that thrombospondin is widely distributed among cell types and
body fluids, more general functions for this protein must be sought. The concentra¬
tions we have found in breast fluids are much higher than elsewhere; the breast may
therefore be the ideal tissue in which to investigate these functions.
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An analysis of the content and morphology of human breast
microcysts
J. M. Dixon, W. N. Scott and W. R. Miller
University Department ofClinical Surgery, Royal Infirmary ofEdinburgh
The composition of 40 human breast microcysts, dissectedfrom eight biopsy and 14 mastectomy specimens
has been analysed. All contained high concentrations of the androgen conjugate, dehydroepiandrosterone
sulphate, the median value being more than 1000 times that ofplasma. In ten cysts sufficientfluid was avail¬
able for cationic analysis and in all the potassium concentration exceeded that of sodium. This composition
suggests an apocrine derivation of the constituents ofbreast microcysts. This is substantiated by thefinding of
PAS diastase positive granules in the epithelium lining all 40 microcysts. Thesefindings indicate that there is a
single population ofbreast microcysts which are lined by epithelium with apocrine secretory activity.
Key words: Fibrocystic disease of breast; hormones; cations; apocrine epithelium.
Introduction
Human breast microcysts which, by definition,
measure less than 3 mm in maximum dimension
are considered to be the precursors of clinically
palpable breast macrocysts.1'2 Two populations of
human breast macrocysts have now been identi¬
fied—these have a different content and are lined
by different types of epithelium.3-6 Little, how¬
ever, is known of the content of human breast
microcysts and, in particular, it is not known if
there exists a single or a dual population. It was
the aim of this study to analyse the content of
human breast microcysts and to determine the
nature of their epithelial lining.
Materials and methods
Forty microcysts were dissected from eight biopsy
and 14 mastectomy specimens before fixation using
a dissecting microscope. In all eight biopsies the
major pathology was cystic disease. A total of 16
macrocysts were present in these eight specimens,
three contained only flattened cysts, three only
apocrine cysts and two had mixtures of both types.
Address for correspondence: Dr J. M. Dixon, University
Department of Clinical Surgery, Royal Infirmary,
Edinburgh, EH3 9YW
The 14 mastectomies were for malignancy. Each
also contained macrocysts, ten only apocrine, one
only flattened and three mixtures of two types. The
40 microcysts were a random sample of the total of
92 microcysts in these specimens. The fluid within
the microcysts was collected after puncture in
calibrated capillary tubes to measure the volume
(range 0-5-20 pi) before dilution in distilled water.
They were stored at — 40°C prior to analysis. The
cyst wall was fixed in 10% formal saline and sub¬
mitted for histological processing, staining and
serial sectioning.
Analysis ofmicrocyst fluid
The DHA sulphate concentration in each of the
40 microcyst fluids was estimated by radioimmuno¬
assay using an antibody previously described.7
Estimations of the concentrations of sodium
(Na+) and potassium (K+) were performed in the
ten fluids where sufficient volume was available
by flame photometry (EEL model 150 flame
photometer) on cyst fluid diluted 1 : 400 in distilled
water.
Histology ofmicrocyst lining
The dissected microcysts were stained by haema-
toxylin and eosin (H & E) and periodic acid Schiff
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Fig. 1. Concentrations of DHA sulphate in 40 breast
microcysts as assessed by radioimmunoassay. For com¬
parison, the ranges and median values (horizontal bars)





Fig. 2. Na+/K+ ratio in the ten microcyst fluids where
sufficient fluid was available for these estimations.
For comparison, the ranges of values for apocrine and










technique after diastase digestion (PAS diastase).
PAS diastase positive granules within cells was
used as a positive method of identifying apocrine
epithelium.2
Results
The concentration of DHA sulphate in fluids from
40 microcysts is shown in Fig. 1. For comparative
purposes, the ranges and median concentrations
of DHA sulphate in apocrine and flattened epi¬
thelial macrocysts are included. All microcyst
fluids contained levels of DHA sulphate at least
ten times greater than the upper limit of normal
for plasma3 and the median value was almost 1000
times greater than that in plasma. Fluids from
more than half the microcysts contained con¬
centrations of DHA sulphate greater than that
seen in any macrocysts. No microcyst had a DHA
sulphate levels within the range of flattened epi¬
thelial macrocysts.
All ten microcyst fluids analysed for Na+ and
K+ contained concentrations of K+ in excess of
those of Na + . The Na+/K+ ratio of these ten
fluids is compared with that of apocrine and flat¬
tened macrocysts in Fig. 2. The Na+/K+ values
for microcysts were all within the range seen in
apocrine macrocysts.
All 40 microcysts were lined by epithelium
which showed some apocrine features. The lining
cells were frequently columnar and had apical
snouts (Fig. 3) but, in others, the epithelium was
cuboidal. The epithelium lining all microcysts
contained PAS diastase positive granules at their
luminal margin (Fig. 4).
Discussion
There exists two major populations of breast
macrocysts which differ in both fluid composition
and morphology of the lining epithelium.3-6 One
population of cysts is lined by apocrine epithelium
and contains fluid high in DHA sulphate and K +
and the other is lined by flattened epithelium and
has low concentrations of DHA sulphate and K +
but high levels of Na + . Only a single population
of their precursors has been identified in this study
and these are lined by epithelium with apocrine
features. In keeping with this, microcysts also
contain fluid with high concentrations of DHA
sulphate and K + . If all macrocysts are derived
from this single population of microcysts, it
remains to determine which factors determine
whether a microcyst retains its active secretory
lining when it enlarges into a palpable breast cyst.
Recent work has shown that patients with
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Fig. i. Histology of a human breast microcyst. Note the columnar epithelium and the apical snouts (H & E x 40).
Fig. 4. Histology of the epithelium lining breast microcysts stained to show the glycolipid granules within the
lining cells (PAS diastase x 200).
apocrine cysts are more likely to (1) have multiple
cysts,9 (2) develop further cysts9 and (3) be at
greater risk of subsequent breast cancer.10 If there
is only a single population of microcysts, as has
been shown in the present study, then it may be
that the same genetic or humoral factors which are
related to multiplicity and cancer risk10 determine
whether a microcyst will develop into an apocrine
or flattened macrocyst.
It has been considered that at least some breast
cysts arise as a consequence of lobular dilatation
and build-up of lobular secretions.11 Studies of
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breast secretions have shown that, although they
contain high concentrations of DHA sulphate,
Na+ is the predominant cation, a composition
different from both macro and microcysts. Simple
blockage of the outflow of lobules with build-up
of secretion resulting in microcyst formation is
therefore unlikely. This study suggests that the
important step in cyst formation is the develop¬
ment of epithelium with marked apocrine activity
within the breast lobule. This is supported by
the finding that in the early stages of microcyst
formation, uniform apocrine change appears in
the lobules involved.12
The finding of concentrations of androgen con¬
jugates up to one thousand times higher than that
in plasma shows that the hormonal micro environ¬
ment of the breast is very different from that in
plasma. The fact that the two differ so markedly
may partly explain why studies of hormones in
plasma and urine have failed to show consistent
differences between controls and those with breast
disease. Further studies are now required to
determine whether measurements of hormones
and their conjugates in breast fluids may provide a
more direct link between hormones and diseases of
the breast.
Acknowledgements
Thanks are accorded to Dr T. J. Anderson and
Dr Joan Lamb, Department of Pathology, Univer¬
sity of Edinburgh for the provision of the dissect¬
ing microscope and for assessing the epithelium
lining the microcysts. J. M. Dixon is a Wellcome
Surgical Fellow and acknowledges the support of
the Wellcome Trust.
References
1. Haagensen CD. Diseases of the Breast. Philadelphia,
WB Saunders, 1971.
2. Schwartz GF. Cystic disease: a definition. In: Angeli
A, Bradlow HL, Dogliotti L eds. Endocrinology of
Cystic Breast Disease. New York: Raven Press,
1983: 1-6.
3. Dixon JM, Miller WR, Scott WN, Steele RJC,
Forrest APM. Subpopulations of human breast
cysts as defined by sodium, potassium and dehydro-
epiandrosterone sulphate content. Langenbecks Arch
Chir 1982; 357: 195.
4. Dixon JM, Miller WR, Scott WN. The morphologi¬
cal basis of human breast cyst populations. Br J Surg
1983;70:604-6.
5. Dixon JM, Miller WR, Yap PL, Scott WN, Forrest
APM. Further studies on human breast cyst fluid. Br
J Surg 1983; 70: 684.
6. Miller WR, Dixon JM, Scott WN, Forrest APM.
Classification of human breast cysts according to
electrolyte and androgen conjugate composition.
Clin Oncol 1983; 9:227-32.
7. Miller WR, Humeniuk V, Kelly RW. Dehydro-
epiandrosterone sulphate in breast secretions. J
Steroid Biochem 1980; 13: 145-51.
8. Azzopardi JG. Problems in Breast Pathology.
London: WB Saunders, 1979.
9. Dixon JM, Miller WR, Scott WN. Natural history
of cystic disease: the importance of cyst type. Br J
Surg 1985; 72: 190-2.
10. Dixon JM, Lumsden AB, Miller WR. The relation¬
ship of cyst type to risk factors for breast cancer and
subsequent breast cancer development. Eur J Cancer
Clin Oncol (in press).
11. Wellings SR. Development of human breast cancer.
Adv Cancer Res 1980; 31: 287-314.
12. Vilanova JR, Simon R, Alvarez J, Rivera-Pomar
JM. Early apocrine change in hyperplastic cystic dis¬
ease. Histopathology 1983; 7: 693-8.
Acceptedfor publication 9 February 1985
SECTION E
MARKERS OF TUMOUR BEHAVIOUR
hi
Europ. J. Cancer Vol. 13, pp. 223-228. Pergamon Press 1977. Printed in Great Britain
Oestrogen Receptor Activity and
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Abstract—-Oestrogen receptor activity (unfilled sites) has been determined in DMBA-
induced rat mammary tumours and at sacrifice, theplasma concentrations ofoestradiol-17/1
and prolactin were determined by radioimmunoassay.
In intact animals, receptor levels were found to fluctuate in inverse relationship with
the plasma oestrogen concentration, but following ovariectomy, levels were significantly
reduced. Administration ofoestrogen to ovariectomized animals did not detectably change
receptor levels but administration ofperphenazine significantly increased receptor levels
towards those seen in intact animals.
In animals bearing two or more tumours, similar receptor concentrations were detected
in tumours from the same animal.
It is concluded that the concentration of oestrogen receptor sites in rat mammary
tumours is influenced by the circulating levels of both oestrogen and prolactin.
INTRODUCTION
DMBA-induced rat mammary tumours, like
some human breast cancers, are hormone-
sensitive [1]. They contain receptors for
oestrogen [2-6], prolactin [7, 8] and pro¬
gesterone [9]. The oestrogen receptors in these
rat tumours have been shown to be similar to
those in human breast cancers chemically [10]
and in their relation to response to endocrine
surgery [4], Prior to evaluating further the
relationship between receptor measurements
and the endocrine responsiveness of experi¬
mental mammary tumours, we have investi¬
gated the influence of endocrine status on the
level of receptor activity.
MATERIAL AND METHODS
Tumours
Female Sprague-Dawley rats were given
DMBA (30 mg) by intragastric instillation.
Tumours induced within 6 months were
measured with calipers twice weekly. Size was
expressed as the product of measurements in
two dimensions. On reaching 1-5 x 1-5 cm
tumours were either studied directly or sub¬
jected to endocrine manipulation prior to
Accepted 15 September 1976.
receptor assay. Tumours were excised after
exsanguination of the rat under ether anaes¬
thesia. Vaginal smears were taken daily from
45 intact animals and the stage in the oestrous
cycle was classified as described by Yoshinaga
et al. [11].
Endocrine manipulation
Fourteen tumour-bearing rats were injected
subcutaneously (s.c.) with perphenazine (5 mg/
kg body weight) for 14 days.
A further 57 tumour-bearing rats were
ovariectomized under ether anaesthesia and
divided into three groups which were treated
differently. In one group (OVX) of 11 rats, no
further treatment was given until sacrifice
14 days later. In a second group (OVX +
OE2), 33 animals were left for 9-14 days and
then injected s.c. with oestradiol 17-/5 (1-5 mg
day in corn oil) for a further 6 days. In the
third (OVX + Perphen) 13 animals were
treated either immediately (9 rats) or after a
period of 6-13 days of no treatment (4 rats)
by subcutaneous injection of perphenazine
(5 mg/kg body weight) for 6-14 days.
Multiple tumours in the same rat
In a total of 24 animals in various reproduc¬
tive states (intact or endocrine manipulated),
223
224 R. A. Hawkins et al.
oestrogen receptor activity was determined in
two or more tumours from the same animal.
Determination of oestrogen receptor concentration
Tumour receptor concentrations were deter¬
mined by a modification of a method described
previously [12]. This modification was neces¬
sary to improve assay precision since by the
original method, the low concentrations of
receptor activity encountered in rat tumours
lead frequently to non-linearity of the resulting
Scatchard [13] graph.
Tumours were left in Tris buffer solution
(0-25 M sucrose, 10 mM Tris and 1 mM ethy¬
lene diamine tetra-acetate pH 8-0) containing
0-5 mM dithiothreitol (14) for 1 hr at 4°C
prior to homogenization at the rate of 300 mg/
ml of Tris buffer and centrifugation of the
homogenate at 105,000 g for 50 min (based on
15). The resulting cytosol was subjected to
saturation analysis as previously described [12].
Determination ofplasma hormone levels
Animals were exsanguinated at death
through the abdominal aorta under ether
anaesthesia, and the blood was used for the
determination of plasma oestradiol-17/f and
plasma prolactin concentrations [16]. Since the
quantity of blood collected was sometimes
limited, assay sensitivity for plasma oestradiol-
17P calculated for 4-0 ml plasma, was 0-13 ng/
100 ml.
For plasma prolactin assay, 12 5I-iodo-pro-
lactin was prepared by the method of Redshaw
and Lynch [17] a procedure which we found
more reproducible than that previously em¬
ployed. The sensitivity for 22 assays varied
from 1 to 7-6 ng prolactin/ml with a mean
value of 3-3 ng/ml. Inevitable deterioration of
prolactin standard occurs on storage (NIAMDD
instructions) and a correction for this has been
made using the quality control data, a pro¬
cedure which results in slightly lower values
than those we reported previously.
Determination of cytosol protein concentrations
Protein concentration was determined by the
method of Lowry, Rosebrough, Farr and
Randall [18] using bovine serum albumin as
standard.
Statistical analysis
Except where otherwise stated, statistical
evaluation was carried out by the Wilcoxon
rank test.
RESULTS
For most rat mammary tumours, the dis¬
sociation constant of binding (Kd) was found
to be 0-4—0-5 x 10"10 molar (see Table 1), in
agreement with our earlier report [12].
The values found for tumour receptor
concentration (P0) by the method described
in this paper are, however, 1-67 + 0-29 (s.e.,
N = 11) times lower than those derived by the
earlier method. By the modified method, a
linear Scatchard plot was obtained for most of
the tumours examined, and tumours with ap¬
parent receptor concentrations down to
0-05 fmoles/mg tissue clearly showed increasing
displacement of (3H) oestradiol-17/f with
increasing mass of non-radioactive oestradiol-
17/1 added.
Effect of the oestrous cycle on tumour receptor concen¬
tration
In 45 cycling rats, tumour receptor concen¬
tration varied during the oestrous cycle (Fig. 1
and Table 1) reaching a minimum in proestrous
which was significantly lower than the values
in all other stages in the cycle (P < 0-01), and
stage of oestrus cycle
Fig. 1. The effect of stage in the oestrous cycle upon tumour
oestrogen receptor concentration and plasma oestradiol-\lji
concentration. Each circle represents the oestrogen receptor
concentration in an individual tumour. Lines join the mean
receptor concentration ( ) and mean plasma oestradiol-17ft
concentration ( ). The standard errors for plasma
oestradiol-\7p concentration have been omitted for clarity but
are to be found in Table 1.
a maximum in metoestrus. The changes in
receptor concentration were in inverse relation
to those in plasma oestradiol~17/f (Fig. 1). The
changes in plasma prolactin concentration
followed, with a delay, those in oestradiol-17/1
but did not reach statistically significant levels.
Effect of ovariectomy and oestrogen administration
Following ovariectomy, tumour receptor
concentrations (Fig. 2) and the plasma levels
of both prolactin and oestradiol-17/1 (Table 1)
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restoration of prolactin levels to those seen in
intact animals (Table 1).
Effect ofperphenazine administration
Tumour concentrations of receptor activity
in untreated rats were compared with the values
in perphenazine-treated rats for both intact and
ovariectomized states. The results are shown in
Fig. 3 and Table 1.
In the intact animal, neither the mean
tumour receptor concentration nor 4he plasma
ocstradiol-17/I concentration after perphena-
zine-treatment was significantly different from
the value found in untreated animals in
dioestrus. Although perphenazine-treatment
significantly increased the plasma prolactin
concentration over the value found in untreated
rats in dioestrus (P < 0-01), the increased
concentration was not significantly greater than
the highest concentration observed in untreated
animals at proestrus.
In ovariectomized animals, perphenazine-
treatment caused a significant elevation in
plasma prolactin concentration and in tumour
receptor concentration (P < 0-01), whilst dis¬
sociation constant of oestrogen binding by the
Table 1. Tumour receptor concentrations and plasma hormone levels in tumour-bearing rats in various endocrine states
Tumour receptor activity Plasma
No. Po P0, protein Oestradiol-
Reproductive of No. Kd (fmoles/mg) (fmoles/mg) 17/? Prolactin
state rats of tumours (x 10-loM) (tissue) (protein) (ng/100ml) (ng/ml)
Sensitivity* — 0-05 1 0-13 3
Intact proestrus 10 13 0-64 1-21 34 4-70 54
± 0T0 ±0-20 ±7 ±0-69 ± 16
oestrus 9 10 0-53 2-42f 58+ 0-41 f 51
±0-04 + 0-23 + 8 ±0-15 ±7
metoestrus 11 11 0-40 § 3-77f 94+ 0-32f 35
±0-03 ±0-60 ±25 ±0-07 ±6
dioestrus 13 17 0-49 2-70f 70 0-70f 26
±0-05 ±0-27 ±11 ±0-17 ±6
Intact + per¬ 14 19 0-39 3-11 72 0-43 77f
phenazine ±0-03 ±0-30 ± 11 ±0-08 ± 16
(dioestrus)
Ovariectomised 11 15 0-72 0-94 23 0-13 12
ovx ±0-11 ±0-17 ±5 ±0-02 ±2
ovx+oe2 33 36 0-62 1-00 22 0-26 40f
+ 0-05 ±0-11 ±3 ±0-05 ±6
ovx + per¬ 13 16 0-42f 1-86 44 0-16 59f
phenazine ±0-005 ±0-19 ±6 ±0-03 ±11
Results are the mean values ± 1 standard error.
♦Sensitivity defined as described under "Methods and Materials" and first section of results.
1P < 0-01, %P < 0-02, §P < 0-05 when compared with appropriate reference value:
during oestrous cycle, values compared with that in proestrus; "Intact + perphenazine" values compared with
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Fig. 2. The effects ofovariectomy and ofovariectomyfollowed
by administration ofoestradiol-17/? on tumour receptor activity.
The values for the tumours from the intact animals shown in
Fig. 1 are reproduced for comparison. Each circle represents
the valuefor an individual tumour P values refer to comparison
with the concentrations in ovariectomised animals.
were significantly diminished relative to the
values found in the tumours of intact animals
(P < 0-01).
Administration of oestrogen to ovariec¬
tomized rats caused an insignificant increase in
detectable receptor activity (Fig. 2), and a
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tumour was significantly reduced (P < 0-01)
following perphenazine-treatment. No differ¬
ences were noted between the values found for
rats treated immediately after ovariectomy and
those in which the start of treatment was
delayed: accordingly the data for these two,














Fig. 3. The effect of perphenazine-administration in vivo
upon tumour oestrogen receptor concentration in (a) ovari-
ectomised and (b) intact rats. Each circle represents the value
from, an individual tumour. P values refer to the effect of
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Fig. 4. Tumour receptor concentrations in rats bearing 2
tumours: receptor concentration for one tumour, A is plotted
against that for the second tumour, B from the same rat. The
rats were sacrificed in various reproductive states. Each circle
represents the value from a single rat.
Receptor concentrations in multiple tumours from the
same rat
When two or more tumours from the same
animal were examined, the receptor concen¬
tration found for one tumour ("A") was more
or less identical to the value for a second
tumour ("B") from the same animal (Fig. 4).
For animals with more than two tumours, only
two values, selected by random selection (tables
of random numbers), have been plotted.
In most cases, tumours from the same animal
contained very similar concentrations of oestro¬
gen receptors. By the Rank Correlation test,
there was a highly significant (P < 0-01)
correlation between the receptor levels in
tumours from the same animal.
DISCUSSION
Oestrogen receptor activity has been deter¬
mined in mammary tumours of the rat in
various endocrine states. It was found necessary
to modify the method previously employed
[12] in three respects (based on 14 and 15) to
permit accurate determination of the relatively
low concentration of receptor binding sites
present in these tissues. By this modified
method, oestrogen receptor activity was de¬
tected in 98-5% of the 136 DMBA-induced
mammary tumours examined. The receptor
activity in these tumours was characterized by
a dissociation constant of binding ranging from
0T6-T80 x 10"10 molar, and in most tumours
dissociation constant was in the range 04—
0-5 x 10~10 molar.
The range of oestrogen receptor concentra¬
tions encountered in rat mammary tumours
is approximately ten times lower than that
found in human breast cancers [12]. A similar
difference is seen between the concentrations
of plasma oestradiol-17/i in the two species
[16, 19],
Although most methods for determining
oestrogen receptor concentrations detect only
empty receptor sites, in general workers do not
report the stage in the cycle at which tumours
have been harvested for receptor assay or
estimate plasma oestrogens at the time the
tumour is harvested. We have shown that
receptor concentrations fluctuate in inverse
relationship with the prevailing oestradiol-17/1
concentration, and that the tumour receptor
concentration is a function of the stage in the
oestrous cycle at which the tumour was excised.
This finding is in contrast to the recent work
of Jordan and Jasper [20] who conducted
receptor assays at 30°C, a temperature at
which exchange between (3H) oestradiol-17/?
and endogenous oestrogen at filled receptor
sites might occur. However, our results agree
with those of Lee and Jacobson [21] and of
Trams, Engel, Lehmann and Maass [22] in the
rat and human uterus respectively, and of
Maass, Engel, Nowakowski, Stolzenbach and
Trams [23] in human breast cancer.
It is known that the effects of oestrogen upon
the oestrogen receptor concentration within a
tissue are complex: cytoplasmic receptor levels
can be altered by increases in circulating
oestrogen in two ways. In addition to (i)
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filling empty receptors, which are then trans¬
located to the cell nucleus, oestrogen may also
(ii) stimulate the synthesis of new receptors
[24, 25]. Our observations that tumour recep¬
tor levels firstly vary during the oestrous cycle
and secondly, fall after ovariectomy, are,
respectively, in keeping with these two effects.
In the rat, changes in circulating oestrogen
level can also lead to alterations in the concen¬
tration of plasma prolactin (see e.g. [26].) This
hormone has also been reported to influence
oestrogen receptor levels in the rat mammary
tumour [27-29], In view of this, it is difficult
to ascribe changes in receptor level to the effect
of a single hormone. Nevertheless, in intact
cycling animals, the tumour levels of detectable
receptor activity found in this study were
inversely related to changes in circulating
oestradiol-17/1 concentration and apparently
unrelated to changes in plasma prolactin
concentration.
In the ovariectomised rats treated with
perphenazine, tumour receptor levels were
clearly elevated in association with a significant
increase in prolactin secretion, but in the ab¬
sence of detectable oestrogen. This effect of
prolactin on oestrogen receptor levels is in
agreement with the findings of Leung and
Sasaki [27, 28] and of Vignon and Rochefort
[29]. Although perphenazine-treatment in
ovariectomised rats also increased the affinity
of the receptors for oestrogen (see Table 1),
this apparent difference probably reflects the
less accurate determination of Kd at low
receptor levels rather than a specific effect of
prolactin.
In ovariectomised rats treated with oestrogen,
tumour receptor levels were not detectably
changed relative to untreated controls, possibly
due to the filling of empty sites by the injected
oestrogen. The failure to detect any effect of
perphenazine-treatment upon tumour receptor
levels in intact animals may either be due to the
fact that the plasma prolactin concentrations
found after treatment were not significantly
greater than those found in untreated animals
at proestrus and oestrus, or may indicate that
the latter concentrations are already sufficient
to maximally stimulate tumour receptor forma¬
tion.
In animals bearing two or more tumours,
despite the existence of a different clone of cells
in each tumour, receptor levels were strongly
correlated between tumours from the same
animal, indicating that the endocrine milieu
may be the major determinant of tumour
receptor level.
These results support the view that endocrine
status markedly influences tumour receptor
level. In particular, we have indicated that
oestrogen receptor levels may be increased by
prolactin or reduced by the filling of empty
receptor sites with oestrogen. If a similar
situation obtains in women with breast cancer,
then endocrine status at biopsy for receptor
assay would influence the receptor levels
detected and hence the predictive value of this
parameter. The adoption of an exchange assay
for measuring total cellular receptors should
help by reducing the effect of circulating
oestrogens on detectable receptor level for (i)
clinical, predictive purposes and (ii) separating
the effects of oestrogen and prolactin on recep¬
tor levels in the rat mammary tumour model.
Acknowledgements—We thank Mrs. Dorothy Gray
for her expert assistance and the Cancer Research
Campaign for Grant No. SP1256. We also thank
Miss Sheila Gore, Medical Computing and Statistics
Group for statistical advice.
We are grateful to the NIAMDD rat pituitary
hormone distribution program as the sole source of our
prolactin reagents and to Drs. A. E. Bolton and W.
Hunter of the Radioimmunoassay Team, Forrest
Road, Edinburgh for anti-oestradiol-17/1 serum.
REFERENCES
1. C. Huggins, G. Briziarelli and H. Sutton, Rapid induction of mammary
carcinoma in the rat and the influence of hormones on the tumours. J. exp.
Med. 109, 25 (1059).
2. R. J. B. King, D. M. Cowan and D. R. Inman, The uptake of (6, 7-3H)
oestradiol by dimethylbenzanthracene-induced rat mammary tumours.
J. Endocr. 32, 83 (1965).
3. B. G. Mobbs, The uptake of tritiated oestradiol by dimethylbenzanthracene
induced mammary tumours of the rat. J. Endocr. 36, 409 (1966).
4. E. V. Jensen, E. R. DeSombre and P. W. Jungblut, Estrogen receptors in
hormone responsive tissues and tumours in Endogenous Factors influencing
post-tumor balance (Edited by R. W. Wissler, T. L. Dao and S. Wood) p. 15,
University Chicago Press, Chicago (1967).
5. S. Sander and A. Attramadal, The in vivo uptake of oestradiol-17/i by
hormone responsive and unresponsive breast tumours of the rat. Acta path,
microbiol. scand. 74, 169 (1968).
228 R. A. Hawkins et al.
6. W. L. McGuire and J. A. Julian, Comparison of macromolecular binding of
estradiol in hormone-dependent and hormone-independent rat mammary
carcinoma. Cancer Res. 31, 1440 (1971).
7. P. A. Kelly, C. Bradley, R. P. C. Smith, J. Meites and H. G. Friesen,
Prolactin binding to rat mammary tumour tissue. Proc. Soc. exp. Biol. (N.Y.)
146, 816 (1974).
8. M. E. Costlow, R. A. Buschow and W. L. McGuire, Prolactin receptors in
an estrogen receptor-deficient mammary carcinoma. Science 184, 85 (1974).
9. L. Terenius, Estrogen and progestogen binders in human and rat mammary
carcinoma. Europ. J. Cancer 9, 291 (1973).
10. W. L. McGuire and M. de la Garza, Similarity of the estrogen receptor in
human and rat mammary carcinoma. J. clin. Endocr. 36, 548 (1973).
11. K. Yoshinga, R. A. Hawkins and J. F. Stocker. Estrogen secretion by the rat
ovary in vivo during the estrous cycle and pregnancy. Endocrinology 85, 103
(1969).
12. R. A. Hawkins, A. Hill and B. Freedman, A simple method for the deter¬
mination of oestrogen receptor concentrations in breast tumours and other
tissues. Clin. chim. Acta 64, 225 (1975).
13. G. Scatchard, The attraction of proteins for small molecules and ions.
Ann. N.Y. Acad. Sci. 51, 660 (1949).
14. W. L. McGuire and M. de la Garza, Improved sensitivity in the measure¬
ment of estrogen receptor in human breast cancer. J. clin. Endocr. (N.Y.) 37,
986 (1973).
15. W. L. McGuire, J. A. Julian and G. C. Chamness, A dissociation between
ovarian dependent growth and estrogen sensitivity in mammary carcinoma.
Endocrinology 89, 969 (1971).
16. R. A. Hawkins, B. Freedman, A. Marshall and E. Killen, Oestradiol-17/?
and prolactin levels in rat peripheral plasma. Brit. J. Cancer 32, 179 (1975).
17. M. R. Redshaw and S. S. Lynch, An improved method for the preparation
of iodinated antigens for radioimmunoassay. J. Endocr. 60, 527 (1974).
18. O. H. Lowry, N. J. Rosebrough, A. L. Farr and R. J. Randall, Protein
measurement with the Folin phenol reagent. J. biol. Chem. 193, 265 (1951).
19. R. A. Hawkins and R. E. Oakey, Estimation ofoestrone sulphate, oestradiol-
17B and oestrone in peripheral plasma concentrations during the menstrual
cycle and in men. J. Endocr. 60, 3 (1974).
20. V. C.Jordan and T. Jasper, Tamoxifen as an anti-tumor agent: oestrogen
binding as a predictive test for tumor response. J. Endocr. 68, 453 (1976).
21. C. Lee and H. I. Jacobson, Uterine estrogen receptor in rats during pubescence
and the estrous cycle. Endocrinology 88, 596 (1971).
22. G. Trams, B. Engel, G. Lehmann and H. Maass, Specific binding of oestradiol
in human uterine tissue. Acta endocr. (Kbh). 72, 351 (1973).
23. H. Maass, B. Engel, H. Nowakowski, G. Stolzenbach and G. Trams,
Estrogen receptors in human breast cancer and clinical correlations. Estrogen
Receptor in Human Breast Cancer (Edited by W. L. McGuire, P. P. Carbone
and E. P. Vollmer) p. 175. Raven Press, New York (1975).
24. M. Sarf and J. Gorski, Control of estrogen binding protein concentration
under basal conditions and after estrogen administration. Biochemistry 10,
2557 (1971).
25. E. E. Baulieu, Aspects of steroid receptor biochemistry. In Breast Cancer: Trends
in Research and Treatment, Monograph No. 2 (Edited by J. C. Heuson, W.
Mattheiem and M. Rozencweig). Raven Press, New York. In press.
26. P. S. Kalra, C. P. Fawcett, L. Krulich and S. M. McCann, The effects
of gonodal steroids on plasma gonadotrophins and prolactin in the rat. Endo¬
crinology 92, 1256 (1973).
27. B. S. Leung and G. H. Sasaki, Prolactin and progesterone effects on specific
estradiol binding in uterine and mammary tissues in vitro. Biochem. biophys.
Res. Commun. 55, 1180 (1973).
28. B. S. Leung and G. H. Sasaki, On the mechanism of prolactin and estrogen
action in 7, 12 dimethylbenz (a) anthracene-induced mammary carcinoma in
the rat II. In vivo tumour responses and estrogen receptor. Endocrinology 97,
564, (1975)
29. F. Vignon and H. Rochefort, Regulation des recepteurs des oestrogenes dans
les tumeurs mammaires: effet de la prolactine in vivo. C. R. Acad. Sci. 278, 103
(1974).
84 R. A. Hawkins et al.
Endocrine manipulation and assessment oj ovary-
dependence
In order to assess ovary-dependence/indep¬
endence, the tumours in one group of animals
(group a) were measured at intervals with
calipers belore and after bilateral ovariectomy
under ether anaesthesia. Tumour size was ex¬
pressed as the product of measurements in two
dimensions.
For a second group of animals (group b)
tumours were measured belore and during
sequential manipulation by ovariectomy, no
treatment lor 10 days and oestradiol-17B admin¬
istration for 6 days (1-5 jug/day s.c. in oil).
Ovary-independent tumours were defined as those
tumours which continued to increase in size lor
the period ofstudy lollowing ovariectomy (usua-
11 \ in >30°,, over 9-14 davs).
Ovary-dependent tumours were classified either
as those tumours showing a continuous decrease
in size lor the period lollowing ovariectomy
(usually St 50% over 9-14 days)—group (a), or
where animals were subsequently lurther treated
by oestrogen administration, as those tumours
regressing upon ovariectomy and clearly regrow-
ing upon oestrogen administration—group (b).
Tumours showing extensive necrosis, changes
due to a large cystic fluid content, or equivocal
growth patterns were regarded as unassessable
and were excluded.
Tumour receptor concentration in intact and ovariecto¬
mised rats bearing transplantable tumours
In an initial experiment, receptor concen¬
trations were determined in the tumours from 23
intact, cycling animals (7 TG3, 10 TG5 and
6 TG6). A lurther 17 rats bearing 23 trans¬
plantable tumours (11 TG3, 11 TG5 and 1 TG6)
were ovariectomised and left for 14 days prior to
sacrifice and determination of tumour receptor
concentration.
Comparison oj receptor concentrations in transplantable
tumours and DMBA-induced tumours
In a second study, receptor concentrations in 2
lines of transplantable tumours (TG3 and TG5)
were compared with those in DMBA-induced
tumours in each of 3 endocrine states.
For receptor assay, tumours were excised from;
(a) 21 ovariectomised rats (6 regressing,
DMBA-induced tumours and 15 growing,
transplantable tumours, 8 TG3, 7 TG5);
(b) 21 rats treated by ovariectomy and sub¬
sequent administration of oestradiol-17B
(15 DMBA-induced tumours showing re¬
gression followed by regrowth, and 6
transplantable tumours showing con¬
tinuous growth i.e. 1TG3, 5TG5);
(c) 22 intact, cycling rats (10 DMBA-induced
tumours, 12 transplantable tumours i.e. 10
TG3, 2 TG5).
Thus in groups (a) and (b), only animals
showing clearly ovary-independent growth for a
DMBA-induced tumour, or clearly ovary-
independent growth lor a transplantable tumour
were examined. In group (c) the tumour speci¬
men lor assay was removed by biopsy (in oestrus,
metoestrus or dioestrus, but not proestrus) under
ether anaesthesia and the animals were then left
approximately 14 days and ovariectomised.
However, it was not possible to determine
the ovary-dependence/independence of these
tumours since the biopsy procedure alone
frequently disturbed the growth of the tumour.
Measurement of plasma oestradiol-\lB and prolactin
concentrations
At sacrifice, the animals were bled through the
abdominal aorta under ether anaesthesia. In all
rats except group (c), bleeding preceded tumour
excision, but in group (c), biopsy specimens of
tumour were taken and animals were not sacri¬
ficed until approximately 4 weeks later.
Plasma was separated by centrifugation at 4°C
and stored at — 2CFC for radioimmunoassay by
methods previously described [7]. The sensiti¬
vities of these assays were calculated to be 3 ng
prolactin/ml plasma and 0.13 ng oestradiol-
17B/100 ml plasma when analyses were con¬
ducted on duplicate, 0.1 ml and single, 4.0 ml
samples of plasma respectively.
Determination oj oestrogen receptor concentration
Tumour tissue, removed either by biopsy
under ether anaesthesia [group (c) only] or after
killing by exsanguination, was placed in Tris
buffer containing dithiothreitol (0.25 M sucrose
10 mM Tris, 1 mM ethylene diamine tetra¬
acetate, 0.5 mM dithiothreitol, pH 8.0) and
stored on ice for 1 hr. The concentration of
oestrogen receptors in each tumour was measured
by a method described previously [6],
Briefly, 600-800 mg tumour was trimmed free
of adhering tissue and capsule at 4°C, cut up
finely with scissors and homogenized in an ice-
cooled tube at the rate of 300 mg/ml buffer, using
a Silverson homogenizer (1 x 20 sec, 1x15 sec at
maximum speed with a 45 sec interval for cooling
between bursts). The resulting homogenate was
centrifuged at 105,000 x g for 50 min to yield a
clear cytosol. Portions (0.1 ml) of cytosol were
incubated, in duplicate, at 4°C with 10 pg
[3H]oestradiol-l 7B (5060 counts/min) and vary¬
ing quantities of non-radioactive oestradiol-17B
(0, 10, 30, 50, 70, 90 and 20,000 pg) in a total
volume of 1.2 ml Tris buffer (composition as
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above except that dithiothreitol was omitted).
After overnight equilibrium, free oestradiol-17B
was removed by the addition of 0.5 ml charcoal
suspension (0.15% charcoal,0.0015% dextran in
Tris buffer w/v), further incubation at 4°C for 15
min and centrifugation for 10 min at 4°C.
The protein-bound fraction was decanted into
5 ml organic scintillator solution for determi¬
nation of 3H activity. After correction for non¬
specific binding using the mean value for the
20,000 pg tubes, the data was analysed according
to Scatchard [8] to derive the dissociation
constant ofbinding (Aj) and the concentration of
receptor sites (P0). The latter was expressed both
as fmole binding sites/mg wet tumour and as
fmole binding sites/mg cytosol protein, using the
protein concentration of the cytosol found on
measurement by the method of Lowry,
Rosebrough, Farr and Randall [9].
The sensitivity of the method was empirically
delined as 0.05 lmole/mg wet tumour or 1
fmole/mg cytosol protein, since a clearly increas¬
ing displacement of [3H] oestradiol-17B with
increasing mass of non-radioactive oestradiol-
17B present was generally observed above this
receptor level.
Statistics
The significance of differences in receptor
concentrations was evaluated by the Wilcoxon
rank test.
RESULTS
Tumour receptor concentrations in intact rats
Low, but detectable levels of oestrogen re¬
ceptor activity were found in two of the three lines
of transplantable tumours, i.e. the TG3 and TG5
lines (Table 1). The dissociation constant of
binding was ofthe order of 0.4 x 10 ~10 molar in
each tumour line and no significant difference in
receptor levels was apparent between the two
tumour lines. In the third tumour line. (TG6),
receptor activity was found in only 2 of 6 tumours
examined and the levels detected were extremely
low.
Ejject oj ovariectomy
The efficacy of ovariectomy was confirmed by
the reduction of plasma oestradiol-17B con¬
centrations to the level of the sensitivity of the
assay (Table 1). Prolactin concentrations were
also significantly reduced in 2 of the groups of rats
bearing tumours (TG3 and TG5) and the
apparent rise in prolactin level in the one rat
bearing a TG6 tumour which was examined after
ovariectomy is probably a spurious result (Table
1).
Despite these changes in plasma hormone
concentrations following ovariectomy, no signi¬
ficant change in receptor level was observed in
either TG3 or TG5 lines of tumours (Table 1, Fig.
2).
Comparison oj receptor levels in transplantable tumours
(iovary-independent) with levels in ovary-dependent,
DMBA-induced tumours
Receptor levels in the transplantable tumours
were compared with those in DMBA-induced
tumours obtained from animals in each of three
endocrine states. Firstly, 14 days after ovariec¬
tomy, (Fig. 3a), receptor concentrations were
significantly (P<0.05) higher in DMBA-
induced tumours which regressed than in the
tumours (non-regressed) of either TG3 or TG5
transplanted line, though there was a consider¬
able overlap between groups. Secondly, when
tumour-bearing animals were subjected to
ovariectomy and subsequent administration of
oestrogen (Fig. 3b), the receptor concentrations
in ovary-dependent, DMBA-induced tumours
were clearly higher than the concentrations in the
ovary-independent, transplantable tumours (P
<0.01).
Thirdly, receptor concentrations in biopsy
specimens from uncharacterised, DMBA-
induced tumours were also significantly higher
than the values found in transplantable tumours
of either TG3 or TG5 line, though again there was
a considerable overlap between the two types of
tumour. Attempts to separate the biopsied,
DMBA-induced tumours into ovary-dependent
and independent types by their response to
subsequent ovariectomy were unsuccessful: The
biopsy procedure alone generally interfered with
tumour growth.
DISCUSSION
Oestrogen receptor activity has been detected
in low but significant amounts in 2 out of3 lines of
transplantable rat mammary tumours. The two
lines containing low receptor levels maintained
the morphological appearance of adenocarci-
nomata whilst the other tumour line without
detectable activity showed some tendency to
progress towards a sarcoma by the time of the
study. Gala and Peck [10] have described two
transplantable, mammary tumours, ofwhich one
was an adenoma with "high" levels of oestrogen
receptor activity, whilst the other was a sarcoma
devoid of receptor activity.
At the time of study, all three transplantable
tumour lines exhibited ovary-independent
growth. Prior to this work, however, at least one
ofthese lines (TG3) had passed through an ovary-




Fig. 1. The ovary-independentgrowth of3 lines oftransplantablemammary tumours. Tumoursizes were
measuredbefore and after bilateral ovariectomy of2 rats bearing transplantable tumoursTor each tumourIine.
For comparison, the effect ofovariectomy ofthe host upon thegrowth of two typical DMBA-induced tumours
is also illustrated. 0 VX indicates the time ofovariectomy, and measurements are plottedagainst days pre (— )
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Fig. 2. Oestrogen receptor concentrations in each of3 lines oftransplantable mammary tumour. For each
tumour line, receptor concentrations are shown in the tumoursfrom intact andovariectomised hosts. Each circle
represents the value for a single tumour.
dependent phase in the very early generations. A
similar progression from dependence to inde¬
pendence has been reported for certain strains of
transplantable mouse tumour [11] and for other
transplantable rat mammary tumours [12, 13].
The mere presence ofoestrogen receptor activity
in a tumour is thus not an indication of ovary-
dependence, in agreement with the lindings of
others [11, 14-16] though as we have previously
reported [ 17], the growth ofat least some of these
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Fig. 3. Oestrogen receptor concentrations in ovary-independent, transplantable tumours were compared
with valuesfound in DMBA-induced tumours in each of3 endocrine states. In (a), ovariectomised rats and
(ib), rats treated sequentially by ovariectomy and oestradiol administration, open circles denote receptor
concentrations from ovary-dependent, DMBA-induced tumours; in (c), intact animals, open circles
represent receptor concentrations in uncharaeterisedDMBA-induced tumours. Solid circles represent receptor
concentrations in transplantable tumours of the TG3 line, and half-solid circles those in transplantable
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induced induced
tumours is increased following oestrogen admin¬
istration, i.e. is oestrogen-sensitive.
The R3230AC transplantable mammary tu¬
mour is also not ovary-dependent yet is sensitive
to oestrogen [ 18] and similarly contains low levels
of oestrogen receptor activity [14]. According to
Sluyser and Van Nie [11] transplantable mam¬
mary tumours may change from "dependent" to
"responsive" to "independent" tumours, in asso¬
ciation with diminishing receptor levels upon
successive transplantations. Although the data
presented here was too small to show such
significant differences in receptor levels between
generations, it is our impression that the receptor
levels in our TG3 and TG5 fines are also
gradually diminishing with succeeding
transplantations.
In the transplantable tumours studied here
(Table 1), as in the R3230AC tumour [19]
available receptor levels were undiminished by
ovariectomy, though this finding could be the
resultant ofa decrease in total receptor sites and an
increase in the number of available sites, upon
removal of endogenous hormones. In contrast,
the level of available receptor activity tails
significantly after ovariectomy in most DMBA-
induced tumours [6, 20, 21] where both receptor
synthesis and general anabolism may depend on
the presence of the ovary. This fall in available
receptor level in DMBA-induced tumours after
ovariectomy, which we [6] and others (20, 21)
have previously reported, was not seen in present
work [Fig. 3, group (a) vs group (c)], probably
because the receptor levels were measured in
tumours from exsanguinated, ovariectomised
rats (group a) but non-exsanguinated, intact rats
(group c). The presence ofa higher blood content
in the latter type of tumour may account for our
finding of receptor levels lower than those which
we found previously [6] for DMBA-induced
tumours from intact rats, and for the lack of
difference between the values for tumours from
intact and ovariectomised rats, since blood
plasma can markedly suppress the level of
receptor activity detected [22].
Early work with DMBA-induced mammary
tumours implied very clear differences in magni¬
tude of receptor levels between dependent and
independent tumours of the rat [1—5]. More
recently, Costlow, Buschow, Reichcrt and
McGuire [23] also found clearly higher levels of
both oestrogen and prolactin receptor activity in
an ovarv-dependent subline (MD) of a trans¬
plantable mammary tumour (MTW9) than in
an ovary-independent subline (MA). In the
present work, significantly lower mean receptor
concentrations were found in the TG3 and TG5
tumour lines (ovary-independent) than in
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DMBA-induced tumours (80-100% ovary-
dependent) in each of three endocrine states.
However, there was a considerable overlap in
receptor values between the two types of tumour
in intact animals, or in animals treated by
ovariectomy only.
This finding of a less striking difference than
was first proposed is in line with the views of
Mobbs and Johnson [15], Boylan and Wittliff
[16] and DeSombre, Kledzik, Marshall and
Meites [13]. In the latter work, in particular, for
both oestrogen receptors and prolactin receptors,
there was a clear overlap between the con¬
centrations found in dependent and independent
mammary tumours. It is to be noted, however,
that strictly only measurements on biopsy speci¬
mens taken prior to endocrine manipulation
relate to the hormonal sensitivity at that time, and
are comparable to the usual clinical situation
where for prognostic use, biopsy material is taken
before endocrine therapy.
For technical reasons (low incidence of
DMBA-induced tumours in inbred rats, low
transplant-acceptance rate in random-bred
rats), the comparisons made here between
DMBA-induced and transplantable tumours are
complicated by the fact that the tumours were
generated in rats ofdifferent strains. These strains
of rat have different basal levels of prolactin (24,
25 and c.f. values in Table 1 with those in
reference [6]), a hormone which has previously
been shown to modulate tumour receptor levels
[20,21]. Thus it is possible that the lower receptor
levels detected in transplanted tumours may be
related to the lower levels of this hormone which
circulate in our inbred rats, rather than to a lesser
degree ofhormonal sensitivity. This possibility is
currently being investigated.
Irrespective of the origin of this overlap in
receptor concentrations between dependent and
independent rat mammary tumours (e.g. effect
ofstrain, hormonal levels or variation in degree of
hormonal sensitivity) extrapolation of these find¬
ings to the clinical situation would suggest that
predictions based on oestrogen receptor con¬
centrations should be made with caution. Thus at
the present time, only "receptor-negative" tu¬
mours, (i.e. those with receptor levels clearly
below the overlap range) can be accurately
predicted to fail to respond to endocrine therapy.
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Letter to the Editor
Progestogen and Oestrogen Receptor
Activity in Ovary-Dependent and Ovary-
Independent Tumours of the Rat
R. A. HAWKINS, A. TESDALE.* B. FREEDMAN.+ J. TELFORD and W. R. MILLER
Department oj Clinical Surgery,§ University of Edinburgh, Edinburgh, Scotland
Although mammary tumours containing oes¬
trogen receptors are more likely to respond to
endocrine therapy, the presence of the oes¬
trogen receptor does not guarantee hormonal
sensitivity [1, 2]: a critical, minimal con¬
centration of receptors must be present [3-5].
Jensen has used the phrase "oestrogen
receptor-rich" to distinguish such tumours
from those . lacking that concentration,
"receptor-poor". An alternative approach has
been suggested by McGuire and his colleagues
[6], who noted that the synthesis of the
progestogen receptor is oestrogen-dependent
and thus the presence of progestogen receptor
activity is a marker of a functional oestrogen
receptor.
We have now examined three types of rat
mammary tumour for both oestrogen and
progestogen receptor activities: these are two
lines of transplantable mammary tumour,
TG-3 and TG-5, which are now
ovary-independent [7] and dimethyl-
benz[a]anthracene (DMBA)-induced mam¬
mary tumours which are pre¬
dominantly ovary dependent.
Tumours were excised for use when 1.0—
2.5 cm in diameter. Cytosol for receptor ana¬
lysis was prepared as previously described ]9],
except that glycerol (10% v/v) and mono-
thioglycerol (1% v/v) were included in the
homogenisation buffer. Oestrogen receptor ac¬
tivity was determined using lOO^ul portions of
tumour cytosol as previously described [8].
Progestogen receptors were determined by in-
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cubating overnight, on ice, either (a) 50-
200 pt\ cytosol with 0.22 nM [7a-3H]Org-
2058 (sp. act. 18.3 Ci/mmol) + 0.22 — 11.1 nM
non-radioactive Org-2058 in Tris—glycerol
buffer, or (b) 200/A diluted cytosol (1.5 x with
buffer) with 0.5 nM [6, 7-3H] R5020 (sp. act.
56.5 Ci/mmol) + 1—1000 nM non-radioactive
R-5020 in Tris buffer. Free and bound hor¬
mone were separated by adsorption on char¬
coal [(a) 500p\ 0.15%w/v or (b) 400jul
0.625% w/v. The data were analysed accord¬
ing to Scatchard [9],
Sucrose density gradient analysis of the
progestogen receptor was carried out as de¬
scribed for the oestrogen receptor [10] with
minor modifications: glycerol (10% v/v] was
included in the homogenisation buffer and
gradients, and the [3H]progestogen and the
non-radioactive progestogen concentrations
were, respectively, 8 and 32.2 nM for Org-
2058 and 1.4 and 23.6 nM for R-5020.
A total of 31 tumours (17 DMBA-induced,
7 TG-3 transplanted and 7 TG-5 transplan¬
ted) were examined for progestogen receptor
activity using [3H] Org 2058 and for oes¬
trogen receptor activity: in 15 tumours (5 of
each type) progestogen receptor activity was
also determined using [3H] R-5020. The re¬
sults are listed in Table 1. Oestrogen receptors
were detected in all three types of tumour, the
mean level detected being significantly higher
in the DMBA-induced tumours than in either
line of transplantable tumour (P<0.01 by
Wilcoxon Rank Sum test). The average dis¬
sociation constant of binding was 0.22
x 10 10(.A/"= 31, range 0.06-0.68 x 10~10)
molar. Progestogen receptor activity was de¬
tected in one of seven TG-5 transplantable
tumours, in four of seven TG-3 transplantable
tumours and in all seventeen DMBA-induced
tumours when assays were carried out with
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Table 1. Oestrogen and progestogen receptor activities in three types of rat mammary tumour
Oestrogen receptor activity* Progestogen receptor activity*
Using [3H]Org-2058 Using [3H]R5020
Tumour Fraction fmoles/mg Fraction fmoles/mg Fraction fmoles/mg
type R + tumour R + tumour R + tumour
Sensitivity 0.05f — 0.15+ — 0.25§
TG-5 7/7 0.41 1/7 0.18 1/5 1.7
transplants (0.11-0.66) (0-0.18) (0-1.7)
TG-3 7/7 0.46 4/7 0.36 4/5 2.1
transplants (0.31-0.65) (0-0.40) (0-2.1)
DMBA- 17/17 3.24 17/17 26.9 5/5 40.6
induced (0.77-7.08) (0.15-144.9) (7-86)
*Fraction R + =No. tissues with detectable receptor activity/total tissues studied,
fmoles/mg tumour = mean (and range) of concentrations found in R+ tissues.
Sensitivities derived arbitrarily as follows:
(•>50 cpm displaced by addition of excess, nonradioactive steroid.
J > 150 cpm displaced by addition of excess, nonradioactive steroid.
§>200 cpm displaced by addition of excess, nonradioactive steroid.
[3H]Org-2058. There was generally good
qualitative agreement between the results of
the two assays for progestogen receptors using
different ligands, and with [3H] R-5020, levels
were detectable in one of five TG-5 transplan¬
ted tumours, four of five TG-3 transplanted
tumours and all of five DMBA-induced tu¬
mours. The levels of activity were very low in
all the transplanted tumours and in one
(using Org-2058) or two (with R-5020) of the
DMBA-induced tumours. Dissociation con¬
stant of binding was 1.7 x 10"10 molar (mean
?z=19, range 0.25—6.3 x 10"10) with the assay
employing Org-2058, and 8.6x10"10 molar
with that employing R-5020. Quantitatively,
progestogen receptor levels were considerably
higher in the DMBA-induced tumours than in
the transplantable tumour lines (P<0.01 by
Wilcoxon Rank test).
The progestogen receptor extracted from
DMBA-induced tumours was found to have a
sedimentation constant of approximately 8—9s
using either radioligand, but no peak in bind¬
ing of [3H] progestogen could be demo¬
nstrated in the transplantable tumours.
Amongst various compounds examined, only
progestogen competed with [3H]Org-2058 for
binding to cytosol from a DMBA-induced
tumour; the binding specificity of [3H] R-5020
is already well established [11, 12]. In our
hands, these two progestogens were effectively
equipotent (Relative Binding Affinities: R5020
96%, Org-2058 100% using [3H]Org-2058,
and R5020 100%, Org-2058 100% using
[3H]R5020). Neither progestogen bound de-
tectably to cytosol, prepared from the prostate
of a male rat and containing androgen
receptors.
In our previous studies of oestrogen re¬
ceptor activity [7, 8, 10], oestrogen translo¬
cation [13], steroid metabolism [14, 15] and
sensitivity to hormones in culture [16] in these
tumour types, we have not found such a
striking difference as that seen here: whilst
oestrogen receptor levels were seven times
higher in the predominantly ovary-dependent,
DMBA-induced tumours than in the ovary-
independent transplantable tumours, proges¬
togen receptor levels were 19-75 times higher.
We conclude that these differences, seen be¬
tween carcinogen-induced tumours and the
advanced generations of transplantable tu¬
mours, provide further support for the hy¬
pothesis of McGuire et al. [6] that progestogen
receptor activity may represent a useful index
of hormonal sensitivity in breast cancers.
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Abstract
Fifty estrogen receptor (ER)-positive breast cancers have been studied to determine the best way of correcting
for differences in cellularity when expressing ER concentration. ER concentration expressed on wet weight
and tumour cytosol protein bases showed a positive correlation with tumour cellularity. In contrast, ER
concentrations expressed on a DNA basis were not significantly related to cellularity. Although such a mode
of correcting for differences in cellularity was imperfect, it did yield a receptor concentration which was less
dependent upon tissue cellularity and which may reflect more accurately the inherent receptor status of the
tumour cells.
Introduction
It is now well established that the ER status of a
breast cancer is of value in predicting the likelihood
of response to endocrine therapy (1). Measuring the
amount of ER present within a tumour improves the
accuracy of this prediction of response (2, 3, 4).
The concentration of ER in a tumour depends
on, amongst other factors, the number of malignant
cells present (5, 6,7). Thus the receptor concentra¬
tion observed in a given tumour will be a complex
measure of both the inherent receptor status of a
tumour and its cellularity. The predictive value of
ER quantitation may therefore be obscured by
expressing results in a manner which does not take
into account tumour cellularity.
In this study, we have investigated the inter¬
relationships between tumour cellularity and re¬
ceptor concentration expressed on wet weight.
tumour cytosol protein, and DNA bases to deter¬
mine which mode of expression provides the best
compensation for differences in tumour cellularity
and thus represents the best measurement of the
amount of ER present per cell.
Material and methods
A total of 50 tumours from patients with primary
breast cancer was studied. This group comprised 39
postmenopausal women and 11 premenopausal or
menopausal women. In all cases the tissue obtained
was from the primary tumour.
All tumours were assayed by the method of
Hawkins et al. (8) but with the addition of mono-
thioglycerol (1% v/v) and glycerol (10% v/v) to the
homogenising buffer. Aliquots of tumour cytosol
were assayed for cytosol protein concentration (9),
* No reprints are supplied by this department.
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and a portion of tumour adjacent to that used for
ER assay was analysed for DNA content (10).
From this data, each ER concentration was ex¬
pressed as fmol/mg wet tissue, fmol/mg cytosol
protein, and fmol/mg DNA. All the tumours in¬
cluded contained ER in concentrations greater than
0.25 fmol/mg wet tissue, 5 fmol/mg cytosol protein,
and 100 fmol/mg DNA. Tumours with negative or
borderline values for receptor concentration were
excluded from this study.
A thin section of tumour adjacent to that used for
receptbr assay was placed in formol-saline and
processed routinely for histology, including staining
with haematoxylin and eosin. Cellularity was as¬
sessed visually by two independent observers using
the system described by Roberts et al. (11) as
modified by us previously (7). The relationship of
the 'cellularity index' (ranging from 1-16) to other
parameters was examined firstly by calculating the
correlation coefficient (r) by the method of least
squares, after logarithmic transformation of the
data, and secondly by the Spearman rank correla¬
tion test. In view of the existence of an apparent
'outlier" in the data (the tumour with the lowest
cellularity), all the data were analysed with (n = 50)
and without (n = 49) the inclusion of this tumour.
The correlation coefficients and f values shown
are those derived from the method of least squares,
except where analysis by the rank method yielded a
significantly different result: in this case, the results
of both analyses are included.
Results
(1) Relationship of tumour cellularity to DNA and
protein contents
Tumour cellularity, assessed histologically as the
'cellularity index', was not related to the con¬
centration of total protein measured in the cytosol
(r = +0.16, p>0.2, n = 50, or r = +0.10, p>0.4,
n = 49) but was significantly correlated with tumour
DNA content (/'= +40, p<0.005, n = 50; r = +0.33,
p<0.025, /7 = 49), as shown in Fig. la and lb,
respectively. By the Spearman rank test, however,
this correlation between cellularity and DNA con¬
tent only attained significance when all the 50
tumours were considered (r = +0.39, p<0.05 for
17 = 50 and r = +0.24, p >0.05 for n = 49).
When the data from premenopausal and post¬
menopausal patients were analysed separately,
insufficient data were available for a useful ana¬
lysis in the former group. In the postmenopausal
patients, however, again the same relationships
were observed (i.e. cellularity index vs protein:
r = +0.07, p>0.6; cellularity index vs DNA con¬
tent: r = +0.44, p<0.01, 17 = 39).
(2) Relationship of receptor concentration to tumour
cellularity
When expressed on a wet weight basis, receptor
concentration was significantly correlated with
tumour 'cellularity index' (r = +0.40, p <0.005,
17 = 50 or r = +0.42, p <0.005, n = 49, Fig. 2a) in
agreement with our previous findings (5, 6, 7).
Expression of receptor concentrations as fmol bind¬
ing sites/mg total cytosol protein (Fig. 2b) did not
eliminate this dependence of receptor concentration
upon 'cellularity index' (r = + 0.34, p<0.02,17 = 50
or 7 = +0.38, p<0.01, n = 49). In contrast, re¬
ceptor concentrations expressed as fmol of binding
sites/mg DNA were no longer significantly related
to the tumour 'cellularity index' (r = +0.13,
/7>0.30, 17 = 50, or r = +0.26, p>0.05, n = 49,
Fig. 2c).
When the data from the postmenopausal patients
were considered separately, the same pattern of
relationships was apparent as was seen with the
whole group (receptor concentration vs cellularity:
wet weight basis r = +0.46,p<0.005; protein basis
r = +0.44,p<0.01; DNA basis r = +0.10,/i>0.5;
17 = 39).
Discussion
These results demonstrate that there is a wide
variation in both DNA (Fig. lb) and estrogen
receptor (Figs. 2a, b, c) contents in tumours which,
by visual assessment of histological sections, con¬
tain similar numbers of malignant epithelial cells.
The variation in receptor content was only slightly
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Fig. 1. The relationship of (a) tumour cytosol protein content, and (b) tumour DNA content, to tumour cellularity index. The correlation
coefficients were (a) 0.16 (p>0.2) and (b) 0.40 (/?<0.005) for all 50 tumours or (a) 0.10 (p>0.4) and (b) 0.33 (p<0.025) when the
tumour of lowest cellularity was excluded.
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Fig. 2. The relationship of estrogen receptor concentration, expressed on the basis of (a) wet weight, (b) cytosolic protein, and (c) tumour
DNA, to cellularity index. The correlation coefficients and probabilities, including (n = 50) and excluding (n = 49) the tumours of lowest
cellularity index were respectively (a) r = 0.40, P<0.005 and r = 0.42, /j<0.005, (b) r = 0.34, p<0.02 and r = 0.38, /)<0.01, and
(c) r = 0.13, p >0.3 and r = 0.26, p>0.05.
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diminished when the 39 postmenopausal patients
were considered on their own (not shown). Never¬
theless, the concentration of receptors per mg wet
tumour or per mg cytosol protein was dependent on
the number of cells present whilst receptor concen¬
tration per mg tumour DNA was unrelated to
cellularity. The scatter of results in the data for the
latter may be partly due to the fact that DNA
content was determined on an adjacent portion of
tissue, rather than on the pellet from receptor assay.
The finding of a positive correlation between ER
on a wet weight basis and tumour cellularity is in
agreement with our earlier findings (5, 6, 7) and it
implies that this method of expression does not
allow for differences in cellularity. It has been
suggested by others (12) that expression of receptor
concentration on a total cytosolic protein basis
should provide a correction for such differences.
However, the results of the present work and another
study (5) indicate that receptor concentrations/mg
cytosol protein are still dependent upon the number
of tumour cells present.
In this study, DNA content was a better bio¬
chemical assessment of cellularity than total cytosol
protein. Thus expression of receptor concentrations
on a DNA basis, whilst not eliminating intra-
tumour variations (13), does provide some correc¬
tion for differences in cellularity. Here the correc¬
tion was incomplete in that there was still a tend¬
ency for the more cellular tumours to have higher
receptor levels, even on a DNA basis. Nonetheless,
such a mode of expression should yield a more
accurate reflection of the inherent ER status of the
tumour cells. Whether or not this mode of expres¬
sion improves the value of tumour ER concentra¬
tion in assessing prognosis or predicting response
remains to be ascertained.
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Binding of [3H]-Methyltrienolone (R1881) by
Human Breast Cancers
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Abstract—The synthetic radioligand [3H]-R1881 binds to both androgen and
progestogen receptors; these two types of receptor activity can be separated by
competition experiments with radioinert steroids of defined biological activity.
Using two standard tissues, rat prostate and human uterus, which are sources of
androgen and progestogen receptors respectively, the optimal conditions for the
determination of each type of activity were established. For the purposes of routine
assay, androgen receptors were quantified after saturation of progestogen receptor
sites with 125 nM radioinert R5020 using [3H]-R1881 and increasing
concentrations of radioinert 1881. Progestogen receptor activity could be
identified using the same radioligand and competition with radioinert
progesterone or R5020, though for routine purposes, progestogen receptors were
quantified using the more specific radioliga?id, [3H]-R5020. The binding of [3H]-
R1881 to tumour cytosol was examined in 122 human breast cancers. Seventy-two
tumours (59%) showed binding. Androgen receptor activity alone was present in 16
tumours, progestogen receptor activity alone in 30 tumours and both types in 26
tumours. Tumours containing progestogen receptor activity also showed binding
to the progestogen [3H]-R5020, whilst those containing androgen receptors alone
did not. Androgen receptor concentration varied from 17 to 210fmol binding
sites/mg cytosol protein (mean value 68) and the mean K,* was 2.15 X 10r9M.
Progestogen receptor concentration varied from 25 to 1350 fmol binding sites/mg
cytosol protein (mean value 410) and the mean was 1.35 X 10~9M. The biological
significance of the presence of these types of receptor in human breast cancers is
currently being assessed from clinical follow-up.
INTRODUCTION
The synthetic androgen, methyltrienolone
(R1881), forms a useful ligand for the measure¬
ment of androgen receptor activity. Unlike the
natural androgen, 5a-dihydrotestosterone, R1881
does not bind with high affinity to serum proteins
such as sex hormone binding globulin and is not
readily metabolised by target tissues [1]. This may
be of particular value in human breast cancers
which actively metabolise steroid hormones [2]
and may be contaminated with serum-derived
material. However, R1881 also binds to pro¬
gestogen receptors [3, 4], which are often present
in breast tumours [5]; this is a complicating factor
in using the ligand for the measurement of
androgen receptors in human breast cancer. The
present study describes the characterization of the
binding of tritiated R1881 in cytosol according to
• Accepted 23 March, 1983.
whether competition occurs with androgen,
progestogen or both types of steroid, the
determination of the optimal conditions needed
for the assay of each steroid receptor and the




Radioinert methyltrienolone (R1881), pro-
megestone (R5020), [3H]-R1881 (58.2 Ci/mmol)
and [3H]-R5020 (56.5 Ci/mmol) were gifts from
Dr J. P. Raynaud (Roussel-Uclaf, France).
Radioinert 5a-dihydrotestosterone (5a-DHT),
progesterone and triamcinolone acetonide were
obtained from Sigma (Poole, U.K.).
T issues
Prostate was obtained from male Sprague
Dawley rats 24 hr after bilateral orchidectomy.
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Human uterus was obtained from patients
undergoing hysterectomy.
Breast cancers were obtained at mastectomy or
biopsy from patients with histologically proven
disease.
All material was transported on ice to a cold
room and immediately processed.
Cytosol preparation
Tissues were dissected free from surrounding
fat and connective tissue, finely cut with scissors
and homogenised at 0°C at a tissue: buffer ratio of
1:5 (w/v) in Tris buffer (10 mM Tris, 0.25 M
sucrose and 1.5 mM EDTA to which 7.8 mg
dithiothreitol, i.e. 0.5 mM, was added per 100 ml
buffer immediately before use) employing a
Silverson homogenizer at minimum speed for
3 X 15 sec with 1-min intervals for cooling. The
homogenate was centrifuged at 105,000 g for 1 hr
in an MSE Superspeed 50 centrifuge and the
resulting supernatant was used as cytosol.
Binding measurements
All measurements were performed at 0°C.
Cytosol (200 p\) was incubated with 500 /ul Tris
buffer, which contained competitor steroid where
appropriate. Studies with [3H]-R1881 were
performed in the absence and presence of 125 nM
R5020. The only competitor studied in the
absence of R5020 was progesterone at a final
concentration of 10 nM, and those in the presence
of R5020 were R1881 (final concentrations 1, 2, 4,
8 and 1000 nM) and 5a-DHT. For studies with
[3H]-R5020, radioinert R5020 was used as
competitor at final concentrations of 1, 2,4, 8 and
1000 nM.
Tubes containing radioinert competitor and
cytosol were left for 40 min before either [3H]-
R1881 or [3H]-R5020 (final concentrations
0.5 nM) was added and the tubes mixed and
incubated overnight. Bound steroid was then
separated from free steroid by the addition of
400 /ul dextran-coated charcoal (0.0625/0.625%
w/v respectively). After 10 min the tubes were
centrifuged and the total supernatant (bound
fraction) was decanted into a counting vial
containing 10 ml of Liquifluor (Packard). The
two phases were mixed, incubated at 37°C for 2 hr
and the radioactivity measured in a Tricarb liquid
scintillation counter.
Cytosol protein
The protein content of each cytosol was
determined by the method of Bradford [6], using
bovine serum albumin as standard.
RESULTS
Human uterus
All cy tosols of human uterus showed binding of
[3H]-R1881. Studies performed with radioinert
steroids as competitors showed that R1881, R5020
and progesterone all inhibited the binding but
that 5a-DHT was ineffective [Table 1(a)]. The
effect of increasing concentrations of radioinert
R5020 is shown in Fig. 1. Although binding was
only completely inhibited with 500 nM R5020,
only a trace of radioligand remained bound at
concentrations above 100 nM. These results
indicate that the binding was to progestogen
receptors, a view supported by a high specific
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Fig. 1. The effects of increasing concentrations of radioinert
R5020on binding of [3H]-/? 1881 by human uterus. Percentage
inhibition of binding was calculated as described in Table 1.
Each point represents the mean of 3 separate estimations.
Experimental conditions are as described in Materials and
Methods.
Table 1. Characterization of [3H]-R1881 binding to cytosols from human
uterus and rat prostate
% inhibition of binding by competitor
5a-DHT R] 881 Pg R5020
Tissue (10 nM) (10 nM) (10 nM) (10 nM) (125 nM)
(a) Human uterus 1.3 ± 0.7 57.7 ±4.1 43.8 ± 4.0 86.2 ± 1.5 97.4 ± 0.5
(b) Rat prostate 71.2 ±3.5 81.3 ±3.6 5.7 ± 2.0 0 5.6 ± 3.2
Values represent the mean ± S.E. of the mean for 4 separate experiments. Percentage
inhibition was calculated from the binding in the presence of the appropriate competitor
and that in the absence of any competitor, both values being corrected for the non-specific
binding found in the presence of 1000 nM radioinert R1881.
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Rat prostate
All cytosols of rat prostate specifically bound
[3H]-R1881. The binding as characterised by
competition studies [Table 1(b)] was different
from that in human uterus. In the rat prostate
system radioinert R1881 and 5a-DHT were
effective competitors, whereas R5020 and pro¬
gesterone had negligible effects. Only at concen¬
trations in excess of 125 nM did R5020 consistently
inhibit binding of [3H]-R1881. Data presented in
Fig. 2 show the effect of including 125 nM R5020
on the binding of [3H]-R1881 analysed according
to Scatchard [7]. At this concentration R5020 had
little effect on the dissociation constant of binding
(1.3X10~9M) but reduced the concentration of
receptor sites by about 5%. These results indicate
that the binding of [3H]-R1881 in rat prostatic
cytosol was to androgen receptors. Absence of
progestogen receptors from rat prostate was
confirmed by lack of specific binding of [3H]-
R5020 in these cytosols (not shown).
bound ( nM )
Fig. 2. Scatchard analysis of the binding of [3H]-R1881 in the
absence (•) and presence (O) of 125 nM R5020 to rat prostatic
cytosol. The latter was obtained by pooling prostates from 5
animals (protein concentration, 8.75 mg/ml). Each point
represents the mean of triplicate estimations. Experimental
conditions are as described in Materials and Methods.
Mixture of cytosols from human uterus and rat
prostate
In order to determine whether it would be
feasible to quantify androgen receptors in the
presence of progestogen receptors by blocking the
progestogen receptor with excess progestogen,
experiments were performed with a mixture of
cytosols from rat prostate and human uterus.
Cytosols were prepared from rat prostate and
human uterus as described in Materials and
Methods and aliquots were mixed in equal
volumes and assayed with tritiated R1881 and
increasing concentrations of radioinert R1881 in
the presence and absence of 125 nM R5020. In
addition, the prostatic and uterine cytosols were
each assayed separately after dilution with an
equal volume of buffer. The results are shown in
Fig. 3. Scatchard analysis showed that the binding
bound ( nM )
Fig. 3. Scatchard analysis of the binding of [3H]-/?1881, in
the presence of 125 nM /?5020 to cytosol of rat prostate diluted
with an equal volume of buffer (•), and to the same cytosol
diluted with an equal volume of cytosol from human uterus
(■). Open symbols represent the binding of each cytosol in the
absence of both radioinert steroids /?1881 and /?5020. Each
point is the mean of triplicate estimations. Prostatic cytosol
was obtained by pooling prostates from 5 animals (protein
concentration 9.5 mg/ml). The protein concentration of
human uterine cytosol was 6 mg/ml. Experimental conditions
are as described in Materials and Methods.
in the combined cytosol was 6.4% higher than
that in rat prostatic cytosol alone, although the
dissociation constants for the single and com¬
bined cytosols were similar. The additional
binding in the combined cytosol over that seen in
the prostatic cytosol alone may represent
incompletely blocked progestogen receptor sites
or the presence of small amounts of androgen
receptor in the uterine preparation, though
Scatchard analysis of the small amount of binding
of [3H]-R1881 in the presence of 125 nM R5020 by
human uterus failed to yield a satisfactory plot.
Human breast cancer
Binding of [3H]-R1881 was measured in the
cytosols from 122 human breast cancers. Tumours
were classified as showing specific binding if
more than 200 cpm were displaced by the addition
of 1000 nM radioinert R1881. This displace¬
ment is equivalent to 5 pmol/1 (which, on the
basis of an average tumour cytosol, would
correspond to approximately 7 fmol/mg protein).
Using this criterion, 72 tumours bound [3H]-
R1881 (Table 2). The binding was characterised
by using radioinert 5a-DHT, progesterone and
R5020 as competitors. These studies show that in
30 tumours, progesterone or R5020 but not 5a-
DHT blocked the binding (progestogen receptor
activity); in 16 tumours 5a-DHT but not
progesterone or R5020 inhibited binding
(androgen receptor activity); and in 26 tumours
all 3 steroids acted as competitors (both
progestogen and androgen receptor activities).
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Table 2. Binding of [3H]-.R 1881 to cytosols of 122 human breast cancers
Binding No. of tumours (% of total)
None 50 (41)
Progestogen receptors* 30 (25)
Progestogen receptors + androgen receptorsf 26 (21)
Androgen receptorsf 16 (13)
* Competition with progesterone and R5020.
tCompetition with progesterone, R5020 and 5a-dihydrotestosterone.
^Competition with 5a-dihydrotestosterone.
Parallel studies were performed using [3H]-R5020
as radioligand. These showed that tumours which
had bound [3H]-R1881 and in which binding had
been blocked by progesterone and R5020 also
specifically bound [3H]-R5020. Conversely,
tumours which had failed to bind [3H]-R1881, or
in which binding to [3H]-R1881 was displaced
only by 5a-DHT, failed to bind [3H]-R5020. Thus
of the 122 tumours investigated, 56 (46%)
contained progestogen receptors and 42 (34%)
contained androgen receptors (Table 2).
Quantitation of androgen receptors was per¬
formed by measuring the effects of increasing
levels of radioinert R1881 on the binding of [3H]-
R1881 in the presence of 125 nM R5020. The
concentrations of progestogen receptors in the
same tumours were obtained by measuring
binding of [3H]-R5020 in the presence of varying
amounts of radioinert R5020. The results are
shown in Table 3. Typical Scatchard plots for the
binding of [3H]-R1881 by the cytosols from 2
human breast cancers (I and II), one of which also
bound R5020(II), are shown in Fig. 4. The mean
dissociation constant of bindingof [3H]-R1881 (in
the presence of 125 nM R5020) for all the positive
tumours was2.15 X 10"9M (range, 1.0-3.9 X 10~9M)
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Fig. 4. (A) Scatchard plot for binding of [3H]-H1881 to
cytosol of a human breast cancer (I) (protein concentration,
3.1 mg/ml). Solid symbols represent binding in the presence of
a fixed concentration of radioinert R5020 (125 nM) and
increasing concentrations of radioinert H1881; open symbol
represents binding of [3H]-H1881 in the absence of both
radioinert HI881 and H5020. This cytosol did not bind [3H]-
H5020. (B) Scatchard plot for binding of [3H]-H1881 to cytosol
of a human breast cancer (II) (protein concentration,
3.5 mg/ml). Symbols as for (A). This cytosol bound [3H]-
H5020, shown in (C). (C) Scatchard plot for binding of [3H]-
H5020 to cytosol of human breast cancer II. Each point
represents the mean of duplicate estimations. (Assay
conditions as described in Materials and Methods.)
DISCUSSION
The use of [3H]-R1881 as a radioligand for the
measurement of steroid receptors in human breast
cancers suffers from the disadvantage that this
synthetic steroid binds to both progestogen and
androgen receptors. Since breast cancers may
contain one or both of these receptors, it is
necessary to characterise the binding of [3H]-
R1881 in each tumour. Therefore, in order to
quantify receptor activity in tumours with both
types of receptor, it is necessary to selectively block
binding to one type of receptor while measuring
Table 3. Concentrations of androgen and progestogen receptor binding sites in cytosols of
human breast cancers
Tumour type
Concentration of binding sites (mol/mg cytosol protein)
[3H]-R1881 binding [3H]-R5020 binding
Mean ± S.E.M. (range) Mean ± S.E.M. (range)
Androgen receptors alone
Progestogen receptors alone
Androgen and progestogen receptors
90 ±17 (19-217)
55 ± 9 (17-210)
428 ± 61 (40-1345)
370 ± 73 (26-1250)
Total binding 68 ± 9 (17-217) 413 ± 46 (26-1345)
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Table 4. Method for routine assay of androgen receptors
in human breast cancer using [3H]-/?1881
All procedures to be performed at 0°C. 500 mg tumour
homogenised in 2.5 ml Tris-sucrose buffer*
Homogenate centrifuged at 105,000g for 1 hr. Resultant
cytosol (200 m1) added in duplicate to 500 /rl buffer containing
125 nM R5020f in the absence and presence of 1, 2, 4, 8 and
1000 nM R1881f (12 tubes)
Tubes mixed and left for 40 min. 100 jul of [3H]-R1881
(0.5 nM — 20,000 cpm) added, tubes mixed and left overnight
400 /rl of dextran-coated charcoal suspension added, tubes
mixed, left for 10 min and centrifuged at 3000 rpm for 10 min.
Supernatant decanted directly into scintillation vials contain¬
ing liquifluor (10 ml), mixed and incubated at 37°C for 2 hr
Vials counted by liquid scintillation spectrometry and data
analysed according to Scatchard using the 1000-nM tubes to
correct for non-specific binding
*If additional material is available, by homogenising 750 mg
in 3.75 ml buffer, it is possible to check that the binding of
[3H]-R1881 is to androgen receptor by also incubating 200 /rl
of cytosol with 500 m1 of 5a-DHT (10 nM) in the presence of
R5020 (125 nM) in duplicate and to assess quantitatively
progesterone receptor activity by incubating cytosol in
duplicate with 500 nl Tris-sucrose buffer with and without
10 nM progesterone (a further 6 tubes).
fValues refer to the final concentration in a total volume of
0.8 ml.
the concentration of the other. Such a technique
has been used successfully to measure androgen
receptors by suppressing binding to the pro¬
gestogen receptor with triamcinolone acetonide
[8]. However, under the assay conditions
employed in the present study, excess of
triamcinolone acetonide did not completely block
progestogen receptor activity until very high
concentrations, which also blocked androgen
receptors, were used. In addition, since an assay
for progestogen receptors using [3H]-R5020 was
already established in our laboratory, it seemed
appropriate to measure androgen receptor activity
with [3H]-R1881 plus excess R5020 to block
binding to the progestogen receptors.
In order to validate our method, we have
studied the binding of [3H]-R1881 in rat prostate,
reported to be a source of androgen receptor in the
absence of significant levels of progestogen
receptor, and human uterus, reported to be a
source of progestogen receptor in the absence of
significant amounts of androgen receptor. Specific
binding of [3H]-R1881 to human uterus was
readily blocked by progesterone and R5020,
confirming that the binding in this tissue was
predominantly to progestogen receptors. There
was only a small but consistent (about 1%)
inhibition of the binding by 5a-DHT; this may
represent the presence of trace amounts of
androgen receptors within the uterine cytosol. In
contrast, the binding of [3H]-R1881 by cytosol of
rat prostate was effectively blocked by 5a-DHT,
whilst progestogens such as progesterone and
R5020 had only minimal effects. The latter may
indicate the presence of low levels of progestogen
activity within rat prostate or a slight cross-
reaction of progestogens with the androgen
receptor.
R5020 at a concentration of 125 nM was
selected for maximal blocking of progestogen
receptor activity with minimal effects on
androgen receptor activity. At this concentration
R5020 blocked around 97% of the binding of [3H]-
R1881 to human uterus but only about 5% of that
to rat prostate. Scatchard analysis of [3H]-R1881
binding by rat prostate in the absence and
presence of 125 nM R5020 showed similar
kinetics, but with a reduction in receptor site
concentration of around 5%. Experiments in
which cytosols from rat prostate and human
uterus were assayed separately and in combina¬
tion confirmed that androgen receptors could be
satisfactorily assayed in the presence of R5020,
with only a very slight underestimation of
receptor sites. Thus these results suggested that
the binding of [3H]-R1881 in these tissues and in
human breast cancers could be characterised as
being due to either progestogen receptors or
androgen receptors, by including competitor
studies with radioinert 5«-DHT, R5020 and
progesterone. It should be noted, however, that
such assays for androgen receptor activity might
have two sources of possible inaccuracy: (a) the
excess concentration of R5020 used might block a
small amount of androgen receptor and tumours
possessing only low levels of androgen receptor
might thus be misclassified as negative; (b)
incomplete blocking of progestogen receptors by
R5020 might lead to their being falsely classified
as positive for androgen receptors, this being most
likely to occur in tumours containing very high
levels of progestogen receptors.
Specific binding of [3H]-R1881 was detected in
cytosols from 72 of 122 human breast cancers.
Binding was characterised as being due to
progestogen receptors (competition by pro¬
gesterone and R5020 but not by 5a-DHT) in 30,
androgen receptor (competition by 5a-DHT but
not by progesterone or R5020) in 16, and to both
androgen and progestogen in 26 tumours
(competition by progesterone, R5020 and 5a-
DHT). This gives an overall incidence of
androgen receptor activity of 34%. The corre¬
sponding figure quoted for other workers using
different methods varies from 19 to 56% [9-13]. In
this study the overall incidence for progestogen
receptors was 46%. This figure is identical to that
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which we found using [3H]-R5020 as ligand in the
same tumours, and is comparable to those
reported by others [14, 15].
Quantitation of androgen receptors demon¬
strated a mean level in the receptor-positive
tumours of 68 fmol/mg cytosol protein, with a
mean KA of 2.15 X 10~9 M. These values are
comparable to those reported for the androgen
receptor by others using different methods
[8, 11, 13].
In conclusion, we have defined a method
whereby the synthetic radioligand[3H]-R1881 can
be used for the simultaneous detection of
progestogen and androgen receptors, though in a
small number of tumours with very low levels of
androgen receptor activity or very high levels of
progestogen receptor activity the androgen
receptor status may be misclassified. Androgen
receptor activity can be quantified by blocking the
progestogen receptors with R5020. This method
is summarised in Table 4. However, accurate
quantitation of progestogen receptors is still best
performed with the specific progestogen ligand,
[3H]-R5020. The clinical significance of the
presence of androgen receptors, or of the
simultaneous presence of both androgen and
progestogen receptors, remains to be determined.
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Androgen Receptor Activity in Human Breast
Cancer and its Relationship with Oestrogen and
Progestogen Receptor Activity
W. R. MILLER, J. TELFORD, J. M. DIXON and R. A. HAWKINS
Department of Clinical Surgery, University of Edinburgh Royal Infirmary, Edinburgh
Abstract—Androgen receptor activity was measured in tumours from 122 patients
with breast cancer. Forty-two tumours (34%) possessed androgen receptors at levels
varying from 17 to 210 fmol/mg cytosol protein (mean value 68). No relationship
was detected between androgen receptors and menopausal status of the patients and
whether or not lymph nodes were invaded with tumour at the time of biopsy. There
were, however, significant positive correlations between the presence of androgen
receptors and that of oestrogen (P < 0.05) and of progestogen receptors (P < 0.025).
These relationships suggest that androgen receptors may be of value in predicting
the hormone responsiveness of breast tumours but definitive proof of this requires
clinical follow-up of the patients studied.
INTRODUCTION
The value of oestrogen and progestogen
receptors in predicting hormone responsiveness
of human breast cancers is well established [1-4].
Androgen receptor activity in breast tumours has
been less extensively investigated. This paper
therefore describes the relationship of androgen
receptors to other steroid receptors.
MATERIALS AND METHODS
Tumour was obtained from 122 patients with
breast cancer. At the time of study 27 patients were
premenopausal (experiencing regular menstrual
periods), 90 were postmenopausal (at least 5 yr
since their last regular menstrual period), four
were menopausal (0-5 yr since the last menstrual
period) and menopausal status was unknown in
one patient. The breast cancer was obtained from
the primary tumour at mastectomy (107 cases),
from invaded lymph nodes during axillary
clearance or sampling (13 cases) or from biopsy of
local recurrent disease (two cases). The presence of
malignant tumour was confirmed histologically
in all samples. All material was transported on ice
to a cold room and immediately processed.
The concentration of androgen receptors was
determined by saturation analysis as previously
described [5], This involved incubation of a
Accepted 16 October 1984.
tumour cytosol overnight at 0°C with [3H]R1881
(58.2 Ci/mmol) in the presence of 125 nM R5020
and varying amounts of radioinert R1881.
Progestogen receptor assays were performed on
the same cytosols as were used for the androgen
receptor assay. The method involved incubating
the cytosol overnight at 0°C with 1 nM
[3H]R5020 (56.5 Ci/mmol) in the absence and
presence of 1, 2, 4, 8 and 100 nM R5020.
Oestrogen receptor measurements were per¬
formed in adjacent portions of the same tumours
using a method previously described [6], Tumour
cytosol was incubated overnight at 4°C with [2, 4,
6, 7-3H] oestradiol-17)3 and varying amounts of
non-radioactive oestradiol-17/3.
In all receptor assays separation of free from
bound steroid was by addition of dextran-coated
charcoal: the bound fraction was measured by
liquid scintillation counting. Concentration of
receptors was determined by Scatchard analysis
[7]. Activities were designated positive if in excess
of 15 fmol/mg cytosol protein for androgen and
progestogen receptors and greater than 5 fmol/mg
cytosol protein for oestrogen receptors.
RESULTS
Androgen receptors were detected in 42 of 122
human breast cancers (34%). The incidence in
primary tumours did not differsignificantly from
that in involved axillary lymph nodes (Table 1).
Both of the local recurrences examined contained
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androgen receptors. The concentration of
androgen receptor measured varied from 17 to
210 fmol/mg cytosol protein (mean value
65 fmol/mg cytosol protein) and was similar in
primary tumours and involved lymph nodes(data
not shown).
The presence or absence of androgen receptors
in relation to menopausal status and lymph node
involvement (as assessed by histological examina¬
tion of axillary nodes removed at the time of
primary treatment) is shown in Table 2. No
significant differences were apparent in either
incidence or level of androgen receptors between
the various subgroups.
There was, however, a significant positive
correlation between the incidence of androgen
and oestrogen receptors (Table 3). Thus 40% of
oestrogen receptor-positive tumours also possessed
androgen receptor activity, whereas only 19% of
oestrogen receptor-negative tumours did so. No
significant relationship was observed between
levels of androgen and oestrogen receptors in
tumours which contained both activities, but the
mean level of androgen receptor was higher in
oestrogen receptor-negative tumours than in
those with oestrogen receptors (data not shown).
There was also a significant positive correlation
between the incidence of the androgen and
progestogen receptor (Table 4). Thus 46% of
progestogen receptor-positive tumours showed
Table 3. The relationship between the incidences of
androgen receptors (AR) and oestrogen receptor (ER)
activity
Oestrogen receptor status AR+ AR- (% AR+)
ER+ 36 55 (40)
ER- 6 25 (19)
The incidences of the two types of receptor were positively
correlated: x2 = 4.18, P < 0.05.
Table 4. The relationship between the incidences of
androgen receptor (AR) and progestogen receptor
(PgR) activity
Progestogen receptor status AR+ AR- (% AR+)
PgR+ 27 32 (46)
PgR- 15 48 (24)
The incidences of the two types of receptor were positively
correlated: x2 = 6.5, P < 0.025.
androgen receptor activity compared with 24% of
the progestogen receptor-negative group. Levels
of the two types of receptors were not significantly
related (data not shown).
The tumours could be subdivided into eight
different groups depending on the presence/
absence of the three types of receptors measured
(Table 5). Each combination of receptors was




receptorst Total (% positive)
Primary 35 107 (33)
Lymph node 5 13 (42)
Local recurrence 2 2 (100)
■(■Androgen receptor positive, >15 fmol/mg cytosol protein.
Table 2. Effects of menopausal status and lymph node
involvement on incidence of aridrogen receptor activity
No. of tumours
with androgen
receptorsf Total (% positive)
Menopausal status
premenopausal 6 27 (22)
menopausal 1 4 (25)
postmenopausal 34 90 (38)
Lymph node status
involved 21 70 (30)
not involved 18 46 (39)
Differences between groups not significant by the chi square test.
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Table 5. Inter-relationships between androgen
receptor, oestrogen receptor and progestogen receptor
activity in human breast cancers
No. (% of total)
AR+ ER+ PgR+ 27 (22)
AR+ ER+ PgR- 9 (7)
AR+ ER- PgR- 6 (5)
AR- ER+ PgR+ 32 (26)
AR- ER+ PgR- 23 (19)
AR- ER- PgR- 25 (21)
Total 122 (100)
represented except that no oestrogen receptor-
negative, progestogen receptor-positive tumours
were identified. Only six tumours contained
androgen receptors alone whereas 27 had all
three types of steroid receptor.
DISCUSSION
The role of both oestrogen receptors and
progestogen receptors in hormone-responsive
human breast cancer has been extensively
evaluated. In contrast, the significance of
androgen receptors in breast tumours is still
uncertain. Response to certain forms of endocrine
therapy is more likely in androgen receptor-
positive rather than androgen receptor-negative
human breast cancers [8-10], but the numbers of
patients studied are small and results remain to be
confirmed in larger investigations.
Although the determinations reported here
have largely been performed on primary tumours
from patients with early breast cancer (and
therefore data on response to endocrine therapy is
as yet minimal), these measurements provided the
opportunity to investigate in a relatively large
series the interrelationships of androgen receptors
with other steroid receptors of established value.
The incidence of androgen receptors in human
breast cancer of 34% and the mean level of
68 fmol/mg cytosol protein as detected in the
present study are similar to the values reported by
others using different methods [9, 10, 11-13].
Incidence and level were not significantly
influenced by the site of tumour biopsy,
menopausal status or lymph node status of the
patients. A similar lack of association between
these factors has been reported by others [14],
although, as in the present study, there was a
tendency for a higher incidence of androgen
receptor activity to be observed in tumours from
postmenopausal patients.
In the present study there was a significant,
positive correlation between the presence of
androgen receptors and that of oestrogen
receptors. Others have reported a similar
correlation [10,14,15], although it is important to
note that the correlation is not absolute and that
many tumours contain only one of the receptors
[16].
The presence of androgen receptors also
correlated with that of progestogen receptors,
though, as with oestrogen receptors, there was a
substantial number of tumours which contained
either type of receptor alone. Because of the
positive correlations between androgen receptors
and both oestrogen and progestogen receptors,
the presence of androgen receptors within breast
cancers may also reflect hormone-dependence.
However, the presence of androgen receptors in
about 20% of oestrogen receptor-negative tumours,
which classically are unlikely to respond to
endocrine therapy, argues against androgen
receptors alone being of predictive value.
Nevertheless, the simultaneous presence of
androgen receptors along with oestrogen and
progestogen receptors (in 22% of tumours in this
study) might increase the likelihood of response
over that associated with tumours possessing
oestrogen and progestogen receptors alone.
Equally, others have suggested [9, 10] that the
presence of androgen receptors might predict
particularly for specific forms of endocrine
therapy, especially those which affect tumour
androgen levels. Clearly, clinical follow-up of the
patients in this study is required to elucidate these
possibilities.
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Prostaglandins in human mammary cancer
D.M.A. Watson1, R.W. Kelly2, R.A. Hawkins1 & W.R. Miller1
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Summary Prostaglandins E2 and F2„ (PGE2 and PGFM) were measured by Gas Liquid Chromatography -
Mass Spectrometry (GLC-MS) in extracts of 100 human mammary carcinomas. All tumours contained
measurable amounts of both prostaglandins but wide variations between individual tumours were observed.
Values for PGE2 ranged from 7 to 762ngg_1 tissue with a median of lOOngg"1 tissue. Values for PGF2n
ranged from 3 to 475 ngg"1 tissue (median 60 ngg"1 tissue). There was a highly significant positive
correlation between amounts of the 2 prostaglandins in individual tumours. Amounts of both PGE2 and
PGF2a were not significantly related to the menopausal status of the patients or the presence of oestrogen and
progesterone receptors.
Human mammary cancers appear to produce
prostaglandin-like material, and this may be
involved in tumour growth and metastases (Bennet
et al., 1977; Rolland et al., 1980). Most
investigations have, however, employed bioassay or
radioimmunoassay techniques which do not
definitively identify prostaglandins. A single study
has reported on determinations performed by GLC-
mass spectrometry but the number of tumours
examined was relatively small (Stamford, 1983).
The present investigation represents a study of 100
human mammary cancers in which PGE2 and
PGF2ci have been identified and quantitated by
GLC-mass spectrometry. Values of prostaglandins




Tumour was obtained from 100 women with
carcinoma of the breast. These patients comprised
15 premenopausal, 10 perimenopausal (within 5
years of the last menstrual period) and 75 post
menopausal women. Tumour was removed at
mastectomy or biopsy from the primary cancer (in
88 women), by biopsy of invaded lymph node (in 9
cases) or secondary recurrences (in 3 cases). For
comparative purposes, material was also obtained
from benign fibroadenoma of the breast in 5
women and from histologically normal breast tissue
in 3 women. This material was placed on ice and
Correspondence: D.M.A. Watson.
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immediately transferred to the laboratory.
Following removal of tissue for histopathological
diagnosis, the remaining material was dissected free
of extraneous fat and divided for prostaglandin and
steroid receptor assays.
Measurement ofprostaglandins
Formation of derivatives Tumour samples were
weighed and homogenized in ethanol (2.5 ml). To 1 ml
duplicates of each sample were added 20 ng of the
internal standards, (20-ethyl PGF2a and 20-methyl
PGE2.). Oximes were formed by adding
hydroxylaminehydrochloride solution (SOmgml"1)
in sodium acetate buffer (3moll"1, pH 5.2) and
heating for 30min at 60°C. The samples were
extracted and purified using a CI8 Seppak column,
washed with 10 ml iso-octane and then 10 ml 50%
methanol to remove neutral lipids. The
prostaglandins were then eluted with 90% methanol
(10 ml). This fraction was evaporated to dryness
and the residue dissolved in ethyl acetate:ethanol
(1:1 v/v), transferred to a small flat-bottomed tube
and methylated with 100 pi diazomethane solution.
Excess diazomethane and solvent were then
evaporated. The residue was further derivatized to
the t-butyldimethylsilyl ether by adding 65 pi 2M-
butyldimethylchlorosilane and 65 p\ 4M-imidazole
(both in dimethylformamide). After mixing, this
solution was transferred to a narrow glass tube
which was then sealed and heated for 30min at
130°C. The excess reagents were removed from this
mixture by eluting the derivative with 3 ml
hexane:ethylacetate (3:1 v/v) from a Sephadex LH-
20 column. The solvent was evaporated and 20/d
toluene added to the derivative. About one
twentieth of this mixture was injected into the gas
chromatograph.
© The Macmillan Press Ltd., 1984
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Gas chromatography - mass spectrometry
Samples were analysed with a Erba Science gas
chromatograph coupled through an all-glass jet
separator to a V.G.305 mass spectrometer. An open
tubular column coated with SE30 and 12m long
(SGE Ltd. London) was used. The flow rate of
helium was 5mlmin_I. The temperatures were
maintained as follows: gas-chromatography column
280°C; separator and lines 260°C; source block
270°C. The signal was processed by a 2150 data
system to allow separate GC traces for each.
For analysis of PGF2a the mass used was m/z
653 and 681 and for PGE2, m/z 666 and 680. The
ions measured were the M-57 ions resulting from
the loss of a t-butyl radical from the molecular ion.
Quantitation was achieved by comparing the areas
of the sample peak with those of the corresponding
standards. Procedural losses were corrected by
monitoring the recovery of the internal standards,
20 methyl PGE2 (m/z 680) and 20 ethyl PGF2C(
(m/z 681). The intra-assay precision was 13%;
values for interassay precision were 18 and 21% for
PGF2a and PGE2 respectively.
Oestrogen receptors
Concentration of oestrogen receptors was
determined by saturation analysis (Hawkins et al.,
1975). Tumour cytosol was incubated overnight at
4°C with [3H] 17 /Loestradiol. Separation of free and
bound steroid was by addition of dextran-coated
charcoal; the bound fraction was measured by
liquid scintillation counting. Concentration of
receptors was determined by Scatchard analysis
(Scatchard, 1949). Activities in excess of
5fmolmg_1 cytosol protein were designated
receptor positive.
Progestogen receptors
Cytosol was incubated with a fixed concentration
of [3H] Organon-2058 (0.22 nM) and varying
concentrations of non-radioactive Organon-2058
(0.22-11.1 nM) with overnight binding at 0°C and
separation of free and bound hormone by charcoal
adsorption (Hawkins et al., 1981). Activities in
excess of lOfmolmg"1 cytosol protein were
designated receptor positive.
Protein concentration in the cytosol was
determined by the method of Bradford (1976).
Statistical analysis
Non-parametric tests (i.e. Wilcoxon's Rank Test
and Spearman's Rank correlation) were used
throughout these studies.
Results









Figure 1 Levels of PGE2 and PGF2a in 100 human
breast cancers. Lines represent the median values.
detected in all carcinomas. Levels in individual
tumours are shown in Figure 1. Range of values for
PGE2 was from 7 to 762ngg"1 tissue with a
median value of 100. The corresponding range for
PGF2a in the same samples was from 3 to
475 ngg-1 tissue (median 60). Values in a group of
5 fibroadenomas ranged from 2-19ngg-1 tissue
(median 9) for PGE2 and 6-14 ngg"1 tissue
(median 12) for PGF2a and those for 3 specimens
of histologically normal breast were 7-14ngg"1
tissue for PGE, and 5-18ngg"1 for PGF2£(.
Within the group of breast cancers, there was a
highly significant correlation between amounts of
PGE2 and PGF2a (Figure 2). (Spearman's Rank
correlation coefficient = 0.543 P<0.001).
There was no significant difference between
prostaglandin levels in primary tumours, lymph
nodes and secondary recurrences (Data not shown).
Nor were there significant differences in amounts of
either PGE2 or PGF2t( in pre, peri and
postmenopausal patients (Figure 3).
Oestrogen receptor activity was detected in 68
tumours (68%) and the relationship between the
presence of receptors and prostaglandin content is
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Figure 2 The relationship between levels of PGE2
and PGF2a. Line is that of linear correlation.
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Figure 3 Levels of prostaglandins in tumours from
pre, peri and postmenopausal patients. Lines represent
median values. No significant differences between the
groups by Wilcoxon Rank Test.
shown in Figure 4. The median value for both
PGE2 and PGF2a was higher in tumours with
oestrogen receptors as compared to those without
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Oestrogen receptor
Figure 4 Levels of prostaglandins in oestrogen
receptor positive ( + ) and negative ( —) tumours. Lines
represent median values. No significant difference
between the groups by Wilcoxon Rank Test.
groups failed to reach statistical significance.
(P<0.1 and P< 0.2, respectively by Wilcoxon Rank
Sum Test).
Progesterone receptors were detected in 34 of the
93 tumours investigated (37%). There was no
significant difference between either PGE2 or
PGF2a levels in progesterone receptor positive and
negative tumours (Figure 5). (P<0.8 and P<0.9
respectively by Wilcoxon Rank Sum Test).
Discussion
To date, the evidence that human breast cancers
contain significant amounts of prostaglandins has
been based on data from either bioassay or
radioimmunoassay. These techniques, although of
value, do not accurately identify different
prostaglandins. In the present study, therefore, we
have used the more definitive technique of GLC-
mass spectrometry which has previously only been
employed for prostaglandin measurements in a
small group of breast cancers (Stamford, 1983).














Figure 5 Levels of prostaglandins in progesterone
receptor positive ( + ) and negative ( —) tumours. Lines
represent median values. No significant difference
between the groups by Wilcoxon Rank Test.
It is almost impossible to measure "in situ" levels
of prostaglandins within tissue preparations
because prostaglandins are not stored in cells but
are synthesised rapidly in response to stimuli.
Biopsy, processing and homogenization of tumour
specimens represent stimuli which would result in
production of large amounts of prostaglandins.
Determination of prostaglandins in tumours can,
therefore, only be directed towards assessing the
potential for prostaglandin production rather than
measurement of endogenous levels (Green, 1979).
Two types of technique have been adopted in this
respect. Tumour may be homogenized directly in
ethanol to obtain "basal" levels or incubated with
or without added precursor to determine
"synthesised" levels. It is not clear which technique
more accurately reflects tumour potential for
producing a local environment of prostaglandins or
indeed if either reflects "in situ" activity. "Basal"
levels will include both the normal content of
tumour cells and material synthesized between
biopsy and inactivation of synthetic ensymes during
homogenisation (Bennet, 1982). The level of
prostaglandin 'synthesized" will depend critically on
precautions taken to protect the highly labile
prostaglandin synthetase system and addition of
arachidonate substrate may not mimic tissue levels
of precursor. We have, therefore, chosen to
measure basal levels of prostaglandins in the
present study because this represents the least
complicated and most practical method of studying
prostaglandins in a large number of cancers.
Using these techniques, measurable amounts of
PGE2 and PGF2a were detected in all tumours.
Prostaglandins were identified on the basis of their
molecular ions (at m/z 666 PGE2, m/z 653 for
PGF2a), retention times and characteristic peaks.
Amounts of PGE2 varied from 7 to 762 ngg"1
tissue and those of PGF2a from 3 to 475ngg"1
tissue. These amounts are comparable to
concentrations demonstrated by other methods
(Bennet, 1982) and were higher than those found in
benign and normal breast. A strong positive
correlation was detected between levels of the two
prostaglandins in individual breast cancers as has
been previously observed (Fulton et al., 1982).
Although the variation in the amounts of both
prostaglandins was large, we have been unable to
identify factors accounting for this variation. Levels
of tumour prostaglandins appeared to be
uninfluenced by menopausal status of the patient,
site of tumour biopsy or whether cytosolic steroid
receptors were present.
The finding of no significant difference in tumour
prostaglandin levels between pre, peri and post¬
menopausal patients agrees with the results of
Rolland et al. (1980) who measured "synthesized"
levels of prostaglandins in microsomal preparations.
Fulton et al. (1982) failed to show an association
with PGF2tt but reported significantly raised PGE2
levels in postmenopausal women. It has been
suggested that oestrogen receptor positive tumours
synthesize greater amounts of prostaglandins
(Campbell et al., 1982). Others have been unable to
show such a correlation (Rolland et al., 1980;
Bennet, 1982). However, in the study which
reported a significant correlation, it was necessary
to make a correction for tumour cellularity before
the association became apparent. In the present
study, a significant correlation was apparent
between tumour cellularity and PGE2 but not
PGF2a (Figure 6). However, multiple regression
analysis of PGE2 and PGF2t( on both oestrogen
receptor and cellularity showed that oestrogen
receptor had no significant effect on prostaglandins
for given levels of cellularity (for PGE2 r = 0.36, for
PGF2ar= 1.12). Indeed, correcting the results for
tumour cellularity may be misleading because this
would be based on the assumption that tumour
cells within the biopsy were solely responsible
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Figure 6 Levels of prostaglandins in tumours with
different grades of cellularity. Cellularity was assessed
as described by Hawkins et al. (1981) using a 4 point
scale for both the proportion of tumour in the tissue
specimen and for the proportion of malignant cells
within the tumour itself. These are expressed as a
product of the two scores to give a range of 1-16.
(Score 1-4 therefore represents tumours with a low
cellularity index, those with 13-16 the highest) PGE2
correlates significantly with cellularity (t = 0.14,
P<0.05, by Kendal Rank Test). PGF2a did not
correlate significantly with cellularity (f = 0.08).
whereas other cell types such as macrophages,
lymphocyctes, plasma cells and fibroblasts may also
be producing prostaglandins. We have, therefore,
preferred to express our results in terms of
prostaglandins extracted per weight of tumour
tissue.
Variation in prostaglandins extractable from
breast cancers may be due to non-specific, non-
tumour factors such as the time interval between
the biopsy and extraction, and the degree of trauma
produced in obtaining the tumour samples.
Enzymes associated with prostaglandin synthesis
are particularly labile (Egan et al., 1978) and it is
essential to minimise any delay in tumour
processing. Substantial amounts of prostaglandins
may be generated in response to trauma (Green,
1979) and variation in degree of tissue trauma
might be expected to be associated with differences
in prostaglandins levels. In practice, it is difficult to
eliminate tissue trauma as even gentle handling may
stimulate biosynthesis of prostaglandins. In this
series of tumours, clinical and pathological
considerations determined the degree of mechanical
trauma to which the specimens were subjected.
However, no significant differences were detected
between prostaglandins extracted from samples
obtained at biopsy and those from mastectomy
specimens.
It has been suggested that tumour prostaglandins
are associated with prognosis and pattern of
metastatic spread of breast cancer. At the present
time, data from this study cannot be assessed for
these parameters. Most tumours were obtained
from patients with early breast cancer who have, as
yet, only short follow-up. The absence of positive
correlations with other factors of known prognostic
value such as steroid receptors and lymph node
status could mean that prostaglandins are either of
independent significance or unrelated to prognosis.
Valid assessment of the data will only be possible
when further follow-up of the patients is available.
We would like to thank Professor A.P.M. Forrest for
allowing us to study material from patients under his care,
Dr J.M.J. Dixon for assessing the cellularity of each
tumour and Dr R.A. Elton, Department of Medical
Statistics and Computing for statistical analysis of the
results.
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Cyclic AMP binding proteins in human breast cancer
W.R. Miller, R.O. Senbanjo, J. Telford & D.M.A. Watson
University Department of Clinical Surgery, Royal Infirmary, Edinburgh EH3 9YW, Scotland, UK.
Summary The characteristics of a method for measuring cyclic AMP binding proteins in cytosols of human
breast cancer are described. Using the assay, binding proteins were demonstrable in all of 100 tumour
cytosols. Levels of binding in individual tumours varied from 0.8 to 15pmolmg_1 cytosol protein (mean
value 5pmolmg_1 cytosol protein) and the dissociation constant ranged from 0.5 to 5.2x10~8m (mean
1.73x10~8m). Whilst replicate measurements within a single portion of tumour were reproducible (intra-
assay coefficient of variation was between 4.5 and 7.8% and that for inter-assay variation was between 2.1
and 4.0%) there were often considerable differences in levels of binding proteins between different portions of
the same tumour. Similar intra-tumour variations have been reported for other binding proteins and steroid
receptors. The inter-relationships with such parameters may elucidate whether the differences are associated
with variations in cellularity, cell type, or other specific factors.
In experimental animals, cyclic AMP binding
proteins are implicated in the growth of mammary
tumours (Cho-Chung, et al., 1978b; Bodwin, et al.,
1980; Bodwin et al., 1981). The corresponding
evidence in human breast cancers has yet to be
fully documented. In the present paper we describe
a method for measuring total cyclic AMP binding
proteins in human breast tumour cytosols and some
characteristics of the assay.
Materials and methods
Reagents
(5'8'-3H) Adenosine 3',5'-cyclic phosphate,
ammonium salt (45Cimmol) was obtained from
Radiochemical Centre, Amersham, and radioinert
adenosine 3'5'-cyclic phosphate, sodium salt from
Sigma (Poole, UK). The following buffers were
employed using analytical reagents - Buffer A
20 mm Tris, 0.25 m sucrose, 2mM magnesium
chloride, 1 mM calcium chloride, 10mM potassium
chloride, 16.26mM HC1 pH 7.5; Buffer B 55 mM
potassium phosphate to which 11 mM theophylline
was added immediately before use; Buffer C as
Buffer B but with the addition of 10 mM
magnesium chloride.
Tissues
Breast cancers were obtained at mastectomy or
biopsy from patients with histologically proven
disease. All material was transported on ice to a
cold room and processed immediately unless stated
Correspondence: W.R. Miller
Received 17 April 1985; and in revised form 11 June 1985.
otherwise. The tumours represented 100 consecutive
cases in which sufficient material was available for
assay after tissue had been taken for routine
histopathological examination and for oestrogen
receptor analysis. Specimens were obtained from
patients with T stage 1 to 4, although the number
of T1 tumours was small.
Cytosol preparation
All procedures were performed at 0-4°C. Tumour
was dissected from surrounding fat and connective
tissue, finely cut with scissors and homogenized in
Buffer A (w/vl:10) using a Silverson homogenizer
at maximum speed for 20 sec then 15 sec, with 1
min interval for cooling. The homogenate was
centrifuged at 105,000 g for 1 h in a MSE
Superspeed 50 centrifuge and the resulting super¬
natant was used as cytosol.
Binding measurements
Cytosol (50 pi) was incubated with 100 pi 5',8'-[3H]
cyclic AMP (25 nM to give a final concentration in
the incubation system of 10nM) and Buffer B
(100pi) containing radioinert cyclic AMP (final
concentration 0,10,20,40,80, and 10,000 nM). Each
system was set up in duplicate and incubated at
room temperature for 3h. To separate protein-
bound cyclic AMP from free nucleotide, 2 ml
Buffer B was added to each tube. The contents
were then mixed and filtered through a Millipore
filter (HAWP 0.45 pm) at 5 mm Hg negative
pressure followed by 20 ml Buffer C at 10 mm Hg
negative pressure. The filters were transferred to
scintillation vials and dried under a stream of air.
Micellar fluor NE 260, Nuclear Enterprises (5 ml)
was added to each vial. The vials were then
© The Macmillan Press Ltd., 1985
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incubated at 37°C for 2h and radioactivity was
measured in a Tricarb liquid scintillation counter
(Packard).
Cytosol protein
The protein content of each cytosol was determined
by the method of Bradford (1976) using bovine
serum albumin as standard.
Results
Assay conditions
Tumour cytosols were incubated with [3H] cyclic
AMP in the absence and presence of 10,000nM
radioinert cyclic AMP for varying times, either at
0°C or 20°C. A typical result is presented in Figure
1. Maximum binding at 20°C was achieved by 2h.
Binding at 0°C was lower than at 20°C at each time
point studied but was still increasing at 5 h
incubation. Overnight incubation at either 0°C or
20°C produced similar binding (data not shown).
For routine assays it was decided to incubate at
20°C for 3 h. The amount of binding under these
conditions was linear with respect to increasing
cytosol protein concentrations up to at least
3.0mgml_1 (Figure 2). The effect of radioinert
cyclic AMP on the binding of [3H] cyclic AMP is
shown in Figure 3(a). Low concentrations of
radioinert cyclic AMP were able to compete with
[3H] cyclic AMP for binding, and there remained
only a low level of non-specific binding in the
presence of a thousand-fold excess of competitor.
The data plotted according to Scatchard (1949),
showed that the dissociation constant of binding
was 2.7x10"8M and that the maximum
concentration of binding sites within the assay
system was about 2.0 nM (Figure 3b). Similar
results were also obtained by performing the assay
with increasing concentrations of radio-labelled
ligand and assessing the non-specific binding by
including a 100-fold excess of cold competitor at
each of these concentrations (data not shown).
Time (h)
Figure 1 The effect of time of incubation on the
binding of [3H] cyclic AMP to a cytosol of breast
carcinoma either at 20°C (•) or 0°C (O). Each point
represents the amount of [3H] cyclic AMP bound in
the absence of radioinert cyclic AMP corrected for
that in the presence of 10,000 nM cold competitor.
Remaining assay conditions as described in Materials
and methods.
Cytosol protein (mg ml 1)
Figure 2 The effect of cytosol concentration on the
binding of [3H] cyclic AMP to cytosols of 2 different
breast carcinomas. Cytosols were prepared as
described in Materials and methods and serially diluted
to give the protein concentrations indicated. The
diluted cytosols were incubated for 3h at 20°C with
increasing concentrations of radioinert cyclic AMP.
The data were analysed by Scatchard plot and each
point represents the maximum number of binding sites
for each system.
Values in breast cancer cytosols
Cytosols from 100 primary breast cancers have
been assayed for cyclic AMP binding proteins. The
results are presented in Table I, and the concen¬
tration of binding sites in individual tumours are
plotted in Figure 4. All tumours showed cyclic
AMP binding but levels varied greatly between
individual tumours, from 0.8 to 15pmolmg_1
cytosol protein.
Table I Levels and dissociation constants of cyclic AMP
binding proteins in cytosols of 100 primary breast cancers
Level Dissociation Constant
pmol mg 1 cytosol protein (M x 10~8)
Mean + sd 4.99 + 3.07 1.7210.96
Range 0.80 -15.05 O LA 1 t-n k>
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Concentration of cold Bound (nM)
competitor (nM)
Figure 3 The effect of radioinert cyclic AMP on the binding of [3H] cyclic AMP to a cytosol of human
breast cancer. Assay conditions were as described in Materials and methods, data plotted as (a) radioactivity




Figure 4 Levels of cyclic AMP binding proteins in
cytosols of 100 primary breast cancers. Horizontal line
represents mean value.
Reproducibility of measurements and effect of
storage
In order to determine the intra-assay precision of
cyclic AMP binding measurements in tumours,
large breast cancers were finely minced. Five
portions, each of ~500mg, were accurately
weighed and cytosols were prepared separately and
assayed. Two tumours were processed in this way;
one possesed a mean value for cyclic AMP binding
proteins from the 5 replicate estimations of
lASpmolmg"1 cytosol protein with an intra-assay
coefficient of variation of 7.9%, the other cancer
had a mean value of 7.48pmolmg_1 cytosol
protein with an intra-assay coefficient of variation
of 4.5%.
To ascertain the interassay variation, 3 tumours
were divided into 5 portions, as described for the
study of intra-assay varitaion. One portion of each
tumour was assayed for cyclic AMP binding
proteins immediately (day 0) and the remaining
portions were stored in separate vials in liquid
nitrogen for 1,3,7 and 14 days until assayed. The
results are shown in Figure 5. There appeared to be
no observable decline in level of binding proteins
with storage, and considering measurements within
the same tumour as replicate estimates, the interassay
coefficients of variation were 2.1%, 2.5% and 4.0%
(that these values are lower than those for the intra-
assay variation is probably a reflection of the larger
number of simultaneous estimations performed in the
study of intra-assay variation).
An estimate of the variation in cyclic AMP
binding protein levels within individual cancers was
obtained by dissecting out portions of tumours
from central, intermediate and peripheral zones
across each of 12 large breast cancers. These were
assayed by the routine method and the results are
presented in Figure 6 as ratios of the values relative
to that in the peripheral zone. Whilst the mean of
the 12 values found in each tumour zone were
similar (and hence the mean value for the zone
ratio was unity), there were often large variations in
cyclic AMP binding protein levels between different
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Figure 5 The effect of storage in liquid nitrogen on
reproducibility of cyclic AMP binding protein levels in









Figure 6 Variation in cyclic AMP binding protein
levels across 12 breast cancers. For experimental
details, see text. Results have been expressed as a ratio
of the value obtained from the intermediate area (I) or
the central area (C) to that in the peripheral area (P).
areas in an individual tumour. This variation was
invariably greater when comparing central and
peripheral zones.
Discussion
Measurements of cyclic AMP binding proteins in
experimental animal cancers have yielded useful
information regarding the state of automony of the
tumours (Cho-Chung et al., 1980a; Bodwin et al.,
1980). Similar data in human breast cancers has not
yet been fully assessed. In the present paper we
describe the characteristics of an assay which might
be used routinely to measure total binding sites for
cyclic AMP in cytosols of human breast cancers.
This method involves incubating tumour cytosol
with radioactively labelled cyclic AMP in the
absence and presence of increasing concentrations
of radioinert competitor. At 20°C, maximum
binding was achieved by 2h and was linear between
cytosol protein concentrations of 0.4 and
3mgml_1. Under these conditions the non-specific
binding assessed by adding 1000-fold excess of
radioinert cyclic AMP was negligible (<0.1% of
the added radioactivity). The binding capacity was
not affected by storage up to 14 days in liquid
nitrogen. The intra-assay coefficent of variation, as
determined on aliquots from minced large tumours,
was between 4.5 and 7.9%, and the inter-assay
value was between 2.1 and 4.0%. These results are
similar to those obtained by others using a different
method (Kvinnsland et al., 1983).
Using the present method, cytosols of 100 human
breast cancers have been assayed for cyclic AMP
binding. All possessed binding activity, levels
varying from 0.8 to 15.0pmolmg_1 cytosol protein
(mean value 5pmolmg_1 cytosol protein). These
values fall within the range for human breast
cancer cytosols reported by others using different
methods (Eppenberger et al., 1980; Kvinnsland et
al., 1983), and are also similar to those found in rat
mammary tumours (Cho-Chung 1978a; Cho-
Chung et al., 19786). The mean dissociation
constant of 1.73 x 10"8 M is also in keeping with
data from experimental animal tumours (Cho-
Chung et al., 19786).
It remains to determine which factors influence
the levels of cyclic AMP binding proteins in
cytosols of individual human breast cancers and, in
particular, whether these levels are related to
prognosis or endocrine responsiveness, as has been
suggested by others (Kvinnsland et al., 1983) and as
is the case in rat mammary tumours (Cho-Chung
1978a, 6, 1980). Assessments in breast cancers will
have to take into account the variation in cyclic
AMP binding proteins between different areas of
the same tumour. Data from the present study
shows that there may be considerable differences in
the level of cyclic AMP binding between each of
three different areas (central, peripheral and inter¬
mediate) of large tumours. No consistent pattern of
variation across the tumours was evident and the
mean value for cyclic AMP binding in this group of
cancers was similar, irrespective of the area of
tumour upon which the estimation was performed.
At present, it is not known whether these
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differences within tumours are associated with
variations in cellularity, cell type or other factors.
Similar intra-tumour variations have been noted
with other binding proteins such as the oestrogen
receptor (Hawkins et al., 1977; Silversward et al.,
1980) and the inter-relationship with these different
types of binding protein may help to elucidate the
problem.
The authors thank Professor A.P.M. Forrest for allow¬
ing them to study material from patients under his care
and for the interest he has shown in the work and Dr
R.A. Hawkins for his helpful suggestions and comments.
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Short Communication
Carcinoembryonic antigen (CEA) in explants of human
breast cancer: comparison of immunohistochemical detection
and release during short-term culture
W.R. Miller, C.M. Sturgeon1 & R.A. Walker2
University Department of Clinical Surgery and 1 Immunoassay Section, Department of Clinical Chemistry,
Royal Infirmary, Edinburgh, 1Department of Pathology, University of Leicester.
A large proportion of human breast cancers
produce CEA (Heyderman & Neville 1977, Wahren
et al., 1978, Cove et al., 1979). Although levels in
plasma of patients with breast cancer have only a
limited use in diagnosis and monitoring progression
of the disease, (Chu & Nemoto 1973, Coombes et
al., 1980; National Institutes of Health Consensus
Development Conference Statement 1981)
measurement of CEA at the tumour level may
provide a useful marker of tumour activity in vitro.
We therefore measured CEA in media from
cultured explants of human breast cancers and
detected the marker in 75% of tumours (Miller et
al., 1980). However, these measurements give no
indication of the proportion and type of cells
producing CEA within the explants. This
information may be obtained by histochemical
staining techniques and the purpose of this study
was to compare the quantitative release of CEA
from explants into media during culture with the
results from immunoperoxidase staining for CEA.
Histologically-proven breast cancers were
obtained from 54 patients at mastectomy. Of these,
4 were classified as infiltrating lobular carcinomas
and 50 infiltrating ductal carcinomas (2 mucinous, 1
medullary and 47 showing no special features). Fifty
specimens were from the primary tumour and 4
were from invaded lymph node.
Each tumour was cut into explants measuring
4x1x1 mm. Four weighed explants were placed on
lens paper mounted on stainless-steel grids in each
of 3 petri-dishes. Waymouths 17B 725/1 medium
(2ml) containing L-glutamine (2mM), 20 mM Hepes
and insulin (lOpgml"1) was added and the dishes
incubated in an atmosphere of 95% 02/5%C02 for
24 h at 37°C. Culture medium was removed and
assayed for CEA by radioimmunoassay.
Correspondence: W.R. Miller, University Department of
Clinical Surgery Medical School. Teviot Place. Edinburgh
EH8 9AG.
Received 26 August 1982; accepted 11 November 1982.
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For radioimmunoassay, CEA was prepared from
liver secondaries of primary colonic cancer by
perchloric acid extraction (Krupey et al., 1968),
followed by chromatography on columns of DEAE-
cellulose, CM-cellulose, concanavallin A-Sepharose
and Sepharose 6B. Rabbit antiserum to the purified
CEA was absorbed extensively against perchloric
acid extracts of normal human liver, lung, spleen
and serum. Using purified CEA both as standard
and for labelling (Sturgeon, 1978), a direct double-
antibody RIA for CEA based on that of Egan et al.
(1972) was developed. The assay was standardized
using the British Standard for CEA (Laurence et al.,
1975), 1 ng of working standard being equivalent to
0.0058 + 0.0004 units of the British Standard.
Standard curves were prepared in culture medium.
The working range of the assays for undiluted
samples was from 3—70 //g 1_ 1 and intra-assay
precision averaged over this concentration range
was 11.4%. Inter-assay precision was 10.0%, 8.3%
and 6.4% at concentrations of 10, 25 and SO^gP1,
respectively.
In order to assess immunohistochemical staining
for CEA, 4 explants (4x1x1 mm) were cut from
each tumour from the area immediately adjacent to
that used for tissue culture. The method used was
as described previously (Walker 1980). Tissue was
fixed in 4% formaldehyde in 0.15 M sodium
chloride, routinely processed and embedded in
paraffin wax. Sections were treated with 0.1%
solution of trypsin (Difco 1:250) for lOmin. Rabbit
anti-CEA serum (Dako-immunoglobulins A115),
which had been absorbed against non-specific cross-
reacting antigen, was applied followed by the 3-
stage peroxidase anti-peroxidase complex method.
Controls used were normal rabbit serum in place of
the primary antiserum; anti-CEA serum absorbed
with CEA: and positive (carcinoma of colon) and
negative (normal breast) control tissues.
Staining was assessed as negative ( —ve), positive
( + ve) or + if only very occasional cells had reacted
(<5%„).
Of 54 tumours, media from 41 contained
measurable amounts of CEA in all replicate cultures
© The Macmillan Press Ltd., 1983
430 W.R. MILLER el at.
after incubation; CEA was not detected in any
culture of the remaining 13 tumours. In tumours
producing CEA, the mean level varied from 3.0-
1200ngmP' culture fluid. Immunohistochemical
staining for CEA gave positive results in 34 cancers.
There was no staining in the appropriate controls.
In all carcinomas which gave a reaction there were
variable numbers of +ve and — ve cells. An
example of tumour graded +ve is shown in Figure
1. The site of staining within cells was either
predominantly at the periphery with a faint
granular cytoplasmic reaction, or throughout the
cytoplasm with occasional focal intensities. All 14
tumours which were graded + ve produced CEA in
culture as did 17 of the 20 graded +ve (Table).
However, one half of the tumours which were — ve
by the immunoperoxidase method had consistently
detectable, but low levels of CEA in media after
culture (Figure 2). Concentrations of CEA produced
during culture were significantly higher (P<0.05) in









Figure 1 Small groups of breast carcinoma cells, with
several individual cells having a prominent positive
reaction for CEA as diffuse or focal staining within
the cytoplasm. Immunoperoxidase, x480.
Table I Correction between immunoperoxidase and
detection of CEA in media from cultured explants
Immunoperoxidase grading
— ve + ve + ve
— ve 10 3 0
Media from
cultured explants + ve 10 17 14



















Figure 2 CEA levels in culture media from tumours
subdivided according to immunoperoxidase grading.
Significant differences by Wilcoxon rank testing. +ve
against ±ve P<0.05, ±ve against —ve PcO.Ol.
with those in tumours graded as ±ve, which in turn
were significantly higher than those graded — ve
(PcO.Ol).
Approximately 75% of human breast cancers
maintained in short term organ culture released
measurable amounts of CEA into the media. This
incidence is in agreement with that reported for
tumour extracts (Cove et al., 1979). From these
data, however, it is not possible to indicate which
cells or cell types are responsible for the production
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of CEA. Such information can be obtained from
histochemical studies and this study shows that
explants from 34/54 tumours investigated possessed
cells which stained positively for CEA using an
immunoperoxidase technique. The incidence of
detection of CEA by the immunoperoxidase
technique ranged in previous studies from 1.5%
(Goldenberg et al., 1978) to 83% (Heyderman &
Neville, 1977). These variations are probably due to
the method employed and to the nature of the
antiserum. Primus et al., (1980) now advocate the
use of the peroxidase-antiperoxidase complex
method in preference to the bridge technique which
they had used previously. Like studies on other
human cancers, the present results showed that only
a proportion of the cells within the tumour explants
stained positively for CEA. The presence of CEA
staining within the cytoplasm supports its role as a
secretory product.
Only 3/34 tumours with immunoperoxidase
staining failed to release CEA into the culture
media. These 3 tumours contained very few
positively staining cells and as different explants
were used for culture, it is possible that this
discrepancy reflects heterogeneity within the
tumour.
In view of the significant positive correlation
between the immunoperoxidase technique and the
presence of radioimmunoassayable CEA in culture
media, it is likely that the cells stained
immunocytochemically are responsible for the
production of CEA during culture. Measurement of
CEA in the culture media may therefore offer a
means of monitoring the activity of these cells in
vitro.
Explants from half of the immuno-
histochemically-negative tumours released CEA into
the medium during culture. The amounts released
were relatively small and, in spite of using the
peroxidase-antiperoxidase method, it is probable
that the technique is insufficiently sensitive in
formalin-fixed paraffin embedded tissue to detect
production of small amounts of CEA. These
immunohistochemically false-negative tumours
represented 10/15 carcinomas which, while
producing CEA in culture, did so in amounts
<2jUgg_1 tumour. This level of sensitivity for the
immunoperoxidase method would be in agreement
with that quoted by Goldenberg et al. (1978) for
similar material from other tumours. The variation
in results may also represent differences in the
nature of the antiserum used for the
immunohistochemistry and the RIA, and/or
heterogeneity within the tumour as previously
mentioned. In order to assess heterogeneity across the
tumours, sections from the paraffin blocks used
originally for histological grading were stained
immunohistochemically. Although 6/45 tumours
examined changed grading on the basis of this
larger section, only one carcinoma which released
CEA during culture but graded — ve by
histochemical staining of the explant, was classified
+ ve in the tumour slice.
It is concluded that RIA of media from cultured
tumour explants provides a sensitive quantitative
estimate of CEA production by breast carcinomas,
and that immunohistochemical staining for CEA
indicates the proportion and nature of the cells
whose activity is being measured within the tumour.
It is suggested that, in order to monitor tumour in
vitro activity by CEA measurements, both methods
should be used in combination.
The authors thank Professor A.P.M. Forrest for allowing
them to study materials from patients under his care and
Ms. B. Jordan for the tumour photomicrograph. This
work was supported by a grant from the Melville Trust.
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INTRODUCTION
The principal function of the breast is the synthesis of proteins, fats and
carbohydrates, all components of milk. The proteins synthesized by the breast,
during lactation, are the final products of highly differentiated glandular tissue.
Therefore, they differ from the first tumour markers used such as CEA, AFP,
HCG and its subunits, which are proteins secreted by young, most often
embryonic or cancerous, cells. In contrast, milk proteins are synthesized by
adult cells arrested at a complete stage of development. Mammary tissue from
primates (Kleinberg and Todd, 1978) and humans (Bussolati etal., 1975) has
been shown to produce and contain lactalbumin and casein even in virgin, nulli-
parous and multiparous breasts. Thus, the breast cells are able to produce milk
proteins at various times of life, other than during gestation and lactation.
Several examples exist of the use of tissue secretory products as an index of
tumour activity (Laurence and Neville, 1977). The development of such systems
for milk proteins produced by breast cancer, needs the maintenance of synthesis
material in cancerous cells. Lactalbumin (Kleinberg, 1975; Kleinberg and Todd,
1978; Woods etal., 1979), and casein (Bussolati et al., 1975; Herbert etal., 1978)
have been observed in cancerous breast cells. Nevertheless, the frequency of
lactalbumin production by cancer cells is lower than by normal cells and the
Serono Symposium No. 46, Markers for Diagnosis and Monitoring of Human Cancer, edited
by M. I. Colnaghi, G. L. Buraggi and M. Ghione, 1982. Academic Press, London and New
York.
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induction of lactalbumin production by prolactin can be stimulated in normal but
not in malignant breast tissue (Wilson era/., 1980). The milk proteins are produced
less by cancer cells. But these milk proteins could be an index, during the
woman's life, of breast activity and secretion. They are an index of, on the one
hand, a particularly favourable hormonal climate for the breast cells to synthesize
and secrete material in the mammary ducts, and, on the other hand, of their
mitotic activity. Petrakis et al. (1975) showed a correlation between breast
secretory activity and breast cancer risk. Furthermore, the breast secretion from
nipple aspirates could have mutagenic activity (Petrakis et al., 1980).
Thus, the use of milk proteins in breast oncology may be of interest in two
potential areas: that in the cancer cells synthesize a protein which is biological
parameter of tumoral activity, or that this protein is an indication of a breast in
an hormonal condition of cancer transformation risk.
Two milk proteins are studied. Firstly, lactalbumin, with a molecular weight of
15,000 daltons (Brew et al., 1970), has a biological role to provide a rapidly
responding control mechanism acting on the lactose synthetase in the milk
(Fitzgerald et al., 1970). Lactalbumin is a major component of the milk (1-2 mg/
ml), and the final product of a highly differentiated adult tissue.
The second protein studied, the sweat a2 -globulin, was described by Jirka (1968).
This mucoprotein is present in a number of external secretions: saliva, tears,
cerumen, colostrum and milk. This product of the mammary and sweat glands
which have a similar embryological origin, has been purified from breast cyst
fluid of patients with breast cyst disease: GCDFP 15 (Haagensen et al., 1979), and
GCDFP 70 (Zangerle etal., 1981). It is a minor component of milk (1-2 pg/ml)
and a major one of breast cyst fluid and breast secretion (1-10 mg/ml); its bio¬
logical role is still unknown.
We have refmed and assessed a radioimmunoassay for lactalbumin and GCDFP
70. We used this assay to study these two milk proteins in serum from different
populations, in culture fluid from breast explants, in breast cyst fluid from breast




Lactalbumin was purified, according to the method of Schultz and Ebner
(1977) from milk of lactating women collected between post-partum days
4 and 10. The protein obtained had a molecular weight of 15,000 daltons and
the enzymatic activity for lactose biosynthesis by transferring galactose, from
UDP-galactose, on glucose. This lactalbumin was used as a tracer after label¬
ling with 1251 (Greenwood et al., 1963) and as a reference preparation. Other
milk proteins, known tumour markers and egg lysozyme serum proteins from
children do not cross-react with human lactalbumin. The sensitivity of the assay
is 75 pg/ml and the interassay variation coefficient less than 4%. In the cases
where human immunoglobulins capable of binding the labelled lactalbumin were
present, we used the method of Woods et al. (1978) to neutralize them.
f
f
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GCDFP 70
Gross cystic disease fluid protein was extracted from breast cyst fluid of
women with breast cystic disease. In biological conditions the molecular weight
is 70,000 daltons. This molecule was used as a tracer and as a reference prepara¬
tion. Any other milk proteins, tumour markers such as CEA, HCG, /3 and a HCG
or serum proteins from normal males do not cross-react in the immunological
reaction. The sensitivity of the assay is 800 pg/ml, and the interassay variation
coefficient is less than 5%.
Sera Studied
Normal Populations
Lactalbumin and GCDFP 70 were assayed in the serum of healthy subjects:
200 adult women, 200 adult men, 20 prepubertal boys and girls, five young women
every 2 days during normal menstrual cycle, 55 gestating women and 19 lactating
women during the 6 days post partum.
Benign Disease Patients
Non-breast benign disease. There were 438 patients investigated with non-
breast benign disease: 62 were bearing different digestive diseases (except viral
hepatitis); 21, lung disease; 112, cardiovascular diseases; 23, infectious diseases;
36, endocrinological diseases; and 27, urogenital diseases.
Breast benign disease. There were 123 adult women investigated with breast
benign disease: 74 were bearing non-cystic disease, such as fibroadenoma, and
49 had breast cystic disease.
Malignant Disease Patients
There were 105 patients investigated with breast cancer at different stages of
evolution; 51 with lung cancer, 62 with digestive cancer, and 32 with different
site cancers.
Breast Cyst Fluid
Forty-two breast cyst fluid samples were obtained by a needle aspiration of the
cyst from women with breast cyst disease. Multiple cysts from the same patients
were analysed in nine women.
Breast Secretion
Nipple aspirates (100-250 pi) gave breast secretion in 100 women without
clinical evidenced breast disease.
Breast Culture
Tumours are cut into explants. Four weighed explants were placed on a lens
pager, mounted on stainless steel grids in Petri dishes and cultured for 24 h at
37 C in 2 ml Waymouths 17/3 725/1 medium, containing normal glutamine,
20 mM Hepes and insulin (10 pg/ml) with an atmosphere of 95% oxygen/5%
COj. After culture, media are removed and deep frozen at -40°C until assayed
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for tumour markers. The explants are weighed, pulverized in liquid N2, and
extracted with a further 2 ml of culture medium. After centrifugation the
resultant cytosol is removed and used for the estimation of milk proteins.
RESULTS
Sera from Normal Populations
Children
GCDFP None of the 20 male and 20 female children before puberty presented
serum values of GCDFP higher than 5 ng/ml.
Lactalbumin. Twelve of the 20 boys (60%) and eight (40%) of the girls did not
have a detectable value of lactalbumin. No value exceeded 3 ng/ml.
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Fig. 2. Serum concentration of luteinizing hormone, progesterone, 170-oestradiol, prolactin
and lactalbumin throughout a menstrual cycle. Samples were withdrawn every 2 days from a
20-year-old fasting woman.
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Healthy Adults
GCDFP. Four of the 400 healthy males and females presented values of
GCDFP higher than 5 ng/ml. There is no correlation between the detectable value
and the sex repartition. No correlation has been found between blood groups.
Lactalbumin. Lactalbumin was detected in the serum of 92/200 men (47.5%)
with levels equal to or less than 4 ng/ml. Three of the 200 (1.5%) had levels higher
than 4 ng/ml. No value exceeded 7.2 ng/ml (Fig. 1).
Out of 200 women, 124 (62%) had detectable values of lactalbumin with a wider
range than in men (Fig. 1). Those women with values higher than 4 ng/ml repre¬
sented 19.5% of the group. In this last group of women, the mean value of
prolactin (694.32 /rill/ml ± 342) is higher than the mean value found in women
without detectable values of lactalbumin (483 ± 268 qlU/ml). There was no
statistical difference concerning the value of 170-oestradiol, progesterone between
the group of women with detectable lactalbumin values and the group without
detectable lactalbumin values.
Menstrual cycle. Of the five women studied throughout their menstrual cycle,
three had detectable values of lactalbumin. Each presented a peak of LH between
days 13 and 19 of the cycle (Fig. 2). In positive lactalbumin women, the lactal¬
bumin values increased quickly at day 2 of the luteal phase, then decreased
progressively. The mean value of lactalbumin was significantly higher during the
luteal phase than during the follicular phase (Fig. 3).
6 r
P < 0.002
\ 1 J M iSD
Fig. 3. Mean lactalbumin levels, with standard deviation, during the follicular (open columns)
and the luteal phase (closed columns) of two women normally cyelated.
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Fig. 5. Evolution of prolactin levels and lactalbumin levels in the post-partum period of a
non-lactating woman with bromergocryptin (Sandoz).
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Gestating women. No serum from gestating women had GCDFP values higher
than 5 ng/ml. Lactalbumin was detected in all the sera of gestating women with
a mean value of 120 ng/ml at the end of gestation.
Lactating women: normal lactation. In 17 women the prolactin and the lactal¬
bumin levels were determined each morning, 15 min before the second suckling,
during the first 6 days following delivery. Mean prolactin levels increased to reach
their maximum on day 2 of the post-partum, then progressively decreased. The
lactalbumin levels increasing during lactation, reached a maximum on day 4 after
delivery and decreased thereafter (Fig. 4).
Non-lactating women. Two women who did not wish to breast feed, received
bromergocryptine (Sandoz). Prolactin levels decreased to normal values after
3 days. Nevertheless, the lactalbumin levels remained low, although reaching a
small peak on day 2 and then decreasing but with levels ten-times less than the
levels found in lactating women (Fig. 5).
GCDFP was found only in one woman without fluctuation, according to the
lactation time.
Patients with Benign Disease
Non-breast Benign Disease
In 315 patients with non-breast benign disease, the incidence of GCDFP
higher than 5 ng/ml was 4/315 (1.2%) and the incidence of lactalbumin higher
than 4 ng/ml was 5/315 (2.5%).
Benign Breast Disease
The incidence of pathological values of GCDFP ( > 5 ng/ml) was clearly
different in patients with breast cyst disease (27/49, 55%) from the incidence
found in patients with non-breast benign disease (1/74, 1.3%). The incidence
of high lactalbumin levels in breast cyst disease patients (11/49, 22%) was also
quite different from that in non-cystic breast disease (9/74, 12%) (Fig. 6).
Patients with Cancer
Non-breast cancer. The incidence of pathological values of GCDFP and lactal¬
bumin in lung, digestive and different site cancer was 10/145 (6.9%) and 2/145
(1.4%), respectively.
Patients with breast cancer. Whatever the state of the disease, the incidence of
lactalbumin values higher than 4 ng/ml was low—5%. In 105 women with breast
cancer at different stages of the disease, the incidence of pathological values of
GCDFP was 64/105 (61%).
Breast cyst fluid. The levels of GCDFP in cyst fluid were high ranging from
2 to 10 mg/ml. Multiple cysts were analysed in nine women and the concentra¬
tion of GCDFP was in the same range in cysts of the same individual. The range
of lactalbumin values was lower than in milk—from 0.1 to 150 ngJmX.
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Fig. 6. Incidence of lactalbumin levels higher than 4 ng/ml (%) in the serum of healthy, with
benign disease and with cancer populations.
Breast secretion. The breast secretions of nipple aspirates had the same range
of GCDFP concentration as in breast cyst fluid. The values of lactalbumin were
lower and never exceeded 125 ng/ml (Fig. 7).
Culture medium. Seventy-five out of 84 human breast cancer explants pro¬
duced GCDFP in the culture fluid with an extremely wide range of levels, varying
from 0.4 to 125 ng/ml. Of the remaining nine, five were equivocal and four had
no evidence of GCDFP production (Fig. 8). Lactalbumin was present in eight only
(9.5%). In cultures producing GCDFP the levels were always much lower in media
on day 2 compared with those on day 1 and values in the explants after culture
were also very low. The combined levels in the culture media exceeded those
present in the explants before culture; this may be evidence of de novo synthesis
during culture. The levels of GCDFP 70 in the culture fluid were not related to:
(1) the menopausal status of the patient,
(2) tumour oestrogen receptor (Fig. 9);
(3) whether the cancer tissue was derived from primary tumour or invaded
node (Fig. 10); or
(4) from patients with early or late disease.
Three explants from normal breast tissue did not produce GCDFP or lactalbumin























Fig. 7. Lactalbumin levels in breast secretion from nipple aspirates of 101 healthy women.
DISCUSSION
Lactalbumin
The purified molecule has the molecular weight and the biological enzymatic
activity previously described (Schmidt and Ebner, 1971; Brew etal., 1970;
Fitzgerald etal., 1970).
The levels found in the serum of normal population were similar to those
assessed by Kleinberg (1975), Woods and Heath (1978) and Woods et al. (1978).
Lactalbumin can be considered as an index of the physiological activity of
the breast.
(1) In lactating women, the serum lactalbumin level evolution is the same as the
kappa casein evolution (Zangerle and Hendrick, 1976; Zangerle et al., 1978;
Franchimont et al., 1979) with values comparable to those described by Martin
et al. (1980). Like kappa casein, the lactalbumin does not follow exactly the
evolution of prolactin.




















Fffc 8. GCDFP values in day 1 fluid of breast cancer explant cultures.
(2) During the menstrual cycle, when present (three out of five women), there
is a cycle of lactalbumin with higher mean values during the luteal phase than
those in the follicular phase, together with higher values of prolactin, 170-oestra-
diol and progesterone.
(3) In a normal population, a sex difference, which does not exist among
prepubertal girls and boys, appears between adult men and women (Fig. 1).
In women, the hormonal difference between the group with detectable lactal¬
bumin and the group without detectable lactalbumin is only significant for
prolactin.
Lactalbumin is not a marker of breast cancer since it is not found in breast
cancer culture fluid and in breast cancer cell cytosols. The absence of lactal¬
bumin in the culture could be attributed to the short time periods of culture and
the complete absence of hormone in the fluid. Nevertheless, in the presence of
Cortisol (Ono and Oka, 1980), prolactin (Wilson et al., 1980; Kleinberg and Todd,
1978) or oestrogen (Ip and Dao, 1978), cancerous cells do not product lactal¬
bumin more than do normal cells.















Fig. 9. CCD TP values repartition in day 1 fluid of breast cancer explant culture, following
the presence (OeR+) or the absence (OeR~) of oestrogen receptor in the tumour.
In the serum of breast cancer patients, the incidence of lactalbumin values
higher than 4 ng/ml is low-5%. The presence of lactalbumin in the serum could
be related to the presence of high risk disease since 22% of patients with breast
cyst disease have values higher than 4 ng/ml (Fig. 6). This cystic mastopathy has
been associated with a tendency to hyperoestrogenism, frequently related to luteal
insufficiency (Mahon et a!., 1973).
The presence of lactalbumin in normal breast secretion (-»■ 125 ng/ml) and in
breast cyst fluid (-+ 125 /rg/ml) shows the persistence of secretory activity of the
breast during normal and pathological conditions.
Following these results, lactalbumin could be considered as an index of mam¬
mary function, but not as a marker for breast cancer. As its production depends
on multiple hormones, its presence in the serum indicates a prevalence of
hormones such as prolactin, acting on the breast metabolism, synthesis, secretion
and mitotic activity or a difference in the sensitivity of the tissue leading to the
same activation. In this condition, the presence of high values of lactalbumin in
the serum could be considered as an index of risk. This hypothesis is re-enforced





















Fig. 10. GCDFP values repartition, in day 1 fluid of breast cancer explant culture from
primary (T) or lymph node invaded (N).
by the studies of Patrakis (1973, 1980), which establish a relation between high
secretion activity and breast cancer risk. Nevertheless, epidemiological studies
are needed to confirm such an hypothesis.
GCDFP
GCDFP is quite different from lactalbumin: it has lower levels in milk and
higher levels in breast secretion and in breast cyst fluid. GCDFP is not at all a
marker of the function of the breast since it is absent in the serum of gestat-
ing or lactating women. Its level is not cyclated during the menstrual cycle.
GCDFP is produced essentially by cancer cells as shown by the 90% positive
value in breast cancer culture medium and its presence in the cytosols of breast
cancer cells. Normal mammary cells in culture do not seem to produce GCDFP.
In'lfte blood, the presence of GCDFP can be correlated only with breast cyst
disease (55%) and breast cancer (68%). It is not significantly found in any other
benign disease or cancer from another origin. Therefore, GCDFP 70 can be con¬
sidered as a marker of breast cancer. The reason why the mammary gland
secretes this milk protein is still unknown.
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It is interesting to note the association of pathological values for the two
diseases: one benign with a high risk, the breast cystic disease, and the other,
breast cancer.
The presence of blood values of GCDFP and lactalbumin in patients with
GCDFP is an argument for the high metabolical activity of such a disease.
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SUMMARY
A series of breast carcinomas of known steroid receptor status have been examined for evidence of binding of
the lectins peanut agglutinin, soy bean agglutinin and wheat germ agglutinin. Correlations were found between oestro¬
gen receptor status and reactivity of carcinomas to peanut agglutinin and soy bean agglutinin but these were not
absolute. Wheat germ agglutinin binding was unrelated to the presence of oestrogen receptors. No relationship was
evident between progestogen receptors and the binding of any lectin. It therefore seems unlikely that lectin histo¬
chemistry can replace steroid receptors as markers of hormone dependence in breast carcinomas.
key words- Breast cancer, lectins, steroid receptors.
INTRODUCTION
The value of steroid receptors in breast car¬
cinomas is now well established with regard to the
prediction of patient response to endocrine
therapy.1 However the biochemical methods for
assaying receptors are still not widely available. The
detection in routinely fixed and processed car¬
cinomas of proteins and/or glycoproteins whose
synthesis is dependent upon hormones, and are
therefore indicators of intact receptor mechanisms,
could have obvious clinical applications. Since
experiments had shown that binding sites for the
lectin peanut agglutinin (Arachis hypogaea) in rat
mammary tissue are hormone dependent, Klein
et al.2-3 investigated the binding of this lectin to
human breast carcinomas and concluded that it
allowed a distinction to be made between hormone
sensitive and non-sensitive tumours.
Peanut agglutinin (PNA) has a high affinity for
the disaccharide /?-D-galactosyl(l ->3)jV-acetyl-D-
* Addressee for correspondence.
galactosamine.4 Binding of the lectin is a constant
feature of normal human breast tissue, once sec¬
tions have been treated with neuraminidase.5 The
reactivity of carcinomas to PNA, in association
with desialation, is related to differentiation.6
Another lectin whose binding to breast carcinomas
is related to differentiation is wheat germ agglutinin
(WGA),7 which has a high affinity for /V-acetyl-D-
glucosamine. Soy bean agglutinin (SBA) is a lectin
which is specific for /?-D-galactose and
A-acetyl-D-galactosamine.8
In this study a series of carcinomas have been
assessed for their reactivity to PNA, SBA and
WGA, and the results have been compared with the
oestrogen and progestogen receptor status of the
tumours.
MATERIALS AND METHODS
Tissue was obtained from 50 primary infiltrating
breast duct carcinomas, excised from the same num¬
ber of patients at Edinburgh Royal Infirmary, and
0022-3417/85/100103-04S01.00
©1985 by John Wiley & Sons, Ltd.
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from three lymph node metastases from two further
patients.
Samples taken for receptor analysis were placed
on ice and processed immediately for homogeniza-
tion at 4°C. Parallel slices were fixed in 4 per cent
formaldehyde in saline and routinely processed.
Oestrogen receptors were assayed using a
multiple point dextran coated charcoal method
with Scatchard analysis.9 Progestrogen receptor
was also assayed by a dextran coated charcoal
method with the use of R5020, a synthetic
progestogen.10
Lectin binding was performed as previously des¬
cribed.6 The lectins were conjugated to horseradish
peroxidase type VI (Sigma Chemical Co.). After
section dewaxing and rehydration they were applied
at the following concentrations: WGA 5/zg/ml;
PNA and SBA 10 /rg/ml. Sections to which SBA-
peroxidase was to be applied were initially treated
with 0-1 per cent trypsin, pH 7-8, for 30 min at 37°C.
Parallel sections which were tested with PNA-
peroxidase were treated with neuraminidase or
acetate buffer at 37°C for 18 h prior to application
of the lectin. Peroxidase was localized using the
diaminobenzidine-hydrogen peroxide reaction.
Controls were the incubation of adjacent sections
with lectin absorbed with the appropriate sugar:
PNA with 0-1 m d-galactose; SBA with 01 m d-
galactose and 01 m A-acetyl-d-galactosamine; and
WGA with 01 m V-acetyl-d-glucosamine. The lec¬
tin results were assessed without knowledge of the
receptor status.
RESULTS
Carcinomas with oestrogen receptor < 5fmol/mg
protein were considered negative; between 5 and 19
fmol/mg protein 'receptor poor' and > 20 fmol/mg
protein 'receptor rich'. The numbers in each cate¬
gory were 14, 9 and 30 respectively. Forty-one
tumours were examined for progestogen receptor
status; 29 were negative, i.e. <5 fmol/mg protein
and 12 were positive. One carcinoma was oestrogen
receptor negative, progestogen receptor positive
but the patient had received the anti-oestrogenic
agent tamoxifen prior to biopsy. There were, there¬
fore, 11 carcinomas which were oestrogen and pro¬
gestogen receptor positive.
The pattern of lectin binding was assessed on the
proportion of cells staining and was similar to that
previously described.6-7 For PNA the reactivity
after neuraminidase treatment was considered; the
majority of cells stained in 27 carcinomas (cate¬
gorized as many) mixtures of positive and negative
cells were seen in 21 tumours (moderate) and in five
carcinomas only a few cells reacted. Similar
methods of assessment were made for SBA and
WGA. Only four carcinomas had many cells react¬
ing with SBA, so these were included with the 15
tumours having moderate numbers of positive cells;
16 carcinomas had a few reactive cells and 18 were
negative. The results for WGA differed with 31 car¬
cinomas having the majority of cells staining, 17
tumours showing moderate numbers of cells react¬
ing and only five carcinomas having few reactive
cells.
The comparisons of PNA, SBA and WGA bind¬
ing with oestrogen and progestogen receptor status
are shown in Table I. The results were analysed by
X2 tests. Since the numbers in the oestrogen receptor
'poor' group were small two separate analyses were
undertaken for all lectins in which this group was
included with (i) the oestrogen receptor negative
tumours and (ii) the oestrogen receptor rich
tumours. Also for SBA the carcinomas with few
Table 1- -The relationship between the proportion of tumour cells binding specific lectins and steroid receptor status
PNA SBA WGA
Many Mod. Few Many/Mod. Few Neg. Many Mod. Few
Oestrogen
receptor
Negative 5 6 3 1 3 10 6 6 2
Poor 4 3 2 4 4 1 4 3 2
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About one-third of human breast cancers require hormones for
their continued growth1, and endocrine ablation or anti-hormone
therapy can cause regression of these tumours. As a consequence,
ovariectomy in premenopausal women or administration of an
anti-oestrogen (tamoxifen) in postmenopausal women represent
major options for treatment of metastatic breast cancer. Alterna¬
tively, chronic administration of agonistic analogues of luteinizing
hormone-releasing hormone (LHRH)2 causes regression of mam¬
mary tumours in experimental animals3-6, and such treatment has
shown promise in a small series of premenopausal women with
advanced breast cancer7. It has been assumed that these results
were achieved by suppressing the pituitary-ovarian axis, as the
treatment causes a reduction in circulating levels of gonadal
steroids similar to that produced by castration6-8. However, LHRH
agonists can exert major effects on tissues other than the pituitary
in animals9,10 and in the human11-15. Such findings, coupled with
reports of LHRH in human breast milk16 and immunohis-
tochemical evidence for the presence of LHRH-like activity in
some human breast tumours17, prompted us to test whether LHRH
agonists could have direct antitumour effects. We now report major
direct effects of LHRH and its agonists on the growth of breast
tumour cells in culture.
For these studies we used the MCF-7 breast tumour cell line,
the growth of which is responsive to sex steroids18"20. In pre¬
liminary studies, addition of the LHRH agonist D-Ser-
(Bu')6LHRH(l-9)-ethylamide (HOE 766; Hoechst) to MCF-7
cells every 2 or 3 days during culture inhibited cell growth, but
this effect was not major and was inconsistent. However, when
the LHRH agonist was added daily to the MCF-7 cells it caused
major consistent suppression of cell growth in a dose-related
manner (Fig. la). Culture of cells in the presence of concentra¬
tions of LHRH agonist in excess of 10-9M resulted in a net
decrease in cell numbers over the 4-day period of the experiment.
These effects were highly reproducible (Table 1). It was also
possible to elicit inhibitory effects on cell growth using native
LHRH, although much higher concentrations were required
than with the LHRH agonist (Fig. 16). The major inhibitory
effects of LHRH agonist on cell growth were blocked completely
by addition of the LHRH antagonist [N-Ac-D-Nal(2)'; D-pCl-
Phe2, D-Trp3, D-Har(Et2)6, D-Ala'°]LHRH, the combination of
this peptide and the agonist having no greater effect than the
antagonist alone (Fig. 1 c); the latter caused only minor but
statistically significant suppression of cell growth.
The fact that the LHRH antagonist blocks the inhibitory
effects of the LHRH agonist on the tumour cells suggests the
involvement of specific receptors. Using whole cell preparations
of the MCF-7 line, we were able to demonstrate specific binding
of 125I-labelled LHRH agonist (Fig. 2), for which LHRH showed
minor but significant competition whilst thyrotropin releasing
hormone (TRH) had no effect. The concentrations of LHRH
agonist required for displacement (10-6-10-4M) indicate that
the binding sites are of apparently low affinity when compared
with extrapituitary binding sites for LH RH agonists in the rat9,21.
However, the present observations are similar to those in other
human extrapituitary tissues (ovary, testis and placenta) which
also possess low-affinity binding sites for LHRH agonists13,22"24.
Moreover, in these tissues11,15,24"26, as in the MCF-7 cells studied
here, concentrations of LHRH agonist which are insufficient to
displace the binding of radiolabeled tracer under receptor-assay
conditions (10-9 M) are capable of eliciting clear-cut biological
effects. This paradox is unexplained but it may be simply a
reflection of the different time periods and temperatures used
for assessment of the receptor-binding potency of LHRH agon¬
ists and that used for assessment of the biological potency.
Alternatively it is possible that high-affinity binding sites for
LHRH agonist are present in MCF-7 cells and these other
tissues, but that they represent a small proportion of the total
binding sites present. It is also noteworthy that, in the present
studies, maximum binding of radiolabeled LHRH agonist was
obtained after only 10 min incubation at 21 °C. Longer incuba¬
tion (20-30 min) resulted in a marked decrease in binding (data
not shown), presumably as a result of proteolytic degradation.
Again, this is similar to findings for binding of LHRH agonist
to the human ovary, testis and placenta13,22,24. This presumed
proteolytic activity associated with MCF-7 cells would also
explain our inability to show consistent inhibitory effects of the
LHRH agonist on cell growth unless the media were replenished
with fresh LHRH agonist every 24 h.
To our knowledge, the present data represent the first
unequivocal demonstration that LHRH is capable of exerting
major direct effects on the growth of human breast cancer cells.
The possibility that these effects represent an anti-steroidal
action, as has been reported for LHRH agonists in other
tissues27,28, cannot be excluded at this stage, as the growth of
the MCF-7 cell line may be stimulated by small amounts
(10-11 M) of oestradiol29 such as are present in the fetal calf
serum included in these cultures.
At present, trials with LHRH agonists are being conducted
in premenopausal women as a form of medical ovariectomy30,31,
but if direct effects on breast tumour cells are possible there is
no reason why application of this therapy should be restricted
to premenopausal patients. Indeed, treatment with LHRH agon¬
ist can produce objective responses in some postmenopausal
women with breast cancer and inactive ovaries32, results which
are consistent with direct antitumour effects of the LHRH agon¬
ist. However, as the present findings suggest that the LHRH
agonist had to be replenished daily to be effective in inhibiting
tumour cell growth, then conventionally used doses of LHRH
Table 1 Reproducibility of the inhibitory effects of LHRH agonist on cell numbers during culture of the MCF-7 line
Concentration of
added LHRH No. of Day of culture
agonist (M) experiments 1 2 3 4
0 (7) 1.35±0.19 1.93 ±0.39 2.49 ±0.36 2.89 ±0.39
10-9 (5) 1.14 ±0.06* 1.07 ± 0.13§ 0.77 ±0.11§ 0.64±0.15§
10-7 (3) 0.96 ± 0.054 0.90 ±0.14+ 0.58 ± 0.12§ 0.39±0.10§
10-6 (2) 0.89 ±0. lOt 0.85 ±0.044 0.51 ± 0.01 § 0.15±0.07§
Values are the mean±s.d. and refer to the ratio of cell numbers on the day of collection to that (0.5 x 106) plated initially on day 0. Experimental
conditions and statistical analysis were as described for Fig. 1.
* P<0.05; t P< 0.02; 4 P<0.01; § P< 0.001; in comparison with respective control values (Student's f-test).
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INTRODUCTION
The growth of the human female breast is clearly under endocrine control.
In the absence of stimulatory hormones, the breast remains rudimentary
whilst major development normally only occurs at times of increased hormone
production such as puberty and pregnancy. It is, therefore, not
surprising that certain breast cancers should also require hormones for
their continued growth. Whilst polypeptide hormones are capable of
influencing events within breast cancers, (Dilley and Kister, 1975, Leung
and Shiu, 1981) the most convincing evidence for the involvement of endo¬
crine agents is for steroid hormones, particularly oestrogens. This
includes the observations that, a) the growth of cell lines of human breast
cancer may be stimulated by oestrogen both in culture (Butler et al, 1981,
Benz et al, 1983) and in immunosuppressed animals (Shafie 1980, Seibert et
al, 1983); b) the administration of oestrogen to breast cancer patients
with metastatic deposits in bone may cause increased urinary calcium
excretion due to accelerated tumour growth (Pearson et al, 1954); c)
oestrogen deprivation therapy causes regression of breast cancers in about
one-third of patients with advanced disease (Henderson and Canellos, 1980);
d) these effects are invariably associated with tumours which possess
receptors for oestrogen (Jensen et al, 1974, McGuire et al, 1975). Endo¬
crine intervention therefore represents a major treatment option for ad¬
vanced breast cancer especially against tumours which are rich in oestrogen
receptors. In premenopausal women, therapy usually takes the form of
castration which classically is achieved by surgical or radiological
ablation of the ovaries. However, with the observation that chronic ad¬
ministration of agonist analogues of LHRH suppresses the pituitary-ovarian
axis (Schally et al, 1970, Petrosa et al, 1980) and may reduce circulating
oestrogen to castrate levels (Nicholson and Maynard, 1979, Klijn and de
Jong, 1982), the concept has developed of using LHRH agonists in the treat¬
ment of breast cancer as a form of chemical ovariectomy (Corbin, 1982, Furr
and Nicholson, 1982). Whilst clinical studies with LHRH agonists have
largely been performed in premenopausal women (Klijn et al, 1984) there
are reports of beneficial anti-tumour effects in postmenopausal patients
who were without measurable ovarian function (Harvey et al, 1984). Such
observations raise the likelihood of direct effects of LHRH agonists on
breast tumours, a possibility supported by the increasing number of reports
describing effects of LHRH agonists on extra pituitary tissues (Khodr and
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Siler Khodr, 1978, Lamberts et al, 1982, Tureck et al, 1982, Tan and
Rousseau, 1983).
The evidence will therefore be presented that LHRH agonists have
direct inhibitory effects on the growth of breast cancer cells in culture
and that tumour cells possess specific binding sites for LHRH and its agonise
in addition to the data that indicate that LHRH agonists produce a thera¬
peutic castration and thereby are of benefit to premenopausal women with
advanced breast cancer.
LHRH agonists as therapy for premenopausal patients with advanced breast
cancer
The use of chronic LHRH agonist treatment as a contraceptive to
suppress follicular development and ovulation is well established (Bergquist
et al, 1981, 1982a- Schmidt-Gollwitzer et al, 1981, 1982). The exact
mechanism by which this is achieved is not fully elucidated but pituitary
desensitization (Belchetz et al, 1978; Sandow et al, 1978; Bergquist et al
1982b) which reduces gonadatrophin drive to the ovaries, is primarily
implicated. Chronic administration of LHRH agonists to premenopausal
women therefore reduces circulating oestrogens to castrate levels, although
this may take several months to achieve (Nicholson et al, in press). These
observations drew attention to the possibility of using LHRH agonists to
treat premenopausal women with oestrogen dependent breast cancer (Corbin,
1982, Furr and Nicholson, 1982). So that a consistent suppression of
gonadal steroids may be maintained, higher doses of agonist are required
than for contraception. This can be achieved via nasal spray (Hardt and
Schmidt-Gollwitzer 1983) but daily injections or infusions result in more
reliable suppression (Klijn and de Jong, 1984).
To date, only small numbers of patients with advanced breast cancer
have been treated with LHRH agonists. Klijn and de Jong (1984) have used
the LHRH agonist, Buserelin, in a variety of regimes involving parental
administration followed by either intranasal or subcutaneous treatment alone
or in combination with other endocrine agents. Of a total of twenty two
women receiving agonist alone, four patients had an objective response and
another four had stabilization of disease. Treatment was associated with
anovulation in all patients although transient peaks of plasma oestradiol
were detected in most. Beneficial effects of other LHRH agonists have
also been documented. Nicholson et al (1985) reported responses in three
of fifteen and Harvey et al (1984) in two of four premenopausal women with
advanced breast cancer treated with Zoladex.
This overall response rate to LHRH agonists is similar to that which
would have been obtained by ovariectomy and there is reason to believe that,
in the majority of premenopausal women, the benefits of LHRH agonists were
achieved by a castration-like effect. Thus, in general, patients with the
best responses to LHRH agonist had complete endocrine castration and
possessed oestrogen receptor-positive tumours whilst non-responders to LHRH
agonists rarely responded to subsequent removal of their ovaries. Only
single cases have been reported of (a) a response in a patient with per¬
sistant plasma oestrogen following LHRH agonist therapy (Klijn et al, 1984),
(b) remission in an oestrogen receptor negative tumour (Klijn et al, 1984)
and (c) response to surgical castration in a patient previously failing
agonist therapy (Nicholson et al, 1985). Treatment with LHRH agonist is,
however, unlikely to replace surgical removal of the ovaries as the primary
endocrine therapy in premenopausal women with advanced breast cancer - at ;
least at the present time. Although ovariectomy is irreversible, it is a !
surgical procedure with very little morbidity and, because of the age-
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Fig. 1 The effects of oestradiol (E2) and antioestrogen, tamoxifen (TAM)
on the growth of human breast cancer cells in culture. Each
point represents the mean value of triplicate systems.
To study effects on growth in culture, cells were grown at 37°C in
Dulbecco's minimal essential medium containing 10% heat-inactivated foeatal
calf serum, under a humidified atmosphere of 5% 00^:95% air. Once growing
in log phase, cells were collected and plated out in 60mm Petri dishes
(0.5 x 106 cells in 4ml culture media). Sufficient dishes were set up so
that each test system could be studied in triplicate at each time point.
Hormones were added to the appropriate test systems after being dissolved
in culture media. Cells were incubated for either 1, 2, 3 or 4 days,
media being replenished each day. Growth was monitored by counting
harvested cells in a haemocytometer after collection by trypsinization.
Further experimental detail has already been published (Miller et al, 1985)
The effects of the LHRH agonist, buserelin, on the growth of MCF-7
cells is shown in Figure 2. All concentrations of the agonist other than
10"1 M caused significant (p < 0.001) inhibition of growth in comparison
with control cells. These inhibitory effects were dose-related and con¬
centrations of buserelin in excess of 10~®M produced a net decrease in
cell numbers after four days of culture. Levels in excess of 10" 2M
agonist resulted in a progressive decrease in cell numbers over the whole
test period. Inhibitory effects were highly reproducible and could be
detected microscopically (see Plate) as early as day 2 of culture.
Although cell numbers are decreased even after short exposure to LHRH
agonist, the remaining cells appear viable and, after an initial delay,
will show increased growth if cultured in media without LHRH agonist. The
specificity of these inhibitory effects was studied by performing similar
studies with native LHRH. the 3-10 fragment of LHRH and the LHRH antagonist
<N-Ac-D-Na(2)1, D-pCL-Phe2, D-Trp3, D-hArg(Et2)6, D-Ala )LHRH. Native
LJ^H was also capable of inhibiting cell growth although much higher con¬
centrations were required than with the LHRH agonist (Figure 3). The
3-10 fragment of LHRH did not significantly affect the growth of the mcf-7
cell line. The major inhibitory effects of LHRH agonist on cell growth
were completely blocked by addition of the LHRH antagonist, the combination
of the two peptides having no greater effect than the antagonist alone
(Figure 4); the latter only caused minor but nevertheless significant






As judged by the displacement of labelled LHRH agonist by unlabelled
LHRH agonist, the MCF-7 cells contained binding sites with a low affinity
(Kd "4 x 10-5M) for the LHRH agonist (Figure 7). However,^these binding
sites showed a high degree of specificity in that only peptides which were
LHRH-like competed for binding with 125I-LHRH agonists. Thus, two LHRH
antagonists ({Ac3-4 dehydro-Pro^, D-pFPhe2, D-Trp^>6}LHRH and {N-AC~D-
Nal(2)1, D-pCl-Phe2, D-Trp2, D-hArgCEt,)6, D-Ala^°}LHRH) both competed for
binding with higher affinity (Kd ~ 10" °M) than did the LHRH agonist Ynilst
native LHRH competed very poorly (Kd >5 x 10"4 ). Surprisingly, J"i0LHRH,
which is completely devoid of any biological activity in-vitro, displaced
binding of 125I-LHRH agonist nearly as effectively as did the unlabelled
agonist itself. Of the other peptides tested, at concentrations up to
ImM, only bradykinin caused any displacement of binding and this was
considered to be due to alteration of the pH of the incubation medium
which contained a pH indicator.
Whilst these results demonstrate the presence on MCF-7 cells of
specific binding sites for LHRH—like peptides, the low affinity of these
sites for the LHRH agonist is puzzling in that biological effects of the
sameqagonist on growth of the MCF-7 cells in-vitro was obtained with doses
(10~'M) far lower than the apparent affinity (Kd) of the Dreceptor (4 x
10~^M) for this peptide. We still have no explanation for this disparity,
but it should be emphasized that it has been evident in every binding
experiment performed. One possibility is that the MCF-7 cells contain two
classes of MlRH-receptors, one of high affinity but low capacity and the
other of low affinity and high capacity, with the former mediating the
biological effects on growth. Unfortunately, because of the low numbers
of LHRH-receptors present and other technical limitations it is not feasible
to test directly this possibility.
It is equally intriguing that LHRH-receptors with relatively low
affinity (Kd's of 10~® to 10-2M) for the LHRH agonist used in the present
studies, have also been reported in other human extra-pituitary tissues
such as the placenta (Currie et al, 1981) and corpus luteum (Popkin et al,
1983, Bramley et al, 1985). Moreover, in the placenta, these receptors
have been shown to mediate biological effects of LHRH-like peptides
(Belisle et al, 1984), and the gene for LHRH has been isolated from the
human placenta (Seeburg and Adelman, 1984).
Therefore, it appears that several human extra-pituitary tissues
contain LHRH-receptors which have a considerably lower affinity for LHRH
agonists than do the respective extra-pituitary LHRH-receptors in the rat
testis (Sharpe and Fraser, 1980) and ovary (Clayton et al, 1979). This may
indicate that the human extra-pituitary LHRH-receptors are designed to
detect a locally-produced LHRH-like peptide, the structure of which is
different from native hypothalamic LHRH. In this respect it is of interest
that LHRH has been reported in human breast milk (Amarant et al, 1982) and
LHRH-like activity has been located immunohistochemically in certain ductal
carcinomas of the breast (Seppala and Wahlstrom, 1980). Most recently,
LHRH-receptors have been identified in a high percentage of ductal breast
carcinomas (Eidne et al, 1985), although it is puzzling that these receptors
were shown to have a relatively high affinity (Kd ~ 10"8m) for an LHRH
agonist, a finding which contrasts with the present findings in cultured
breast tumour cells. The only major differences in technique used by
Eidne et al (1985), when compared with the present studies, were the use
of a membrane preparation and the use of an LHRH nonapeptide agonist with
modifications at positions 6, 7 and 9 of the molecule, as opposed to the
agonist used in our studies which had modifications only at positions 6 and
9. In preliminary studies using membrane preparations from breast cancer
tissue, we have again found binding sites with low affinity (~ 10~^M) for
our LHRH agonist (data not shown), which suggests that the important
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Fig. 7 Displacement of the binding of 125i-labelled LHRH
agonist to isolated MCF-7 cells by increasing
concentrations of unlabelled LHRH agonist (LHRH-A),
two LHRH antagonists (ANTAG^ and ANTAGj), LHRH and^-^LHRH as well as several other peptides. Non¬
specific binding was determined by addition of
7 x 10~^M unlabelled LHRH-A. Each point is the
mean of triplicate incubations.
LHRH ANTAG^ = (Ac3-4 dehydro-Pro3, D-pFPhe2,
D-Trp3»6)LHRH
LHRH ANTAG2 = (N-Ac-D-Nal(2)1, D-pCl-Phe2, D-Trp3,
D-hArg(Et2)6, D-Alal0)LHRH
LHRH-A = (D-Ser-t-bu6, des-Gly-NH210)LHRH ethylamide
difference between our studies and those of Eidne et al (1985) is the use
of an LHRH agonist with an additional modification at position 7.
Taken together, our findings and those of Eidne et al (1985) suggest
that LHRH-like molecules may be capable of exerting direct effects on some
human breast tumours, although what proportion of tumours might respond,
and the nature of the response, remains to be determined. In our studies,
we have tested for inhibitory effects of LHRH agonists on the growth of 3
breast tumour cell lines and only in the MCF-7 cells were major effects
obtained; in the MDA-MB-231 cells no effects on growth were observed whilst
in the T-47D line, only minor inhibition of cell growth was obtained (see
Figure 5). However, a recent report has described major inhibitory
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effects of an LHRH agonist on prolactin-stimulated growth of T-47D cells
(Witzner and Benz, 1984), which perhaps suggests that LHRH exerts its
inhibition only when growth of the cancer cells is stimulated, the nature
of the stimulus being specific for different cell lines, i.e. oestrogen
for MCF-7 cells and prolactin to T-47D cells. With respect to these
findings, we have also identified low affinity binding sites for LHRH
agonist in cells from the '|jk47D (Kp 6 x 10~5m) and MDA-MB-231 (Kjj 1.5
x 10~^M) lines (data not shown).
SUMMARY
In premenopausal women with advanced breast cancer, treatment with
LHRH agonists may cause a medical ovariectomy and thereby induce the
regression of oestrogen—dependent tumours. However, there is good evidence
from laboratory studies of breast cancer cells in culture and beneficial
results of LHRH agonist therapy in postmenopausal women which suggest a
more direct anti—tumour effect. The inhibitory action of LHRH and its
analogues on cultured tumour cells appears to be mediated by a specific
recognition mechanism and the presence of specific binding sites on breast
cancer cells can be demonstrated. If the anti-tumour effects of LHRH
agonist are to be fully exploited in clinical practice, future research
should be directed towards elucidating the mechanism by which LHRH agonists
inhibit tumour growth and to determining the optimal regime for adminis¬
tration of the agent.
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Hormones and Female Breast Cancer
Clinical Relevance
Andrew Patrick Forrest and William R. Miller
Breast cancer is the most common female cancer which is reported to
now affect one in every 11 women in the United States.1 It is a disease
that typically disseminates early, but recurs late. Once invasive cancer
is established, micrometastatic disease occurs quickly so that local treat¬
ment alone, traditionally believed to be the key stone of successful man¬
agement, cannot hope to cure. Typically, the tumor is slow growing, so
that many years may elapse before metastases become clinically evident.
Such long-term follow-up studies, as that reported by Brinkley and Hay-
bittle,2 indicate that even 25 years following the initial treatment of breast
cancer, women have an excess mortality from metastatic disease (Fig. 1).
In their series of 704 patients treated in East Anglia between 1947-1950,
statistical cure i.e., the attainment of a group that is subject only to normal
mortality rates, has not yet been demonstrated.
There would appear to be only three possibilities for improvement
of this grave situation: (1) to employ effective systemic treatment to elim¬
inate micrometastases at the time of initial treatment of invasive disease;
(2) to detect the disease at a pre-invasive stage, i.e., before micrometastatic
spread has occurred; and (3) to prevent induction or promotion of the
breast tumor by eliminating causative factors.
HORMONES
The growth of breast cancer, like that of cancer of the prostate, is
influenced by hormones. This fact was unequivocally demonstrated by
two surgeons: the first, George Beatson of Glasgow who, in 1896 reported
that oophorectomy could induce remission of advanced disease in pre¬
menopausal patients;3 the second, Charles Huggins of Chicago, who dem¬
onstrated in 1945 that adrenalectomy had a similar effect in postmeno¬
pausal women.4 Evidence that the effect of castration on the progress of
human breast cancer was due to deprivation of estrogenic hormones was
first reported by Pearson and his colleagues in 1954, from the Memorial
Sloan-Kettering Cancer Center in New York.5 They measured the daily
excretion of calcium in the urine of six women with metastatic bone
disease throughout several menstrual cycles, following oophorectomy
and then after the administration of ethinyl-estradiol (Fig. 2). A cyclical
134








Fig. 1. Long-term follow-up of 704 patients with breast cancer after initial treatment in
Cambridge, England. Redrawn from Brinkley DM, Haybittle JL.2 _
pattern of urinary calcium was evident during the menstrual cycle and
was abolished by oophorectomy, when the level of urinary calcium dra¬
matically fell. The subsequent administration of ethinyl-estradiol stim¬
ulated calcium secretion. These changes were believed to be due to the
increase and reversal of bone breakdown as a result of removal and re¬











Fig. 2. Excretion of urinary calcium in postmenopausal women with breast cancer metastatic
to bone before and after oophorectomy and following administration of ethinyl-estradiol. Re¬
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Further evidence for the involvement of estrogen in the growth of
human breast cancer was provided by Jensen and colleagues,6 who dem¬
onstrated that the cytosol of approximately 70% of breast cancers contained
high affinity binding proteins for estradiol similar to those present in
the cells of other normal estrogen-sensitive tissues. This receptor mech¬
anism is an essential step whereby estrogens exert their effect on nuclear
events,7 cell division and growth. Work in several laboratories has shown
that at least 90% of tumors that respond to hormonal treatment contain
estrogen receptors, whereas cancers that do not possess this receptor
mechanism rarely respond to hormonal measures, a fact of value in the
management of patients with advanced disease.8,9
Direct effects of estrogen on human breast cancer cells have been
studied in the MCF-7 cell line, both in culture10 " and following innoc-
ulation into immune-deprived (nude) mice.12,13 Thus, under appropriate
culture conditions, concentrations of estrogen (as little as lCT" molar),
have been shown to promote cell growth14 (Fig. 3). Additionally, innoc-
ulates in nude mice will grow only in the presence of implants of estro¬
gen.12,13 Recent work suggests that in the MCF-7 cell line, the effects of
estrogen may be mediated through the autocrine action of induced growth
factors.15
The rarity of the breast cancer in males, and the reduction in its
incidence in women following castration early in life, suggests that es¬
trogen is also an important factor for the development of the disease in
humans. Evidence to implicate other hormones, e.g., progesterone, tes¬
tosterone, growth hormone, and prolactin in the initiation, promotion,
or growth of human breast cancer, is less convincing.
Sim/my of ialrogciis
The major source ot estrogens in premenopausal women Is the ovai les,
the cyclical secretion of which produces high circulating levels of estradiol
and estrone at various periods of the menstrual cycle. Following the
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menopause, circulating levels of estrogen are much reduced16""18 and they
appear not to be derived either from the ovaries or, despite previous
belief, the adrenals.19,20 In postmenopausal women, estrogens would ap¬
pear to be formed by the peripheral conversion or aromatisation of pre¬
cursor adrenal C19 steroids (dehydroepiandrosterone [DHA], its sulphate
[DHA-S], and androstenedione).21-23 There is good evidence that a major
site for this activity is fat,24 and this explains the correlation between
the degree of obesity and the levels of circulating estrogen in post¬
menopausal women.25 There is also good evidence for the local synthesis
of estrogens within the breast both in fat26 and also in the cancer itself.27"29
In our laboratory, one half of all breast cancers incubated in vitro with
androgen precursors were found to synthesize estrogens.30
The breast has an abundant supply of aromatizible C19 steroid pre¬
cursors. Studies by our group,31 by Bradlow & co-workers in New York32
and by Angeli and^ssociates in Turin,33 have shown that human breast
secretions, whether aspirated from the nipple or obtained by needle as¬
piration of breast cysts, contain remarkably high concentrations of DHA
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therefore, have the materials and mechanisms to form an effective factory
for the local synthesis of estrogenic hormones.
THERAPY
The first method by which cure rates may be improved is the ad¬
ministration of effective systemic therapy to eradicate micrometastic dis¬
ease. Since the original studies of Fisher et al.34 and Bonadonna et al.,3i
many controlled randomized trials have been reported in which it has
been shown that chemotherapy, when administered as part of initial
treatment, can prolong the interval to recurrent disease. Conclusions
regarding effects on mortality have been less certain, possibly because
the results of many trials are considered in isolation. An overview of
data on mortality from all available trials involving over 10,000 random¬
ized women was presented at a meeting convened jointly by the UK
Breast Cancer Trials Co-ordinating Subcommittee and the Project on Con¬
trolled Therapeutic Trials of the UICC in London in October 1984, where
it was reported that the administration of chemotherapy, particularly
variants of the initial CMF (cyclophosphamide, methotrexate, 5-fluoro-
uracil) regimen, significantly reduced short-term mortality (from a vari¬
able period of less than 1 to more than 5 years). In women first diagnosed
after 50 years of age, reductions in mortality were only moderate (from
20% in control to 16%—18% in treated patients) but, in younger women,
the effect was approximately twice as great.36
Chemotherapy may have unpleasant side effects, and interest in hor¬
monal manipulations has been rekindled by the report from Toronto,
that when irradiation of the ovaries is combined with long-term steroid
therapy (prednisone 7.5 mg daily) as part of the initial therapy of early
breast cancer, survival in the premenopausal patient is significantly pro¬
longed.37 The development of a new range of pharmaceutical agents with
potent anti-estrogenic effects, e.g., tamoxifen (Fig. 5), aminoglutethimide
(Fig. 6), and LH-RH agonists (Fig. 7), has further stimulated the use of
endocrine treatment in early disease.
Tamoxifen
First tested in 1966 by Harper and Walpole,38 tamoxifen, a synthetic
triphenylethylene (Fig. 5), antagonizes the actions of estrogen by binding
to the estrogen receptor protein but forming a complex which is inef¬
fective.39 Tamoxifen receptors have also been demonstrated in human
breast cancer cytosols,40 but their significance is uncertain. In MCF-7
human breast cancer cell line, tamoxifen inhibits growth, an effect which
is reversed by the addition of estrogen.
The use of tamoxifen in postmenopausal women with advanced cancer
of the breast is now well established, 30% to 40% obtaining benefit.41 As
tamoxifen has few significant side effects, it has particular attractions for
use as an adjuvant to primary therapy, and a number of controlled trials






Fig. 5. Tamoxifen. Fig. 6. Aminoglutethimide.
Fig. 7. LH-RH agonisl: Buserelin.
comparing tamoxifen with no systemic therapy and tamoxifen plus che¬
motherapy, with chemotherapy alone, have now been reported. As with
chemotherapy, prolongation of the disease-free interval has been re¬
peatedly observed (Fig. 8) and firm evidence for reduction in mortality
is now available. At the London overview,36 which included 16,000 women
admitted to controlled trials, a highly significant reduction in short-term
mortality (less than 1 to more than 5 years of follow-up) was observed
in women aged 50 years or older at diagnosis. This was similar in extent












Fig. 8. The effect of adjuvant tamoxifen therapy on possibility of recurrence in 1285 women
with primary cancer of the breast. Redrawn from Baum M et al.42
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It is important to know whether equal benefit can be achieved by
the routine use of tamoxifen as first treatment for recurrent disease. This
question is being addressed in Scottish centers in which tamoxifen therapy
at the time of initial treatment is compared with tamoxifen given at the
time of first recurrence.43 In this trial, which includes over 1400 women,
those receiving initial tamoxifen therapy do so for 5 years, when a sec¬
ondary randomization is carried out to proceed with or discontinue
the drug.
Aminoglutethimide
Initially developed for use as an anticonvulsant, aminoglutethimide,
an analogue of glutethimide (a hypnotic) (Fig. 6), was withdrawn because
of its suppressing effect on the function of the adrenal and thyroid glands.
It was this property, of inhibiting adrenal synthesis of steroids, that led
to its use combined with hydrocortisone as treatment of postmenopausal
women with advanced breast cancer (medical adrenalectomy).44 The action
of aminoglutethimide on the adrenal is to inhibit the conversion of cho¬
lesterol to pregnenolone, which is the rate limiting step whereby steroid
hormones are synthesized.45 The enzyme inhibited is a cytochrome P450
complex, as are many other enzyme systems, including that of aroma-
tization.46 In postmenopausal women, this latter action would be directed
against the peripheral synthesis of estrogens from C19-steroid precursors
in fat and other tissues. We have demonstrated an anti-aromatase effect
also in the breast by in vitro incubation of human breast cancer in the
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The effect of aminoglutethimide in inducing remission of advanced
breast cancer is more or less identical to that of adrenalectomy, and this
has been confirmed in a controlled randomized trial comparing these two
procedures.48 The benefit achieved is similar to that of tamoxifen, but
aminoglutethimide may induce a further response after initial tamoxifen
therapy has failed.49,50
Although side effects (gastrointestinal disturbance, lethargy and al¬
lergic manifestations) can be troublesome, a trial of aminoglutethimide
as systemic treatment in early disease is underway.51 Preliminary reports
suggest that the disease-free interval is prolonged, but survival data are
not yet available.
Other more specific and more potent inhibitors of the aromatase sys¬
tem are being developed. These include 4-hydroxyandrostenedione,52
which shortly will be available for clinical trial.
LH-RH Agonists
Many of the synthetic analogues of luteinizing hormone-releasing
hormone (LH-RH) have agonistic effects (Fig. 7). Their action is similar
to that of pharmacologic doses of the natural hormone. After an initial
surge in gonadotrophin release, the pituitary is desensitized to further
stimulation so that secretion of LH and FSH is blocked.53 The chronic
effect in premenopausal women is to produce a "medical oophorectomy."
The LH-RH agonist buserelin has also been shown in our laboratories to
have a direct effect on the growth of the MCF-7 cell line in culture
A disadvantage of the initial preparations of these agonists was the















Fig. 10. Effect of LH-RH agonist on growth of MCF-cells in culture.54
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A long-acting depot preparation has now been developed. The use of this
agent in patients with breast cancer is still at a preliminary stage/5 but
studies have been reported in male patients with advanced prostatic can¬
cer.56 Circulating levels of testosterone are suppressed, this being asso¬
ciated with clinical remission of the disease. This agent is clearly of con¬
siderable interest in the management of premenopausal women with
breast cancer.
Prediction
As only a proportion of patients have tumors that are sensitive to
hormonal influences, the therapeutic effect of adjuvant therapy in those
which do may be very great indeed. As indicated above, assays of estrogen
receptor activity in a tumor can aid the prediction of response of patients
with advanced breast cancer to endocrine therapy. Additional discrim¬
ination has been reported by simultaneous assays of receptor for pro¬
gesterone receptor activity, replenishment of which is apparently de¬
pendent on an intact and functioning estrogen receptor system. Evidence
is beginning to accrue that these assays may be of value in predicting
which patients are most likely to gain benefit from adjuvant systemic
therapy.57"59 Detailed studies of receptor activity and other possible in¬
dices of tumour sensitivity such as aromatase activity are clearly required.
EARLY DIAGNOSIS
There is firm evidence that the early detection of breast cancer through
regular screening by clinical examination and mammography influences
the mortality of the disease benefically. This has come from the random¬
ized study carried out in New York, in which 30,000 women age 50 to 69
years were offered annual clinical and mammographic screening on four
occasions; 30,000 women, not offered screening, acted as controls.60 Over
an initial 5-year period, 303 cancers were detected in the screened group
and 284 in the controls. Case fatality rates proved significantly better in
the women in the group offer screening (Fig. 11), an effect most pro¬
nounced in those whose cancer had been detected by screening and par¬
ticularly when the lesion was only evident on mammography (Fig. 12).
Because the age-specific mortality from breast cancer in the population
offered screening has also proved to be significantly less than in the
control group over a period of 14 years, lead-time bias cannot account
for this difference. Several controlled randomized trials are also in prog¬
ress in Sweden, Canada, and in Edinburgh, Scotland, but case fatality
and mortality statistics are not yet available.
Mortality apart, cancers detected through screening are smaller in
size and less likely to have metastasized to the regional lymph nodes
than those which are discovered spontaneously. This has the advantage
of allowing more conservative local therapy with preservation of the
breast.
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years after diagnosis
In the United States, regular clinical and mammographic examination
of the breast is recommended for all women older than age 50 years.61
This is expensive, and simpler methods of presymptomatic detection, e.g.
by single oblique mammograms, are under trial elsewhere.62 The selective
screening of those known to be at risk could have many advantages.
Factors known to influence the risk of breast cancer include age, a
family history of breast cancer, and previous benign breast disease. En-
years after diagnosis
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vironmental factors are also important, and include social class and the
Western way of life: dietary fat and body weight are considered by some
to be most relevant.63,64 Other more direct hormonal influences have also
been shown to bear on breast cancer risk.65,66 The ablation of ovarian
function early in life reduces the incidence of breast cancer,67 whereas
prolongation of active menstrual life increases this. Nulliparous women
are more at risk of developing the disease than are muciparous, and the
greater the number of pregnancies the more is its incidence reduced.66
This is largely, but not entirely, explained by the younger age at first
full-term pregnancy in those with multiple births, an association first
brought out in an international study reported by MacMahon and col¬
leagues.68 A recent case-control study has indicated that US women having
their first full-term pregnancy after the age of 30 years have a four- to
five-fold excess risk compared to those having their first birth before age
18 years.69
If hormonal factors are of importance as determinants of risk, it would
be expected that exogenously administered hormones would influence
the risk of breast cancer. Three areas have provoked intense investigation:
(1) the administration of high doses of stilbestrol (up to 15 g/pregnancy)
during pregnancy; (2) use of oral contraceptives; and (3) hormone re¬
placement therapy in postmenopausal women. To date, the evidence re¬
mains controversial (for recent review see reference 70).
Of recent interest was the observation by Pike and colleagues71,72
that the prolonged use of oral contraceptives before the age of 25 years
was associated with an increased risk of breast cancer. This finding has
been confirmed by a study from Oxford.73 Although it was suggested that
the increased risk was particularly associated with oral contraceptives
of high progestogen potency, the classification of progestogenic activity
(based on delay in menses) is not valid for the effect of progesterone on
the breast.74 Other case-control and cohort studies in young women are
now underway to examine this finding further.
The search for an underlying endocrine abnormality associated with
an increased risk from breast cancer is clearly worthwhile. Numerous
case-control studies have been carried out, in which assays of plasma
and urinary hormones in women with established disease have been
compared with normal controls. In general, the results are conflicting.
Such studies have a major drawback: the hormone milieu may radically
change between initial induction of the tumor and clinically evident
disease. Prospective studies, in which the endocrine profile is established
in normal women who are subsequently followed up to determine whether
they develop breast cancer, are of greater relevance. Examples are the
studies of Bulbrook and associates in the Island of Guernsey75,76 and
DeWaard and co-workers in Utrecht.77 Such prospective studies are com¬
plex and expensive. Comparisons of hormone levels in women known,
for other reasons, to be at high or low risk are more easy to perform.
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Examples include comparisons of Western and Asiatic women,78,79 women
with and without a strong family history,80 and nulliparous and parous
women.81 Various differences have been described, some of the most im¬
portant of which are summarized in Table 1.
The results of assays of circulating hormones are difficult to interpret.
Differences are small and often conflicting. There are sampling problems
(hormone levels do not remain static over a 24-hour period), and when
differences are reported, they are often of statistical import for groups
rather than discriminatory in individual patients. The advent of salivary
assays, which do not require repeated intravenous sampling, may allow
some of these difficulties to be resolved.
Of greatest interest are those studies which may monitor the supply
of hormones actually available to the breast, e.g., assays of free circulating
estrogen.84 This can also be studied by assays of the hormonal composition
of human breast secretions, but information on estrogen content of such
fluids is scanty.
The application of risk factors and hormonal assays to the detection
of women at risk from breast cancer has not proved fruitful. These have
Table 1. Examples of Hormonal Changes Described in Women at Varying Risk
From the Development of Breast Cancer
Hormones Population studied Results Reference
Urinary androgens Women subsequently developing Lower etiocholanolone 75, 76
breast cancer versus those in cancer group
remaining disease-free
No difference 77
Japanese versus British women Lower etiocholanolone 78
in Japanese
Urinary estrogens Asian versus Western women Estriol ratio higher in 79
Asians
Parous versus nulliparous Estriol ratio higher in 81
parous
Parous versus nulliparous No difference 82
No family history versus strong No difference 80
history
Total plasma No family history versus strong Higher estrogens in 83
estrogens history strong history
No difference 80
Free plasma Women subsequently developing Higher free estradiol in 84
estrogen breast cancer versus those breast cancer group
remaining disease-free
16ahydroxylation No family history versus strong Higher in strong history 85
history
Noctural plasma Nulliparous versus parous Lower in parous 86
prolactin
Plasma Benign disease versus normal Lower in benign disease 87
progesterone women
No difference 88
Salivary Benign disease versus normal No difference 89
progesterone women
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been tested in combination in the HIP study of New York, the Guernsey
study and the BCDDP project, but the sensitivity and specificity is too
low to allow the definition of a sufficiently small proportion of women
which contains the majority of cancers.90"92 For example, using a logistic
analysis including age at menarche, family history, age at first birth, and
etiocholanolone excretion, Farewell was able to identify only 82% of cancer
cases in 55% of the population (or 47% of the cancers in 17% of the pop¬
ulation).90
PREVENTION
From these considerations, it seems unlikely that hormonal assays
will permit the definition of a pattern of abnormality which will identify
women at risk with sufficient precision to be useful in a breast cancer
screening program. This is disappointing as, were it possible to detect
"risk" patterns of hormone levels, the way would also be paved for in¬
tervention studies that could lower the incidence of the disease.
A good example is the suggestion that luteal phase insufficiency, i.e.,
inadequate progesterone secretion in the second half of the menstrual
cycle, may, by allowing unopposed estrogen action on the breast, increase
risk (Fig. 13). Were this so, the defect could readily be corrected by pro¬
gesterone administration. Unfortunately this suggestion is not supported
by recent evidence from the use of serum and of salivary assays to doc¬
ument circulating progesterone levels in groups of women with and
without breast disease during whole menstrual cycles (Fig. 14).88,89 Before
corrective therapy can be applied, there must be uncontroversial evidence
of a reproducible and correctible abnormality, and it is there that the
days of luteal phase
Fig. 13. Plasma progesterone values: 109 patients with breast disease and 50 control women
during days 1-12 of the thermal plateau. Reproduced with permission from Mauvais-Jarvis P
et al.B7
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Fig. 14. Circatrigintan variations in salivary progesterone in premenopausal women. Re¬
produced with permission from Read GF el al."9
problem lies. We are still a long way from using hormonal manipulations
to prevent breast cancer.
It is concluded that knowledge of hormonal aspects of breast cancer
has not proven to have immediate clinical relevance, either in the early
diagnosis of the disease or its prevention. However, the development of
new therapeutic agents which influence the endocrine system now offers
hope of the better control of established disease. Breast cancer starts in
the epithelium of the lobule and its terminal duct, and it is the supply
of estrogen and possibly other hormones to that composite unit (terminal
duct lobular unit) which is likely to prove of greatest significance. For
further progress, hormonal interactions within the breast need to be
studied.
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It is common knowledge that hormones control normal breast
development in the human female. Growth of the breast mostly occurs
at puberty and during pregnancy and, conversely, involutionary changes
take place after pregancy and the menopause. Hormone excess or
imbalance is also implicated in the aetiology of breast abnormalities
including cancer. Despite this, the parts played by individual
hormones in these processes are ill-defined. This chapter will
examine the roles of the ovarian steroids, oestrogen and progestogen,
by considering (a) their involvement in the development of normal
breast; (b) the histological appearance and biochemical activity of
the breast in the absence of ovarian production of these steroids,
i.e. after the menopause or castration; (c) the effects of exogenous
administration of oestrogen and progestogen, particularly in
postmenopausal women and (d) the evidence that risk of breast cancer
is changed by prolonged stimulation with oestrogen alone or in
combination with progestogen as might occur following late natural
menopause or replacement hormone therapy.
HORMONES AND BREAST DEVELOPMENT
Development of the Adult Breast
The breast is a relatively quiescent organ until puberty. At
this time, which may precede first menstruation by several years,
discs of stromal connective tissue develop underneath the nipple and
areola. Within these discs, lactiferous ducts lengthen and branch to
open at the nipple which itself becomes everted. Simultaneously,
lobular buds develop although the lobules themselves are not
completely formed until ovulatory menstrual cycles occur. Mature
breast lobules are the functional units of the adult breast (Figure
1a) and thousands may exist in each breast. The epithelial (or
2
parenchymal) component comprises only a small proportion of the total
breast volume and the breast is mostly composed of supporting fibrous
tissue and fat.
Although the adult non-lactating breast produces limited amounts
of secretion which appear to be reabsorbed during transit through the
duct system it is only during pregnancy and lactation that the breast
achieves full secretory status and all lobules fully develop. Both
ductal and glandular elements of the breast proliferate greatly so
that by the end of pregnancy, the breast is composed of a compact mass
of lobules each containing multiple alveoli lined by secretory cells
(Figure 1b). These produce colostrum during pregnancy and milk during
lactation.
Hormone Involvement
Major breast development coincides with puberty and pregnancy.
These are times at which the output of many hormones is dramatically
increased. At puberty, hormones of pituitary origin increase in
addition to ovarian production of oestrogen and progesterone.
Similarly, during pregnancy, the foetal-placental unit not only
secretes additional oestrogen and progesterone but is also responsible
for the production of polypeptides with properties similar to those of
growth hormone, prolactin and gonadotrophins. The roles of individual
hormones are not readily defined and breast development probably
requires synergistic cooperation between a multiplicity of hormones
(Figure 2). The most convincing evidence for this comes from studies
in experimental animals. Thus, the response of mammary tissue to
hormones administered singly or in combination to rats in which
endogenous hormones were reduced by oophorectomy, adrenalectomy and
hypophysectomy showed that (a) the minimal requirements for ductal
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growth were oestrogen, corticosteroid and growth hormone; (b)
prolactin induced some development of lobules and alveoli; (c) full
breast development similar to that seen in late pregnancy required at
least oestrogen, progestogen, prolactin and growth hormone (Lyons et
al. 1958). These observations are compatible with the hormonal
changes and breast responses that occur naturally in women during
puberty and pregnancy. Thus, spontaneous breast development does not
occur in adolescent girls lacking oestrogen but oestrogen induced
growth is dependent upon at least the simultaneous presence of
gonadotrophins and Cortisol (Perzelan et al. 1982). Similarly
synergistic effects have also been noted between oestrogen and
prolactin (Goldzieher, 1958).
Actions of oestrogen and progestogen
Because of synergism and other interactions, no individual
endocrine agent can be considered in isolation. Nevertheless certain
generalisations may be made about the effects of oestrogen and
progestogen on the breast.
First, the major actions of oestrogen appear to be on the ductal
system in the breast. In most animal species, oestrogen
administration promotes proliferation of ductal epithelium although
acinar development may also be stimulated, particularly with high
concentrations (Bonser et al. 1961, Bassler 1970). Whilst data from
experimental animals are not necessarily applicable to humans,
histological examination of breasts from women receiving oestrogen
therapy suggest that similar changes are induced in the human breast
(Haagensen 1971). Differential sensitivity to oestrogen may also be
demonstrated in explants of normal human breast growing in culture,
larger ducts being more responsive than either intralobular ducts or
the lobules (van Bogaert 1 978).
In contrast to oestrogen, the actions of progesterone appear to
be directed more towards lobulo-alveolar development. Thus
administration of progesterone, especially in combination with
oestrogen, to immature animals produces pronounced effects on acinar
growth (Bonser et al. 1961, Bassler 1 970). The sequence of events
occurring within the human breast at puberty also suggest that the
primary action of progestogen is to stimulate lobular development.
Thus, lobulo-alveolar structures do not appear until the onset of
ovulatory cycles in which progesterone is secreted from a functional
corpus luteum (Bonser et al. 1961). In vitro studies are also
confirmatory. Progesterone stimulates DNA synthesis in intralobular
ducts from whose end-buds 1obular-alveolar structures arise,
established lobules and ducts being much less sensitive (van Bogaert,
1978). However, effects of progesterone on the ductal system cannot
totally be excluded and DNA synthesis in ductal and ductular
epithelium has been reported to be higher in the luteal phase of the
menstrual cycle compared with the follicular phase (Meyer 1977).
In terms of secretory activity within the resting breast, as
measured by nipple aspirates, we could find no difference between the
phases of the menstrual cycle. However, in parous women oral
contraceptives significantly reduced the incidence of breast
secretions (Table 1), this effect being particularly associated with
combined hormone pills. Interestingly, oral contraceptives did not
reduce the frequency with which breast secretions were obtained from
nulliparous women who, as a group, yielded secretions significantly
less than parous women. These observations emphasise the complex
interplay between oestrogen, progestogen and breast development and
illustrate that (1) there is synergism (but little evidence of
antagonism) between the hormones; (2) separate elements of the breast
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have different hormone sensitivity; (3) differing hormone sensitivity
may be displayed by the same elements of the breast (a) at different
developmental periods, e.g. developing versus established lobules and
(b) before and after pregnancy. As a result it can be predicted that,
following the menopause, there will be great variation in atrophic
changes between different parts of the breasts and different
individuals and that the role of individual hormones in the




With the decline of ovarian function, breast involution occurs.
The process may begin before cessation of menses, a preclimacteric-
phase occurring between 35 and 45 years of age (Vorherr 1 974). This
involves a decrease in glandular epithelium with some involution of
acinar and lobular tissue (Figure 3a). In the post-climacteric phase,
there is a much more significant reduction of glandular tissue with a
concomitant increase in fat deposition and a relative predominance of
connective tissue (Figure 3b and c). The loss of lobular and alveolar
structures is most striking and sometimes only the collecting ducts
and microcystic remnants (Figure 3d) remain to mark the site of a
lobule. Eventually the ducts also degenerate leaving only small
islands of atrophic epithelial parenchyma surrounded by connective
tissue and fat. The changes in relative proportions of the main
elements are shown in Figure 4. Whilst glandular tissue might
consitute about one third of the mature breast, after the menopause it
rapidly diminishes and may represent only 5% of the gland in senility.
In contrast the proportion of fat increases with age and represents
the largest component of the postmenopausal breast. Involution is by
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no means a uniform process. Frequently, one part of the breast may
have lost all its lobules whilst another part still retains a normal
lobular pattern. It is therefore not unusual to see numerous and
well-preserved lobules in women of advanced age. The presence of
persistent lobules (Figure 5a and b) in postmenopausal women may be
associated with increased risk of breast cancer, being found more
often in mastectomy specimens (for breast cancer) than in breasts at
routine autopsy (Wellings, Jensen, and Marcus, 1975).
Secretory and Biochemical Activity
Although its glandular component is much reduced, the
postmenopausal breast is not a completely inert structure. As is
shown in Table 1 it is still possible to obtain nipple secretions
from breasts of about one third of postmenopausal women. This clearly
indicates that the remaining glandular elements of the breast are
functional. Furthermore, parenchyma, stroma and adipose tissue from
postmenopausal breasts are all able to metabolise steroid hormones
including progestogens, androgens and oestrogens (Miller 1986).
Pathways of activation and deactivation exist. One interesting route
of metabolism is the conversion of oestrone sulphate which is the
major, albeit inactive, circulating oestrogen into the most potent
naturally-occurring oestrogen, oestradiol. Additionally, breast fat,
a major constituent of the breast after the menopause, is able to
synthesise oestrogen from androgen precursors (Berenek et al. 1984).
This activity is not uniformly distributed throughout the breast and,
for example, enhanced oestrogen synthesis is associated with fat from
areas of breasts containing cancer. A localized phenomenon of this
type could account for the focal nature of persistent lobules in
postmenopausal breasts. Local biosynthesis of active hormones assumes
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greater importance after the menopause once circulating ovarian-
derived hormones diminish and may account for the high concentrations
of both androgens and oestrogens within normal postmenopausal breasts
(van Landeghem et al. 1985 a, b). These levels are not significantly
different from those in premenopausal breast and are much higher than
circulating postmenopausal concentrations.
Hormone Replacement Therapy in Postmenopausal Women
Little information is available on the effects of hormone therapy
on the breasts of postmenopausal women and most is anecdotal. The
single largest study is that of Huseby and Thomas (1954) who looked
for changes in the normal atrophic breast tissue of patients with
advanced breast cancer who were at least 5 years past their menopause
and who were being treated with large doses of oestrogenic hormones.
This type of study has limitations in terms of the "normality" of the
breast tissue, the possibility that the presence of cancer or other
previous therapies may have influenced the breast and the
pharmacological doses of hormones administered. Of the 36 patients
examined, breast tissue from 34 showed evidence of epithelial
stimulation with increased numbers of small ducts, interlobular
connective tissue and formation of new lobules. Whilst these changes
are the reverse of the normal atrophic processes occurring at the
menopause, only in one instance had all the breast tissue been
"restored" to the premenopausal state. In the remainder, the
histological pattern was distinctly abnormal. Such consistent changes
have not been noted by others. Foote and Stewart (1945) could
identify proliferative changes in only one of four breast specimens
from postmenopausal or castrate women receiving oestrogen and, in a
series of only 3 cases, Auchincloss and Haagensen (1940) found merely
dilation of ducts in one specimen although the others had evidence of
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marked epithelial stimulation with numerous large gland fields. In
summary, therefore, although responses vary between individuals,
administration of oestrogen in high doses to postmenopausal women
tends to reverse the process of breast involution. The effects of
progestogens either alone or in combination with oestrogen have not
been documented.
OESTROGEN. PROGESTOGEN AND BREAST CANCER
The aetiology of breast cancer has a strong hormonal component
(Table 2). In view of their proliferative properties within normal
breast, it is understandable that oestrogen and progestogen should be
implicated. The last section of this chapter will therefore present
the aetiological evidence linking hormone excess or imbalance to
increased risk of breast cancer and the possible mechanism by which
oestrogen and progestogen may promote the development of this
malignancy.
Aetiological Evidence
In humans, the single greatest risk factor for breast cancer is
being a woman. The incidence in males is 1$ of that in females,
although administration of oestrogen, whether for sexual problems or
for cancer of the prostate, increases the risk. In women, breast
cancer does not occur before puberty and is rare before 25 years;
thereafter incidence increases gradually with age until the menopause
at which it decreases slightly before increasing again with advancing
years (De Waard et al. 1964). There are also other factors which point
to the involvement of hormones in cancer risk.
Thus an extended reproductive life whether by early menarche or
late menopause increases a woman's risk of breast cancer (MacMahon et
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al. 1975). The data for age at menopause are particularly impressive
and it is estimated that women with a menopause at 55 years or older
have twice the risk as those whose menopause occurred naturally before
45 years of age (Trichopoulos et al. 1972). Conversely, artificially
induced menopause, particularly early in life protects against breast
cancer (Feinleib 1968). Overall, surgical menopause is associated
with a 4055 reduction in risk and oophorectomy before the age of 35
years decreases the risk to one third of that in women with a natural
menopause (Trichopoulos et al. 1 972). These statistics have
interesting implications suggesting that (1) ovarian activity plays a
part in the development of at least 2/3 of breast cancers occurring in
women undergoing a natural menopause and (2) as the breasts of women
at 35 years have already been exposed to over half the normal period
of ovarian activity, it is not simple exposure to ovarian hormones
that causes breast cancer. The protection of oophorectomy and hazard
of late menopause appear to be lifelong as is reflected by the reduced
incidence of induced menopause (Lilienfield 1956) and the later age at
natural menopause (by 1-2 years) (Haagensen 1971) of breast cancer
patients compared with the general population.
Whilst it is generally agreed that a prolonged reproductive life
increases risk of breast cancer, there is no consensus as to why this
should be so. Indeed, two diametrically opposing theories have
appeared. In one hypothesis (Henderson et al. 1985), it is suggested
that increased risk results from the cumulative effects of regular
cyclic stimulation to which the breast is exposed. Oestrogen and
progestogen act in concert to promote proliferation of cells
susceptible to carcinogenic agents. Proponents of this hypothesis
cite, as supportive evidence, the protective action of pregnancy
(MacMahon et al. 1973), especially early in life, which breaks up
regular cyclicity. The second but opposite theory is based on
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"oestrogen windows" (Korenman 1980) and postulates that, at each end
of reproductive life, menstrual cycles are irregular and there are
major periods of anovulation during which the breast is subject to
oestrogens "unopposed" by progestogens. Certainly, prior to the
menopause there is a variable period of time (as long as 8 years)
during which menstrual cycles are irregular (Treloar et al. 1967).
Longer cycles become more prevalent and these appear to be anovulatory
(Sherman et al. 1 976). There is also a suggestion that women with a
late menopause have longer menstrual cycles than women with an early
menopause (Wallace et al. 1978) and are therefore more likely to be
exposed to more anovulatory cycles. Since anovulation is one of the
major reasons for nulliparity, the increased risk of nulliparous women
to breast cancer has been used to support the luteal inadequacy
hypothesis. Indeed, it has been reported that infertile women with
endogenous progesterone deficiency have over a five fold greater risk
of breast cancer compared with those infertile for other reasons
(Cowan et al 1981). The increased risk was, however, confined to
premenopausal women, many of whom had received exogenous progestogen
and the possibility cannot be excluded that administration of the
hormone was reponsible for the altered risk. The relative merits of
these opposing hypotheses will be discussed further when the
endocrinological actions of oestrogen and progestogen are considered.
Exogenous Hormones
Evidence for exogenous oestrogen alone or in combination with
progestogen influencing risk of breast cancer comes from three sources
(a) adminstration of contraceptive steroids to premenopausal women;
(b) administration of hormones during pregnancy;
(c) administration of hormones at and after the menopause.
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(a) Oral Contraceptives: The influence of these preparations on risk
of breast cancer has been studied extensively. In general, most case-
control studies have failed to find a positive association between
oral contraceptive use and risk (Vessey, 1984). However, it is
possible that subgroups of women may have reason for concern such as
those taking contraceptive steroids from an early age and for a long
period of time and also those at already increased risk for other
reasons. It has also been suggested by Pike et al. (1983) that
contraceptive pills with high progestogenic potency are particularly
assocatied with adverse risk. Whilst the study has been heavily
criticised especially in terms of assessment of progestogenic potency,
it draws attention to the problems of classifying all contraceptive
steroids within the category of "the pill". A further complicating
factor in assessing effects of oral contraceptives is that exogenous
steroids are being administered against a background of normal ovarian
steroid. It is conceivable therefore that the effects of contraceptive
steroids on the breast could be either protective or deleterious
depending on the nature and regularity of ovarian activity.
(b) Hormones during Pregnancy: particularly in the USA, very high
doses of diethylstiboestrol were given to women during the 1950s and
1960s with the objective of preventing abortion and late pregnancy
toxaemia. It is therefore doubly tragic that not only was the therapy
ineffective but the treated women had an increased risk of breast
cancer, although it has taken over 20 years for this to become
apparent (Greenberg, 1984).
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(c) Hormone Replacement at or after the Menopause: Postmenopausal-
associated oesteoporesis and other less debilitating effects of the
menopause such as "hot flushes" and genital atrophy may be effectively
treated by oestrogen replacement therapy (which usually involves the
use of conjugated oestrogens). Whilst there is unequivocal evidence
that such replacement therapy may cause endometrial cancer (Brunton,
198^), effects on breast cancer are much more controversial. Most,
but not all, case-control studies suggest that oestrogen replacement
carries with it an increased risk but this is only of a very modest
size (Table 3). There also appears to be positive relationships
between risk and dose of oestrogen and duration of use (Ross et al.
1 980, Brinton et al. 1 981 , Hoover et al. 1 981). It might be expected
that, if replacement therapy is hazardous by increasing duration of
exposure of the breast to oestrogen, administration to oophorectomized
women would abolish the protective effects of early castration. No
consensus exists as to whether this is so. Thus, whilst Brinton et
al. (1981) reported a 50$ increase in risk following use of menopausal
hormones in oophorectomized women, Ross et al. (1980) could only find
an increased risk in patients with intact ovaries. Effects of
replacement oestrogen are clearly not restricted or concentrated in
oophorectomized women. Oestrogen therapy may also be contra-indicated
in certain groups of women such as those with a family history of
breast cancer or an experience of previous benign breast disease.
These results have led to the suggestion that breasts already prone to
cancer for other reasons may be particularly susceptible to the
effects of oestrogen.
In contrast to endometrial cancer in which the addition of
progestogens reduces the hazards of oestrogen therapy (Gambrell 1982),
the corresponding data for breast cancer is scanty. However, a recent
study (Gambrell et al. 1983) has provided preliminary evidence that
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the combination of progestogen to oestrogen may also decrease risk to
breast cancer.
BIOCHEMICAL CONSIDERATIONS
Current dogma (Moolgavkar & Knudson 1981) suggests that breast
cancers arise as a result of somatic mutations of DNA in
undifferentiated breast stem cells (although whether these are of
ductal or lobulo-alveolar origin is still in dispute). These errors
in cell division are caused by initiating factors such as ionizing
radiation and, perhaps, specific chemical carcinogens and viruses.
Insofar as castration early in life gives marked protection against
breast cancer, ovarian hormones must also have at least a permissive
role in the development of the disease. These hormones are, however,
not mutagenic in human systems and do not appear to damage nucleic
acids. Their roles are therefore probably as promotors either to
stimulate stem cell proliferation thereby increasing the population of
cells susceptible to carcinogens or to encourage the selective growth
of already transformed cells. The proliferative effects on the breast
of oestrogen alone or in combination with progesterone would be
compatible with such a mechanism of action. Furthermore the known
risk factors, of early menarche, late menopause and exogenous
administration of high doses of replacement oestrogen would also be in
keeping with the promotion of breast cancer by the cumulative effects
of excessive oestrogen. As a consequence of this concept,
considerable work has been performed in an effort to demonstrate high
levels of circulating oestrogen in patients with breast cancer and
women at high risk to the disease. However, no consistent abnormality
has been found in either urinary or plasma levels of oestrogens
(Zumoff 1981, Forrest & Miller, 1985). A major problem in such
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studies is that circulating levels of oestrogens do not necessarily
reflect levels of oestrogens within the breast particularly in
postmenopausal women. Indeed it may be pertinent that whilst
circulating oestrogens fall markedly after the menopause, oestrogen
within the breast is not significantly different in pre- and
postmenopausal women. Furthermore whilst the major circulating
oestrogens in postmenopausal women are oestrone and its sulphate
(Samojlik et al. 1982), oestradiol tends to predominate within the
breast (van Landeghem et al. 1985a). This is highly suggestive of
local metabolism within the breast and, as has already been reviewed,
evidence exists for metabolic pathways which would increase
oestrogenicity within the breast including the conversion of oestrone
sulphate to oestradiol and the transformation of androgens to
oestrogens.
To put these effects into some kind of perspective, the risk
factors linking exogenous and endogenous oestrogen excess with breast
cancer are not as strong as the same factors in association with
endometrial cancer. The breast must therefore be less susceptible to
the tumour-promoting effects of oestrogens than the endometrium. This
is supported by the larger amounts of oestrogen required to change the
risk of breast cancer compared with that of endometrial cancer and the
relative difficulty in demonstrating oestrogen receptor sites in
normal breast compared with endometrium. Since the incidence rates
of breast cancer are generally higher than those of endometrial cancer
(Thomas 1984), either oestrogens play a lesser role in the genesis of
breast cancer or the effects of oestrogens are subject to different
modifying influences in the two tissues, e.g. oestrogen uptake,
metabolism or interaction with other hormones is different. In any
event, oestrogen would appear to be only one piece in the
multifactorial jigsaw of breast cancer development.
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Whether progesterone is another piece of the jigsaw is more
debatable. The fundamental problem is to decide whether progestogens
are co-promotors, oestrogen antagonists or neither. The case that
progestogens may be hazardous is that, like oestrogens, they have
proliferative properties in normal breast. The same risk factors
which have been discussed in relation to oestrogen excess would
therefore also favour promotional effects of progesterone. There is
also undoubted synergism between oestrogen and progestogen (see Figure
6) and in most hormone-sensitive tissues the action of progesterone
depends upon oestrogen. For example, the progestogen receptor protein
which mediates the major action of progestogens is induced by
oestrogen (Horowitz & McGuire, 1978).
Conversely the case for protective effects of progesterone is
largely based on the epidemiological data that luteal insufficiency is
associated with increased risk of breast cancer and that
administration of progestogen to oestrogen during replacement therapy
reduces risk of endometrial cancer and, perhaps, breast cancer. There
is also some biochemical evidence that progestogens have
antioestrogenic potential (Figure 6). Thus, in the uterus,
progesterone blocks the production of oestrogen receptors (Hsueh et
al. 1975). Furthermore in endometrium and breast cancers,
progestogens induce the enzyme, oestrogen 17 3 dehydrogenase, which
catalyses the interconversion between oestradiol and oestrone. If, as
a result, oestradiol is converted to oestrone, the oestrogenicity of
the breast could be reduced. Equally, however, as the reaction is
reversible, induction of enzyme activity could result in increased
concentration of oestradiol. It seems possible that in endometrium
the predominate direction is from oestradiol to oestrone (Tseng et al.
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1981) whereas perfusion studies sugest that the reverse reaction is
preferred in the breast (McNeill et al. 1985).
This highlights the difficulties in assessing the effects of both
progestogens and oestrogens on the breast. Differences exist between
the breast and other target organs not only in direct sensitivity to
steroid hormones but in the fate of the hormones within the tissues.
Thus, whereas cell division is apparently increased in the breast
during the luteal phase of the cycle (Anderson and Ferguson, 1982),
progesterone secreted from the corpus luteum inhibits mitosis in the
endometrium (Novak and Woodruff, 1979). The distribution of oestrogen
between cytoplasmic and nuclear compartments also differs completely
in endometrial and breast cells (van Landeghem et al. 1985a).
Similarly the application of observations from established breast
cancers to the process of carcinogenesis is also fraught with dangers.
Epithelial cells from malignant human breast tumours quite often have
a different response to hormones than the normal mammary gland. For
example the administration of high doses of oestrogen to
postmenopausal women can lead to regression of cancerous growth whilst
simultaneously stimulating proliferation of normal cells (Foote &
Stewart, 1945). Furthermore, as the role of steroid hormones in
carcinogenesis is probable not on differentiated normal cells but on
undifferentiated stem cells or partially transformed cells, it is
necessary to know the hormone sensitivity of the latter. A major
handicap in assessing the potential effects of steroid hormones on
induction of breast disease must therefore be the lack of suitable in
vitro models for the developing and postmenopausal breast and the
cells at risk to carcinogenic transformation within these tissues.
Until answers to basic questions are available from these models, we
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necessarily must be still in the realms of speculation and the
therapeutic implications of steroid hormones will remain difficult to
evaluate.
CONCLUSIONS
The evidence for the involvement of hormones in the development
of the breast and its malignant tumours has been reviewed. Both
oestrogen and progestogen have important and necessary roles to play
in the natural development of the normal breast at puberty and during
pregnancy. The involutionary changes occurring at and after the
menopause result from diminished ovarian production of these hormones
and can be reversed, at least in part, by exogenous administration of
oestrogen. Prolonged and excessive oestrogen stimulation of the
breast by delayed menopause occurring naturally or by hormone
replacement therapy is associated with a small, but variable, increase
in risk to breast cancer. The effects of progestogens are so
controversial that it is unclear whether they are protective or
hazardous to the breast. Only when more basic information is
available from laboratory and clinical research will the exact
benefits and dangers of steroid hormones become evident. This
evidence will be useful not only for prevention of breast cancer but
also for safe contraception and optimal treatment of menopausal
disorders.
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TABLE 2 FACTORS ASSOCIATED WITH INCREASED RISK OF BREAST CANCER
Genetic : Family history of breast cancer
Environmental: Domicile in Western Europe and North American
industrial societies.
Heavy body build and high calorific diet.
Irradiation.
Hormonal : Female sex
Long menstrual life (early menarche, late menopause)
Anovulatory menstrual cycles
Nulliparity
Late age of first pregnancy
Prolonged high dose oestrogen therapy
(Previous benign breast disease?)
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TABLE 3. RECENT CASE-CONTROL STUDIES OF RELATIVE RISK OF BREAST CANCER
H WOMEN RECEIVING MENOPAUSAL OESTROGEN REPLACEMENT
Reference Relative Comment
Risk
Sartwell et al. 1977 0.82 No relationship with duration of
use.
Ross et al. 1980 1 .1
Brinton et al. 1981 1.24
Hoover et al. 1981 1.4
Kelsey et al. 1981 0.9
Hulka et al. 1982 1.7
Sherman et al. 1983 0.6
Nomura et al. 1986 0.7-1.1
Risk increased with dose and
duration of use, particularly in
women with intact ovaries.
Risk increased with dose and
duration of use, particularly in
castrate women.
Risk increased with dose and
duration of use, particularly
in women with a family history of
breast cancer.
Risk not related to cumulative
dose - few long-term users.
Risk not related to dose or
duration of use but associated with
injectable oestrogen.
Risk associated positively with
body mass.
Relative risk varies with type of
controls. Risk increased in those
with family history of breast
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LEGENDS TO FIGURES
Figure 1 (a) A group of normal resting lobules in loose fibrous tissue
and fat, surrounding a terminal duct with secretions;
nulliparous 18 years old woman, x 50, H & E.
(b) Fully developed lactational breast of a 27 year old
woman, with expanded acinar structures separated by
fibrous septae, sometimes containing ducts, x 50, H & E.
Figure 2. The multiplicity of hormones required for development of
the breast depicted schematically from (a) a rudimentary
prepubertal state to (b) the pubertal breast showing
ductal elongation and ramification to (c) the adult
breast with lobular-alveolar units and finally to (d) the
pregnant breast showing full lobular development and
multiple alveoli.
Figure 3. (a) Involuted lobules arranged around residual branched
duct, surrounded by dense collagen, x 50, H & E.
(b) Postmenopausal involuted lobule in fibrous tissue and
fat. x 50, H & E.
(c) Same lobule as 3 (b) at higher magnification to show
prominent, paler outer myoepithelial layer (myoid
atrophy) of ductules, x 160, H & E.
(d) Postmenopausal cystic lobular atrophy with adjacent duct
showing prominent myoid layer at higher magnification, x
160, H & E.
Figure JL Changes with age in the relative proportions of the
principle elements of the breast.
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Figure 5. (a) Persistent lobule in post menopausal breast, surrounded
by fat. x 50, H & E.
(b) Higher magnification to show persistence of normal
resting parenchymal architecture, x 160, H & E.
Figure £. Interactions between oestrogen and progestogen which may
be either synergistic to increase cell proliferation
(cell on the left) or antagonistic to decrease cell
proliferation (cell on the right).
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